



(51) International Patent Classification:

C07D 231/12 (2006.01) **C07D 409/12** (2006.01)
C07D 213/74 (2006.01) **C07D 239/72** (2006.01)
C07D 213/75 (2006.01) **C07D 413/12** (2006.01)
C07D 401/04 (2006.01) **C07D 417/04** (2006.01)
C07D 401/12 (2006.01) **C07D 417/12** (2006.01)
C07D 405/12 (2006.01) **C07D 471/04** (2006.01)
C07D 239/36 (2006.01) **C07D 487/04** (2006.01)
C07D 239/42 (2006.01)

(21) International Application Number:

PCT/US2016/054464

(22) International Filing Date:

29 September 2016 (29.09.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3169/DEL/2015 1 October 2015 (01.10.2015) IN

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY

[US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).


(72) Inventors: BRONSON, Joanne J.; c/o Bristol-Myers

Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). CHEN, Ling; c/o Bristol-Myers

Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **DITTA, Jonathan L.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **DZIERBA, Carolyn Diane**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **JALAGAM, Prasada Rao**; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2&3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Karnataka, Bangalore 560 099 (IN). **LUO, Guanglin**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **MACOR, John E.**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **MAISHAL, Tarun Kumar**; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2&3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Karnataka, Bangalore 560 099 (IN). **NARA, Susheel Jethanand**; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2&3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Karnataka, Bangalore 560 099 (IN). **RAJAMANI, Ramkumar**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SISTLA, Ramesh Kumar**; c/o Syngene International Limited, Biocon Special Economic Zone,

[Continued on next page]

(54) Title: BIARYL KINASE INHIBITORS



(I),

(57) Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.



Biocon Park, Plot No. 2&3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Karnataka, Bangalore 560 099 (IN). **THANGAVEL, Soodamani**; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2&3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Karnataka, Bangalore 560 099 (IN).

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(74) **Agents:** **MINGO, Pamela A.** et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

BIARYL KINASE INHIBITORS

CROSS REFERENCE TO RELATED APPLICATION

This application claims the priority of Indian Provisional Application Serial
5 3169/DEL/15 filed October 1, 2015 which is herein incorporated by reference in its
entirety.


The present disclosure is generally directed to compounds which can inhibit
adaptor associated kinase 1 (AAK1), compositions comprising such compounds, and
10 methods for inhibiting AAK1.

Adaptor associated kinase 1 (AAK1) is a member of the Ark1/Prk1 family of
serine/threonine kinases. AAK1 mRNA exists in two splice forms termed short and
long. The long form predominates and is highly expressed in brain and heart
(Henderson and Conner, *Mol. Biol. Cell.* **2007**, *18*, 2698-2706). AAK1 is enriched
15 in synaptosomal preparations and is co-localized with endocytic structures in cultured
cells. AAK1 modulates clathrin coated endocytosis, a process that is important in
synaptic vesicle recycling and receptor-mediated endocytosis. AAK1 associates with
the AP2 complex, a hetero-tetramer which links receptor cargo to the clathrin coat.
The binding of clathrin to AAK1 stimulates AAK1 kinase activity (Conner et. al.,
20 *Traffic* **2003**, *4*, 885-890; Jackson et. al., *J. Cell. Biol.* **2003**, *163*, 231-236). AAK1
phosphorylates the mu-2 subunit of AP-2, which promotes the binding of mu-2 to
tyrosine containing sorting motifs on cargo receptors (Ricotta et. al., *J. Cell Bio.*
2002, *156*, 791-795; Conner and Schmid, *J. Cell Bio.* **2002**, *156*, 921-929). Mu2
phosphorylation is not required for receptor uptake, but phosphorylation enhances the
25 efficiency of internalization (Motely et. al., *Mol. Biol. Cell.* **2006**, *17*, 5298-5308).

AAK1 has been identified as an inhibitor of Neuregulin-1/ErbB4 signaling in
PC12 cells. Loss of AAK1 expression through RNA interference mediated gene
silencing or treatment with the kinase inhibitor K252a (which inhibits AAK1 kinase
activity) results in the potentiation of Neuregulin-1 induced neurite outgrowth. These
30 treatments result in increased expression of ErbB4 and accumulation of ErbB4 in or
near the plasma membrane (Kuai et. al., *Chemistry and Biology* **2011**, *18*, 891-906).
NRG1 and ErbB4 are putative schizophrenia susceptibility genes (Buonanno, *Brain
Res. Bull.* **2010**, *83*, 122-131). SNPs in both genes have been associated with

multiple schizophrenia endophenotypes (Greenwood et. al., *Am. J. Psychiatry* **2011**, *168*, 930-946). Neuregulin 1 and ErbB4 KO mouse models have shown schizophrenia relevant morphological changes and behavioral phenotypes (Jaaro-Peled et. al., *Schizophrenia Bulletin* **2010**, *36*, 301-313; Wen et. al., *Proc. Natl. Acad. Sci. USA.* **2010**, *107*, 1211-1216). In addition, a single nucleotide polymorphism in an intron of the AAK1 gene has been associated with the age of onset of Parkinson's disease (Latourelle et. al., *BMC Med. Genet.* **2009**, *10*, 98). These results suggest that inhibition of AAK1 activity may have utility in the treatment of schizophrenia, cognitive deficits in schizophrenia, Parkinson's disease, neuropathic pain, bipolar disorder, and Alzheimer's disease.


In its first aspect the present disclosure provides a compound of formula (I)




(I),

or a pharmaceutically acceptable salt thereof, wherein:


15 A is selected from






wherein “” denotes the point of attachment to B;


B is selected from



wherein “*” indicates the point of attachment to $\mathbf{R}^5$ and “**” indicates the point of attachment to ring A;

R¹ is selected from hydrogen, amino, -CO₂H, cyclopropyl, difluoromethyl, ethyl, halo, hydroxymethyl, methoxy, methoxymethyl, methyl, -NHC(O)CH₃, -NHCO₂CH₃, trifluoromethoxy, trifluoromethyl,






5 wherein R^a is selected from hydrogen, halo and methyl;

R^2 is selected from hydrogen, cyano, $-\text{CH}_2\text{OH}$, halo, and methyl;


R^3 is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, fluoromethyl, halo, hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluoromethoxy, trifluoromethyl, $-\text{CH}_2\text{N}(\text{CH}_3)_2$, and a five-membered aromatic ring
10 containing one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur;

R^4 is selected from hydrogen, halo, and methyl;


R^5 is selected from




15 R^6 is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl, and trifluoromethyl;
provided that when A is




then B is




R¹ is selected from




R⁵ is selected from




In a first embodiment of a first aspect the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein A is selected from




In a second embodiment of the first aspect, B is selected from



In a third embodiment of the first aspect the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein A is selected from



In a fourth embodiment B is selected from



In a second aspect the present disclosure provides a composition comprising a pharmaceutically acceptable amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In a third aspect the present disclosure provides a method of inhibiting adaptor associated kinase 1 (AAK1) activity, comprising contacting AAK1 with a compound of formula (I), or a pharmaceutically acceptable salt thereof.

In a fourth aspect the present disclosure provides a method for treating or managing a disease or a disorder mediated by AAK1 activity, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In a first embodiment of the fourth aspect the disease or disorder is selected from Alzheimer's disease, bipolar disorder, pain, Parkinson's disease, and schizophrenia. In a second

embodiment the pain is neuropathic pain. In a third embodiment the neuropathic pain is fibromyalgia or peripheral neuropathy.

Other aspects of the present disclosure may include suitable combinations of embodiments disclosed herein.

5 Yet other aspects and embodiments may be found in the description provided herein.

BRIEF DESCRIPTION OF THE FIGURES

Aspects of the disclosure are illustrated in Figure 1, which shows results
10 obtained from a formalin pain model using AAK1 homozygous (-/-) knockout mice and their wild-type (+/+) littermates. The AAK1 homozygous (-/-) knockout mice show a clear reduction in both acute and tonic pain response as compared to their wild-type (+/+) littermates.

This disclosure is based, in part, on the discovery that AAK1 knockout mice
15 exhibit a high resistance to pain. That discovery prompted research that ultimately led to the discovery of AAK1 inhibitors, compositions comprising them, and methods of their use.

The description of the present disclosure herein should be construed in congruity with the laws and principals of chemical bonding. In some instances it
20 may be necessary to remove a hydrogen atom in order to accommodate a substituent at any given location.

It should be understood that the compounds encompassed by the present disclosure are those that are suitably stable for use as pharmaceutical agent.

As used in the present specification, the following terms have the meanings
25 indicated:

All patents, patent applications, and literature references cited in the specification are herein incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure, including definitions, will prevail.

As used herein, the singular forms “a”, “an”, and “the” include plural
30 reference unless the context clearly dictates otherwise.

In some instances, the number of carbon atoms in any particular group is denoted before the recitation of the group. For Example, the term “C₁₋₆ alkyl” denotes an alkyl group containing one to six carbon atoms. Where these designations

exist they supercede all other definitions contained herein.

The term "halo," as used herein, refers to Br, Cl, F, and/or I.

Asymmetric centers may exist in the compounds of the present disclosure. It should be understood that the disclosure encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit AAK1. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.

Certain compounds of the present disclosure may also exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for Example because of steric hindrance or ring strain, may permit separation of different conformers. The present disclosure includes each conformational isomer of these compounds and mixtures thereof.

The term "compounds of the present disclosure", and equivalent expressions, are meant to embrace compounds of formula (I), and pharmaceutically acceptable enantiomers, diastereomers, and salts thereof. Similarly, references to intermediates are meant to embrace their salts where the context so permits.

The present disclosure is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general Example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ^{13}C and ^{14}C . Isotopically-labeled compounds of the disclosure can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for Example as standards and reagents in determining biological activity. In the case of stable isotopes, such

compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

The compounds of the present disclosure can exist as pharmaceutically acceptable salts. The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds of the present disclosure which are water or oil-soluble or dispersible, which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting a suitable nitrogen atom with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate; digluconate, dihydrobromide, dihydrochloride, dihydroiodide, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Examples of acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.

Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, and N,N’-

dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

One embodiment of this disclosure encompasses methods of inhibiting adaptor
5 associated kinase 1 (AAK1), both *in vitro* and *in vivo*, which comprise contacting AAK1 with a compound of formula I or a pharmaceutically acceptable salt thereof.

When it is possible that, for use in therapy, therapeutically effective amounts of a compound of formula (I), as well as pharmaceutically acceptable salts thereof, may be administered as the raw chemical, it is possible to present the active
10 ingredient as a pharmaceutical composition. Accordingly, the disclosure further provides pharmaceutical compositions, which include therapeutically effective amounts of compounds of formula (I) or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. Unless otherwise indicated, a “therapeutically effective amount” of a compound is an
15 amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another
20 therapeutic agent.

The term “therapeutically effective amount,” as used herein, refers to an amount of a compound or compounds sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition. A “therapeutically
25 effective amount” of a compound means an amount of therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of the disease or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of
30 another therapeutic agent. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or

simultaneously. The compounds of formula (I) and pharmaceutically acceptable salts thereof, are as described above. The carrier(s), diluent(s), or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another
5 aspect of the present disclosure there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents, or excipients. The term "pharmaceutically acceptable," as used herein, refers to those compounds, materials, compositions, and/or dosage
10 forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.

Pharmaceutical formulations may be presented in unit dose forms containing
15 a predetermined amount of active ingredient per unit dose. Dosage levels of between about 0.01 and about 250 milligram per kilogram ("mg/kg") body weight per day, preferably between about 0.05 and about 100 mg/kg body weight per day of the compounds of the present disclosure are typical in a monotherapy for the prevention and treatment of disease. Typically, the pharmaceutical compositions of this
20 disclosure will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending on the condition being treated, the severity of the condition, the time of administration, the route of
25 administration, the rate of excretion of the compound employed, the duration of treatment, and the age, gender, weight, and condition of the patient. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Treatment may be initiated with small dosages substantially less than the optimum dose of the
30 compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compound is most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects.

When the compositions of this disclosure comprise a combination of a compound of the present disclosure and one or more additional therapeutic or prophylactic agent, both the compound and the additional agent are usually present at dosage levels of between about 10 to 150%, and more preferably between about 10
5 and 80% of the dosage normally administered in a monotherapy regimen.

Compounds of the disclosure may be administered in combination with one or more additional therapeutic or prophylactic agents. For Example, when used for the treatment of pain, possible additional agents include immunosuppressive agents, anti-inflammatory agents, and/or other agents used in the treatment of pain.

10 Immunosuppressants suitable for use in the methods and compositions of this disclosure include those known in the art. Examples include aminopterin, azathioprine, cyclosporin A, D-penicillamine, gold salts, hydroxychloroquine, leflunomide, methotrexate, minocycline, rapamycin, sulfasalazine, tacrolimus (FK506), and pharmaceutically acceptable salts thereof. A particular
15 immunosuppressant is methotrexate.

Additional Examples of immunosuppressants include anti-TNF antibodies, such as adalimumab, certolizumab pegol, etanercept, and infliximab. Others include interleukin-1 blockers, such as anakinra. Others include anti-B cell (CD20) antibodies, such as rituximab. Others include T cell activation blockers, such as
20 abatacept.

Other immunosuppressants include inosine monophosphate dehydrogenase inhibitors, such as mycophenolate mofetil (CellCept®) and mycophenolic acid (Myfortic®).

Anti-inflammatory drugs suitable for use in the methods and compositions of
25 this disclosure include those known in the art. Examples include glucocorticoids and NSAIDs. Examples of glucocorticoids include aldosterone, beclometasone, betamethasone, cortisone, deoxycorticosterone, dexamethasone, fludrocortisones, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, and pharmaceutically acceptable salts thereof.

30 Examples of NSAID include salicylates (*e.g.*, aspirin, amoxiprin, benorilate, choline magnesium salicylate, diflunisal, faislamine, methyl salicylate, magnesium salicylate, salicyl salicylate, and pharmaceutically acceptable salts thereof), arylalkanoic acids (*e.g.*, diclofenac, aceclofenac, acemetacin, bromfenac, etodolac,

indometacin, nabumetone, sulindac, tolmetin, and pharmaceutically acceptable salts thereof), arylpropionic acids (*e.g.*, ibuprofen, carprofen, fenbufen, fenoprofen, flurbiprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, tiaprofenic acid, suprofen, and pharmaceutically acceptable salts thereof), arylanthranilic acids
5 (*e.g.*, meclofenamic acid, mefenamic acid, and pharmaceutically acceptable salts thereof), pyrazolidine derivatives (*e.g.*, azapropazone, metamizole, oxyphenbutazone, phenylbutazone, sulfinprazone, and pharmaceutically acceptable salts thereof), oxicams (*e.g.*, lornoxicam, meloxicam, piroxicam, tenoxicam, and pharmaceutically acceptable salts thereof), COX-2 inhibitors (*e.g.*, celecoxib, etoricoxib, lumiracoxib,
10 parecoxib, rofecoxib, valdecoxib, and pharmaceutically acceptable salts thereof), and sulphonanilides (*e.g.*, nimesulide and pharmaceutically acceptable salts thereof).

Other agents used in the treatment of pain (including but not limited to neuropathic and inflammatory pain) include, but are not limited to, agents such as pregabalin, lidocaine, duloxetine, gabapentin, carbamazepine, capsaicin, and other
15 serotonin/norepinephrine/dopamine reuptake inhibitors, and opiates (such as oxycontin, morphine, and codeine).

In the treatment of pain caused by a known disease or condition, such as diabetes, infection (*e.g.*, herpes zoster or HIV infection), or cancer, compounds of the disclosure may be administered in combination with one or more additional
20 therapeutic or prophylactic agents directed at the underlying disease or condition. For Example, when used to treat diabetic neuropathy, compounds of the disclosure may be administered in combination with one or more anti-diabetic agents, anti-hyperglycemic agents, hypolipidemic/lipid lowering agents, anti-obesity agents, anti-hypertensive agents and appetite suppressants. Examples of anti-diabetic agents
25 include biguanides (*e.g.*, metformin, phenformin), glucosidase inhibitors (*e.g.*, acarbose, miglitol), insulins (including insulin secretagogues and insulin sensitizers), meglitinides (*e.g.*, repaglinide), sulfonylureas (*e.g.*, glimepiride, glyburide, gliclazide, chlorpropamide, and glipizide), biguanide/glyburide combinations (*e.g.*, Glucovance), thiazolidinediones (*e.g.*, troglitazone, rosiglitazone, and pioglitazone),
30 PPAR-alpha agonists, PPAR-gamma agonists, PPAR alpha/gamma dual agonists, glycogen phosphorylase inhibitors, inhibitors of fatty acid binding protein (aP2), glucagon-like peptide-1 (GLP-1) or other agonists of the GLP-1 receptor, dipeptidyl

peptidase IV (DPP4) inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors (*e.g.*, dapagliflozin, canagliflozin, and LX-4211).

Pharmaceutical formulations may be adapted for administration by any appropriate route, for Example by the oral (including buccal or sublingual), rectal, 5 nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intracutaneous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, intravenous, or intradermal injections or infusions) route. Such formulations may be prepared by any method known in the art of pharmacy, for Example by bringing into association the active ingredient with the 10 carrier(s) or excipient(s). Oral administration or administration by injection are preferred.

Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in- 15 water liquid emulsions or water-in-oil emulsions.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a 20 similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for Example, starch or mannitol. Flavoring, preservative, dispersing, and coloring agent can also be present.

Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, 25 magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate, or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants, 30 disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, and the like.

Lubricants used in these dosage forms include sodium oleate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, betonite, xanthan gum, and the like. Tablets are formulated, for Example, by preparing a powder mixture, granulating or slugging, adding a lubricant and
5 disintegrant, and pressing into tablets. A powder mixture is prepared by mixing the compound, suitable comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginat, gelating, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or and absorption agent such as betonite, kaolin, or
10 dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to
15 prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc, or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present disclosure can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a
20 sealing coat of shellac, a coating of sugar or polymeric material, and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups, and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
25 Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners, or saccharin or other artificial sweeteners, and the like can also
30 be added.

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for Example by coating or embedding particulate material in polymers,

wax, or the like.

The compounds of formula (I), and pharmaceutically acceptable salts thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.

- 5 Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

The compounds of formula (I) and pharmaceutically acceptable salts thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled
10 with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for
15 Example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the
20 epidermis of the recipient for a prolonged period of time. For Example, the active ingredient may be delivered from the patch by iontophoresis as generally described in *Pharmaceutical Research* 1986, 3(6), 318.

Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes,
25 gels, sprays, aerosols, or oils.

Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.

Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for Example in the
30 range 20 to 500 microns which is administered in the manner in which snuff is taken, *i.e.*, by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or nasal drops, include aqueous or oil solutions of the

active ingredient.

Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurized aerosols, nebulizers, or insufflators.

5 Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.

 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, and soutes which render the formulation isotonic with the
10 blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for Example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for Example water for injections, immediately
15 prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.

 It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for Example those suitable for
20 oral administration may include flavoring agents.

 The term "patient" includes both human and other mammals.
Unless otherwise indicated, the terms "manage," "managing", and "management" encompass preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, and/or lengthening the time
25 that a patient who has suffered from the disease or disorder remains in remission. The terms encompass modulating the threshold, development and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.

 The term "treating" refers to: (i) preventing a disease, disorder or condition
30 from occurring in a patient that may be predisposed to the disease, disorder, and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease, disorder, or condition, i.e., arresting its development; and (iii) relieving the disease, disorder, or condition, i.e., causing regression of the disease, disorder, and/or

condition.

This disclosure is intended to encompass compounds having Formula (I) when prepared by synthetic processes or by metabolic processes including those occurring in the human or animal body (*in vivo*) or processes occurring *in vitro*.

5

EXAMPLES

The present disclosure will now be described in connection with certain embodiments which are not intended to limit its scope. On the contrary, the present disclosure covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following Examples, which include specific
10 embodiments, will illustrate one practice of the present disclosure, it being understood that the Examples are for the purposes of illustration of certain embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects.


15 The abbreviations used in the present application, including particularly in the illustrative schemes and Examples which follow, are well-known to those skilled in the art. Some of the abbreviations that may be used are as follows: MeOH for methanol; min for minutes, EtOAc or ETOAC for ethyl acetate; h or hr or hrs for hours; Ph₃P for triphenylphosphine, DIAD for diisopropyl azodicarboxylate; RT or rt
20 or r.t. for room temperature or retention time (context will dictate); *t_R* for retention time; EtOH for ethanol; DMSO for dimethylsulfoxide; THF for tetrahydrofuran; dppf for diphenylphosphinoferrocene; TFA for trifluoroacetic acid; NMP for *N*-methylpyrrolidine; CBz or Cbz for benzyloxycarbonyl; DCM for dichloromethane; IPA for isopropyl alcohol; DMAP for *N,N*-dimethylaminopyridine; BOC or Boc for
25 *tert*-butoxycarbonyl; (BOC)₂O for di-*tert*-butyl dicarbonate; DMF for *N,N*-dimethylformamide; OAc for acetate; Cbz for carbobenzyloxy; TMS for trimethylsilane; LDA for lithium diisopropylamide; MOM-Cl for chloromethyl methyl ether; KHMDS for potassium hexamethyldisilazide; KOtBu for potassium *tert*-butoxide; DAST for diethylaminosulfur trifluoride; BuOH for *n*-butanol; *n*-BuLi
30 for *n*-butyllithium; NBS for *N*-bromosuccinimide; LAH for lithium aluminum hydride; DMF for *N,N*-dimethylformamide; dppf for 1,1'-bis(diphenylphosphino)ferrocene; TosMIC or TOSMIC for tosylmethyl isocyanide;

TEA for triethylamine; PMB for p-methoxybenzyl; Ac for acetyl; DDQ for 2,3-dichloro-5,6-dicyano-1,4-benzoquinone; and AIBN for 2,2'-azoisobutyronitrile.


The compounds of the present disclosure may be prepared using the reactions and techniques described in this section as well as other synthetic methods known to those of ordinary skill in the art. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformation being affected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvents, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.

Compounds of Formula Ia can be synthesized following General Scheme I. The two key reactions, Suzuki coupling and ether formation, could alternate as shown depending on the commercially available starting materials. The Suzuki coupling substrates, boronic acids/boronates, were either commercially available or prepared from corresponding halogen intermediates (Cl/Br/I) with various standard literature conditions. The ether formation can be achieved by S_NAR when a fluorine intermediate (Formula IV) is available, by Mitsunobu reaction or alkylation with suitable amino alcohol when an OH is available (Formula III/V), and by Buchwald's Pd-catalyzed ether formation reaction when a Cl intermediate (Formula III/V) is available. In cases where R^5 is bigger than H, an activated form of the amino alcohol (Formula VII) was used as the OH-alkylating reagent. Sometimes NH_2 and OH were protected and deprotected during the reaction sequence.

General Scheme I:



X/Y = Cl, Br, I or Boronic acid/boronate; A/B = C or N (phenyl or pyridine).



Formula VII

A common activated amino alcohol reagent for ether formation when R⁵ is not H.

In the following Examples, proton NMR spectra were recorded on either a
 5 Bruker 400 or 500 MHz NMR spectrometer. Chemical shifts are reported in δ values relative to tetramethylsilane. Liquid chromatography (LC)/mass spectra were run on a Shimadzu LC coupled to a Waters Micromass ZQ using at least one of the following methods.

10 Prep LC/MS methods:

Method A:

Waters Xbridge C18, 19x150 mm, 5 μ m; Guard Column: Waters XBridge C18, 19x10 mm, 5 μ m; Mobile Phase A = 5:95 Acetonitrile:water with 10 mM NH₄OAc; Mobile
 15 Phase B = 95:5 Acetonitrile:water with 10 mM NH₄OAc; Gradient: 10-35% B over

25 min, followed by a 10 min hold at 35% B and 5 min hold at 100% B; Flow:15 mL/min.

Method B:

- 5 Waters Xbridge C18, 19x150 mm, 5 μ m; Guard Column: Waters XBridge C18, 19x10 mm, 5 μ m; Mobile Phase A = 5:95 Acetonitrile:water with 10 mM NH₄OAc; Mobile Phase B = 95:5 Acetonitrile:water with 10 mM NH₄OAc; Gradient:10-40% B over 25 min, followed by a 10 min hold at 40% B and 5 min hold at 100% B; Flow:15 mL/min.

10

Method C:

- Waters Xbridge C18, 19x150 mm, 5 μ m; Guard Column: Waters XBridge C18, 19x10 mm, 5 μ m; Mobile Phase A = 5:95 Methanol:water with 10 mM NH₄OAc; Mobile Phase B = 95:5 Methanol:water with 10 mM NH₄OAc; Gradient:10-40% B over 25 min, followed by a 10 min hold at 40% B and 5 min hold at 100% B; Flow:15 mL/min.

15

Analytical LC/MS methods:

- 20 Method A1:

Ascentis Express C18 column (50x2.1 mm-2.7 μ m); mobile phase: A = 10 mM NH₄OAc in Water/ACN (98:2), B = 10 mM NH₄OAc in Water/ACN (2:98); Run: 0 – 100% B for 1.7 min, then 100% B over 1.3 min, then 100 – 0% B over 0.2 min; flow rate = 1 mL/min; λ = 254 nm.

25

Method A2:

Phenomenex C18 2 x 30 mm (3 μ m), A = 10% MeOH - 90% H₂O - 0.1% TFA, B = 90% MeOH - 10% H₂O - 0.1% TFA; Gradient = 0 – 100% B over 2 min, then hold at 100% B for 1 min; Flow rate = 1.0 mL/min

30

Method B:

Column –ACQUITY UPLC BEH C18 (2.1 X 50 mm), 1.7 μ m; Mobile phase A = 0.1% TFA in water; Mobile phase B = Acetonitrile; Gradient = %B: 0 – 98% B over 1.6 min, then hold at 98% B for 0.65 min; Flow = 1 mL/min.

5

Method C:

Column –ACQUITY UPLC BEH C18 (2.1 X 50 mm), 1.7 μ m; Mobile phase A = 0.1% NH₄OAc in water; Mobile phase B = Acetonitrile; Gradient = %B: 5 – 95% B over 1.1 min, then hold at 95% B for 1.4 min; Flow = 1 mL/min.

10

Method C1:

Ascentis Express C18 column (50x4.6 mm-2.7 μ m); mobile phase: A = 5 % ACN, 95 % Water, 10 mM NH₄OAc, B = 95 % ACN, 5 % Water, 10 mM NH₄OAc; Run: 0 – 100% B over 4 min.; flow rate = 4 mL/min; oven temp = 50 °C; λ = 254 nm.

15

Method D:

Ascentis Express C18 column (50x2.1 mm-2.7 μ m); mobile phase: A = 10 mM NH₄OAc in Water, B = ACN; Run: 0 – 100% B for 1.7 min, then 100% B over 2.3 min; flow rate = 1 mL/min.

20

Method E:

Ascentis Express C18 column (50x2.1 mm-2.7 μ m); mobile phase: A = 95% Water: 5% Acetonitrile; 0.1% TFA, B = 5% Water: 95% Acetonitrile; 0.1% TFA; Run: 0 – 100% B over 3 min, then 100% B over 1.2 min; flow rate = 1.1 mL/min; oven temp = 50 °C

25

Method F:

Ascentis Express C18 column (50x2.1 mm-2.7 μ m); mobile phase: A = 0.1% HCOOH in water; Acetonitrile; Run: 0 – 100% B over 1.7 min, then 100% B over 2.3 min; flow rate = 1.0 mL/min.

30

Method G:

Column-Kinetex XB-C18 (75X3 mm-2.6 μ m); mobile phase: A = 10 mM NH₄OAc in Water/ACN (98:2), B = 10 mM NH₄OAc in Water/ACN (2:98); Run: 20 – 100%

- 5 B over 4.0 min, then 100% B over 0.6min, then 100 – 20% B over 0.1 min; flow rate = 1 mL/min.

Method H:

Ascentis Express C18 column (50x2.1 mm-2.7 μ m); mobile phase: A = 95% Water:

- 10 5% Acetonitrile; 10mM NH₄OAc, B = 5% Water:95% Acetonitrile; 10 mM NH₄OAc; Run: 0 – 100% B over 3 min, then 100% B over 1.2 min; flow rate = 1.1 mL/min; oven temp = 50 °C

Method I:

- 15 Ascentis Express C18 column (50x2.1 mm-2.7 μ m); mobile phase: A = 95% Water: 5% Acetonitrile; 0.1% TFA, B = 5% Water:95% Acetonitrile; 0.1% TFA; Run: 0 – 100% B over 3 min, then 100% B over 1.2 min; flow rate = 1.1 mL/min; oven temp = 50 °C


20 Method J:

Ascentis Express C18 column (50x4.6 mm-2.7 μ m); mobile phase: A = 95% Water: 5% Acetonitrile; 0.1% TFA, B = 5% Water:95% Acetonitrile; 0.1% TFA; Run: 0 – 100% B over 4.0 min, then 100% B over 1.1 min; flow rate = 4.0 mL/min; oven temp = 50 °C


25

Example 251

(S)-1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-amine




30



Part A. 4-methyl-5H-1,2,3-oxathiazole 2,2-dioxide

Step 1 Sulfamoyl chloride formation: To a 1000 mL 4 neck round-bottomed flask equipped with a mechanical stirring and an addition funnel, was charged DCM (400 mL) and chlorosulfonyl isocyanate (124 mL, 1430 mmol). Under N₂, this solution was cooled to 0°C. Then formic acid (53.9 mL, 1430 mmol) was added to DCM (100 mL) and this solution was transferred to the addition funnel and the solution was added slowly to the vigorously stirring reaction mixture. Gradually a thick slurry formed. A slow exotherm was observed so additional dry ice was added to acetone bath. Once temperature was stabilized, addition of the formic acid was continued. Addition was done in ~ 25 min. The mixture was allowed to gradually warm to room temperature and was stirred overnight.


Step 2: To a separate 5L 4 neck reaction flask was charged hydroxyacetone (72.5 mL, 953 mmol), pyridine (116 mL, 1430 mmol), and DCM (2000 mL). This solution was cooled to -5°C under N₂. The sulfamoyl chloride solution was added slowly via Teflon tube over 10 min. After the addition, the reaction was stirred for 15 min then the ice bath was removed and the reaction mixture allowed to warm to room temperature. As the reaction progressed, a gummy material formed. The material was purified via silica gel chromatography (300 g silica gel eluting with DCM). Obtained 4-methyl-5H-1,2,3-oxathiazole 2,2-dioxide (72.4 g, 536 mmol, 56 % yield) as a colorless solid. ¹H NMR (400MHz, CHLOROFORM-d) δ 5.09 (s, 2H), 2.44 (s, 3H); LCMS (ESI) *m/e* 136.0 [(M+H)⁺, calcd for C₃H₆NO₃S 136.0].



Part B. 2-(tert-butoxycarbonylamino)-2,4-dimethylpentanoic acid 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine 2,2-dioxide

A suspension of 4-methyl-5H-1,2,3-oxathiazole 2,2-dioxide (0.541 g, 4 mmol) in methyl *tert*-butyl ether (30 mL) was cooled below 0 °C with an ice/IPA bath. To the cooled solution was added a solution of (2-methylallyl)magnesium

chloride, 0.5 M in THF (9.60 mL, 4.80 mmol). The reaction mixture was allowed to warm to rt overnight. It was then quenched with a saturated solution of NH₄Cl (50 mL) and EtOAc (20 mL) was added. The organic phase was separated, washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 2-(*tert*-butoxycarbonylamino)-2,4-dimethylpentanoic acid 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine 2,2-dioxide (0.567 g, 2.96 mmol, 74 % yield). ¹H NMR (400MHz, CHLOROFORM-*d*) δ 5.06 (quin, *J*=1.5 Hz, 1H), 4.87 (dd, *J*=1.7, 0.8 Hz, 1H), 4.50 (br. s., 1H), 4.40 (d, *J*=8.6 Hz, 1H), 4.29 (d, *J*=8.7 Hz, 1H), 2.56 (d, *J*=13.8 Hz, 1H), 2.40 - 2.30 (m, 1H), 1.86 (br. s, 3H), 1.49 (s, 3H); LCMS (ESI) *m/e* 192.1 [(M+H)⁺, calcd for C₇H₁₄NO₃S 192.1].



Part C. benzyl 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide


To a N₂ flushed, 100 mL round-bottomed flask was added a solution of 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine 2,2-dioxide (0.55 g, 2.88 mmol) in THF (10 mL). A solution of potassium *tert*-butoxide (4.31 mL, 4.31 mmol) in THF was added. The temperature rose to 27 °C and the solution became a suspension. The mixture was stirred at room temperature for 1 h. Benzyl carbonochloridate (1.026 mL, 7.19 mmol) was added slowly. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then quenched with water (50 mL) and extracted with EtOAc (2x70 mL). The organic extracts were washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give benzyl 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (0.66 g, 2.028 mmol, 71 % yield). ¹H NMR (400MHz, CHLOROFORM-*d*) δ 7.58 - 7.32 (m, 5H), 5.43 - 5.25 (m, 2H), 5.01 (t, *J*=1.5 Hz, 1H), 4.81 (d, *J*=0.9 Hz, 1H), 4.63 (d, *J*=9.5 Hz, 1H), 4.21 (d, *J*=9.5 Hz, 1H), 2.87 (d, *J*=14.1 Hz, 1H), 2.56 (d, *J*=14.1 Hz, 1H), 1.78 (br. s, 3H), 1.64 (s, 3H); LCMS (ESI) *m/e* 326.1 [(M+H)⁺, calcd for C₁₅H₂₀NO₅S 326.1].

The racemic compounds was separated by chiral super critical fluid chromatography (Column: OJ-H (3x25cm, 5 μ m); Mobile Phase: CO₂/ MeOH (90/10)) to give the two enantiomers.

Analytical super critical fluid chromatography conditions: Column: OJ-H (0.46x25cm, 5 μ m); BPR pressure: 100 bars; Temperature: 35 °C; Flow rate: 3.0 mL/min; Mobile Phase: CO₂/ MeOH (90/10); Detector Wavelength: UV 200-400nm


Enantiomer 1: (*S*)-benzyl 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide HPLC retention time = 2.53 min.

Enantiomer 2: (*R*)-benzyl 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide HPLC retention time = 2.97 min.




Part D. (S)-4-isobutyl-4-methyl-1,2,3-oxathiazolidine 2,2-dioxide

To a stirred solution of (*S*)-benzyl 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (800 mg, 2.459 mmol) in MeOH (20 mL) was added Pd/C (262 mg, 0.246 mmol) under a nitrogen atmosphere. The reaction mixture was stirred under 1 atm hydrogen pressure for 16 h. The reaction mixture was passed through diatomaceous earth pad and the diatomaceous earth pad was washed with EtOAc (15 mL). The organic layer was evaporated under reduced pressure to afford (*S*)-4-isobutyl-4-methyl-1,2,3-oxathiazolidine 2,2-dioxide (462 mg, 2.39 mmol, 97% yield, 95% purity) as colorless oil. The material was carried forward without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.69 (br, 1H) 4.33 (d, *J*=8.03 Hz, 1 H) 4.17 - 4.26 (m, 1 H) 1.68 - 1.81 (m, 1 H) 1.53 - 1.63 (m, 1 H) 1.43 - 1.51 (m, 1 H) 1.34 (s, 3 H) 0.81 - 1.00 (m, 6 H).



Part E. (S)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide


To a stirred solution of (S)-4-isobutyl-4-methyl-1,2,3-oxathiazolidine 2,2-dioxide (7 g, 15.21 mmol) in DCM (70 mL) cooled to 0 °C was added DMAP (1.858 g, 15.21 mmol) and (BOC)₂O (5.30 mL, 22.82 mmol). The reaction mixture was stirred at rt for 12 h. The reaction mixture was transferred to a separating funnel containing water (20 mL) and was extracted with DCM (2 x 60 mL). The combined organic layers were washed with brine (50 mL), dried over (Na₂SO₄), and concentrated under reduced pressure. The residue was purified via silica gel chromatography (30 % ethyl acetate in pet ether) to afford (S)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (4.4 g, 14.70 mmol, 97 % yield) as a colorless oil. ¹H NMR (400 MHz, CHLOROFORM-d) δ 4.45 (d, J=9.0 Hz, 1H), 4.20 (d, J=9.0 Hz, 1H), 2.07 - 1.98 (m, J=8.0 Hz, 1H), 1.83 - 1.69 (m, 2H), 1.59 (s, 3H), 1.56 (s, 9H), 0.99 (dd, J=8.0, 6.5 Hz, 6H).



Part F. (S)-tert-butyl (1-(4-bromo-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate


A solution of 4-bromo-2-fluorophenol (0.651 g, 3.41 mmol) in DMF (15 mL) was treated with Cs₂CO₃ (2.22 g, 6.82 mmol). The mixture was stirred for 40 min at RT. (S)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (1 g, 3.41 mmol) was added to the solution and the mixture was heated at 80 °C overnight. It was concentrated, diluted with brine and ethyl acetate. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford an oil. The crude product was purified by silica-gel chromatography (5-20% EtOAc-hexane) to afford (S)-tert-butyl (1-(4-bromo-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (1.13 g, 94% yield) as a colorless oil. LCMS (ESI) *m/e* 304.0 [(M+H-Boc)⁺, calcd for C₁₈H₂₈BrFNO₃ 404.1]; LC/MS retention time (method D): *t_R* = 2.81 min. De-Boc mass was detected by LCMS. ¹H NMR (300 MHz, CDCl₃): δ 7.11-

7.28 (m, 2H), 6.84-6.93 (m, 1H), 3.96-4.18 (m, 2H), 1.75-1.85 (m, 2H), 1.49-1.55 (m, 1H), 1.39 (s, 3H), 1.31-1.38 (m, 9H), 0.91-1.01 (m, 6H) ppm.



5 *Part G: (S)-tert-butyl (1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A solution of 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 0.450 mmol), (*S*)-tert-butyl (1-(4-bromo-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (182 mg, 0.450 mmol), and XPhos 2nd generation
 10 precatalyst (333 mg, 0.450 mmol) in tetrahydrofuran (8 mL) was purged with argon for 5 min. A solution of cesium carbonate (293 mg, 0.901 mmol) in water (1 mL) was added and the reaction mixture was stirred at 70 °C for 14 h. The reaction mixture was allowed to cool to room temperature. Water (15 mL) was added and the solution extracted with EtOAc (2 x 20 mL). The combined organic extracts were
 15 washed with brine (25 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by prep.TLC (30% EtOAc in hexanes). The fractions containing product were collected and stirred in DCM (25 mL), passed through diatomaceous earth pad and the diatomaceous earth pad was washed with DCM (20 mL). The combined filtrate was
 20 collected and concentrated under reduced pressure to afford (*S*)-tert-butyl (1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (100 mg, 0.231 mmol, 51% yield) as a white solid. LCMS (ESI) *m/e* 420.2 [(M+H)⁺, calcd for C₂₃H₃₅FN₃O₃, 420.3]; LC/MS retention time (method A1) *t*_R = 2.59 min.





Part H: (S)-1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-amine

To a stirred solution of (S)-tert-butyl (1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (100 mg, 0.231 mmol) in DCM (2 mL) cooled to 0 °C was added TFA (0.3 mL, 3.89 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The solution was concentrated under reduced pressure, residue obtained as yellow oil was purified via preparative LC/MS (method A). Obtained (S)-1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-amine (27 mg, 0.084 mmol, 36% yield) as a pale yellow solid.

¹H NMR (300 MHz, METHANOL-*d*₄) δ 7.24 (s, 1H), 7.09 (s, 2H), 4.12 (d, *J* = 15.1 Hz, 2H), 2.24 (s, 6H), 1.91 - 1.76 (m, 2H), 1.73 - 1.59 (m, 1H), 1.47 (s, 3H), 1.06 (dd, *J* = 6.6, 7.4 Hz, 6H) ppm. ¹⁹F NMR (300MHz, METHANOL-*d*₄) δ -135.4. LCMS (ESI) *m/e* 320.2 [(M+H)⁺, calcd for C₁₈H₂₇FN₃O, 320.2]; LC/MS retention time (method H) *t*_R = 1.06 min. LCMS (ESI) *m/e* 320.0 [(M+H)⁺, calcd for C₁₈H₂₇FN₃O, 320.2]; LC/MS retention time (Method E) *t*_R = 0.84 min.

Example 252


(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2,3-dimethylpyrido[2,3-*b*]pyrazin-8-yl)benzonitrile



Part A: 8-bromo-2,3-dimethylpyrido[2,3-*b*]pyrazine


To a stirred solution of biacetyl (68.7 mg, 0.798 mmol) and 4-bromopyridine-2,3-diamine (150 mg, 0.798 mmol) in ethanol (4 mL) was added acetic acid (0.2 mL) under a nitrogen atmosphere. The reaction mixture was heated at 95 °C for 2 h. The reaction mixture was allowed to cool to room temperature and concentrated under

reduced pressure. Water (10 mL) was added and the solution extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 8-bromo-2,3-dimethylpyrido[2,3-*b*]pyrazine (125 mg, 0.525 mmol, 66% yield) as a brown solid. The product was
 5 carried forward without further purification. ¹H NMR (400 MHz, CDCl₃): δ 8.16 (d, *J* = 11.20 Hz, 1H), 7.74 (d, *J* = 11.60 Hz, 1H), 2.80 (s, 3H), 2.76 (s, 3H) ppm.




Part B: (S)-tert-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate
 10

(*S*)-tert-butyl (1-(4-bromo-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.57 g, 1.386 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (0.422 g, 1.663 mmol), PdCl₂(dppf) (0.051 g, 0.069 mmol), potassium acetate (0.408 g, 4.16 mmol), and dioxane (5 mL) were charged to a
 15 pressure rated vial. The vial was purged of oxygen and the mixture stirred under nitrogen at 80 °C overnight. The mixture was cooled to ambient temperature, vacuum filtered, and concentrated under reduced pressure. Obtained (*S*)-tert-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (600 mg, 1.30 mmol, 100% crude yield) as a brown
 20 oil that was used without further purification. LCMS (ESI) *m/e* 481.1 [(*M*+Na)⁺, calcd C₂₅H₃₉BN₂NaO₅, 481.3]; LC/MS retention time (method A2): *t_R* = 2.49 min.



*Part C: (S)-tert-butyl (1-(2-cyano-4-(2,3-dimethylpyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*
 25

A stirred solution of 8-bromo-2,3-dimethylpyrido[2,3-*b*]pyrazine (75 mg, 0.315 mmol), (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (142 mg, 0.315 mmol) and XPhos 2nd generation precatalyst (12.39 mg, 0.016 mmol) in tetrahydrofuran (8 mL) was
 5 purged with nitrogen for 2 min. To this mixture was added a solution of cesium carbonate (205 mg, 0.630 mmol) in water (0.5 mL) and the reaction mixture was stirred at 75 °C under a nitrogen atmosphere for 14 h. Water (30 mL) was added and the solution was extracted with EtOAc (2 x 15 mL). The combined organic extracts were washed with brine (20 mL). The organic layer was dried over sodium sulfate,
 10 filtered, and concentrated under reduced pressure. The residue was purified via prep.TLC (mobile phase of 50 % EtOAc in hexanes). Fractions containing the product were collected and stirred in DCM (25 mL), passed through diatomaceous earth pad and the diatomaceous earth pad was washed with DCM (20 mL). The filtrate was collected and concentrated under reduced pressure to afford ((*S*)-*tert*-
 15 butyl (1-(2-cyano-4-(2,3-dimethylpyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (106 mg, 0.149 mmol, 47% yield) as a pale brown solid. LCMS (ESI) *m/e* 490.2 [(M+H)⁺, calcd for C₂₈H₃₆N₅O₃, 490.3]; LC/MS retention time (Method F) *t*_R = 2.38 min



20


*Part D: (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2,3-dimethylpyrido[2,3-*b*]pyrazin-8-yl)benzonitrile*

To a stirred solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(2,3-dimethylpyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (100 mg, 0.141 mmol)
 25 in DCM (5 mL) cooled to 0 °C was added TFA (0.25 mL, 3.24 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 h. The solution was concentrated under reduced pressure to afford a brown oil. The crude material was purified via preparative HPLC using method-B to afford (*S*)-
 30 2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2,3-dimethylpyrido[2,3-*b*]pyrazin-8-yl)benzonitrile (22 mg, 39%) as a pale yellow solid. ¹H NMR (400MHz,


METHANOL-*d*₄) δ 8.71 - 8.60 (m, 2H), 8.56 - 8.46 (m, 1H), 8.40 - 8.32 (m, 1H), 7.49 (d, J = 9.0 Hz, 1H), 4.36 (d, J = 4.0 Hz, 2H), 2.86 (s, 3H), 2.83 (s, 3H), 2.02 - 1.86 (m, 2H), 1.80 - 1.71 (m, 1H), 1.58 (s, 3H), 1.10 (m, 6H). LCMS (ESI) m/e 390.0 [(M+H)⁺, Calcd for C₂₃H₂₇N₅O, 390.2]; LC/MS retention time (Method E) t_R = 1.15 min.

Example 253

(*S*)-1-(2-fluoro-4-(pyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine




10




Part A: 8-Bromopyrido[2,3-*b*]pyrazine

To a stirred solution of 4-bromopyridine-2,3-diamine (100 mg, 0.532 mmol) and oxalaldehyde (30.9 mg, 0.532 mmol) in EtOH (4 mL) was added acetic acid (0.4 mL) under a nitrogen atmosphere. The reaction mixture was heated at 95 °C for 2 h. The reaction mixture was allowed to cool to room temperature, concentrated under reduced pressure and diluted with water (10 mL). The solution was extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 8-bromo-2,3-dimethylpyrido[2,3-*b*]pyrazine (125 mg, 0.525 mmol, 66% yield) as a brown solid in good purity based on ¹H NMR. The product was carried forward without further purification. ¹H NMR (300 MHz, CDCl₃): δ 9.08 (d, J = 1.8 Hz, 1H), 8.98 (d, J = 1.8 Hz, 1H), 8.32 (d, J = 8.7 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H) ppm.



Part B: (S)-tert-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate


A mixture of (*S*)-*tert*-butyl (1-(4-bromo-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (1.751 g, 4.33 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.1 g, 4.33 mmol), and potassium acetate (0.850 g, 8.66 mmol) in 1,4-dioxane (20 mL) was heated at 90 °C overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water and ethyl acetate. The ethyl acetate layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a yellowish semi-solid. The residue was purified by silica gel chromatography (5-10% EtOAc-hexane) to obtain (*S*)-*tert*-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate as colorless oil (1.7 g, 3.77 mmol, 87% yield). LCMS (ESI) *m/e* 352.2 [(M+H-Boc)⁺, calcd for C₂₄H₄₀BFNO₅ 452.2]; LC/MS retention time (method B): *t_R* = 1.33 min. De-Boc mass was detected by LCMS. ¹H NMR (400 MHz, CDCl₃) : δ 7.45-7.49 (m, 2H), 6.94-6.98 (m, 1H), 4.60 (bs, NH, 1H), 4.16 (m, 1H), 4.00 (m, 1H), 1.82 (m, 2H), 1.60 (m, 1H), 1.59 (s, 3H), 1.39 (s, 9H), 1.24 (s, 12H), 0.92-0.99 (m, 6H) ppm.



Part C: (S)-tert-butyl (1-(2-fluoro-4-(pyrido[2,3-b]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A stirred solution of 8-bromopyrido[2,3-*b*]pyrazine (75 mg, 0.357 mmol), (*S*)-*tert*-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (161 mg, 0.357 mmol) and XPhos 2nd generation precatalyst (14.05 mg, 0.018 mmol) in tetrahydrofuran (8 mL) was purged with

nitrogen for 2 min. To this mixture, a solution of cesium carbonate (233 mg, 0.714 mmol) in water (0.5 mL) was added and the reaction mixture was stirred at 75 °C under a nitrogen atmosphere for 14 h. Water (30 mL) was added and the solution was extracted with EtOAc (2 x 15 mL). The combined organic extracts were washed with brine (20 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by prep.TLC (mobile phase of 50% EtOAc in hexanes). Fractions containing the product were collected and stirred in DCM (25 mL), passed through diatomaceous earth pad, and the diatomaceous earth pad was washed with DCM (20 mL). The filtrate was collected and concentrated under reduced pressure to afford (*S*)-*tert*-butyl 1-(2-fluoro-4-(pyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (110 mg, 0.145 mmol, 41% yield) as a yellow solid. LCMS (ESI) *m/e* 455.2 [(M+H), calc for C₂₅H₃₂FN₄O₃, 455.2]; LC/MS retention time (Method A1): *t_R* = 2.40 min.



*Part D: (S)-1-(2-fluoro-4-(pyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine*



To a stirred solution of (*S*)-*tert*-butyl 1-(2-fluoro-4-(pyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (100 mg, 0.220 mmol) in DCM (5 mL) cooled to 0 °C was added TFA (1 mL, 12.98 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The solution was concentrated under reduced pressure to afford a brown oil which was purified via preparative HPLC using method-A. The purification afforded (*S*)-1-(2-fluoro-4-(pyrido[2,3-*b*]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine (2.7 mg, 7.08 μmol, 3% yield) as a pale yellow solid.

¹H NMR (400MHz, METHANOL-*d*₄) δ 9.10 (d, *J* = 1.5 Hz, 1H), 9.00 (d, *J* = 2.0 Hz, 1H), 8.66 - 8.56 (m, 1H), 8.45 (d, *J* = 8.5 Hz, 1H), 8.22 (dd, *J* = 2.5, 12.5 Hz, 1H), 8.15 - 8.12 (m, 1H), 7.35 (t, *J* = 8.5 Hz, 1H), 4.04 - 3.90 (m, 2H), 1.91 - 1.82 (m, 2H), 1.60 (d, *J* = 5.5 Hz, 1H), 1.34 (s, 3H), 1.04 (m, 6H). LCMS (ESI) *m/e* 355.0

$[(M+H)^+]$, Calcd for $C_{20}H_{24}FN_4O$, 355.1; LC/MS retention time (method H) $t_R = 1.09$ min.


Example 254

- 5 (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-amino-3H-imidazo[4,5-b]pyridin-7-yl)benzonitrile




- 10 *Part A: 4-bromopyridine-2,3-diamine*

To a stirred solution of 4-bromo-2-nitropyridin-3-amine (1 g, 4.59 mmol) in a mixture of EtOH (20 mL) and water (5 mL) was added tin(IV) chloride (3.00 g, 11.52 mmol) over a period of 1 min. The reaction mixture was heated to 90 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature, then
 15 poured into saturated aq. sodium bicarbonate solution (50 mL) and extracted with DCM (2 x 100 mL). The combined organic extracts were washed with water (100 mL), brine (100 mL), organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 4-bromopyridine-2,3-diamine (460 mg, 2.446 mmol, 53% yield) as a pale brown solid. The compound was taken to the
 20 next step without further purification. LCMS (ESI) m/e 187.9 $[(M+H)^+]$, calcd for $C_5H_7BrN_3$, 187.9; LC/MS retention time (Method C) $t_R = 0.52$ min.



- 25 *Part B: (S)-tert-butyl (1-(4-bromo-2-formylphenoxy)-2,4-dimethylpentan-2-yl)carbamate.*


To a 20 mL vial was added 5-bromo-2-hydroxybenzaldehyde (81 mg, 0.403 mmol), (*S*)-*tert*-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (107.4 mg, 0.366 mmol), and K₂CO₃ (152 mg, 1.098 mmol) in DMF (1.2 mL) to give a white suspension. The vial was sealed and the mixture was heated at 80 °C for 17 h. The reaction mixture was cooled to rt and partitioned between water and EtOAc. The layers were separated. The organic layer was washed with water, brine, dried (Na₂SO₄) and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (up to 40% EtOAc/hexanes) to afford (*S*)-*tert*-butyl (1-(4-bromo-2-formylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (115 mg, 0.278 mmol, 76%) as a colorless oil. ¹H NMR (400 MHz, Chloroform-d) δ 10.43 (s, 1H), 7.89 (d, *J* = 2.6 Hz, 1H), 7.59 (dd, *J* = 8.9, 2.6 Hz, 1H), 6.93 (d, *J* = 8.8 Hz, 1H), 4.58 (s, 1H), 4.29 (d, *J* = 8.8 Hz, 1H), 4.09 (d, *J* = 8.8 Hz, 1H), 1.94 - 1.74 (m, 2H), 1.48 (dd, *J* = 13.9, 4.8 Hz, 1H), 1.39 (s, 3H), 1.37 (s, 9H), 0.98 (dd, *J* = 6.6, 4.8 Hz, 6H); (ESI) *m/e* 314.0, 316.0 Br pattern [(M-Boc+H)⁺, calcd C₁₄H₂₁BrNO₂, 414.1]; LC/MS retention time (method A2): *t*_R = 2.39 min.



Part C. (*S*)-*tert*-butyl (1-(2-cyano-4-(2,3-diaminopyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate


To a stirred solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (100 mg, 0.218 mmol), 4-bromopyridine-2,3-diamine (41.0 mg, 0.218 mmol) and cesium carbonate (142 mg, 0.436 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was added XPhos 2nd generation precatalyst (17.16 mg, 0.022 mmol) under a nitrogen atmosphere. The reaction mixture was heated at 95 °C for 2 h. The solution was concentrated under reduced pressure, water (20 mL) was added and the solution extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (50 mL) and brine (20 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica

gel chromatography (EtOAc in hexanes) to afford (*S*)-*tert*-butyl (1-(2-cyano-4-(2,3-diaminopyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (92 mg, 0.180 mmol, 83% yield). The product was carried forward without further purification. LCMS (ESI) m/e 384.2 [(M+H)⁺, calcd for C₂₄H₃₄N₅O₃, 440.3]; LC/MS retention time (method B) t_R = 0.91 min.



Part D. (S)-tert-butyl (1-(4-(2-amino-3H-imidazo[4,5-b]pyridin-7-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate

To a stirred solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(2,3-diaminopyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (90 mg, 0.176 mmol) in a mixture of methanol (10 mL) and water (1 mL) was added cyanic bromide (24.25 mg, 0.229 mmol) under nitrogen atmosphere and the reaction mixture was allowed to stirred at room temperature for 12 h. The solution was concentrated under reduced pressure. Water (15 mL) was added and the solution was extracted with EtOAc (2 x 25 mL). The combined organic extracts were washed with water (20 mL), organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(4-(2-amino-3H-imidazo[4,5-b]pyridin-7-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate (83 mg, 0.168 mmol, 95% yield) as a pale brown solid. The product was carried forward without further purification. LCMS (ESI) m/e 465.3 [(M+H)⁺ calcd for C₂₅H₃₃N₆O₃, 465.3]; LC/MS retention time (method B) t_R = 0.93 min.




Part E: (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-amino-3H-imidazo[4,5-b]pyridin-7-yl)benzonitrile

To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2-amino-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate (82 mg, 0.166 mmol) in CH₂Cl₂ (6 mL) cooled to 0 °C was added TFA (0.3 mL, 3.89 mmol). The reaction mixture was allowed to stir at room temperature for 3 h. The solution was concentrated under reduced pressure. The residue was purified via preparative LC/MS (method-A) to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-amino-3*H*-imidazo[4,5-*b*]pyridin-7-yl)benzonitrile (19 mg, 0.052 mmol, 31% yield) as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.37 - 8.20 (m, 2H), 7.70 - 7.43 (m, 2H), 7.31 (d, *J* = 9.0 Hz, 1H), 4.16 (d, *J* = 3.5 Hz, 2H), 1.93 - 1.77 (m, 2H), 1.70 - 1.62 (m, 1H), 1.44 (s, 3H), 1.06 (m, 6H). LCMS (ESI) *m/e* 365.0 [(*M*+*H*)⁺, calcd for C₂₀H₂₅N₆O, 365.2]; LC/MS retention time (method H) *t*_R = 0.95 min. LCMS (ESI) *m/e* 365.0 [(*M*+*H*)⁺, calcd for C₂₀H₂₅N₆O, 365.2]; LC/MS retention time (Method E) *t*_R = 0.78 min.

15

Example 255

(*S*)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine




20

Part A: (S)-Tert-butyl (1-(4-bromo-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

To a mixture of 4-bromo-2-(trifluoromethyl) phenol (4 g, 16.60 mmol) in DMF (50 mL) cooled at 0 °C, was added K₂CO₃ (6.88 g, 49.8 mmol) in portions followed by slow addition of (*S*)-*tert*-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (5.36 g, 18.26 mmol) in 10 mL DMF. The reaction mixture was slowly

allowed to warm to room temperature then stirred at 80 °C for 12 h. The reaction mixture was cooled to 0 °C and quenched with aqueous ammonium chloride (100 mL). The reaction mixture was extracted with ethyl acetate (2 x 100 mL). The organic layer was washed with water (2 x 50 mL), brine (50 mL), dried over Na₂SO₄, and concentrated to afford crude (*S*)-*tert*-butyl (1-(4-bromo-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (6.5 g, 13.16 mmol, 79% yield) as a colorless oil which was carried forward without further purification. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.74-7.81 (m, 2H), 7.19 (d, *J* = 8.80 Hz, 1H), 6.52 (s, 1H), 4.02-4.24 (m, 2H), 1.69-1.80 (m, 2H), 1.41-1.50 (m, 1H), 1.40 (s, 9H), 1.25 (s, 3H), 0.83-0.96 (m, 6H) ppm.




Part B: (S)-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A solution of (*S*)-*tert*-butyl (1-(4-bromo-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (6.5 g, 14.31 mmol), bis(pinacolato)diboron (7.27 g, 28.6 mmol), potassium acetate (4.21 g, 42.9 mmol) in 1,4-dioxane (100 mL) was purged with argon for 5 min. PdCl₂ (dppf)-CH₂Cl₂ adduct (1.168 g, 1.431 mmol) was added to the reaction mixture under argon and was heated at 84 °C for 14 h. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth bed was washed with ethyl acetate (200 mL). The organic layer was washed with water (100 mL). The aqueous layer was re-extracted with ethyl acetate (2X100 mL). The organic layer was collected, washed with brine, dried over Na₂SO₄, and concentrated which afforded crude (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate. The crude product was dissolved in 50 mL of DCM, adsorbed on silica gel (60-120), purified silica gel chromatography (0-15% of ethyl acetate/hexane) to give (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (6.01 g, 11.99

mmol, 84% yield) as a off-white semi-solid. ¹H NMR (400 MHz, DMSO-d₆): δ 7.87-7.90 (m, 1H), 7.80 (s, 1H), 7.21 (d, *J* = 8.40 Hz, 1H), 6.53 (s, 1H), 4.07-4.25 (m, 2H), 1.70-1.79 (m, 2H), 1.45-1.50 (m, 1H), 1.26-1.35 (m, 9H), 1.08-1.20 (m, 12H), 0.82-0.91 (m, 6H) ppm.


5



Part C: (S)-tert-butyl (1-(4-(2,3-diaminopyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate


To a stirred solution of (*S*)-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (100 mg, 0.199 mmol), 4-bromopyridine-2,3-diamine (37.5 mg, 0.199 mmol) and cesium carbonate (130 mg, 0.399 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was added XPhos 2nd generation precatalyst (15.69 mg, 0.020 mmol) under a nitrogen atmosphere. The reaction mixture was heated at 95 °C for 2 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. Water (20 mL) was added and the solution extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (50 mL) and brine (20 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford (*S*)-tert-butyl (1-(4-(2,3-diaminopyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (71 mg, 0.068 mmol, 34% yield) as a brown oil. LCMS (ESI) *m/e* 483.2 [(M+H)⁺, calcd for C₂₄H₃₄F₃N₄O₃, 483.2]; LC/MS retention time (method B) *t_R* = 0.97 min.

25



Part D: (S)-tert-butyl (1-(4-(2-amino-3H-imidazo[4,5-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2,3-diaminopyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (70 mg, 0.145 mmol) in a mixture of MeOH (4 mL) and water (0.5 mL) was added cyanic bromide (23.05 mg, 0.218 mmol) under a nitrogen atmosphere. The reaction mixture was allowed to stir at room temperature for 12 h. The solution was concentrated under reduced pressure. The brown solid obtained was washed with diethyl ether (2 x 8 mL). the solid was collected by vacuum filtration and dried under vacuum at room temperature to afford (*S*)-*tert*-butyl (1-(4-(2-amino-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (83 mg, 0.082 mmol, 56% yield) as a brown solid. The product was carried forward without further purification. LCMS (ESI) *m/e* 508.2 [(*M*+*H*)⁺, calcd for C₂₅H₃₃F₃N₅O₃, 508.2]; LC/MS retention time (Method F) *t_R* = 2.06 min.




*Part E: (S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine*


To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2-amino-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.079 mmol) in DCM (3 mL) cooled to 0 °C was added TFA (0.25 mL, 3.24 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (*S*)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine (5.9 mg, 0.014 mmol, 18% yield) as a pale yellow solid. ¹H NMR (400MHz, METHANOL-*d*₄) δ 8.32 (d, *J* = 2.0 Hz, 1H), 8.27 - 8.18 (m, 1H), 7.59 - 7.45 (m, 2H), 7.33 (d, *J* = 9.0 Hz, 1H), 4.30 - 4.13 (m, 2H), 1.98 - 1.81 (m, 2H), 1.71 (d, *J* = 8.5 Hz, 1H), 1.51 (s, 3H), 1.06 (m, 6H) ppm. LCMS (ESI) *m/e* 408.2 [(*M*+*H*)⁺, calcd for C₂₀H₂₅F₃N₅O, 408.2]; LC/MS retention time (method H) *t_R* = 1.23 min. LCMS (ESI) *m/e* 408.0 [(*M*+*H*)⁺, calcd for C₂₀H₂₅F₃N₅O, 408.2]; LC/MS retention time (method I) *t_R* = 0.91 min.

Example 256

(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazol-2-amine




5



Part A: 4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-amine

A stirred solution of 4-chloropyridin-2-amine (100 mg, 0.778 mmol) and (4-methoxy-3-(trifluoromethyl)phenyl)boronic acid (171 mg, 0.778 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen for 2 min. To this mixture, XPhos 2nd generation precatalyst (61.2 mg, 0.078 mmol) under a nitrogen atmosphere was added and the reaction mixture was heated at 95 °C for 2 h. The reaction mixture was allowed to cool to room temperature. Water (15 mL) was added and the solution was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (20 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford 4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-amine (145 mg, 0.492 mmol, 63% yield) as a yellow solid. LCMS (ESI) *m/e* 269.1 [(M+H)⁺, calcd for C₁₃H₁₂F₃N₂O, 269.0]; LC/MS retention time *t_R* = 0.70 min.


20



Part B: N-((4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)carbamothioyl)benzamide


25

To a stirred solution of 4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-amine (140 mg, 0.522 mmol) in acetone (30 mL) was added benzoyl isothiocyanate (94 mg, 0.574 mmol) dropwise at room temperature under a nitrogen atmosphere. The reaction mixture was heated at 65 °C for 2 h. The reaction mixture was allowed
 5 to cool to room temperature and poured in 50 g of ice. The solid obtained was collected by vacuum filtration. The solid was washed with water (2 x 50 mL) then dried under vacuum at room temperature to afford *N*-((4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)carbamothioyl)benzamide (220 mg, 0.408 mmol, 78% yield) as a yellow solid. The product was carried forward without further
 10 purification. LCMS (ESI) *m/e* 430.0 [(M-H)⁻, Calcd for C₂₁H₁₅F₃N₃O₂S, 430.1]; LC/MS retention time (method A1) *t_R* = 3.20 min.




Part C: 1-(4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiourea

To a stirred solution of *N*-((4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)carbamothioyl)benzamide (210 mg, 0.487 mmol) in methanol (25 mL) was added a solution of sodium hydroxide (78 mg, 1.947 mmol) in water (5 mL) at room temperature and the reaction mixture was heated to 65 °C for 2 h. The reaction mixture was poured in 40 g of ice and the pH of the mixture was adjusted to pH 7
 20 with (1.5 N aq. HCl solution). The solid obtained was collected by vacuum filtration and dried under vacuum to afford 1-(4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiourea (169 mg, 0.454 mmol, 93% yield) as a pale brown solid. The product was carried forward without further purification. LCMS (ESI) *m/e* 328.0 [(M+H)⁺ Calcd for C₁₄H₁₃F₃N₃OS, 328.1]; LC/MS retention
 25 time (Method F) *t_R* = 2.18 min.




Part D: N-(4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazol-2-amine

To a stirred solution of 1-(4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiourea (167 mg, 0.449 mmol) in EtOH (20 mL) was added chloroacetaldehyde (50% solution in water) (1.5 mL, 0.449 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was heated at 85 °C for 4 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The mixture was added to 20 g of ice and the solid obtained was collected by vacuum filtration. The solid was washed with water (2 x 10 mL) then dried under vacuum to afford *N*-(4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazol-2-amine (162 mg, 0.424 mmol, 94% yield) as an off white solid. The product was used as is to the next step without further purification. LCMS (ESI) m/e 352.0 [(M+H)⁺], calcd for C₁₆H₁₃F₃N₃OS, 352.1]; LC/MS retention time (method B) t_R = 0.84 min.




Part E: 4-(2-(thiazol-2-ylamino)pyridin-4-yl)-2-(trifluoromethyl)phenol

To a stirred solution of *N*-(4-(4-methoxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazol-2-amine (160 mg, 0.419 mmol) in dichloromethane (6 mL) cooled to 0 °C was added BBr₃ (1M in DCM) (1.2 mL, 1.200 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was cooled to 0 °C and dry MeOH (15 mL) was slowly added. The reaction mixture was then stirred for 10 min. The solution was concentrated under reduced pressure to afford 4-(2-(thiazol-2-ylamino)pyridin-4-yl)-2-(trifluoromethyl)phenol (125 mg, 0.274 mmol, 66% yield) as a pale yellow solid. The product was carried forward without further purification. LCMS (ESI) m/e 338.0 [(M+H)⁺], calcd for C₁₅H₁₁F₃N₃OS, 338.1]; LC/MS retention time (Method F) t_R = 1.99 min.



Part F: (S)-tert-butyl (2,4-dimethyl-1-(4-(2-(thiazol-2-ylamino)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

To a stirred solution of 4-(2-(thiazol-2-ylamino)pyridin-4-yl)-2-(trifluoromethyl)phenol (120 mg, 0.356 mmol) and potassium carbonate (49.2 mg, 0.356 mmol) in DMF (10 mL) was stirred under a nitrogen atmosphere for 15 min. A solution of (*S*)-*tert*-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (104 mg, 0.356 mmol) in DMF (1 mL) was added and the reaction mixture was heated at 80 °C for 14 h. The solution was concentrated under reduced pressure. Water (50 mL) was added and the solution extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(2-(thiazol-2-ylamino)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (110 mg, 0.086 mmol, 24% yield) as a brown solid. The product was carried forward without further purification. LC/MS method L, LCMS (ESI) *m/e* 551.2 [(M+H)⁺, calcd for C₂₇H₃₄F₃N₄O₃S, 551.2]; LC/MS retention time *t_R* = 2.72 min.




Part G: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazol-2-amine

A stirred solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(2-(thiazol-2-ylamino)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (108 mg, 0.196 mmol) in dichloromethane (3 mL) was cooled to 0 °C under a nitrogen atmosphere was added TFA (0.15 mL, 1.96 mmol) and the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazol-2-amine (54.8 mg, 0.114 mmol, 58% yield) as a pale yellow solid. ¹H NMR (400MHz

,METHANOL- d_4) δ = 8.38 (d, J = 5.5 Hz, 1H), 8.04 - 7.93 (m, 2H), 7.41 - 7.31 (m, 2H), 7.29 (d, J = 1.0 Hz, 1H), 7.22 (dd, J = 1.5, 5.5 Hz, 1H), 6.97 - 6.93 (m, 1H), 4.08 - 3.98 (m, 2H), 1.96 - 1.79 (m, 1H), 1.70 - 1.53 (m, 2H), 1.32 (s, 3H), 1.02 (m, 6H). LCMS (ESI) m/e 451.0 [(M+H)⁺, calcd for C₂₂H₂₆F₃N₄OS, 451.2]; wavelength 220 nm, LC/MS retention time (method H) t_R = 2.04 min. LCMS (ESI) m/e 451.0 [(M+H)⁺, calcd for C₂₂H₂₆F₃N₄OS, 451.2]; wavelength 220 nm, LC/MS retention time (method I) t_R = 1.18 min.

Example 257

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazol-2-amine




Part A: 4-(3-chloro-4-methoxyphenyl)pyridin-2-amine

A stirred solution of 4-chloropyridin-2-amine (1 g, 7.78 mmol) and (3-chloro-4-methoxyphenyl)boronic acid (1.450 g, 7.78 mmol) in a mixture of 1,4-dioxane (15 mL) and water (3 mL) was purged with nitrogen for 2 min. To this mixture, XPhos 2nd generation precatalyst (0.612 g, 0.778 mmol) was added under a nitrogen atmosphere. The reaction mixture was heated at 95 °C for 2 h. The reaction mixture was allowed to cool to room temperature. Water (100 mL) was added and the solution was extracted with EtOAc (2 x 120 mL). The combined organic extracts were washed with brine (120 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography (EtOAc in hexanes) to afford 4-(3-chloro-4-methoxyphenyl)pyridin-2-amine (1.62 g, 4.62 mmol, 59% yield) as a yellow solid. LCMS (ESI) m/e 235.0 [(M+H)⁺, calcd for C₁₂H₁₂ClN₂O 235.1]; LC/MS retention time (method A1) t_R = 2.70 min.




Part B: N-((4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)carbamothioyl)benzamide

To a stirred solution of 4-(3-chloro-4-methoxyphenyl)pyridin-2-amine (1.5 g, 6.39 mmol) in acetone (30 mL) was added benzoyl isothiocyanate (1.147 g, 7.03 mmol) dropwise at room temperature under a nitrogen atmosphere. The reaction mixture was heated at 65 °C for 12 h. The reaction mixture was allowed to cool to room temperature and poured in 50 g of ice. The solid was collected by vacuum filtration and washed with water (2 x 50 mL), then dried under vacuum at room temperature to afford *N-((4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)carbamothioyl)benzamide* (2.1 g, 2.217 mmol, 35% yield) as a yellow solid. The product was carried forward without further purification. LCMS (ESI) m/e 398.0 [(M+H)⁺, calcd for C₂₀H₁₇ClN₃O₂S, 398.1]; LC/MS retention time (Method F) t_R = 2.47 min.




Part C: 1-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)thiourea

To a stirred solution of *N-((4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)carbamothioyl)benzamide* (2 g, 5.03 mmol) in methanol (25 mL) was added a solution of sodium hydroxide (0.804 g, 20.11 mmol) in water (5 mL) at room temperature. The reaction mixture was heated at 65 °C for 2 h. The reaction mixture was poured in 40 g of ice and the pH of the mixture was adjusted to pH 7 with (1.5 N aq. HCl solution). The solid obtained was collected by vacuum filtration and dried under vacuum to afford 1-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)thiourea (700 mg, 1.692 mmol, 34% yield) as a pale brown solid. The product was carried forward without further purification. LCMS (ESI) m/e 294.0 [(M+H)⁺ calcd for C₁₃H₁₃ClN₃OS, 294.0]; LC/MS retention time (method B) t_R = 0.87 min.



Part D: N-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)thiazol-2-amine


To a stirred solution of 1-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)thiourea (400 mg, 1.362 mmol) in EtOH (20 mL) was added chloroacetaldehyde (50% in
 5 water) (1.5 mL, 1.362 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was heated at 85 °C for 4 h. The reaction mixture was allowed to cool to room temperature then concentrated under reduced pressure. To this residue 20 g of ice was added and the solid obtained was collected by vacuum filtration. The solid was washed with water (2 x 10 mL) and dried under vacuum for afford *N*-(4-(3-
 10 chloro-4-methoxyphenyl)pyridin-2-yl)thiazol-2-amine (210 mg, 0.476 mmol, 35% yield) as an off white solid. The product was used as is for the next step without further purification. LCMS (ESI) m/e 318.0 [(M+H)⁺, calcd for C₁₅H₁₃ClN₃OS, 318.0]; LC/MS retention time (method B) t_R = 0.79 min.



15


Part E: 2-Chloro-4-(2-(thiazol-2-ylamino)pyridin-4-yl)phenol

To a stirred solution of *N*-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)thiazol-2-amine (200 mg, 0.453 mmol) in DCM (10 mL) cooled to -10 °C was added BBr₃ (1 mL, 10.58 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was
 20 allowed to warm to room temperature and stirred for 10 h. The reaction mixture was cooled to -10 °C, and dry MeOH (25 mL) was added dropwise and the solution stirred for 10 min. The solution was concentrated under reduced pressure. The yellow solid was used as is in the next step without further purification. LCMS (ESI) m/e 304.0 [(M+H)⁺, calcd for C₁₄H₁₁ClN₃OS, 304.0]; LC/MS retention time (method
 25 B) t_R = 0.68 min.



Part F: *(S)*-tert-butyl 1-(2-chloro-4-(2-(thiazol-2-ylamino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-ylcarbamate

A solution of 2-chloro-4-(2-(thiazol-2-ylamino)pyridin-4-yl)phenol (120 mg, 0.261 mmol) and potassium carbonate (36.0 mg, 0.261 mmol) in DMF (10 mL) was stirred under a nitrogen atmosphere for 15 min. To this mixture, a solution of (*S*)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (76 mg, 0.261 mmol) in (1 mL of DMF) was added and the reaction mixture was heated at 80 °C for 14 h. The solution was concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford (*S*)-tert-butyl 1-(2-chloro-4-(2-(thiazol-2-ylamino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-ylcarbamate (60 mg, 0.078 mmol, 30% yield) as colorless oil. The product was carried forward without further purification. LCMS (ESI) m/e 517.3 [(M+H)⁺, calcd for C₂₆H₃₄ClN₄O₃S, 517.2]; LC/MS retention time (method B) t_R = 1.09 min.





Part G: *(S)*-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazol-2-amine

To a stirred solution of (*S*)-tert-butyl 1-(2-chloro-4-(2-(thiazol-2-ylamino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-ylcarbamate (55 mg, 0.071 mmol) in DCM cooled to 0 °C was added TFA (0.2 mL, 2.60 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room

temperature and stirred for 2 h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazol-2-amine (7.2 mg, 0.017 mmol, 24% yield) as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ = 8.39 - 8.31 (m, 1H), 7.86 - 7.77 (m, 1H), 7.73 - 7.67 (m, 1H), 7.37 (s, 1H), 7.28 - 7.23 (m, 2H), 7.21 - 7.17 (m, 1H), 6.95 (s, 1H), 4.07 - 3.98 (m, 2H), 1.91 - 1.82 (m, 1H), 1.78 - 1.68 (m, 1H), 1.65 - 1.56 (m, 1H), 1.37 (s, 3H), 1.03 (m, 6H) ppm. LCMS (ESI) *m/e* 417.0 [(M+H)⁺, calcd for C₂₁H₂₆ClN₄OS 417.1]; LC/MS retention time (method H) *t*_R = 1.84 min. LCMS (ESI) *m/e* 417.0 [(M+H)⁺, calcd for C₂₁H₂₆ClN₄OS 417.1]; LC/MS retention time (method I) *t*_R = 1.12 min.

Example 258


(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazole-2-carboxamide



Part A: *N*-(4-chloropyridin-2-yl)thiazole-2-carboxamide

A solution of 4-chloropyridin-2-amine (200 mg, 1.556 mmol), thiazole-2-carbaldehyde (197 mg, 1.742 mmol) and copper(I) iodide (89 mg, 0.467 mmol) in DMF (3 mL) was heated at 80 °C for 24 h. The reaction mixture was allowed to cool to room temperature. Water (30 mL) was added and the solution was extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was washed with diethyl ether and the solid was collected by vacuum filtration and dried under vacuum at room temperature to afford *N*-(4-chloropyridin-

2-yl)thiazole-2-carboxamide (240 mg, 0.861 mmol, 55% yield) as a pale brown solid. LCMS (ESI) m/e 240.0 [(M+H)⁺, calcd for C₉H₇ClN₃OS, 239.9]; LC/MS retention time (Method F) t_R = 2.15 min.




5

Part B: (S)-Tert-butyl (2,4-dimethyl-1-(4-(2-(thiazole-2-carboxamido)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

To a stirred solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (105 mg, 0.209 mmol) (prepared as described in Example 255, Part B), *N*-(4-chloropyridin-2-yl)thiazole-2-carboxamide (50 mg, 0.209 mmol), cesium carbonate (136 mg, 0.417 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was bubbled nitrogen gas. Added XPhos 2nd generation precatalyst (24.62 mg, 0.031 mmol) in one portion and the reaction mixture was heated at 85 °C for 2 h. The solution was concentrated under reduced pressure. Water (30 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(2-(thiazole-2-carboxamido)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (62 mg, 0.064 mmol, 31% yield) as yellow oil. LCMS (ESI) m/e 579.2 [(M+H)⁺, calcd for C₂₈H₃₄F₃N₄O₄S, 579.2]; LC/MS retention time (method B) t_R = 1.22 min.

25




Part C: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazole-2-carboxamide

To a stirred solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(2-(thiazole-2-carboxamido)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (60 mg, 0.062 mmol) in DCM (3 mL) was added TFA (0.21 mL, 2.73 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 4 h. The solution was concentrated under reduced pressure. The residue was purified via preparative LC/MS using method-A to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazole-2-carboxamide (7.4 mg, 0.015 mmol, 24% yield) as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-d₄) δ 8.55 (s, 1H), 8.44 (d, *J* = 6.0 Hz, 1H), 8.03 - 8.06 (m, 3H), 7.99 (d, *J* = 3.2 Hz, 1H), 7.5 (d, *J* = 1.6 Hz, 1H), 7.44 (d, *J* = 8.5 Hz, 1H), 4.26 - 4.15 (m, 2H), 1.94 - 1.77 (m, 2H), 1.74 - 1.63 (m, 1H), 1.48 (s, 3H), 1.05 (m, 6H) ppm. LCMS (ESI) *m/e* 479.0 [(*M*+H)⁺, calcd for C₂₃H₂₆F₃N₄O₂S, 479.2]; LC/MS retention time (method H) *t_R* = 2.06 min. LCMS (ESI) *m/e* 479.0 [(*M*+H)⁺, calcd for C₂₃H₂₆F₃N₄O₂S, 479.2]; LC/MS retention time (method I) *t_R* = 1.45 min.

Example 259


*(S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-3H-imidazo[4,5-*b*]pyridin-2-amine*



Part A. (S)-tert-butyl (1-(4-bromo-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 4-bromo-2-methylphenol (0.2 g, 1.069 mmol), K₂CO₃ (0.443 g, 3.21 mmol) and (*S*)-*tert*-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (0.376 g,

1.283 mmol) in DMF (5 mL) was heated at 80 °C overnight. The reaction mixture was cooled to 0 °C and quenched with aqueous ammonium chloride (50 mL). The reaction mixture was extracted with ethyl acetate (2x50 mL). The organic layer was washed with water (2x50 mL), brine (50 mL), dried over Na₂SO₄, and concentrated to afford (*S*)-*tert*-butyl (1-(4-bromo-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.3 g, 0.749 mmol, 70% yield). The material was carried forward without further purification. LCMS (ESI) *m/e* 346.0 [(M+H-Bu)⁺, calcd for C₁₉H₃₁BrNO₃ 400.1]; LC/MS retention time (method D): *t*_R = 3.27 min.




10

Part B. (S)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate

A mixture of (*S*)-*tert*-butyl (1-(4-bromo-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.3 g, 0.749 mmol), bis(pinacolato)diboron (0.209 g, 0.824 mmol), potassium acetate (0.221 g, 2.248 mmol) and PdCl₂ (dppf)-CH₂Cl₂ adduct (0.031 g, 0.037 mmol) in 1,4-dioxane (25 mL) was heated at 90 °C overnight. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth bed was washed with ethyl acetate (100 mL). The organic layer was washed with water (50 mL). The aqueous layer was re-extracted with ethyl acetate (2x50 mL). The organic layer was collected, washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure to afford crude (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate (0.2 g, 0.447 mmol, 60% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.61 (t, *J* = 14.40 Hz, 2H), 6.81 (d, *J* = 10.80 Hz, 1H), 4.61 (bs, 1H), 4.08 (d, *J* = 11.60 Hz, 1H), 3.94 (d, *J* = 11.60 Hz, 1H), 2.24 (s, 3H), 1.76-1.84 (m, 2H), 1.61-1.66 (m, 1H), 1.51 (s, 3H), 1.33-1.43 (m, 12H), 0.95-0.98 (m, 6H) ppm.


20

25



Part C: *(S)-tert-butyl (1-(4-(2,3-diaminopyridin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate*


To a stirred solution of *(S)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate* (150 mg, 0.335 mmol), 4-bromopyridine-2,3-diamine (63.0 mg, 0.335 mmol) and cesium carbonate (218 mg, 0.671 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was added XPhos 2nd generation precatalyst (26.4 mg, 0.034 mmol) under a nitrogen atmosphere. The reaction mixture was heated at 95 °C for 2 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. Water (20 mL) was added and the solution was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (50 mL), brine (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography (EtOAc in hexanes) to afford *(S)-tert-butyl (1-(4-bromo-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate* (0.3 g, 0.749 mmol, 70% yield) as a pale yellow semi-solid. LCMS (ESI) *m/e* 429.2 [(M+H)⁺, calcd for C₂₄H₃₇N₄O₃; 429.2]; LC/MS retention time (method A2) *t_R* = 2.11 min.



Part D: *(S)-tert-butyl (1-(4-(2-amino-3H-imidazo[4,5-b]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate*

To a stirred solution of *(S)-tert-butyl (1-(4-(2,3-diaminopyridin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate* (70 mg, 0.101 mmol) in a mixture of MeOH (4 mL) and water (0.5 mL) was added cyanic bromide (16.09 mg, 0.152 mmol) under a nitrogen atmosphere. The reaction mixture was allowed to stir at room temperature for 12h. The solution was concentrated under reduced pressure.



- The brown solid obtained was washed with diethyl ether (2 x 8 mL), collected by vacuum filtration, and dried under vacuum at room temperature to afford (*S*)-*tert*-butyl (1-(4-(2-amino-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (58 mg, 0.081 mmol, 80% yield) as a brown solid.
- 5 The product was carried forward without further purification. LCMS (ESI) *m/e* 454.4 [(M+H)⁺, calcd for C₂₅H₃₆N₅O₃; 454.2] LC/MS retention time (method B) *t_R* = 0.97 min.



- 10 *Part E: (S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-3H-imidazo[4,5-*b*]pyridin-2-amine*
- To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2-amino-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (55 mg, 0.076 mmol) in dichloromethane (3 mL) was cooled to 0 °C was added TFA (0.25 mL, 3.24 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to
- 15 warm to room temperature and was stirred for 2h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-C to afford (*S*)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine (6.9 mg, 0.019 mmol, 25% yield)
- 20 as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 7.87 - 7.71 (m, 2H), 7.58 - 7.47 (m, 1H), 7.45 - 7.36 (m, 1H), 7.04 (d, *J* = 8.5 Hz, 1H), 4.19 - 3.99 (m, 2H), 2.40 (s, 3H), 1.89 (d, *J* = 11.0 Hz, 2H), 1.70 (d, *J* = 9.0 Hz, 1H), 1.51 (s, 3H), 1.07 (m, 6H) ppm. LCMS (ESI) *m/e* 354.0 [(M+H)⁺, Calcd for C₂₀H₂₈N₅O, 354.2]; LC/MS retention time (method H) *t_R* = 0.99 min. LCMS (ESI) *m/e* 354.0 [(M+H)⁺,
- 25 Calcd for C₂₀H₂₈N₅O, 354.2]; LC/MS retention time (method I) *t_R* = 0.85 min.


Example 260

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazole-2-carboxamide



Part A. (S)-tert-butyl (1-(4-bromo-2-chlorophenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 4-bromo-2-chlorophenol (1.2 g, 5.78 mmol), K₂CO₃ (2.398 g, 17.35 mmol) and (S)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (2.036 g, 6.94 mmol) in DMF (20 mL) was heated at 80 °C overnight. The reaction mixture was cooled to 0 °C and quenched with aqueous ammonium chloride (50 mL). The reaction mixture was extracted with ethyl acetate (2x50 mL). The organic layer was washed with water (2x50 mL), brine (50 mL), dried over Na₂SO₄, and concentrated to afford (S)-tert-butyl (1-(4-bromo-2-chlorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (1.5 g, 3.45 mmol, 60% yield) as a pale yellowish semi-solid. LCMS (ESI) *m/e* = 366.0 [(M+H-^tBu)⁺, calcd for C₁₈H₂₈BrClNO₃ 420.1]; LC/MS retention time (method A2): *t*_R = 2.51 min.




Part B. (S)-tert-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of (S)-tert-butyl (1-(4-bromo-2-chlorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (1.2 g, 2.85 mmol), bis(pinacolato)diboron (0.797 g, 3.14 mmol), potassium acetate (0.840 g, 8.56 mmol) and PdCl₂ (dppf)-CH₂Cl₂ adduct (0.116 g, 0.143 mmol) in 1,4-dioxane (20 mL) was heated at 90 °C overnight. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth

bed was washed with ethyl acetate (100 mL). The organic layer was washed with water (50 mL). The aqueous layer was re-extracted with ethyl acetate (2x50 mL). The organic layer was collected, washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (1.2 g, 2.57 mmol, 90% yield) as colorless liquid. ¹H NMR (400 MHz, CDCl₃): δ 7.78 (d, *J* = 1.60 Hz, 1H), 7.61-7.63 (m, 1H), 6.91 (d, *J* = 8.00 Hz, 1H), 4.10-4.19 (m, 1H), 4.63 (s, 1H), 4.02 (d, *J* = 8.80 Hz, 1H), 1.79-1.87 (m, 2H), 1.57-1.62 (m, 1H), 1.51 (s, 3H), 1.33-1.41 (m, 12H), 0.96-0.98 (m, 6H) ppm.


10



Part C: (S)-tert-butyl (1-(2-chloro-4-(2-(thiazole-2-carboxamido)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

15 A stirred solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (98 mg, 0.209 mmol), *N*-(4-chloropyridin-2-yl)thiazole-2-carboxamide (50 mg, 0.209 mmol), cesium carbonate (136 mg, 0.417 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen gas for 10 min. XPhos 2nd generation
20 precatalyst (24.62 mg, 0.031 mmol) was added in one portion and the reaction mixture was heated at 85 °C for 2 h. The solution was concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced
25 pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(2-(thiazole-2-carboxamido)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.076 mmol, 37% yield) as a pale brown oil. The product was carried forward without further purification.

LCMS (ESI) m/e 545.2 [(M+H)⁺, calcd for C₂₇H₃₄ClN₄O₄S, 545.2]; LC/MS retention time (Method F) t_R = 2.89 min.



5 *Part D: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazole-2-carboxamide*

To a stirred solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(2-(thiazole-2-carboxamido)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (78 mg, 0.074 mmol) in DCM (2 mL) cooled to 0 °C was added TFA (0.2 mL, 2.60 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazole-2-carboxamide (7 mg, 0.015 mmol, 20% yield) as a pale yellow solid.


15 LCMS (ESI) m/e 445.0 [(M+H)⁺, calcd for C₂₂H₂₆ClN₄O₂S, 445.1]; LC/MS retention time (method H) t_R = 1.85 min. LCMS (ESI) m/e 445.0 [(M+H)⁺, calcd for C₂₂H₂₆ClN₄O₂S, 445.1]; LC/MS retention time (method I) t_R = 1.36 min. ¹H NMR (400 MHz, METHANOL-*d*₄) δ = 8.54 (d, J =1.0 Hz, 1H), 8.42 (d, J =5.0 Hz, 1H), 8.08 (d, J =3.0 Hz, 1H), 8.00 (d, J =3.0 Hz, 1H), 7.88 (d, J =2.5 Hz, 1H), 7.76 (dd, J =2.0, 8.5 Hz, 1H), 7.48 (dd, J =1.8, 5.3 Hz, 1H), 7.30 (d, J =8.5 Hz, 1H), 3.8 (m, 2H), 1.7-1.9 (m, 2H), 1.5-1.6 (m, 1H), 1.31 (s, 3H), 0.90-0.95 (m, 6H) ppm.


20

Example 261

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)thiazole-2-carboxamide


25





Part A: *(S)-tert-butyl (1-(2-cyano-4-(2-(thiazole-2-carboxamido)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

To a stirred solution of *(S)-tert-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate* (96 mg, 0.209 mmol) (prepared as in Example 254, Part B-G), *N*-(4-chloropyridin-2-yl)thiazole-2-carboxamide (50 mg, 0.209 mmol), cesium carbonate (136 mg, 0.417 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was bubbled nitrogen gas for 5 min. To this mixture was added XPhos 2nd generation precatalyst (24.62 mg, 0.031 mmol) in one portion and the reaction mixture was heated to 85 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature, then concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford *(S)-tert-butyl (1-(2-cyano-4-(2-(thiazole-2-carboxamido)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate* (57 mg, 0.095 mmol, 45% yield) as a pale brown oil in 89% purity based on UV from LCMS. LCMS (ESI) *m/e* 536.2 [(M+H)⁺ calcd for C₂₈H₃₄N₅O₄S, 536.2]; LC/MS retention time (Method F) *t_R* = 2.63 min.



Part B: *(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)thiazole-2-carboxamide*


To a stirred solution of *(S)-tert-butyl (1-(2-cyano-4-(2-(thiazole-2-carboxamido)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate* (55 mg, 0.091 mmol) in DCM (2 mL) cooled to 0 °C was added TFA (0.2 mL, 2.60 mmol)

dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)thiazole-2-carboxamide (13 mg, 0.029 mmol, 32% yield) as a pale yellow solid.

¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.54 (d, *J* = 1.0 Hz, 1H), 8.44 (d, *J* = 5.5 Hz, 1H), 8.13 (d, *J* = 2.0 Hz, 1H), 8.11 - 8.06 (m, 2H), 8.00 (d, *J* = 3.0 Hz, 1H), 7.50 (dd, *J* = 1.8, 5.3 Hz, 1H), 7.38 (d, *J* = 8.5 Hz, 1H), 4.08 (d, *J* = 2.0 Hz, 2H), 1.88 (s, 1H), 1.71 - 1.52 (m, 2H), 1.35 (s, 3H), 1.03 (m, 6H) ppm. LCMS (ESI) *m/e* 436.0 [(*M*+*H*)⁺, calcd for C₂₃H₂₆N₅O₂S, 436.2]; LC/MS retention time (method H) *t*_R = 1.62 min. LCMS (ESI) *m/e* 436.0 [(*M*+*H*)⁺, calcd for C₂₃H₂₆N₅O₂S, 436.2]; LC/MS retention time (method I) *t*_R = 1.26 min.

Example 262


(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)-4-methylthiazol-2-amine



Part A. *N*-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)-4-methylthiazol-2-amine

To a stirred solution of 1-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)thiourea (400 mg, 0.967 mmol) (prepared as described in Example 257, Part C) in EtOH (20 mL) was added 1-chloropropan-2-one (1.5 mL, 0.967 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was heated at 85 °C for 4 h. The reaction mixture was allowed to cool to room temperature then concentrated under reduced pressure. To the residue 20 g of ice was added and the solid was collected by vacuum filtration. The solid was washed with water (2 x 10 mL) and dried under vacuum to afford *N*-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)-4-methylthiazol-2-

amine (130 mg, 0.157 mmol, 16% yield) as an off white solid. The product was carried forward without further purification. LCMS (ESI) m/e 332.0 [(M+H)⁺], calcd for C₁₆H₁₅ClN₃OS, 332.0]; LC/MS retention time (method B) t_R = 0.84 min.




5

Part B: 2-Chloro-4-(2-((4-methylthiazol-2-yl)amino)pyridin-4-yl)phenol

To a stirred solution of *N*-(4-(3-chloro-4-methoxyphenyl)pyridin-2-yl)-4-methylthiazol-2-amine (125 mg, 0.151 mmol) in DCM (10 mL) cooled to -10 °C was added BBr₃ (1.00 mL, 10.58 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was cooled to 0°C, and dry MeOH (20 mL) was added dropwise and the reaction mixture was stirred for 15 min. The solution was concentrated under reduced pressure. The residue was washed with diethyl ether (15 mL) and the solid obtained was collected by vacuum filtration and dried under vacuum to afford 2-chloro-4-(2-((4-methylthiazol-2-yl)amino)pyridin-4-yl)phenol (62 mg, 0.137 mmol, 91% yield). The product was carried forward without further purification. LCMS (ESI) m/e 318.0 [(M+H)⁺], calcd for C₁₅H₁₃ClN₃OS, 318.0]; LC/MS retention time (Method F) t_R = 2.02 min.

10

15




20

Part C: (S)-tert-butyl (1-(2-chloro-4-(2-((4-methylthiazol-2-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A stirred solution of 2-chloro-4-(2-((4-methylthiazol-2-yl)amino)pyridin-4-yl)phenol (102 mg, 0.321 mmol) and potassium carbonate (444 mg, 3.21 mmol) in DMF (10 mL) was stirred under a nitrogen atmosphere for 15 min. To this mixture was added a solution of (*S*)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (122 mg,

25

0.417 mmol) in (1 mL of DMF) and the reaction mixture was heated at 80 °C for 14 h. The solution was concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(2-((4-methylthiazol-2-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (92 mg, 0.071 mmol, 22% yield) as colorless oil. LCMS (ESI) *m/e* 531.2 [(M+H)⁺, calcd for C₂₇H₃₆ClN₄O₃S, 531.2]; LC/MS retention time (Method F) *t_R* = 2.73 min.




Part D: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)-4-methylthiazol-2-amine


To a stirred solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(2-((4-methylthiazol-2-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (90 mg, 0.069 mmol) in DCM (4 mL) cooled to 0 °C was added TFA (0.36 mL, 4.67 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-B to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)-4-methylthiazol-2-amine (1.1 mg, 2.53 μmol, 4% yield) as a pale yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.40 - 8.28 (m, 1H), 7.84 - 7.77 (m, 1H), 7.72 - 7.62 (m, 1H), 7.40 (s, 1H), 7.31 (s, 2H), 7.26 - 7.22 (m, 1H), 7.02 (s, 1H), 3.89 - 3.85 (m, 2H), 3.34 - 3.30 (m, 2H), 3.14 - 3.12 (m, 3H), 1.48 - 1.42 (m, 2H), 1.27 - 1.23 (m, 1H), 1.18 (s, 3H), 0.94 (m, 6H). LCMS (ESI) *m/e* 431.0 [(M+H)⁺, calcd for C₂₂H₂₈ClN₄OS, 431.2]; LC/MS retention time (method H) *t_R* = 1.89 min. LCMS (ESI) *m/e* 431.0 [(M+H)⁺, calcd for C₂₂H₂₈ClN₄OS, 431.2]; LC/MS retention time (method I) *t_R* = 1.20 min.

Example 264

(*R*)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine




5



*Part A: 7-(6-fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine*

A stirred solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (50 mg, 0.326 mmol), (6-fluoro-5-methylpyridin-3-yl)boronic acid (50.4 mg, 0.326 mmol), and cesium carbonate (212 mg, 0.651 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen. XPhos 2nd generation precatalyst (38.4 mg, 0.049 mmol) was added in one portion and the reaction mixture was heated to 85 °C and stirred for 2 h. The solution was concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford 7-(6-fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (38 mg, 0.165 mmol, 51% yield). LCMS (ESI) *m/e* 229.2 [(*M*+*H*)⁺, calcd for C₁₂H₁₀FN₄, 229.1]; LC/MS retention time (method D) *t_R* = 1.86 min.

20





*Part B: (R)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine*

To a stirred solution of (*R*)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine (5 mg, 0.013 mmol) and (*R*)-2-amino-2,4-dimethylpentan-1-ol (27.4 mg, 0.209 mmol) in DMF (2 mL) was added cesium carbonate (52.3 mg, 0.160 mmol) under a nitrogen atmosphere. The reaction mixture was heated at 85 °C for 6 h. The reaction mixture was passed through diatomaceous earth and the diatomaceous earth pad was washed with MeOH (5 mL). The filtrate was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (*R*)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine (5 mg, 0.013 mmol, 8% yield) as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.82 (d, *J* = 1.5 Hz, 1H), 8.57 (d, *J* = 4.5 Hz, 1H), 8.37 (dd, *J* = 1.0, 2.5 Hz, 1H), 8.24 (d, *J* = 2.5 Hz, 1H), 7.19 (d, *J* = 4.5 Hz, 1H), 6.81 (d, *J* = 2.5 Hz, 1H), 4.49 (s, 2H), 2.42 (s, 3H), 1.93 - 1.78 (m, 2H), 1.67 (dd, *J* = 5.5, 14.1 Hz, 1H), 1.46 (s, 3H), 1.07 (m, 6H). LCMS (ESI) *m/e* 340.2 [(*M*+*H*)⁺, calcd for C₁₉H₂₆N₅O, 340.2]; LC/MS retention time (method J) *t*_R = 1.68 min. LCMS (ESI) *m/e* 340.2 [(*M*+*H*)⁺, calcd for C₁₉H₂₆N₅O, 340.2]; LC/MS retention time (method H) *t*_R = 1.86 min.

Example 265


(*R*)-1-((3-chloro-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine



Part A: 7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine

A stirred solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (100 mg, 0.651 mmol), (5-chloro-6-fluoropyridin-3-yl)boronic acid (114 mg, 0.651 mmol), and cesium carbonate (424 mg, 1.302 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen. PdCl₂(dppf)-CH₂Cl₂ adduct (80 mg, 0.098

mmol) was added in one portion and the reaction mixture was heated to 85 °C and stirred for 2 h. The solution cooled to room temperature and was concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford 7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (56 mg, 0.122 mmol, 19 % yield). LCMS (ESI) m/e 249.0 [(M+H)⁺, calcd for C₁₁H₇ClFN₄, 249.0]; LC/MS retention time (method B) t_R = 0.95 min.




*Part B: (R)-1-((3-chloro-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine*


To a stirred solution of (*R*)-2-amino-2,4-dimethylpentan-1-ol (15.39 mg, 0.117 mmol) and 7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (54 mg, 0.117 mmol) in DMF (5 mL) was added cesium carbonate (38.2 mg, 0.117 mmol) under a nitrogen atmosphere. The reaction mixture was heated at 80 °C and stirred for 12 h. The solution was concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (*R*)-1-((3-chloro-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine (2 mg, 5.28 μmol, 5% yield) as a pale yellow solid. ¹H NMR (400MHz, METHANOL-*d*₄) δ = 8.98 - 8.86 (m, 1H), 8.79 - 8.72 (m, 1H), 8.60 (d, *J* = 4.5 Hz, 1H), 8.25 (d, *J* = 2.5 Hz, 1H), 7.24 (d, *J* = 4.5 Hz, 1H), 6.83 (d, *J* = 2.5 Hz, 1H), 4.68 - 4.58 (m, 2H), 1.99 - 1.85 (m, 2H), 1.72 (d, *J* = 9.0 Hz, 1H), 1.54 (s, 3H), 1.08 (m, 6H) ppm. LCMS (ESI) m/e 360.2, [(M+H)⁺, calcd for C₁₈H₂₃ClN₅O, 360.1]; LC/MS retention time (method I) t_R = 1.12 min. LCMS (ESI) m/e 360.2 [(M+H)⁺, calcd for C₁₈H₂₃ClN₅O, 360.1]; LC/MS retention time (method H) t_R = 1.50 min.

Example 266


(*R*)-1-((5-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-3-methylpyridin-2-yl)oxy)-
2,4-dimethylpentan-2-amine



5

*Part A: Sodium (E)-3-ethoxy-3-oxoprop-1-en-1-olate*


Ethyl acetate (5 g, 56.8 mmol) was added to a solution of NaH (60%) (3.40 g, 142 mmol) in THF (50 mL) at room temperature. The internal temperature of the
10 reaction mixture was adjusted to 40 °C and ethyl formate (8.41 g, 114 mmol) was added dropwise to maintain the internal temperature between 40-42°C. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was filtered under argon and the white solid obtained was washed with hexane. The resulting white solid was dried to afford sodium (*E*)-3-ethoxy-3-oxoprop-1-en-1-olate (4.8 g,
15 34.8 mmol, 61% yield). The product was taken to next step without further purification. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.06 (d, *J* = 5.60 Hz, 1H), 4.06 (d, *J* = 5.60 Hz, 1H), 3.76-3.88 (m, 2H), 1.03-1.12 (m, 3H) ppm.

20 *Part B: 2-Cyclopropylpyrazolo[1,5-*a*]pyrimidin-7(4H)-one*

To a solution of 5-cyclopropyl-1H-pyrazol-3-amine (1 g, 8.12 mmol) in ethanol (10 mL) was added sodium (*E*)-3-ethoxy-3-oxoprop-1-en-1-olate (1.121 g, 8.12 mmol) portionwise and the mixture stirred for 5 min. The reaction mixture was heated at 88 °C for 14 h. The reaction mixture was concentrated under reduced
25 pressure. Dichloromethane was added to the residue and the mixture stirred for 20 min. An off-white solid formed and was collected by vacuum filtration and dried to

afford 2-cyclopropylpyrazolo [1, 5-*a*] pyrimidin-7(4*H*)-one (0.8 g, 4.57 mmol, 56% yield) which was carried forward without further purification. LCMS (ESI) *m/e* 176.2 [(M+H)⁺, calcd for C₉H₁₀N₃O 176.1]; LC/MS retention time (method A1): *t_R* = 1.43 min.


5



Part C: 7-Chloro-2-cyclopropylpyrazolo[1,5-a]pyrimidine

2-Cyclopropylpyrazolo [1,5-*a*] pyrimidin-7-ol (0.5 g, 2.85 mmol) was cooled to 0 °C in a 100 mL round bottom flask. POCl₃ (1.330 mL, 14.27 mmol) was added dropwise followed by slow addition of DIPEA (0.748 mL, 4.28 mmol) to the reaction mixture and stirred for 5 min at 0 °C. The reaction mixture was allowed to warm to room temperature and heated at 105 °C for 12 h. The reaction mixture was concentrated under reduced pressure. The brown residue obtained was diluted with ice-water and basified with saturated sodium carbonate solution and extracted with ethyl acetate (3 x25 mL). The ethyl acetate layer was dried over Na₂SO₄, filtered, and concentrated to afford the crude 7-chloro-2-cyclopropylpyrazolo [1,5-*a*] pyrimidine (crude yield) (0.48 g, 2.479 mmol, 87% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 194.2 [(M+H)⁺, calcd for C₉H₉ClN₃ 194.0]; LC/MS retention time (method A1): *t_R* = 1.95 min.


20



Part D: 2-cyclopropyl-7-(6-fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine

To a stirred solution of 7-chloro-2-cyclopropylpyrazolo[1,5-*a*]pyrimidine (100 mg, 0.516 mmol), (6-fluoro-5-methylpyridin-3-yl)boronic acid (80 mg, 0.516 mmol), and cesium carbonate (337 mg, 1.033 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen. XPhos 2nd generation precatalyst (61.0 mg, 0.077 mmol) was added in one portion and the reaction mixture was heated

to 85 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford 2-cyclopropyl-7-(6-fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (52 mg, 0.081 mmol, 16% yield). The product was carried forward without further purification. LCMS (ESI) *m/e* 269.2 [(M+H)⁺, calcd for C₁₅H₁₄FN₄, 269.1]; LC/MS retention time (method H) *t_R* = 2.31 min.





*Part E: (R)-1-((5-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine*

To a stirred solution of (R)-1-((5-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine (3 mg, 7.67 μmol) and (R)-2-amino-2,4-dimethylpentan-1-ol (22.25 mg, 0.170 mmol) in THF (2 mL) was added potassium *tert*-butoxide (1M in THF) (0.130 mL, 0.130 mmol) under a nitrogen atmosphere. The reaction mixture was stirred at rt for 12 h. The solution was concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (30 mL) and brine (30 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified via preparative LC/MS using method-A to afford (R)-1-((5-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine (3 mg, 7.67 μmol, 6% yield) as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.86 (d, *J* = 3.0 Hz, 1 H), 8.45 (d, *J* = 4.5 Hz, 1H), 8.38 - 8.32 (m, 1H), 7.07 (d, *J* = 4.5 Hz, 1H), 6.46 (s, 1H), 4.50 (s, 2H), 2.42 (s, 3H), 2.22 - 2.11 (m, 1H), 1.93 - 1.79 (m, 2H), 1.67 (dd, *J* = 5.5, 14.1 Hz, 1H), 1.47 (s, 3H), 1.13 - 1.04 (m, 8H), 0.97 - 0.92 (m, 2H) ppm. LCMS (ESI) *m/e* 380.2 [(M+H)⁺, calcd for C₂₂H₃₀N₅O, 380.2];

LC/MS retention time (method I) $t_R = 1.98$ min. LCMS (ESI) m/e 380.2 $[(M+H)^+]$, calcd for $C_{22}H_{30}N_5O$, 380.2]; LC/MS retention time (method H) $t_R = 2.30$ min.


Example 267

- 5 (S)-2,4-dimethyl-1-((7-(2-methylpyridin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-amine



- 10 *Part A: 1-(5-bromo-2-methoxyphenyl)thiourea*


To a stirred solution of 5-bromo-2-methoxyaniline (1 g, 4.95 mmol) in conc. HCl (5 mL) and water (20 mL) was added potassium thiocyanate (0.481 g, 4.95 mmol) and the reaction mixture was heated at 100 °C for 24 h. The reaction mixture was allowed to cool to room temperature. Water (150 mL) was added and the solution was extracted with $CHCl_3$ (3 x 80 mL). The combined organic extracts were washed with brine (150 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford 1-(5-bromo-2-methoxyphenyl)thiourea (960 mg, 2.94 mmol, 59% yield) as a white solid. LCMS (ESI) m/e 261.0 $[(M+2H)^+]$, calcd for $C_8H_9BrN_2OS$, 260.9]; LC/MS retention time (method A1) $t_R = 2.09$ min.



Part B: 7-Bromo-4-methoxybenzo[d]thiazol-2-amine

To a stirred solution of 1-(5-bromo-2-methoxyphenyl)thiourea (960 mg, 2.94 mmol) in $CHCl_3$ (25 mL) cooled to 0 °C was added bromine (0.303 mL, 5.88 mmol)


dropwise over a period of 3 min under a nitrogen atmosphere. The reaction mixture was stirred at ambient temperature for 30 min, then heated to reflux at 70 °C for 1 h. The reaction mixture was allowed to cool to room temperature. The solid obtained was collected by vacuum filtration. The solid was dried under vacuum at room
 5 temperature to afford 7-bromo-4-methoxybenzo[d]thiazol-2-amine (940 mg, 2.79 mmol, 95% yield) as a pale yellow solid. The product was carried forward without further purification. LCMS (ESI) m/e 259.0 [(M+H)⁺, calcd for C₈H₈BrN₂OS, 258.9]; LC/MS retention time (method A1) t_R = 1.78 min.



10

Part C: 7-bromo-4-methoxybenzo[d]thiazole

To a stirred solution of 7-bromo-4-methoxybenzo[d]thiazol-2-amine (100 mg, 0.386 mmol) in tetrahydrofuran (6 mL) was added *tert*-butyl nitrite (0.25 mL, 2.085 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was heated at 55
 15 °C for 14 h. The reaction mixture was allowed to cool to room temperature. Water 10 mL was added and the solution extracted with EtOAc (2 x 15 mL). The combined organic extracts were washed with brine (10 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford 7-bromo-4-methoxybenzo[d]thiazole
 20 (89 mg, 0.350 mmol, 91% yield) as an off-white solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 9.22 (s, 1H), 7.61 (d, *J* = 8.40 Hz, 1H), 7.07 (d, *J* = 8.40 Hz, 1H), 4.06 (s, 3H) ppm. LCMS (ESI) m/e 244.0 [(M+H)⁺, calcd for C₈H₇BrNOS, 244.0]; LC/MS retention time (method A1) t_R = 2.17 min.




25

Part D: 7-bromobenzo[d]thiazol-4-ol


To a stirred solution of 7-bromo-4-methoxybenzo[d]thiazole (80 mg, 0.315 mmol) in DCM (5 mL) cooled to 0 °C was added BBr₃ 1M in DCM (0.629 mL, 0.629 mmol) dropwise under nitrogen atmosphere. The reaction mixture was

allowed to warm to room temperature and stirred for 50 min. The reaction mixture was cooled to 0 °C, quenched slowly with dry MeOH (15 mL) then stirred for 10 min. the solution was concentrated under reduced pressure. Obtained 7-bromobenzo[d]thiazol-4-ol (78 mg, 0.312 mmol, 99% yield) as a brown solid. The solid was used as is to the next step without further purification. LCMS (ESI) m/e 229.8 [(M+H)⁺, Calcd for C₇H₅BrNOS, 229.9]; LC/MS retention time (method A1) t_R = 2.09 min.



Part E: (S)-tert-butyl (1-((7-bromobenzo[d]thiazol-4-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate


To a stirred solution of 7-bromobenzo[d]thiazol-4-ol (75 mg, 0.300 mmol) in DMF (5 mL) was added potassium carbonate (166 mg, 1.200 mmol) and the reaction mixture was stirred at room temperature for 10 min. A solution of (S)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (88 mg, 0.300 mmol) in 0.5 mL of DMF was added. The reaction mixture was heated at 80 °C and stirred for 14 h. The reaction mixture was allowed to cool to room temperature, then was concentrated under reduced pressure. Water (15 mL) was added and the solution was extracted with EtOAc (2 x 15 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Obtained (S)-tert-butyl (1-((7-bromobenzo[d]thiazol-4-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (105 mg, 0.156 mmol, 52% yield). The material was used as is in the next step without further purification. LCMS (ESI) m/e 443.0 [(M+H)⁺, calcd for C₁₉H₂₈BrN₂O₃S, 443.1]; LC/MS retention time (method A1) t_R = 2.56 min.



Part F: *(S)*-tert-butyl (2,4-dimethyl-1-((7-(2-methylpyridin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate

A stirred solution of *(S)*-tert-butyl (1-((7-bromobenzo[d]thiazol-4-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (40 mg, 0.060 mmol), (2-methylpyridin-4-yl)boronic acid (8.15 mg, 0.060 mmol) and cesium carbonate (38.8 mg, 0.119 mmol) in a mixture of 1,4-dioxane (10 mL) and water (2 mL) was purged argon for 2 min. PdCl₂(dppf)-CH₂Cl₂ adduct (2.431 mg, 2.98 μmol) was added in one portion and the reaction mixture was heated at 85 °C for 12 h.

The reaction mixture was allowed to cool to room temperature. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (100 mL) and brine (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography (EtOAc in hexanes) to afford *(S)*-tert-butyl (2,4-dimethyl-1-((7-(2-methylpyridin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate (26 mg, 0.055 mmol, 93% yield) in 97% purity based on UV from LCMS. LCMS (ESI) *m/e* 456.2 [(M+H)⁺, calcd for C₂₅H₃₄N₃O₃S, 456.2]; LC/MS retention time (method A1) *t_R* = 2.58 min.



Part G: *(S)*-2,4-dimethyl-1-((7-(2-methylpyridin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-amine


To a stirred solution of *(S)*-tert-butyl (2,4-dimethyl-1-((7-(2-methylpyridin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate (25 mg, 0.053 mmol) in DCM (5 mL) was added TFA (4.10 μL, 0.053 mmol) dropwise under a nitrogen atmosphere at room temperature. The reaction mixture was stirred at room temperature for 12 h. The solution was concentrated under reduced pressure. The crude material was

purified via preparative LC/MS using method-B to afford (*S*)-2,4-dimethyl-1-((7-(2-methylpyridin-4-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine (5 mg, 8.48 μ mol, 16% yield) as a pale yellow solid. ^1H NMR (400 MHz, METHANOL-*d*₄) δ 9.52 (s, 1 H), 8.76 (d, *J* = 6.0 Hz, 1H), 8.19 - 8.07 (m, 2H), 7.95 (d, *J* = 8.5 Hz, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 4.54 - 4.36 (m, 2H), 2.85 (s, 3H), 2.00 - 1.88 (m, 2H), 1.79 (d, *J* = 9.0 Hz, 1H), 1.59 (s, 3H), 1.14 - 0.97 (m, 6H) ppm. LCMS (ESI) *m/e* 356.2 [(*M*+*H*)⁺, calcd for C₂₀H₂₆N₃OS, 356.2]; LC/MS retention time (method H) *t*_R = 1.89 min. LCMS (ESI) *m/e* 356.2 [(*M*+*H*)⁺, calcd for C₂₀H₂₆N₃OS, 356.2]; LC/MS retention time (method I) *t*_R = 1.35 min.


10

Example 269

(*S*)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)benzo[*d*]thiazol-7-yl)pyridin-2-yl)carbamate



15




Part A: (*S*)-methyl (4-(4-((2-(Boc-amino)-2,4-dimethylpentyl)oxy)benzo[*d*]thiazol-7-yl)pyridin-2-yl)carbamate

To a stirred solution of (*S*)-*tert*-butyl (1-((7-bromobenzo[*d*]thiazol-4-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (40 mg, 0.060 mmol) (prepared as described in Example 267, Parts A-E), methyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)carbamate (16.56 mg, 0.060 mmol) and cesium carbonate (38.8 mg, 0.119 mmol) in a mixture of 1,4-dioxane (10 mL) and water (2 mL) was purged argon for 2 min. PdCl₂(dppf)-CH₂Cl₂ adduct (2.431 mg, 2.98 μ mol) was added in one portion and the reaction mixture was heated at 85 °C for 10 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. Water (50 mL) was added and the solution was extracted with EtOAc (2 x

25

50 mL). The combined organic extracts were washed with water (100 mL) and brine (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford (*S*)-methyl (4-(4-((2-(Boc-amino)-2,4-dimethylpentyl)oxy)benzo[d]thiazol-7-yl)pyridin-2-yl)carbamate (96 mg, 0.039 mmol, 66% yield). The product was carried forward without further purification. LCMS (ESI) m/e 515.2 [(M+H)⁺, calcd for C₂₆H₃₅N₄O₅S, 515.2]; LC/MS retention time (method A1) t_R = 2.57 min.



10 *Part B: (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)benzo[d]thiazol-7-yl)pyridin-2-yl)carbamate*

To a stirred solution of (*S*)-methyl (4-(4-((2-(Boc-amino)-2,4-dimethylpentyl)oxy)benzo[d]thiazol-7-yl)pyridin-2-yl)carbamate (96 mg, 0.039 mmol) in DCM (2 mL) was added TFA (0.15 mL, 1.947 mmol) dropwise under a nitrogen atmosphere. The reaction mixture was allowed to stir at ambient temperature for 3 h. The solution was concentrated under reduced pressure. The residue was purified via preparative LC/MS using method-B to afford (*S*)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)benzo[d]thiazol-7-yl)pyridin-2-yl)carbamate (7 mg, 10.57 μ mol, 28% yield) as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 9.44 (s, 1H), 8.39 (d, J = 5.5 Hz, 1H), 8.29 (d, J = 1.0 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.43 (dd, J = 1.8, 5.3 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 4.45 (d, J = 10.0 Hz, 1H), 4.31 (d, J = 10.5 Hz, 1H), 3.83 (s, 3H), 1.91 (s, 2H), 1.83 - 1.73 (m, 1H), 1.58 (s, 3H), 1.15 - 0.98 (m, 6H) ppm. LCMS (ESI) m/e 415.2 [(M+H)⁺, calcd for C₂₁H₂₇N₄O₃S, 415.2]; LC/MS retention time (method H) t_R = 1.87 min.



20

25 LCMS (ESI) m/e 415.2 [(M+H)⁺, calcd for C₂₁H₂₇N₄O₃S, 415.2]; LC/MS retention time (method I) t_R = 1.60 min.

Example 270


(*S*)-2,4-dimethyl-1-(4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine

30




Part A: 5-amino-6-chloropyrimidine-4-thiol

- 5 To a solution of 4,6-dichloropyrimidin-5-amine (250 mg, 1.524 mmol) in methanol (15 mL) was added sodium hydrosulfide hydrate (113 mg, 1.524 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 75 °C for 1 h. The reaction mixture was concentrated under reduced pressure and 10% aqueous sodium hydroxide solution was added. The pH was adjusted to pH 5 by adding acetic acid.
- 10 The solution was extracted with ethyl acetate (2 x 50 mL). The ethyl acetate layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 5-amino-6-chloropyrimidine-4-thiol (270 mg, 1.186 mmol, 78% yield) as a pale brown solid which was taken to next step without further purification. LCMS (ESI) *m/e* 162.4 [(M+H)⁺, calcd for C₄H₅ClN₃S 162.0]; LC/MS retention time (method B): *t_R* =
- 15 0.55 min.




Part B: 7-chloro-2-methylthiazolo[5,4-d]pyrimidine

- A mixture of 5-amino-6-chloropyrimidine-4-thiol (200 mg, 1.238 mmol) and triethylorthoacetate (5 mL, 27.1 mmol) was stirred at 130 °C for 3 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with pet ether/ethyl acetate (0-25%) to afford 7-chloro-2-methylthiazolo[5,4-d]pyrimidine (65 mg, 0.350 mmol, 28% yield) as a brown solid. LCMS (ESI) *m/e* 186.4 [(M+H)⁺, calcd for C₆H₅ClN₃S 185.98]; LC/MS retention time (method B): *t_R* = 0.72 min.
- 25



Part C: *(S)*-tert-butyl (2,4-dimethyl-1-(4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

- A solution 7-chloro-2-methylthiazolo[5,4-*d*]pyrimidine (40 mg, 0.215 mmol),
- 5 *(S)*-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (108 mg, 0.215 mmol), cesium carbonate (140 mg, 0.431 mmol) in 1,4-dioxane (4 mL) and water (1 mL) was purged with nitrogen gas for 5 min. PdCl₂(dppf)-CH₂Cl₂ adduct (8.80 mg, 10.77 μmol) was added to the reaction mixture
- 10 and reaction mixture was heated at 85 °C for 12 h. The reaction mixture was concentrated and to the residue was added water (50 mL) and the solution was extracted with ethyl acetate (2x30 mL). The organic layer was separated, washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Preparative TLC using
- 15 30% ethyl acetate in hexanes. The required spot was collected, dissolved in dichloromethane (25 mL), filtered and concentrated under reduced pressure to afford *(S)*-tert-butyl (2,4-dimethyl-1-(4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (56 mg, 0.049 mmol, 23% yield) as yellow oil. LCMS (ESI) *m/e* 525.6 [(M+H)⁺, calcd for C₂₅H₃₂F₃N₄O₃S 525.2];
- 20 LC/MS retention time (method B): *t_R* = 1.42 min.



Part D: *(S)*-2,4-dimethyl-1-(4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine


- 25 To a solution of *(S)*-tert-butyl (2,4-dimethyl-1-(4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (50 mg, 0.044 mmol) in dichloromethane (2 mL), was added TFA (0.3 mL, 3.89 mmol). The

reaction mixture was allowed to stir for 2 h at room temperature, then concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (*S*)-2,4-dimethyl-1-(4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine (5 mg, 0.012 mmol, 26% yield) as a pale yellow solid. LCMS (ESI) *m/e* 425.2 [(*M*+*H*)⁺, calcd for C₂₀H₂₄F₃N₄OS 425.2]; LC/MS retention time (method H): *t*_R = 2.96 min; LC/MS retention time (method I): *t*_R = 2.29 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 9.18 (d, *J*=2.01 Hz, 1H), 9.11 - 9.16 (m, 1H), 9.06 (s, 1H), 7.41 (d, *J*=8.53 Hz, 1H), 4.10 (d, *J*=6.02 Hz, 2H), 2.98 (s, 3H), 1.83 - 1.91 (m, 1H), 1.64 (m, 2H), 1.35 (s, 3H), 1.03 (m 6H) ppm.


10

Example 271

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)benzonitrile



15




*Part A: (S)-tert-butyl (1-(2-cyano-4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A solution 7-chloro-2-methylthiazolo[5,4-*d*]pyrimidine (prepared as described in Example 270) (40 mg, 0.215 mmol), (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (99 mg, 0.215 mmol), cesium carbonate (140 mg, 0.431 mmol) in 1,4-dioxane (4 mL) and water (1 mL) was purged with nitrogen gas for 5 min. PdCl₂(dppf)-CH₂Cl₂ adduct (8.80 mg, 10.77 μmol) was added to the reaction mixture and reaction mixture was heated at 85 °C for 12 h. The reaction mixture was concentrated and to the residue was added water (50 mL) and the solution was extracted with ethyl acetate (2x50 mL). The organic layer was

25

separated, washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by preparative TLC using 30% ethyl acetate in hexanes. The required spot was collected, dissolved in dichloromethane (25 mL), filtered and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(2-cyano-4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (82 mg, 0.095 mmol, 44% yield) as colorless oil. LCMS (ESI) *m/e* 482.6 [(M+H)⁺, calcd for C₂₅H₃₂N₅O₃S 482.2]; LC/MS retention time (method B): *t*_R = 1.33 min.



10



*Part B: (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)benzonitrile*

To a solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.086 mmol) in dichloromethane (5 mL) was added TFA (6.65 µL, 0.086 mmol). The reaction mixture was allowed to stir for 3 h at room temperature and then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method B) which afforded (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)benzonitrile (15 mg, 0.038 mmol, 44% yield) as a pale yellow solid. LCMS (ESI) *m/e* 382.2 [(M+H)⁺, calcd for C₂₀H₂₄N₅OS 382.2]; LC/MS retention time (method H): *t*_R = 2.56 min; LC/MS retention time (method I): *t*_R = 2.17 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 9.20 (d, *J*=2.01 Hz, 1H), 9.14 (dd, *J*=9.04, 2.01 Hz, 1H), 9.08 (s, 1H), 7.49 (d, *J*=9.04 Hz, 1H), 4.38 (d, *J*=2.01 Hz, 2H), 2.99 (s, 3H), 1.96 -1.86 (m, 2H), 1.77 (d, *J*=5.02 Hz, 1H), 1.58 (s, 3H), 1.09 (m, 6H) ppm.

25

Example 272

(S)-1-((3-chloro-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine




Part A: 7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyrimidine

5 A solution 7-chloropyrazolo[1,5-*a*]pyrimidine (65 mg, 0.423 mmol), (5-chloro-6-fluoropyridin-3-yl)boronic acid (74.2 mg, 0.423 mmol), cesium carbonate (276 mg, 0.847 mmol) in a mixture in 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen gas for 5 min. PdCl₂(dppf)-CH₂Cl₂ adduct (17.28 mg, 0.021 mmol) was added to the reaction mixture and reaction mixture was heated at 85 °C

10 for 90 min. The reaction mixture was concentrated and to the residue was added water (15 mL) and the solution was extracted with ethyl acetate (2x15 mL). The organic layer was separated, washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, and concentrated under reduced pressure to afford crude 7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (95 mg, 0.191 mmol, 45% yield) as a

15 pale yellow solid which was taken to next step without any further purification. LCMS (ESI) *m/e* 249.5 [(M+H)⁺, calcd for C₁₁H₇ClFN₄ 249.0]; LC/MS retention time (method B): *t*_R = 0.89 min.



20 *Part B: (S)-1-((3-chloro-5-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine*



To a solution of 7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (40 mg, 0.161 mmol) and (*S*)-2-amino-2,4-dimethylpentan-1-ol (21.11 mg, 0.161 mmol) in tetrahydrofuran (3 mL) was added potassium *tert*-butoxide (1M in THF)

25 (0.161 mL, 0.161 mmol) under a nitrogen atmosphere. The reaction mixture was

allowed to stir for 2 h at room temperature, then concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) which afforded (*S*)-1-((3-chloro-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine, TFA (10 mg, 0.021 mmol, 13% yield) as a pale yellow solid. LCMS (ESI) *m/e* 360.2 [(M+H)⁺, calcd for C₁₈H₂₃ClN₅O·TFA 360.2]; LC/MS retention time (method H): *t_R* = 2.14 min; LC/MS retention time (method I): *t_R* = 1.94 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.87 - 8.94 (m, 1H), 8.75 (d, *J*=2.51 Hz, 1H), 8.59 (d, *J*=4.52 Hz, 1H), 8.25 (d, *J*=2.51 Hz, 1H), 7.24 (d, *J*=4.52 Hz, 1H), 6.83 (d, *J*=2.01 Hz, 1H), 4.64 (d, *J*=4.02 Hz, 2H), 1.89 - 1.96 (m, 2H), 1.73 (d, *J*=8.53 Hz, 1H), 1.55 (s, 3H), 1.08 (m, 6H) ppm.

Example 275


(*S*)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine



Part A: 7-(6-Fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine

A stirred solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (65 mg, 0.423 mmol), (6-fluoro-5-methylpyridin-3-yl)boronic acid (65.6 mg, 0.423 mmol), cesium carbonate (276 mg, 0.847 mmol) in a mixture of 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen for 5 min. PdCl₂(dppf)-CH₂Cl₂ adduct (17.28 mg, 0.021 mmol) was added in one portion and the reaction mixture was heated at 85 °C and stirred for 2 h. The reaction mixture was allowed to cool to room temperature. Water (50 mL) was added and the solution was extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (70 mL) and brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in

hexanes) to afford 7-(6-fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (79 mg, 0.211 mmol, 50% yield). LCMS (ESI) *m/e* 229.2 [(M+H)⁺, calcd for C₁₂H₁₀FN₄, 229.0]; LC/MS retention time (method A1) *t_R* = 1.70 min.



5



*Part B: (S)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine*

To a stirred solution of 7-(6-fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (40 mg, 0.107 mmol) and (*S*)-2-amino-2,4-dimethylpentan-1-ol (14.03 mg, 0.107 mmol) in tetrahydrofuran (3 mL) was added potassium *tert*-butoxide (1M in THF) (0.267 mL, 0.267 mmol) under a nitrogen atmosphere at ambient temperature. The reaction mixture was allowed to stir for 2 h. MeOH (2 mL) was added to the reaction mixture and the reaction mixture was filtered. The filtrate was concentrated under reduced pressure and purified via preparative LC/MS using method-A to afford (*S*)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine (25 mg, 0.072 mmol, 68% yield) as a pale yellow solid. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.73 - 8.95 (m, 1H), 8.53 - 8.66 (m, 1H), 8.31 - 8.46 (m, 1H), 8.18 - 8.30 (m, 1H), 7.12 - 7.27 (m, 1H), 6.67 - 6.87 (m, 1H), 4.51 - 4.66 (m, 2H), 2.51 (s, 3H), 1.82 - 2.03 (m, 2H), 1.61 - 1.77 (m, 1H), 1.54 (s, 3H), 0.94 (m, 6H) ppm. LCMS (ESI) *m/e* 340.2 [(M+H)⁺, calcd for C₁₉H₂₆N₅O, 340.2]; LC/MS retention time (method H) *t_R* = 2.15 min. LCMS (ESI) *m/e* 340.2 [(M+H)⁺, calcd for C₁₉H₂₆N₅O, 340.2]; LC/MS retention time (method I): *t_R* = 1.97 min.

25


Example 276

*(S)-1-((2-(fluoromethyl)-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine*



Part A: (6-bromo-3-fluoropyridin-2-yl)methanol


- 5 A solution of 6-bromo-3-fluoropyridin-2-ylmethanol (250 mg, 1.226 mmol) in methanol (3 mL) and tetrahydrofuran (5 mL) was cooled to 0 °C then sodium borohydride (46.4 mg, 1.226 mmol) was added in two portions. The reaction mixture was stirred for 30 min. The reaction mixture was concentrated under reduced pressure. Water (15 mL) was added to the reaction mixture and the solution was
- 10 extracted with ethyl acetate (2 x 15 mL). The combined organic extracts were washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford crude (6-bromo-3-fluoropyridin-2-yl)methanol (236 mg, 1.100 mmol, 90% yield). LCMS (ESI) m/e 206.0 (bromo pattern) [(M+H)⁺, calcd for C₆H₆BrFNO 205.9]; LC/MS retention time (Method G)
- 15 *t_R* = 1.17 min.



Part B: 6-bromo-3-fluoro-2-(fluoromethyl)pyridine


- A solution of (6-bromo-3-fluoropyridin-2-yl)methanol (230 mg, 1.072 mmol) in dichloromethane (8 mL) was cooled to -20 °C and DAST (0.142 mL, 1.072 mmol) was added under a nitrogen atmosphere. The reaction mixture was allowed to stir at room temperature for 12 h. The reaction mixture was cooled to 0 °C, quenched with 10% aqueous sodium bicarbonate solution (15 mL) and extracted with ethyl acetate (2 x 15 mL). The organic layer was washed with water (20 mL) and brine (20 mL),
- 25 dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford crude 6-bromo-3-fluoro-2-(fluoromethyl)pyridine (170 mg, 0.662 mmol, 62% yield) as brown oil. The product was taken to next step without further purification. LCMS

(ESI) m/e 208.0, 210.0 (bromo pattern) $[(M+H)^+]$, calcd for $C_6H_5BrF_2N$ 208.0];
LC/MS retention time (method B): t_R = 0.81 min.



5 *Part C: 7-(5-fluoro-6-(fluoromethyl)pyridin-2-yl)pyrazolo[1,5-a]pyrimidine*

A solution 7-chloropyrazolo[1,5-a]pyrimidine (75 mg, 0.488 mmol), 6-bromo-3-fluoro-2-(fluoromethyl)pyridine (102 mg, 0.488 mmol), tetrakis(triphenylphosphine)palladium (0) (28.2 mg, 0.024 mmol) and hexamethylditin (0.101 mL, 0.488 mmol) in 1,4-dioxane (2 mL) was purged with
10 nitrogen gas for 2 min and irradiated at 130 °C in a microwave for 90 min. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was added and the solution was extracted with ethyl acetate (2x10 mL). The organic layer was separated, washed with water (10 mL) and brine (10 mL), dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified
15 by silica gel column chromatography (ethyl acetate in hexanes) to afford 7-(5-fluoro-6-(fluoromethyl)pyridin-2-yl)pyrazolo[1,5-a]pyrimidine (72 mg, 0.120 mmol, 25% yield) as a yellow solid. LCMS (ESI) m/e 247.0 $[(M+H)^+]$, calcd for $C_{12}H_9F_2N_4$ 247.1]; LC/MS retention time (Method C): t_R = 0.79 min.



20

Part D: (S)-1-((2-(5-fluoro-6-(fluoromethyl)pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine



To a solution of (S)-2-amino-2,4-dimethylpentan-1-ol (27.7 mg, 0.211 mmol) and 7-(5-fluoro-6-(fluoromethyl)pyridin-2-yl)pyrazolo[1,5-a]pyrimidine (52 mg,
25 0.211 mmol) in tetrahydrofuran (5 mL) was added potassium *tert*-butoxide (0.317 mL, 0.317 mmol) under a nitrogen atmosphere. The reaction mixture was allowed to stir for 12 h at room temperature then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method B) which afforded (S)-1-((2-

(fluoromethyl)-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine (6 mg, 0.017 mmol, 8% yield) as a pale yellow solid. LCMS (ESI) *m/e* 358.3 [(M+H)⁺, calcd for C₁₉H₂₅FN₅O 358.2]; LC/MS retention time (method H): *t_R* = 1.26 min; LC/MS retention time (method I): *t_R* = 1.08 min. ¹H NMR (400 MHz, Methanol-*d*₄): δ 9.29 - 9.35 (m, 1H), 8.63 - 8.67 (m, 1H), 8.25 - 8.34 (m, 1H), 7.82 - 7.87 (m, 1H), 7.76 - 7.82 (m, 1H), 6.83 - 6.88 (m, 1H), 5.59 - 5.87 (m, 2H), 4.34 - 4.41 (m, 1H), 4.24 - 4.32 (m, 1H), 1.85 - 1.99 (m, 2H), 1.69 - 1.78 (m, 1H) 1.57 (s, 3H) 1.10 (m, 6H) ppm.

10

Example 277

2-amino-2-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-4-methylpentan-1-ol




15

Part A: 3-tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate


To a solution of methyl 2-((*tert*-butoxycarbonyl)amino)-3-hydroxypropanoate (2 g, 9.12 mmol) in acetone (50 mL) and 2,2-dimethoxypropane (10 mL, 9.12 mmol) was added BF₃•OEt₂ (0.2 mL, 1.578 mmol) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred for 2 h. The reaction mixture was concentrated under reduced pressure. Water (150 mL) was added to the residue and the solution was extracted with ethyl acetate (2 x 100 mL). The ethyl acetate layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate in hexanes) to afford 3-*tert*-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (1.92 g, 7.40 mmol, 81% yield) as yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 4.50-4.35 (m, 1H), 4.20-4.10 (m, 1H), 4.10-4.00 (m,

1H), 3.76 (s, 3H), 1.62 (s, 3H), 1.52 (s, 3H), 1.44 (s, 9H) ppm.



Part B: 3-tert-butyl 4-methyl 2,2-dimethyl-4-(2-methylallyl)oxazolidine-3,4-
5 dicarboxylate


A solution of LHMDS (1M in THF) (5.37 mL, 5.37 mmol) in THF (5 mL) was cooled to -80 °C and 3-tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (0.87g, 3.36 mmol) in THF (4 mL) was added. The reaction mixture was stirred for 30 min at room temperature. The reaction mixture was cooled to at -
10 80°C and 3-bromo-2-methylprop-1-ene (1.409 g, 10.43 mmol) was added under a nitrogen atmosphere. The reaction was stirred at -80°C for 2 h and at room temperature for 14 h. The reaction mixture was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate (2 x 50 mL). The ethyl acetate layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄,
15 filtered, and concentrated under reduced pressure to afford crude product which was purified by silica gel chromatography (ethyl acetate in hexanes) to afford 3-tert-butyl 4-methyl 2,2-dimethyl-4-(2-methylallyl)oxazolidine-3,4-dicarboxylate (400 mg, 1.276 mmol, 38% yield) as colorless oil. ¹H NMR (300 MHz, CDCl₃): δ 5.00 (m, 1H), 4.78 (m, 1H), 4.15-4.10 (m, 2H), 3.76 (s, 3H), 3.19-2.93 (dd, *J* = 14.1 Hz, 1H),
20 2.56 (m, 1H), 1.83 (m, 3H), 1.62 (s, 3H), 1.57 (s, 3H), 1.44 (s, 9H) ppm.



Part C: Tert-butyl 4-(hydroxymethyl)-2,2-dimethyl-4-(2-methylallyl)oxazolidine-3-
25 carboxylate


A solution of 3-tert-butyl 4-methyl 2,2-dimethyl-4-(2-methylallyl)oxazolidine-3,4-dicarboxylate (560 mg, 1.787 mmol) in tetrahydrofuran (15 mL) was cooled to 0 °C

then LAH (1M in THF) (2.5 mL, 2.500 mmol) was added dropwise under a nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 20 min. The reaction mixture was quenched carefully by dropwise addition of water (25 mL) and extracted with ethyl acetate (2 x 50 mL). The ethyl acetate layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford crude *tert*-butyl 4-(hydroxymethyl)-2,2-dimethyl-4-(2-methylallyl)oxazolidine-3-carboxylate (320 mg, 1.121 mmol, 63% yield) as colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.95-4.85 (m, 2H), 4.75-4.65 (d, *J* = 11.6 Hz, 1H), 3.97-3.90 (m, 1H), 3.85-3.75 (m, 1H), 3.60-3.40 (m, 2H), 2.22-2.10 (m, 1H), 1.80-1.70 (d, *J* = 6.8 Hz, 3H), 1.45-1.35 (s, 15H) ppm.




Part D: (2-(difluoromethyl)pyridin-4-yl)boronic acid

A solution of hypodiboric acid (576 mg, 6.42 mmol), potassium acetate (1260 mg, 12.84 mmol), and 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (204 mg, 0.428 mmol) in ethanol (20 mL) was purged with nitrogen for 5 min. XPhos 2nd generation precatalyst (168 mg, 0.214 mmol) was added under nitrogen atmosphere to give a suspension and the reaction mixture was purged under nitrogen for 5 min. 4-Chloro-2-(difluoromethyl)pyridine (700 mg, 4.28 mmol) was added and the reaction mixture was heated at 80 °C for 3 h. The reaction mixture was passed through diatomaceous earth and the diatomaceous earth pad was washed with EtOAc (50 mL). The filtrate was evaporated to dryness under reduced pressure. Obtained (2-(difluoromethyl)pyridin-4-yl)boronic acid (740 mg, 4.28 mmol, quantitative crude yield). Carried on without further purification. LCMS (ESI) *m/e* 174.0 [(M+H)⁺, calcd for C₆H₇BF₂NO₂ 174.0]; LC/MS retention time (Method C): *t*_R = 0.43 min.



Part E: 4-bromo-2-(difluoromethyl)pyridine


A solution of (2-(difluoromethyl)pyridin-4-yl)boronic acid (4.59 g, 26.5 mmol), 2-bromo-4-(difluoromethyl)-5-fluoropyridine (3 g, 13.27 mmol), tripotassium phosphate (2 M in water) (19.91 mL, 39.8 mmol) and XPhos 2nd generation precatalyst (0.313 g, 0.398 mmol) in THF (12 mL) was purged with nitrogen for 5 minutes. The solution was then heated at 80 °C for 14 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (100 mL) and stirred for 10 min. The reaction mixture was passed through diatomaceous earth and the diatomaceous earth pad was washed with EtOAc (50 mL). The filtrate was evaporated to dryness under reduced pressure. The residue was dissolved in EtOAc (200 mL) and washed with water (120 mL) and brine (200 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford 2',4-bis(difluoromethyl)-5-fluoro-2,4'-bipyridine (2.5 g, 7.39 mmol, 55.6 % yield) as pale brown solid. LCMS (ESI) *m/e* 275.0 [(M+H)⁺, calcd for C₁₂H₇F₅N₂ 275.2]; LC/MS retention time (method B): *t_R* = 1.59 min.



Part F: Tert-butyl 4-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-2,2-dimethyl-4-(2-methylallyl)oxazolidine-3-carboxylate

To a solution of 2',4-bis(difluoromethyl)-5-fluoro-2,4'-bipyridine (45 mg, 0.164 mmol) and *tert*-butyl 4-(hydroxymethyl)-2,2-dimethyl-4-(2-methylallyl)oxazolidine-3-carboxylate (46.8 mg, 0.164 mmol) in tetrahydrofuran was added potassium *tert*-butoxide (1 M in THF) (0.7 mL, 0.700 mmol) under a nitrogen atmosphere. The reaction mixture was stirred for 1h. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was added and extracted with ethyl acetate (2 x 15 mL). The ethyl acetate layer was washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford crude product *tert*-butyl 4-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-2,2-dimethyl-4-(2-methylallyl)oxazolidine-3-

carboxylate (75 mg, 0.093 mmol, 57% yield) as yellow oil which was taken to next step without purification. LCMS (ESI) m/e 540.2 [(M+H)⁺, calcd for C₂₇H₃₄F₄N₃O₄ 540.2]; LC/MS retention time (Method G): t_R = 4.09 min.




5

Part G: Tert-butyl 4-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-4-isobutyl-2,2-dimethyloxazolidine-3-carboxylate

To a solution of *tert*-butyl 4-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-2,2-dimethyl-4-(2-methylallyl)oxazolidine-3-carboxylate (62 mg, 0.077 mmol) in methanol (5 mL) was added palladium on carbon (15 mg, 0.014 mmol) under a nitrogen atmosphere. The reaction mixture was stirred under 1 atm of hydrogen gas for 18 h. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth bed was washed with methanol (15 mL). The filtrate was concentrated under reduced pressure to afford *tert*-butyl 4-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-4-isobutyl-2,2-dimethyloxazolidine-3-carboxylate (73 mg, 0.047 mmol, 61% yield). LCMS (ESI) m/e 542.3 [(M+H)⁺, calcd for C₂₇H₃₆F₄N₃O₄ 542.3]; LC/MS retention time (method B): t_R = 1.24 min.

15



20

Part H: 2-amino-2-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-4-methylpentan-1-ol



A solution of *tert*-butyl 4-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-4-isobutyl-2,2-dimethyloxazolidine-3-carboxylate (72 mg, 0.047 mmol) in 1,4-dioxane (4 mL) and 6N HCl (4 mL) was heated at 90 °C for 2 h. The reaction mixture was cooled to room temperature then was concentrated under

25

reduced pressure. The crude material was purified by prep LC/MS (method A) to afford 2-amino-2-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-4-methylpentan-1-ol (1.5 mg, 3.62 μ mol, 8% yield) as a pale yellow solid. LCMS (ESI) m/e 402.2 [(M+H)⁺, calcd for C₁₉H₂₄F₄N₃O₂ 402.2]; LC/MS retention time (method H): t_R = 1.47 min; LC/MS retention time (method I): t_R = 1.16 min. ¹H NMR (400 MHz, Methanol-*d*₄): δ 8.75 (d, J =5.5 Hz, 1H), 8.70 (s, 1H), 8.37 (s, 1H), 8.23 (s, 1H), 8.21 - 8.16 (m, 1H), 7.33 - 6.67 (m, 2H), 4.28 (d, J =1.0 Hz, 2H), 3.71 (d, J =11.0 Hz, 1H), 3.58 (d, J =11.0 Hz, 1H), 1.91 (s, 1H), 1.59 (t, J =5.8 Hz, 2H), 1.02 (t, J =6.5 Hz, 6H) ppm.

10

Example 281


(S)-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine

15

Part A: (S)-benzyl (1-(4-bromophenoxy)-2,4-dimethylpent-4-en-2-yl)carbamate


A mixture of 4-bromophenol (0.3 g, 1.734 mmol), (S)-benzyl 4-methyl-4-(2-methylallyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (0.733 g, 2.254 mmol), K₂CO₃ (0.599 g, 4.34 mmol) in DMF (6.94 mL) was heated at 80 °C overnight under nitrogen. The reaction mixture was extracted with ethyl acetate (2x100 mL), washed with water (75 mL), brine (75 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-20% of ethyl acetate/hexane) to afford (S)-benzyl (1-(4-bromophenoxy)-2,4-dimethylpent-4-en-2-yl)carbamate (0.8 g, 1.683 mmol, 97% yield). LCMS (ESI) m/e 418.3; 420.3 (bromo pattern) [(M+H)⁺, calcd for C₂₁H₂₆BrNO₃ 418.1]; LC/MS retention time (method B): t_R = 1.22 min.

25



Part B: *(S)*-benzyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pent-4-en-2-yl)carbamate

A solution of *(S)*-benzyl (1-(4-bromophenoxy)-2,4-dimethylpent-4-en-2-yl)carbamate (0.2 g, 0.478 mmol), bis(pinacolato)diboron (0.182 g, 0.717 mmol), and potassium acetate (0.141 g, 1.434 mmol) in 1,4-dioxane (2.39 mL) was purged with argon for 5 min. PdCl₂(dppf)-CH₂Cl₂ adduct (0.039 g, 0.048 mmol) was added to the reaction mixture was heated under argon at 80 °C overnight. The reaction mixture was extracted with ethyl acetate (2x50 mL). The ethyl acetate layer was washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-15% of ethyl acetate/hexane) to afford *(S)*-benzyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pent-4-en-2-yl)carbamate (0.13 g, 0.263 mmol, 55% yield) as gummy liquid. LCMS (ESI) *m/e* 466.2 [(M+H)⁺, calcd for C₂₇H₃₇BN₂O₅ 466.3]; LC/MS retention time (Method F): *t*_R = 2.55 min.




Part C: *(S)*-benzyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpent-4-en-2-yl)carbamate

A solution of 8-bromo-6-chloroimidazo[1,2-*b*]pyridazine (0.05 g, 0.215 mmol), *(S)*-benzyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pent-4-en-2-yl)carbamate (0.110 g, 0.237 mmol), and potassium phosphate tribasic (2M in water) (0.323 mL, 0.645 mmol) in 1,4-dioxane (1.075 mL) was purged with argon for 5 min. Tetrakis(triphenylphosphine)palladium(0) (triphenylphosphine)palladium(0) (0.012 g, 10.75 μmol) was added to the reaction

mixture under argon and the mixture was heated to 100 °C overnight. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2x30 mL). The ethyl acetate layer was washed with water (20 mL), brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica
 5 gel chromatography (0-60% of ethyl acetate/hexane) to afford (*S*)-benzyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpent-4-en-2-yl)carbamate (0.05 g, 0.092 mmol, 43% yield) as a gummy liquid. LCMS (ESI) *m/e* 491.2 [(M+H)⁺, calcd for C₂₇H₂₈ClN₄O₃ 491.2]; LC/MS retention time (method A1): *t_R* = 2.88 min.

10




*Part D: (S)-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine*


To a solution of (*S*)-benzyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpent-4-en-2-yl)carbamate (0.055 g, 0.100 mmol) in ethyl
 15 acetate (2 mL) was added palladium on carbon (0.027 g, 0.025 mmol). The reaction mixture was stirred under hydrogen at 1 atm overnight at room temperature. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth pad was washed with methanol (50 mL). The filtrate was concentrated under
 20 reduced pressure to give (*S*)-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine (0.024 g, 0.070 mmol, 70% yield) as brown gummy liquid. LCMS (ESI) *m/e* 325.2 [(M+H)⁺, calcd for C₁₉H₂₅N₄O 325. 2]; LC/MS retention time (Method A1): *t_R* = 1.80 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.48 (d, *J* = 4.8 Hz, 1H), 8.22 - 8.19 (m, 1H), 8.18 - 8.13 (m, 2H), 7.80 (d, *J* = 1.3 Hz, 1H), 7.34
 25 (d, *J* = 4.8 Hz, 1H), 7.26 - 7.22 (m, 2H), 4.22 (d, *J* = 10.3 Hz, 1H), 4.13 (d, *J* = 10.3 Hz, 1H), 1.94 - 1.81 (m, 2H), 1.75 - 1.66 (m, 1H), 1.52 (s, 3H), 1.09 (d, *J* = 6.5 Hz, 3H), 1.05 (d, *J* = 6.3 Hz, 3H) ppm.

Example 282

(*S*)-1-(2-chloro-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine




5



*Part A: 7-bromo-2-methyl-3H-imidazo[4,5-*b*]pyridine*

A mixture of 4-bromopyridine-2,3-diamine (0.15 g, 0.798 mmol), AcOH (0.069 mL, 1.197 mmol), and PPA (0.340 mL, 0.798 mmol) was heated at 150 °C for 2 h. The reaction mixture was diluted with water and the pH was adjusted to 13 with aqueous NaOH (10%). The solution was extracted with ethyl acetate (2x100 mL). The ethyl acetate layers were washed with water, brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 7-bromo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine (0.130 g, 0.460 mmol, 58% yield). LCMS (ESI) *m/e* 212.0 [(M+H)⁺, calcd for C₇H₇BrN₃ 212.0]; LC/MS retention time (method B): *t*_R = 0.49 min.

15



*Part B: (S)-tert-butyl (1-(2-chloro-4-(2-methyl-3H-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*


20

A solution of 7-bromo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine (0.1 g, 0.472 mmol), (*S*)-tert-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (0.265 g, 0.566 mmol), and K₂CO₃ (0.196 g, 1.415 mmol) in 1,4-dioxane (4 mL) and water (1 mL) was purged with argon for 5 min. PdCl₂(dppf)-

25

CH₂Cl₂ adduct (0.019 g, 0.024 mmol) was added to the reaction mixture under argon and the mixture was heated to 100 °C overnight. The reaction mixture was extracted with ethyl acetate (2x30 mL). The ethyl acetate layer was washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product which was purified by silica gel chromatography (0 - 10% of CHCl₃/MeOH) to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.08 g, 0.169 mmol, 36% yield) as a brown solid. LCMS (ESI) *m/e* 473.2 [(M+H)⁺, calcd for C₂₅H₃₄ClN₄O₃ 473.2]; LC/MS retention time (method B): *t*_R = 0.98 min.

10




*Part C: (S)-1-(2-chloro-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine*

To a solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.05 g, 0.106 mmol) in dichloromethane (0.5 mL) cooled to 0 °C was added 4*N* HCl in 1,4-dioxane (0.661 mL, 2.64 mmol) under nitrogen. The reaction mixture was stirred at room temperature for 1 h, then was concentrated under reduced pressure. The crude material was purified by preparative LC/MS (method A) to afford (*S*)-1-(2-chloro-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, 2 TFA (0.017 g, 0.029 mmol, 27% yield) as a pale yellow solid. LCMS (ESI) *m/e* 373.0 [(M+H)⁺, calcd for C₂₀H₂₆ClN₄O 373.2]; LC/MS retention time (method H): *t*_R = 0.83 min; LC/MS retention time (method I): *t*_R = 0.92 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.19 (d, *J* = 2.2 Hz, 1H), 8.02 (dd, *J* = 2.3, 8.6 Hz, 1H), 7.94 (d, *J* = 8.3 Hz, 1H), 7.73 (d, *J* = 8.4 Hz, 1H), 7.27 (d, *J* = 8.7 Hz, 1H), 4.23 (d, *J* = 10.2 Hz, 1H), 4.17 (d, *J* = 10.2 Hz, 1H), 2.65 (s, 3H), 1.97 - 1.85 (m, 2H), 1.77 - 1.68 (m, 1H), 1.53 (s, 3H), 1.09 (d, *J* = 6.5 Hz, 3H), 1.06 (d, *J* = 6.5 Hz, 3H) ppm.


25

Example 283

(*S*)-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine




5



*Part A: (S)-tert-butyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A solution of 8-bromo-6-chloroimidazo[1,2-*b*]pyridazine (0.03 g, 0.129 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.065 g, 0.129 mmol), and potassium phosphate tribasic (2m in water) (0.194 mL, 0.387 mmol) in 1,4-dioxane (0.645 mL) was purged with argon for 10 min. Tetrakis(triphenylphosphine)palladium (0) (7.46 mg, 6.45 μmol) was added to the reaction mixture under argon and the mixture was heated to 100 °C overnight. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2x 30 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (0-20% of ethyl acetate/hexane) to give (*S*)-*tert*-butyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.042 g, 0.073 mmol, 57% yield). LCMS (ESI) *m/e* 527.2 [(M+H)⁺, calcd for C₂₅H₃₁ClF₃N₄O₃ 527.2]; LC/MS retention time (method A2): *t*_R = 1.28 min.





Part B: *(S)*-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine

To a solution of *(S)*-*tert*-butyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.04 g, 0.076 mmol) in methanol (3 mL) was added palladium on carbon (0.020 g, 0.019 mmol). The reaction mixture was hydrogenated under 1 atm H₂ for 1 h. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth bed was washed with methanol (20 mL). The filtrate concentrated under reduced pressure. The crude product was dissolved in dichloromethane (2 mL), cooled to 0 °C and TFA (0.088 mL, 1.139 mmol) was added under nitrogen. The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure and the crude compound was purified by RP-HPLC (TFA in water and acetonitrile) to afford *(S)*-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (0.030 g, 0.055 mmol, 72% yield) as an off-white solid. LCMS (ESI) *m/e* 393.2 [(M+H)⁺, calcd for C₂₀H₂₄F₃N₄O, 393.2]; LC/MS retention time (Method A1): *t*_R = 2.02 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.57 (d, *J* = 4.8 Hz, 1H), 8.50 (d, *J* = 2.0 Hz, 1H), 8.42 (dd, *J* = 2.2, 8.8 Hz, 1H), 8.28 (d, *J* = 1.4 Hz, 1H), 7.88 (d, *J* = 1.4 Hz, 1H), 7.49 (d, *J* = 8.8 Hz, 1H), 7.47 (d, *J* = 4.8 Hz, 1H), 4.35 (d, *J* = 10.2 Hz, 1H), 4.29 (d, *J* = 10.2 Hz, 1H), 1.95 - 1.85 (m, 2H), 1.79 - 1.70 (m, 1H), 1.56 (s, 3H), 1.09 (d, *J* = 6.5 Hz, 3H), 1.05 (d, *J* = 6.4 Hz, 3H) ppm.

Example 284


(S)-1-(2-chloro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine



Part A: 4-iodo-1H-pyrazolo[3,4-b]pyridine

5 To a solution of 2-fluoro-4-iodonicotinaldehyde (0.2 g, 0.797 mmol) in 2-propanol (2 mL) was added hydrazine monohydrate (0.2 mL, 6.37 mmol) and the reaction mixture was heated to 60 °C for 3 h. The reaction mixture was concentrated under reduced pressure. To the residue was added water and ethyl acetate (8 mL). The ethyl acetate layer was separated. The aqueous layer was washed ethyl acetate
10 (2x6 mL). The combined The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 4-iodo-1H-pyrazolo[3,4-b]pyridine (0.150 g, 0.612 mmol, 77% yield) as a off white solid which was taken to next step without purification. LCMS (ESI) *m/e* 246.0 [(M+H)⁺, calcd for C₆H₅IN₃ 246.0]; LC/MS retention time (method A2): *t_R* = 1.65 min.


15



Part B: (S)-tert-butyl (1-(2-chloro-4-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of 4-iodo-1H-pyrazolo[3,4-b]pyridine (0.030 g, 0.122 mmol), (S)-
20 *tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (0.057 g, 0.122 mmol) and potassium phosphate, dibasic (0.043 g, 0.245 mmol) in

1,4-dioxane (6 mL) and water (2 mL) was purged with argon for 10 min. PdCl₂(dppf)-CH₂Cl₂ adduct (10.00 mg, 0.012 mmol) was added to the reaction mixture under argon and heated to 60 °C for 3 h. The reaction mixture was diluted with ethyl acetate and the organic layer was separated. The aqueous layer was
 5 extracted with ethyl acetate (2x5 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Prep TLC using 40% ethyl acetate in hexane. The required spot was collected, dissolved in 10% methanol in dichloromethane (20 mL), filtered and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate
 10 (0.032 g, 0.063 mmol, 52% yield) as a pale yellow solid. LCMS (ESI) *m/e* 459.2 [(M+H)⁺, calcd for C₂₄H₃₂ClN₄O₃ 459.2]; LC/MS retention time (method A2): *t_R* = 2.16 min.



15



*Part C: (S)-1-(2-chloro-4-(1H-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine*

To a solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.032 g, 0.063 mmol) in
 20 dichloromethane (0.5 mL) cooled to 0 °C was added HCl in 1,4-dioxane (4M) (0.016 mL, 0.063 mmol) and the mixture stirred at 0 °C for 10 min. The reaction mixture was warmed to room temperature and stirred for 3 h. The mixture was concentrated under reduced pressure and to the residue diethyl ether (5 mL) was added and stirred for 30 min. The solvent was separated and the solid was dried under high vacuum to
 25 afford (*S*)-1-(2-chloro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine, 0.5 HCl (0.023 g, 0.059 mmol, 93% yield) as a pale yellow solid. LCMS (ESI) *m/e* 359.2 [(M+H)⁺, calcd for C₁₉H₂₄ClN₄O, 359.2]; LC/MS retention time (Method A1): *t_R* = 1.91 min. ¹H NMR (400 MHz, Methanol-*d*₄): δ 8.67 (d, *J* = 5.2 Hz, 1H), 8.55 (s, 1H), 8.04 (d, *J* = 2.4 Hz, 1H), 7.92 (dd, *J* = 8.4, 2.0

Hz, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 4.31 - 4.23 (m, 2H), 1.98 - 1.85 (m, 2H), 1.75 - 1.70 (m, 1H), 1.55 (s, 3H), 1.08 - 1.03 (m, 6H) ppm.

Example 286


5 (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile



10 *Part A: (S)-tert-butyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A solution of 8-bromo-6-chloroimidazo[1,2-*b*]pyridazine (0.04 g, 0.172 mmol), (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 285) (0.079 g, 0.172 mmol), and potassium phosphate tribasic (2M in water) (0.258 mL, 0.516 mmol) in 1,4-dioxane (0.860 mL) was purged with argon for 5 min. Tetrakis(triphenylphosphine)palladium(0) (9.94 mg, 8.60 μ mol) was added to the reaction mixture under argon and the mixture was heated to 100 °C overnight. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2x30 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (0-20% of ethyl acetate/hexane) to give (*S*)-*tert*-butyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.055 g, 0.091 mmol, 53% yield) as a yellow solid. LCMS (ESI) m/e

484.2 [(M+H)⁺, calcd for C₂₅H₃₁ClN₅O₃ 484.2]; LC/MS retention time (method B):
 t_R = 1.18 min.




5 *Part B: (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-chloroimidazo[1,2-b]pyridazin-8-yl)benzonitrile*

To a solution of (*S*)-*tert*-butyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.015 g, 0.031 mmol) in dichloromethane (1 mL) cooled to 0 °C was added TFA (0.048 mL, 0.620 mmol).

10 The reaction mixture was allowed to stir for 2 h at room temperature. The mixture was concentrated under reduced pressure. Toluene (3 mL) was added and the mixture concentrated under reduced pressure (repeated 2 more times). The crude material was purified by prep LC/MS (method A) to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile (7.8 mg,
 15 0.020 mmol, 66% yield) as a pale yellow solid. LCMS (ESI) m/e 384.0 [(M+H)⁺, calcd for C₂₀H₂₃ClN₅O 384.2]; LC/MS retention time (method H): t_R = 1.63 min; LC/MS retention time (method I): t_R = 1.29 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.66 (d, *J* = 2.3 Hz, 1H), 8.58 - 8.49 (m, 1H), 8.22 (d, *J* = 1.3 Hz, 1H), 7.87 (d, *J* = 1.3 Hz, 1H), 7.58 - 7.53 (m, 1H), 7.45 (d, *J* = 8.9 Hz, 1H), 4.27 - 4.19 (m, 2H), 1.94 -
 20 1.78 (m, 2H), 1.71 - 1.63 (m, 1H), 1.45 (s, 3H), 1.10 - 1.02 (m, 6H) ppm.

Example 287

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(imidazo[1,2-*b*]pyridazin-8-yl)benzonitrile





To a stirred solution of (*S*)-*tert*-butyl (1-(4-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 286) (0.035 g, 0.072 mmol) in methanol (6 mL) was added palladium on carbon (0.019 g, 0.018 mmol). The mixture was stirred under 1 atm hydrogen gas for 1 h. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth bed was washed with methanol (25 mL). The filtrate was concentrated under reduced pressure. The crude product was dissolved in dichloromethane (3 mL) and cooled to 0 °C. TFA (0.111 mL, 1.446 mmol) was added at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature. The mixture was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(imidazo[1,2-*b*]pyridazin-8-yl)benzonitrile (13 mg, 0.037 mmol, 51% yield) as a pale yellow gummy liquid. LCMS (ESI) *m/e* 350.2 [(*M*+*H*)⁺, calcd for C₂₀H₂₄N₅O 350.2]; LC/MS retention time (Method F): *t_R* = 1.70 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.57 (d, *J* = 2.3 Hz, 1H), 8.52 (d, *J* = 4.8 Hz, 1H), 8.46 (dd, *J* = 2.4, 8.9 Hz, 1H), 8.23 (d, *J* = 1.3 Hz, 1H), 7.83 (d, *J* = 1.3 Hz, 1H), 7.43 - 7.39 (m, 2H), 4.13 - 4.07 (m, 2H), 1.92 - 1.84 (m, 1H), 1.73 - 1.57 (m, 2H), 1.35 (s, 3H), 1.06 - 1.01 (m, 6H) ppm.

20

Example 288

(*S*)-1-(2-fluoro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine




25

Part A: (S)-Tert-butyl (1-(2-fluoro-4-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

To a solution of 4-iodo-1H-pyrazolo[3,4-b]pyridine (prepared as described in Example 284) (0.030 g, 0.122 mmol) in 1,4-dioxane (6 mL) and water (2 mL) was
 5 added (*S*)-tert-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 253, Part B) (0.055 g, 0.122 mmol) and potassium phosphate, dibasic (0.043 g, 0.245 mmol). The reaction mixture was purged with argon for 10 min and PdCl₂(dppf)-CH₂Cl₂ adduct (10.00 mg, 0.012 mmol) was added. The reaction mixture was again purged
 10 with argon for 10 min and heated for 3 h at 60 °C. The reaction mixture was diluted with ethyl acetate and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (2x5 mL). The ethyl acetate layer was washed with water, brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Preparative TLC using 40% EtOAc in hexane.
 15 The required spot was collected, dissolved in 10% MeOH in DCM (20 mL), filtered and concentrated under reduced pressure to afford (*S*)-tert-butyl (1-(2-fluoro-4-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.038 g, 0.086 mmol, 70% yield) as a pale yellow solid. LCMS (ESI) *m/e* 443.2 [(M+H)⁺, calcd for C₂₄H₃₂FN₄O₃ 443.2]; LC/MS retention time (method D): *t_R* = 2.13 min.

20




Part B: (S)-1-(2-fluoro-4-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine

A solution of (*S*)-tert-butyl (1-(2-fluoro-4-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.038 g, 0.086 mmol) in
 25 dichloromethane (0.5 mL) was cooled to 0 °C and HCl in 1,4-dioxane (4M) (0.5 mL, 2.00 mmol) was added. The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure. To the residue was added diethyl ether (5 mL) and the mixture stirred for 30 min. The solid formed

was collected by vacuum filtration and dried under high vacuum to afford (*S*)-1-(2-fluoro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine, 1.2 HCl (0.031 g, 0.076 mmol, 88% yield) as a colorless solid. LCMS (ESI) *m/e* 343.2 [(*M*+*H*)⁺, calcd for C₁₉H₂₄FN₄O 343.2]; LC/MS retention time (method H): *t*_R = 1.84 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.66 (d, *J* = 5.2 Hz, 1 H), 8.51 (s, 1 H), 7.81 - 7.76 (m, 2 H), 7.49 - 7.42 (m, 2 H), 4.31 - 4.20 (m, 2 H), 1.91 - 1.84 (m, 2 H), 1.74 - 1.70 (m, 1 H), 1.52 (s, 3 H) 1.08 - 1.04 (m, 6 H) ppm.

Example 289

(*S*)-1-(2-fluoro-4-(1-methyl-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine




15

Part A: 4-iodo-1-methyl-1*H*-pyrazolo[3,4-*b*]pyridine


A solution of 4-iodo-1*H*-pyrazolo[3,4-*b*]pyridine, prepared as described in Example 284 (0.050 g, 0.204 mmol) in DMF (0.5 mL) was cooled to 0 °C and NaH (8.16 mg, 0.204 mmol) was added. The reaction mixture was stirred for 30 min at 0 °C and iodomethane (0.029 g, 0.204 mmol) was added. The reaction mixture was stirred for 10 min at 0 °C and at room temperature for 1 h. The reaction mixture was quenched with ice and diluted with ethyl acetate (5 mL). The organic layer was separated. The aqueous layer was again extracted with ethyl acetate (2x5 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified via silica gel chromatography (30% ethyl acetate in hexanes) to afford 4-iodo-1-methyl-1*H*-pyrazolo[3,4-*b*]pyridine (0.030 g, 0.114 mmol, 56% yield) as a brown solid. LCMS

(ESI) m/e 259.9 [(M+H)⁺, calcd for C₇H₇IN₃ 259.9]; LC/MS retention time (Method C): t_R = 0.87 min.



5 *Part B: (S)-tert-butyl (1-(2-fluoro-4-(1-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

To a solution of 4-iodo-1-methyl-1H-pyrazolo[3,4-b]pyridine (0.030 g, 0.114 mmol) in 1,4-dioxane (6 mL) and water (2 mL) was added (S)-tert-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 285) (0.052 g, 0.114 mmol) and
 10 potassium phosphate, dibasic (0.040 g, 0.229 mmol). The reaction mixture was purged with argon for 10 min and PdCl₂(dppf)-CH₂Cl₂ adduct (9.33 mg, 0.011 mmol) was added. The reaction mixture was again purged with argon for 10 min and heated for 3 h at 60°C. The reaction mixture was filtered through diatomaceous earth and
 15 the diatomaceous earth bed was washed with ethyl acetate (2x5 mL). The reaction mixture was purified by Preparative TLC by (30% ethyl acetate in hexanes). The required spot was collected, dissolved in 10% Methanol in DCM (20 mL), filtered and concentrated under reduced pressure to afford (S)-tert-butyl (1-(2-fluoro-4-(1-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.042 g, 0.090 mmol, 79% yield) as an off-white solid. LCMS (ESI)
 20 m/e 457.2 [(M+H)⁺, calcd for C₂₅H₃₄FN₄O₃ 457.2]; LC/MS retention time (method A2): t_R = 2.31 min.





Part C: *(S)*-1-(2-fluoro-4-(1-methyl-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine

To a solution *(S)*-*tert*-butyl 1-(2-fluoro-4-(1-methyl-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.040 g, 0.086 mmol) in DCM (0.5 mL) at 0 °C was added HCl in 1,4-dioxane (0.6 mL, 19.75 mmol). The reaction mixture was allowed to stir for 1.5 h at room temperature, then was concentrated under reduced pressure. The solid was washed with diethyl ether (5 mL) and lyophilized over 16 h. The crude material was purified by prep LC/MS (method B) to afford *(S)*-1-(2-fluoro-4-(1-methyl-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine (0.0202 g, 0.057 mmol, 66% yield) as a pale yellow solid. LCMS (ESI) *m/e* 357.2 [(M+H)⁺, calcd for C₂₀H₂₆FN₄O 357.2]; LC/MS retention time (method H): *t*_R = 1.16 min; LC/MS retention time (method I): *t*_R = 0.99 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.59 (m, 1 H), 8.25 (s, 1 H), 7.73 - 7.68 (m, 2 H), 7.42 - 7.35 (m, 2 H), 4.29 - 4.26 (m, 1 H), 4.20 - 4.24 (m, 1 H), 4.18 (s, 3 H), 1.86 - 1.94 (m, 2 H), 1.69 - 1.77 (m, 1 H), 1.54 (s, 3 H) 1.05 (m, 6 H) ppm.

Example 291


2,4-dimethyl-1-(4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine



Part A: 7-bromo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine


A solution of 4-bromopyridine-2,3-diamine (0.2 g, 1.064 mmol), PPA (0.680 mL, 1.064 mmol) and AcOH (0.061 mL, 1.064 mmol) was heated at 150 °C for 3 h. The reaction mixture was quenched with 10% NaOH solution (18 mL) to maintain

pH-14 and extracted with ethyl acetate (15 mL). The ethyl acetate layer was washed with sat K₂CO₃ solution (5 mL), brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 7-bromo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine (0.170 g, 0.801 mmol, 75% yield) as a pale yellow solid. LCMS (ESI) *m/e* 212.0 (bromo pattern) [(M+H)⁺, calcd for C₇H₇BrN₃ 212.0]; LC/MS retention time (method A2): *t*_R = 1.35 min.



Part B. *(S)*-tert-butyl (2,4-dimethyl-1-(4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A solution of 7-bromo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine (0.030 g, 0.141 mmol), *(S)*-tert-butyl(2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 290) (0.071 g, 0.141 mmol) and potassium phosphate, dibasic (0.049 g, 0.283 mmol) in 1,4-dioxane (6 mL) and water (2 mL) was purged with argon for 20 min and PdCl₂(dppf)-CH₂Cl₂ adduct (0.012 g, 0.014 mmol) was added. The reaction mixture was again purged with argon for 10 min and heated for 19 h at 60°C. The reaction mixture was cooled to room temperature and was diluted with ethyl acetate (10 mL) The organic layer was separated the aqueous layer was extracted with ethyl acetate (2x4 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by Preparative TLC using 3% methanol in dichloromethane. The required spot was collected, dissolved 15% methanol in dichloromethane (30 mL), filtered and concentrated under reduced pressure to afford *(S)*-tert-butyl (2,4-dimethyl-1-(4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.035 g, 0.039 mmol, 27% yield) as a yellow solid. LCMS (ESI) *m/e* 507.2 [(M+H)⁺, calcd for C₂₆H₃₄F₃N₄O₃ 507.2]; LC/MS retention time (method B): *t*_R = 1.01 min.




Part C. (S)-2,4-dimethyl-1-(4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine


- 5 To a solution (S)-tert-butyl (2,4-dimethyl-1-(4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.030 g, 0.033 mmol) in dichloromethane (0.5 mL) at 0 °C was added HCl in 1,4-dioxane (4M) (0.5 mL, 2.000 mmol) and the reaction mixture was allowed to stir at 0 °C for 10 min. The reaction mixture was allowed to stir for 1 h at room temperature, then was
- 10 concentrated under reduced pressure. The crude material was purified by prep LC/MS (method B) to afford (S)-2,4-dimethyl-1-(4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine (0.0045 g, 10.98 μmol, 33% yield) as a pale yellow solid. LCMS (ESI) m/e 407.0 [(M+H)⁺, calcd for C₂₁H₂₆F₃N₄O 407.2]; LC/MS retention time (method H): t_R = 1.37 min; LC/MS
- 15 retention time (method I): t_R = 0.93 min. ¹H NMR (400 MHz, MeOD): δ 8.44 (d, J = 2.00 Hz, 1H), 8.36 (m, 1H), 8.07 (d, J = 8.80 Hz, 1H), 7.92 (d, J = 8.40 Hz, 1H), 7.39 (d, J = 8.40 Hz, 1H), 4.26 (m, 2H), 2.75 (s, 3H), 1.86-1.90 (m, 2H), 1.71-1.75 (m, 1H), 1.53 (s, 3H), 1.06 (d, J = 6.40 Hz, 3H), 1.02 (d, J = 6.00 Hz, 3H) ppm.

20

Example 292


(S)-1-(4-(1H-pyrazolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine





Part A: 4-iodo-1H-pyrazolo[3,4-b]pyridine


To a solution of 2-fluoro-4-iodonicotinaldehyde (0.2 g, 0.797 mmol) in 2-propanol (2 mL), hydrazine monohydrate (0.2 mL, 6.37 mmol) was added and the
 5 reaction mixture was heated at 60 °C for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was diluted with ethyl acetate (8 mL) and water. The ethyl acetate layer was separated and the aqueous layer was again extracted with ethyl acetate (2x6 mL). The ethyl acetate layer was washed with
 brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford
 10 4-iodo-1H-pyrazolo[3,4-b]pyridine (0.117 g, 0.478 mmol, 60% yield) as an off-white solid. LCMS (ESI) *m/e* 246.0 [(M+H)⁺, calcd for C₆H₅IN₃ 246.0]; LC/MS retention time (Method A1): *t_R* = 1.56 min.



15 *Part B: (S)-tert-butyl (1-(4-(1H-pyrazolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

To a solution of 4-iodo-1H-pyrazolo[3,4-b]pyridine (0.030 g, 0.122 mmol) in 1,4-dioxane (6 mL) and water (2 mL), (S)-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.061 g, 0.122
 20 mmol) and potassium phosphate, dibasic (0.043 g, 0.244 mmol) was added. The reaction mixture was purged with argon for 10 min and PdCl₂(dppf)-CH₂Cl₂ adduct (9.98 mg, 0.012 mmol) was added. The reaction mixture was again purged with argon for 10 min and heated for 4 h at 60°C. The reaction mixture was diluted with
 25 ethyl acetate (10 mL) and the aqueous layer was washed with ethyl acetate (2x8 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The reaction mixture was purified by

Preparative TLC by 70% ethyl acetate in hexanes. The required spot was collected, dissolved 15% MeOH in DCM(20 mL), filtered and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.031 g, 0.058 mmol, 47% yield) as an off-white solid. LCMS (ESI) *m/e* 493.2 [(*M*+*H*)⁺, calcd for C₂₅H₃₂F₃N₄O₃ 493.2]; LC/MS retention time (method B): *t_R* = 1.11 min.





Part C: (*S*)-1-(4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine

To a solution (*S*)-*tert*-butyl (1-(4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.030 g, 0.056 mmol) in DCM (0.5 mL) at 0 °C was added HCl in 1,4-dioxane (0.5 μL, 0.016 mmol) and the reaction mixture was allowed to stir at 0 °C for 10 min. The reaction mixture was allowed to stir for 1 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (*S*)-1-(4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine (0.0055 g, 0.013 mmol, 24% yield). LCMS (ESI) *m/e* 393.0 [(*M*+*H*)⁺, calcd for C₂₀H₂₄F₃N₄O 393.2]; LC/MS retention time (method H): *t_R* = 1.43 min; LC/MS retention time (method I): *t_R* = 1.06 min. ¹H NMR (400 MHz, MeOD): δ 8.58 (d, *J* = 4.80 Hz, 1H), 8.27 (s, 1H), 8.13 (m, 1H), 8.07 (d, *J* = 2.00 Hz, 1H), 7.42 (d, *J* = 8.80 Hz, 1H), 7.38 (d, *J* = 4.80 Hz, 1H), 4.04 (m, 2H), 1.81-1.91 (m, 1H), 1.54-1.66 (m, 2H), 1.31 (s, 3H), 1.01 (m, 6H) ppm.

25


Example 293

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)benzonitrile



Part A. 7-bromo-2-methyl-3H-imidazo[4,5-b]pyridine

- 5 A solution of 4-bromopyridine-2,3-diamine (0.2 g, 1.064 mmol), PPA (0.680 mL, 1.064 mmol) and AcOH (0.061 mL, 1.064 mmol) was heated at 150 °C for 3 h. The reaction mixture was quenched with 10% NaOH solution (18 mL) to maintain pH-14 and extracted with ethyl acetate (15 mL). The ethyl acetate layer was washed with saturated K₂CO₃ solution (5 mL), brine, dried over Na₂SO₄, filtered, and
- 10 concentrated under reduced pressure to afford 7-bromo-2-methyl-3H-imidazo[4,5-b]pyridine (0.170 g, 0.801 mmol, 75% yield) as a pale yellow solid. LCMS (ESI) *m/e* 212.0 (bromo pattern) [(M+H)⁺, calcd for C₇H₇BrN₃ 212.0]; LC/MS retention time (method A2): *t_R* = 1.35 min.




- 15 *Part B. (S)-tert-butyl (1-(2-cyano-4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

To a solution of 7-bromo-2-methyl-3H-imidazo[4,5-b]pyridine (0.030 g, 0.141 mmol) in 1,4-dioxane (6 mL) and water (2 mL) was added (S)-tert-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 285) (0.065 g, 0.141 mmol) and

20 potassium phosphate, dibasic (0.049 g, 0.283 mmol). The reaction mixture was

purged with argon for 30 min and PdCl₂(dppf)-CH₂Cl₂ adduct (0.012 g, 0.014 mmol) was added. The reaction mixture was again purged with argon for 10 min and heated for 16 h at 100 °C. The reaction mixture was diluted with ethyl acetate (10 mL) and the organic layer was separated. The aqueous layer was again extracted with ethyl
 5 acetate (2 x 8 mL). The combined ethyl acetate layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Preparative TLC by (70% ethyl acetate in hexanes). The required spot was collected, dissolved in 15% Methanol in dichloromethane (20 mL), filtered, and concentrated under reduced pressure to afford the (*S*)-*tert*-butyl (1-(2-cyano-4-(2-
 10 methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.040 g, 0.081 mmol, 57 % yield) as a pale yellow solid. LCMS (ESI) *m/e* 464.3 [(M+H)⁺, calcd for C₂₆H₃₄N₅O₃ 464.3]; LC/MS retention time (method B): *t_R* = 0.95 min.



15



*Part C: (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)benzonitrile*

To a solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.040 g, 0.081 mmol) in DCM (1 mL) at 0 °C was added HCl in 1,4-dioxane (0.8 mL, 3.20 mmol). The
 20 reaction mixture was allowed to stir for 1 h at room temperature, then concentrated under reduced pressure. The solid residue was washed with diethyl ether (5 mL) and dried under vacuum to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)benzonitrile, 1.5 HCl (0.032 g, 0.074 mmol, 91%
 25 yield) as a brown solid. LCMS (ESI) *m/e* 364.2 [(M+H)⁺, calcd for C₂₁H₂₆N₅O 364.2]; LC/MS retention time (Method A1): *t_R* = 2.28 min. ¹H NMR (300 MHz, MeOD): δ 8.51-8.45 (m, 2H), 8.20 (d, *J* = 8.7 Hz, 1H), 8.08 (d, *J* = 8.7 Hz, 1H), 7.43

(d, $J = 8.7$ Hz, 1H), 4.32 (m, 2H), 2.87 (s, 3H), 1.87-1.99 (m, 2H), 1.70-1.76 (m, 1H), 1.29 (s, 3H), 1.05 (m, 6H) ppm.


Example 294

5 (S)-2,4-dimethyl-1-(2-methyl-4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)phenoxy)pentan-2-amine



10 *Part A. 4-bromo-2-nitropyridin-3-amine*

To a solution of 2-nitropyridin-3-amine (4 g, 28.8 mmol) in AcOH (40 mL) was added potassium acetate (2.82 g, 28.8 mmol) and the mixture stirred for 1 h at room temperature. Br₂ (1.481 mL, 28.8 mmol) was added slowly to the reaction mixture and the mixture stirred at room temperature for 16 h. The solid formed was collected by vacuum filtration, washed with diethyl ether (2x10 mL) and dried under high vacuum to afford 4-bromo-2-nitropyridin-3-amine (6 g, 27.5 mmol, 96% yield) as a yellow solid. LCMS (ESI) m/e 218.0 [(M+H)⁺, calcd for C₅H₅BrN₃O₂ 218.0]; LC/MS retention time (method B): $t_R = 0.61$ min.




20

Part B: 4-bromopyridine-2,3-diamine

To a solution of 4-bromo-2-nitropyridin-3-amine (2 g, 9.16 mmol) in ethanol (60 mL) and water (25 mL) was added tin (II) chloride (8.69 g, 45.8 mmol) and the reaction mixture was heated at 80 °C for 4.5 h. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate (25 mL) and filtered

25


through diatomaceous earth to remove the emulsion. The ethyl acetate layer was separated and the aqueous layer was again extracted with ethyl acetate (2x15 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was washed with n-hexane(15
5 mL) to remove the color impurities to afford 4-bromopyridine-2,3-diamine (0.9 g, 4.44 mmol, 49% yield) as a black solid. LCMS (ESI) *m/e* 188.0 (bromo pattern) [(M+H)⁺, calcd for C₅H₇BrN₃ 188.0]; LC/MS retention time (Method A1): *t_R* = 1.90 min.



10

Part C: 7-bromo-2-methyl-3H-imidazo[4,5-b]pyridine


A mixture of 4-bromopyridine-2,3-diamine (0.9 g, 4.44 mmol), PPA (0.680 mL, 4.44 mmol) in AcOH (0.254 mL, 4.44 mmol) was heated at 150 °C for 3 h. At room temperature the reaction mixture was basified with 10% NaOH solution(20
15 mL) and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated K₂CO₃(10 mL) solution, brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a solid. The solid was washed with n-hexane(15 mL) and dried the solid under high vacuum to afford 7-bromo-2-methyl-3H-imidazo[4,5-b]pyridine (0.540 g, 2.53 mmol, 57% yield) as a pale yellow color
20 solid. LCMS (ESI) *m/e* 212.0 (bromo pattern) [(M+H)⁺, calcd for C₇H₇BrN₃ 212.0]; LC/MS retention time (Method A1): *t_R* = 2.07 min.



*Part D: (S)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(2-methyl-3H-imidazo[4,5-
25 b]pyridin-7-yl)phenoxy)pentan-2-yl)carbamate*

To a solution of 7-bromo-2-methyl-3*H*-imidazo[4,5-*b*]pyridine (0.030 g, 0.140 mmol) in 1,4-dioxane (6 mL) and water (2 mL) was added (*S*)-*tert*-butyl(2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 285) (0.069 g, 0.154 mmol) and potassium phosphate, dibasic (0.073 g, 0.421 mmol). The reaction mixture was purged with argon for 30 min and PdCl₂(dppf)-CH₂Cl₂ adduct (0.011 g, 0.014 mmol) was added. The reaction mixture was again purged with argon for 10 min and heated for 3 h at 100 °C. The reaction mixture was diluted with ethyl acetate (8 mL) and the organic layer was separated. The aqueous layer was again extracted with ethyl acetate (2x5 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Preparative TLC by (70% ethyl acetate in hexanes). The required spot was collected, dissolved in 15% methanol in dichloromethane (30 mL), filtered and concentrated under reduced pressure. The residue was washed with diethyl ether (4 mL) and dried under high vacuum to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)pentan-2-yl)carbamate (0.040 g, 0.066 mmol, 47% yield) as a colorless solid. LCMS (ESI) *m/e* 453.3 [(M+H)⁺, calcd for C₂₆H₃₇N₄O₃ 453.3]; LC/MS retention time (method B): *t*_R = 0.98 min.

20



*Part E: (S)-2,4-dimethyl-1-(2-methyl-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)pentan-2-amine*

To a solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)pentan-2-yl)carbamate (0.040 g, 0.066 mmol) in dichloromethane (0.8 mL) at 0 °C was added HCl in 1,4-dioxane (0.8 mL, 3.20 mmol) and stirred at 0 °C for 5 min. The reaction mixture was allowed to stir for 1 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method B) to afford (*S*)-2,4-dimethyl-1-(2-



methyl-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)pentan-2-amine, 2 TFA (0.015 g, 0.028 mmol, 42% yield) as a pale yellow solid. LCMS (ESI) *m/e* 353.2 [(M+H)⁺, calcd for C₂₁H₂₉N₄O 353.2]; LC/MS retention time (method H): *t_R* = 1.08 min; LC/MS retention time (method I): *t_R* = 0.83 min. ¹H NMR (400 MHz, MeOD):

5 δ 8.09 (d, *J* = 8.40 Hz, 1H), 7.91-7.96 (m, 3H), 7.10 (d, *J* = 8.40 Hz, 1H), 4.18 (m, *J* = 10.40 Hz, 1H), 4.11 (d, *J* = 10.40 Hz, 1H), 2.80 (s, 3H), 2.41 (s, 3H), 1.86-1.94 (m, 2H), 1.68-1.73 (m, 1H), 1.53 (s, 3H), 1.07 (d, *J* = 6.40 Hz, 3H), 1.03 (d, *J* = 6.40 Hz, 3H) ppm.

10

Example 295

(*S*)-1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine




15

Part A. 4-bromo-2-nitropyridin-3-amine


To a solution of 2-nitropyridin-3-amine (4 g, 28.8 mmol) in AcOH (40 mL) was added potassium acetate (2.82 g, 28.8 mmol) and stirred for 1 h at room temperature. Br₂ (1.481 mL, 28.8 mmol) was added slowly to the reaction mixture and stirred at room temperature for 16 h. The solid formed was filtered, washed with diethyl ether (2x10 mL) and dried under high vacuum to afford 4-bromo-2-nitropyridin-3-amine (6 g, 27.5 mmol, 96% yield) as a yellow solid. LCMS (ESI) *m/e* 217.9 [(M+H)⁺, calcd for C₅H₅BrN₃O₂ 217.9]; LC/MS retention time (method B): *t_R* = 0.67 min.

25



Part B: N-(4-bromo-2-nitropyridin-3-yl)-2-methoxyacetamide


A solution of 4-bromo-2-nitropyridin-3-amine (0.550 g, 2.52 mmol) in Pyridine (1 mL) was cooled to 0 °C. 2-methoxyacetyl chloride (0.410 g, 3.78 mmol) was added to the reaction mixture and the mixture stirred for 15 min at 0 °C. The reaction mixture was stirred at room temperature for 6 h. The reaction mixture was concentrated under reduced pressure. The residue was diluted with water (10 mL) and ethyl acetate (1 mL). The organic layer was separated. The aqueous layer was extracted with ethyl acetate (2x8 mL). The combined ethyl acetate layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified via silica gel chromatography (100% ethyl acetate in hexane) to *N*-(4-bromo-2-nitropyridin-3-yl)-2-methoxyacetamide (0.3 g, 1.013 mmol, 40% yield) as a yellow color solid. LCMS (ESI) *m/e* 290.0 (bromo pattern) [(M+H)⁺, calcd for C₈H₉BrN₃O₄ 290.0]; LC/MS retention time (Method A1): *t*_R = 2.35 min.



Part C: N-(2-amino-4-bromopyridin-3-yl)-2-methoxyacetamide

To a solution of *N*-(4-bromo-2-nitropyridin-3-yl)-2-methoxyacetamide (0.050 g, 0.169 mmol) in methanol (1.5 mL), water (0.5 mL) mixture, iron (0.075 g, 1.350 mmol) was added followed by ammonium chloride (0.090 g, 1.688 mmol) and the reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth bed was washed with 10% methanol in dichloromethane (10 mL). The filtrate was concentrated under reduced pressure and water (10 mL) was added to the residue. The compound was extracted with ethyl acetate (2x8 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The solid obtained was washed with diethyl ether (5 mL) to afford *N*-(2-amino-4-bromopyridin-3-yl)-2-


methoxyacetamide (0.030 g, 0.115 mmol, 68% yield) as a brown solid LCMS (ESI) m/e 260.0 (bromo pattern) $[(M+H)^+]$, calcd for $C_8H_{11}BrN_3O_2$ 260.0]; LC/MS retention time (Method A1): t_R = 1.49 min.



5

Part D: 7-bromo-2-(methoxymethyl)-3H-imidazo[4,5-b]pyridine

A mixture of *N*-(2-amino-4-bromopyridin-3-yl)-2-methoxyacetamide (0.165 g, 0.621 mmol) CsF (0.9 g, 5.92 mmol) and *N,N*-dimethylformamide (15 mL) was taken in a sealed tube and heated at 130 °C for 16 h. The reaction mixture was quenched with chilled water (15 mL) and extracted with ethyl acetate (15 mL). The organic layer was separated and the aqueous layer was again extracted with ethyl acetate (2x10 mL). The combined ethyl acetate layers were washed with water (20 mL), brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The solid was washed with hexane (2x5 mL) to afford 7-bromo-2-(methoxymethyl)-3H-imidazo[4,5-b]pyridine (0.1 g, 0.397 mmol, 64% yield) as a brown solid. LCMS (ESI) m/e 242.0 $[(M+H)^+]$, calcd for $C_8H_9BrN_3O$ 242.0]; LC/MS retention time (method B): t_R = 0.52 min.




Part E: (S)-tert-butyl (1-(4-(2-(methoxymethyl)-3H-imidazo[4,5-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

To a solution of 7-bromo-2-(methoxymethyl)-3H-imidazo[4,5-b]pyridine (0.025 g, 0.099 mmol) in 1,4-dioxane (6 mL) and water (2 mL) was added (*S*)-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example

25

255, Parts A and B) (0.055 g, 0.109 mmol) and potassium phosphate, dibasic (0.052 g, 0.298 mmol). The reaction mixture was purged with argon for 30 min and PdCl₂(dppf)-CH₂Cl₂ adduct (8.10 mg, 9.92 μmol) was added. The reaction mixture was again purged with argon for 10 min and heated for 16 h at 100 °C. The reaction mixture was diluted with ethyl acetate (8 mL) and the organic layer was separated. The aqueous layer was again extracted with ethyl acetate (2x5 mL). The combined ethyl acetate layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Prep TLC (70% ethyl acetate in hexanes). The required spot was collected, dissolved in 15% methanol in dichloromethane (30 mL), filtered and concentrated under reduced pressure. The residue was washed with diethyl ether (4 mL) and dried under high vacuum to afford (*S*)-*tert*-butyl (1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.030 g, 0.056 mmol, 56% yield) as an off-white solid. LCMS (ESI) *m/e* 537.3 [(M+H)⁺, calcd for C₂₇H₃₆F₃N₄O₄ 537.3]; LC/MS retention time (method B): *t*_R = 1.05 min.



*Part F: (S)-1-(4-(2-(methoxymethyl)-3H-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine*


To a solution of (*S*)-*tert*-butyl (1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.030 g, 0.056 mmol) in dichloromethane (1 mL) at 0 °C was added TFA (0.6 mL, 7.79 mmol). The reaction mixture was allowed to stir for 2 h at room temperature, then was concentrated under reduced pressure. To the residue was added water (2 mL). The solution was cooled to 0 °C then basified with saturated NaHCO₃ solution (8 mL) and extracted with ethyl acetate (2x6 mL). The ethyl acetate layer was washed with water, brine, dried over Na₂SO₄, filtered, and concentrated under

reduced pressure to afford the crude product. The crude product was washed with diethyl ether (2 mL) to afford (*S*)-1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine (0.020 g, 0.046 mmol, 82% yield) as an off-white solid. LCMS (ESI) *m/e* 437.2 [(*M*+*H*)⁺, calcd for C₂₂H₂₈F₃N₄O₂ 437.2]; LC/MS retention time (Method A1): *t*_R = 2.13 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.40 (d, *J*=2.01 Hz, 1 H), 8.30 (dd, *J*=8.78, 2.26 Hz, 1 H) 8.03 (d, *J*=8.53 Hz, 1 H), 7.81 (d, *J*=8.53 Hz, 1 H), 7.29 (d, *J*=8.53 Hz, 1 H), 4.76 (s, 2 H), 3.94 - 4.01 (m, 2 H), 3.53 (s, 3 H), 1.85 (dt, *J*=12.80, 6.15 Hz, 1 H), 1.51 - 1.63 (m, 2 H), 1.28 (s, 3 H), 1.01 (m, 6 H) ppm.


10

Example 296

(*S*)-1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amine



15


*Part A: N-(4-bromo-2-nitropyridin-3-yl)-2-methoxyacetamide*

A solution of 4-bromo-2-nitropyridin-3-amine (0.550 g, 2.52 mmol) in pyridine (1 mL) was cooled to 0 °C and 2-methoxyacetyl chloride (0.410 g, 3.78 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C and at room temperature for 6 h. The reaction mixture was concentrated by high vacuum and the residue was diluted with water (10 mL) and ethyl acetate (1 mL). The organic layer was separated and the aqueous layer was again extracted with ethyl acetate (2x8 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified via silica gel

25


chromatography (100% ethyl acetate in hexane) to afford *N*-(4-bromo-2-nitropyridin-3-yl)-2-methoxyacetamide (0.3 g, 1.013 mmol, 40% yield) as a yellow solid. LCMS (ESI) *m/e* 290.0 (bromo pattern) [(M+H)⁺, calcd for C₈H₉BrN₃O₄ 290.0]; LC/MS retention time (Method A1): *t*_R = 2.35 min.

5



Part B: N-(2-amino-4-bromopyridin-3-yl)-2-methoxyacetamide


To a solution of *N*-(4-bromo-2-nitropyridin-3-yl)-2-methoxyacetamide (0.050 g, 0.169 mmol) in methanol (1.5 mL) water (0.5 mL) mixture was added iron (0.075 g, 1.350 mmol) followed by ammonium chloride (0.090 g, 1.688 mmol) and the
 10 reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was filtered through diatomaceous earth and the diatomaceous earth bed was washed with 10% methanol in dichloromethane (10 mL). The filtrate was concentrated under reduced pressure and water (10 mL) was added to the residue. The compound was extracted
 15 with ethyl acetate (2x8 mL). The ethyl acetate layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The solid obtained was washed with diethyl ether (5 mL) to afford *N*-(2-amino-4-bromopyridin-3-yl)-2-methoxyacetamide (0.030 g, 0.115 mmol, 68% yield) as a brown solid. LCMS (ESI) *m/e* 260.0 (bromo pattern) [(M+H)⁺, calcd for C₈H₁₁BrN₃O₂ 260.0]; LC/MS retention
 20 time (Method A1): *t*_R = 1.49 min.



Part C: 7-bromo-2-(methoxymethyl)-3H-imidazo[4,5-b]pyridine


A mixture of *N*-(2-amino-4-bromopyridin-3-yl)-2-methoxyacetamide (0.165 g, 0.621 mmol), CsF (0.9 g, 5.92 mmol) and *N,N*-dimethylformamide (15 mL) was
 25 taken in a sealed tube and heated at 130 °C for 16 h. The reaction mixture was quenched with chilled water (15 mL) and then diluted with ethyl acetate (15 mL). Then organic layer was separated and the aqueous layer was washed with ethyl acetate (2x10 mL). The ethyl acetate layer was washed with water (20 mL), brine,

dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The solid was washed with hexane (2x5 mL) to afford 7-bromo-2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridine (0.1 g, 0.397 mmol, 64% yield) as a brown solid. LCMS (ESI) *m/e* 242.0 (bromo pattern) [(M+H)⁺, calcd for C₈H₉BrN₃O 242.0]; LC/MS retention time (method B): *t*_R = 0.52 min.



*Part D: (S)-tert-butyl (1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate*

To a solution of 7-bromo-2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridine (0.030 g, 0.119 mmol) in 1,4-dioxane (6 mL) water (2 mL) mixture was added (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 259, Part A and B) (0.059 g, 0.131 mmol) and potassium phosphate, dibasic (0.062 g, 0.357 mmol). The reaction mixture was purged with argon for 30 min and PdCl₂(dppf)-CH₂Cl₂ adduct (9.72 mg, 0.012 mmol) was added. The reaction mixture was again purged with argon for 10 min and heated for 16 h at 100°C. The reaction mixture was diluted with ethyl acetate (8 mL) The organic layer was separated and the aqueous layer was washed with ethyl acetate (2x5 mL). The combined ethyl acetate layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The reaction mixture was purified by Preparative TLC using 70% ethyl acetate in hexanes. The required spot was collected, dissolved 15% methanol in dichloromethane (30 mL), filtered and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.035 g, 0.056 mmol, 47% yield) as an off white-solid. LCMS (ESI) *m/e* 483.3 [(M+H)⁺, calcd for C₂₇H₃₉N₄O₄ 483.3]; LC/MS retention time (method B): *t*_R = 1.00 min.




Part E: (S)-1-(4-(2-(methoxymethyl)-3H-imidazo[4,5-b]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amine


- 5 To a solution (S)-tert-butyl (1-(4-(2-(methoxymethyl)-3H-imidazo[4,5-b]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.030 g, 0.048 mmol) in dichloromethane (1 mL) at 0 °C was added TFA (0.6 mL, 7.79 mmol) and the reaction mixture was allowed to stir for 2 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep
- 10 LC/MS (method A) to afford (S)-1-(4-(2-(methoxymethyl)-3H-imidazo[4,5-b]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amine (0.0055 g, 0.014 mmol, 29% yield) as a pale yellow solid. LCMS (ESI) m/e 383.2 [(M+H)⁺, calcd for C₂₂H₃₁N₄O₂ 383.2]; LC/MS retention time (method H): t_R = 1.11 min; LC/MS retention time (method I): t_R = 1.00 min. ¹H NMR (400 MHz, MeOD): δ 7.97 (d, J = 8.40 Hz, 1H), 7.89 (d, J = 4.40 Hz, 1H), 7.86 (d, J = 2.00 Hz, 1H), 7.72 (d, J = 8.40 Hz, 1H), 7.04 (d, J = 8.40 Hz, 1H), 4.74 (s, 2H), 4.04 (d, J = 10.00 Hz, 1H), 3.99 (d, J = 9.60 Hz, 1H), 3.51 (s, 3H), 2.38 (s, 3H), 1.82-1.86 (m, 2H), 1.61-1.66 (m, 1H), 1.43 (s, 3H), 1.05 (d, J = 6.40 Hz, 3H), 1.01 (d, J = 6.40 Hz, 3H) ppm.
- 15

20

Example 302


(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)benzonitrile






Part A. 3,3-dibromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one

To a solution of 4-chloro-1H-pyrrolo[2,3-b]pyridine (1 g, 6.55 mmol) in *t*-BuOH (60 mL) was added pyridinium tribromide (5.24 g, 16.38 mmol) portionwise. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated, diluted with water and ethyl acetate. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford 3,3-dibromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (2.1 g, 5.79 mmol, 88% yield) as an off-white solid which was carried forward without further purification. LCMS (ESI) *m/e* 324.8 Br pattern [(M+H)⁺, calcd for C₇H₄Br₂ClN₂O, 324.8]; LC/MS retention time (method B): *t*_R = 0.82 min.




Part B. 4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one

To a solution of 3,3-dibromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (350 mg, 1.072 mmol) in MeOH (5 mL) was added acetic acid (5 mL) then zinc dust (351 mg, 5.36 mmol) in portions. The mixture was stirred at room temperature for 1h. The reaction mixture was diluted with ethyl acetate (50 mL), filtered through diatomaceous earth and the filtrate neutralized with 10% aq. NaHCO₃ solution. The organic layer was separated out, dried over Na₂SO₄, filtered, and concentrated to afford a brownish solid. The solid was washed with hexane (2 x 20 mL) to afford 4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (164 mg, 0.973 mmol, 91% yield) as an off white solid. LCMS (ESI) *m/e* 168.9 [(M+H)⁺, calcd for C₇H₆ClN₂O, 169.0]; LC/MS retention time (method B): *t*_R = 0.58 min.



Part C. *(S)-tert-butyl (1-(2-cyano-4-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A solution of 4-chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (0.05 g, 0.297 mmol), *(S)-tert-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate* (prepared as in Example 254, Part B-G) (0.136 g, 0.297 mmol), PdCl₂(dppf) (10.85 mg, 0.015 mmol) and Cs₂CO₃ (0.290 g, 0.890 mmol) were taken in 1,4-dioxane (2 mL) and water (0.4 mL) heated at 90 °C overnight. The reaction mixture was concentrated, diluted with brine and ethyl acetate. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated. The brown solid was washed with hexane and dried under vacuum to afford *(S)-tert-butyl (1-(2-cyano-4-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate* (120 mg, 0.258 mmol, 87% yield) as a pale solid. LCMS (ESI) *m/e* 465.2 [(M+H)⁺, calcd for C₂₆H₃₃N₄O₄ 465.2]; LC/MS retention time (method B): *t*_R = 1.00 min.





Part D. *(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)benzonitrile*

To a solution of *(S)-tert-butyl (1-(2-cyano-4-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate* (0.12 g, 0.258 mmol) in dichloromethane (2 mL) was added hydrogen chloride in 1,4-dioxane (0.646 mL, 2.58 mmol) and the mixture stirred at room temperature for 3 h. The reaction mixture was concentrated, neutralized with 10% aq. NaHCO₃ solution and

diluted with ethyl acetate. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl)benzonitrile (6 mg, 0.015 mmol, 6% yield) as a pale yellow solid. LCMS (ESI) *m/e* 365.0 [(M+H)⁺, calcd for C₂₁H₂₅N₄O₂ 365.2]; LC/MS retention time (method H): *t*_R = 1.00 min; LC/MS retention time (method I): *t*_R = 0.97 min. ¹H NMR(400 MHz, methanol-*d*₄): δ 8.14-8.16 (d, *J* = 5.6 Hz, 1H), 8.02 (s, 1H), 7.94-7.97 (m, 1H), 7.39-7.42 (d, *J* = 8.8 Hz, 1H), 7.11-7.12 (d, *J* = 5.6 Hz, 1H), 4.29-4.33 (m, 2H), 3.3 (s, 2H), 1.88-1.98 (m, 2H), 1.69 - 1.74 (m, 1H), 1.54 (s, 3H), 1.01-1.09 (m, 6H) ppm.

Example 303


(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-2(3*H*)-one



*Part A. (S)-Tert-butyl (2,4-dimethyl-1-(4-(2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate*

A solution of 4-chloro-1*H*-pyrrolo[2,3-*b*]pyridin-2(3*H*)-one (0.05 g, 0.297 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.178 g, 0.356 mmol), Cs₂CO₃ (0.193 g, 0.593 mmol) and PdCl₂(dppf) (10.85 mg, 0.015 mmol) in 1,4-dioxane (3 mL) and water (0.5 mL)

mixture was heated at 80 °C overnight. The reaction mixture was concentrated, diluted with brine and ethyl acetate. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford a brown solid which was dissolved in ethyl acetate, passed through pad of silica-gel and the filtrate concentrated to afford
 5 (S)-tert-butyl (2,4-dimethyl-1-(4-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (120 mg, 0.236 mmol, 79% yield) as an off-white solid. LCMS (ESI) *m/e* 508.2 [(M+H)⁺, calcd for C₂₆H₃₃F₃N₃O₄ 508.2]; LC/MS retention time (method B): *t*_R = 1.17 min.



10



Part B. (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one

To a solution of (S)-tert-butyl (2,4-dimethyl-1-(4-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.12
 15 g, 0.236 mmol) in dichloromethane (3 mL) at 0 °C was added hydrogen chloride in 1,4-dioxane (0.591 mL, 2.364 mmol). The mixture was stirred at room temperature overnight, then was concentrated under reduced pressure, diluted with aq. NaHCO₃ solution and ethyl acetate. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated which afforded off-white solid as crude product. The crude
 20 material was purified by prep LC/MS (method A) to afford (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (6 mg, 0.014 mmol, 6% yield) as a pale yellow solid. LCMS (ESI) *m/e* 408.0 [(M+H)⁺, calcd for C₂₁H₂₅F₃N₃O₂ 408.2]; LC/MS retention time (method H): *t*_R = 1.38 min; LC/MS retention time (method I): *t*_R = 1.05 min. ¹H NMR (400 MHz, methanol-*d*₄): δ 8.17-8.18 (d, *J* = 5.6 Hz, 1H), 7.92-7.96 (m, 2H), 7.42-7.44 (d, *J* = 8.0 Hz, 1H), 7.14-7.16 (d, *J* = 5.6 Hz, 1H), 4.22-4.31 (m, 2H), 3.3 (s, 2H), 1.87-1.92 (m, 2H), 1.71 - 1.76 (m, 1H), 1.54 (s, 3H), 1.02-1.08 (m, 6H) ppm.

25

Example 321

2-methyl-1-((2-methyl-6-(2-methylpyrimidin-4-yl)pyridin-3-yl)oxy)propan-2-amine




5

Part A. 4-(5-fluoro-6-methylpyridin-2-yl)-2-methylpyrimidine

In a microwave tube 4-chloro-2-methylpyrimidine (50 mg, 0.389 mmol), 6-bromo-3-fluoro-2-methylpyridine (73.9 mg, 0.389 mmol), 1,1,1,2,2,2-hexamethyldistannane (127 mg, 0.389 mmol) and Pd(Ph₃P)₄ (22.47 mg, 0.019 mmol) were taken in DMF (4 mL). The reaction mixture was purged with nitrogen and heated at 160 °C under microwave for 1 h. The reaction mixture was concentrated, diluted with brine and ethyl acetate. The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated which afforded brownish oil. The crude product was purified by silica gel chromatography (20-40% ethyl acetate-hexane) to afford 4-(5-fluoro-6-methylpyridin-2-yl)-2-methylpyrimidine (72 mg, 0.354 mmol, 91% yield). LCMS (ESI) *m/e* 204.5 [(M+H)⁺, calcd for C₁₁H₁₁FN₃ 204.1]; LC/MS retention time (method B): *t*_R = 0.75 min.

15



Part B. 2-methyl-1-((2-methyl-6-(2-methylpyrimidin-4-yl)pyridin-3-yl)oxy)propan-2-amine


To a solution of 2-amino-2-methylpropan-1-ol (8.77 mg, 0.098 mmol) in tetrahydrofuran (2 mL) was added NaH (2.362 mg, 0.098 mmol). The mixture was stirred for 10 min and then 4-(5-fluoro-6-methylpyridin-2-yl)-2-methylpyrimidine (20 mg, 0.098 mmol) were added to the solution. The reaction mixture was stirred

25


overnight at room temperature. The reaction mixture was quenched with water, diluted with brine and ethyl acetate. The organic layer was separated, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford 2-methyl-1-((2-methyl-6-(2-methylpyrimidin-4-yl)pyridin-3-yl)oxy)propan-2-amine (11 mg, 0.040 mmol, 41%
 5 yield) as a pale yellow solid. LCMS (ESI) *m/e* 273.3 [(M+H)⁺, calcd for C₁₅H₂₁N₄O 273.2]; LC/MS retention time (method H): *t_R* = 0.76 min; LC/MS retention time (method I): *t_R* = 0.56 min. ¹H NMR (400 MHz, methanol-*d*₄): δ 8.74 (d, *J* = 5.2 Hz, 1H), 8.28 (d, *J* = 8.8 Hz, 1H), 8.05 (d, *J* = 5.2 Hz, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 3.82
 10 (s, 2H), 2.67 (s, 3H), 2.50 (s, 3H), 1.19 (s, 6H) ppm.

Example 322

(*S*)-1-((2-(difluoromethyl)-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine




15




Part A: 6-bromo-2-(difluoromethyl)-3-fluoropyridine

A solution of 6-bromo-3-fluoropyridine (2 g, 9.80 mmol) in DCM (10 mL) was cooled to 0 °C. DAST (1.295 mL, 9.80 mmol) was added dropwise and the mixture stirred for 5 min at 0 °C. The reaction mixture was warmed to room temperature and stirred for 12 h. The reaction mixture was diluted with DCM (50 mL) and washed with saturated sodium bicarbonate solution (20 mL), water (2 x 20 mL), brine (1 x 20 mL), dried over Na₂SO₄, filtered, and concentrated under reduced
 20 pressure to afford crude 6-bromo-2-(difluoromethyl)-3-fluoropyridine (1.2 g, 5.31 mmol, 54% yield) as a light yellow solid which was carried forward without further purification. LCMS (ESI) *m/e* 225.9 [(M+H)⁺, calcd for C₆H₄BrF₃N 225.9]; LC/MS retention time (Method A1): *t_R* = 2.73 min.



Part B: 7-(6-(difluoromethyl)-5-fluoropyridin-2-yl) pyrazolo [1,5-a] pyrimidine

A solution of 7-chloropyrazolo[1,5-a]pyrimidine (0.1 g, 0.651 mmol), 6-bromo-2-(difluoromethyl)-3-fluoropyridine (0.162 g, 0.716 mmol) and 1,1,1,2,2,2-hexamethyldistannane (0.235 g, 0.716 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen gas for 10 min. Pd(Ph₃P)₄ (0.075 g, 0.065 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas for another 10 min. The reaction mixture was heated at 150 °C for 1.5 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica-gel chromatography (pet ether/ethyl acetate (0-40%)) to afford 7-(6-(difluoromethyl)-5-fluoropyridin-2-yl) pyrazolo [1,5-a] pyrimidine (40 mg, 0.151 mmol, 23% yield) as a yellow solid. LCMS (ESI) *m/e* 265.0 [(M+H)⁺, calcd for C₁₂H₈F₃N₄ 265.1]; LC/MS retention time (Method A1): *t*_R = 2.08 min.




Part C: (S)-1-((2-(difluoromethyl)-6-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine

A solution of (S)-2-amino-2,4-dimethylpentan-1-ol (0.016 g, 0.125 mmol) in DMF (4 mL) was cooled to 0 °C. NaH (3.00 mg, 0.125 mmol) was added followed by slow addition of 7-(6-(difluoromethyl)-5-fluoropyridin-2-yl)pyrazolo[1,5-a]pyrimidine (0.033 g, 0.125 mmol) and stirred for 5 min at 0 °C. The reaction mixture was heated at 60 °C for 2 h. The reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (20 mL) and the organic layer was separated out. The ethyl acetate layer was dried over Na₂SO₄, and concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) to afford (S)-1-((2-(difluoromethyl)-6-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine (4 mg, 10.23 μmol, 8% yield) as a pale yellow solid.

LCMS (ESI) m/e 376.2 [(M+H)⁺, calcd for C₁₉H₂₄F₂N₃O 376.2]; LC/MS retention time (method H): t_R = 2.21 min; LC/MS retention time (method I): t_R = 1.77 min. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.31 (d, J = 8.80 Hz, 1H), 8.72 (d, J = 4.40 Hz, 1H), 8.40 (d, J = 2.40 Hz, 1H), 7.94 (d, J = 8.80 Hz, 1H), 7.76 (d, J = 4.40 Hz, 1H), 7.20-7.47 (m, 1H), 6.92 (d, J = 2.80 Hz, 1H), 4.01 (s, 2H), 1.80-1.85 (m, 1H), 1.41-1.52 (m, 2H), 1.20 (s, 3H), 0.92-0.97 (m, 6H) ppm.

Example 332


(*S*)-1-(2-chloro-4-(pyrazolo[1,5-*a*]pyridin-3-yl)phenoxy)-2,4-dimethylpentan-2-amine



Prepared as described in Example 282 using (*S*)-*tert*-butyl 1-(2-chloro-4-(pyrazolo[1,5-*a*]pyrimidin-3-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.04 g, 0.031 mmol) in the final step to afford crude product. The crude material was purified by prep HPLC (method B) to afford (*S*)-1-(2-chloro-4-(pyrazolo[1,5-*a*]pyridin-3-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (11 mg, 0.031 mmol, 89% yield) as a pale yellow solid. LCMS (ESI) m/e 359.1 [(M+H)⁺, calcd for C₁₉H₂₄ClN₄O, 359.1]; LC/MS retention time (method D); t_R = 2.14 min. LC/MS retention time (Method E); t_R = 1.84 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.95 (dd, J = 1.60, 7.20 Hz, 1H), 8.65 (dd, J = 1.60, 4.00 Hz, 1H), 8.56 (s, 1H), 8.29 (d, J = 2.40 Hz, 1H), 8.04 (dd, J = 2.40, 8.60 Hz, 1H), 7.25 (d, J = 8.80 Hz, 1H), 7.07 (dd, J = 4.00, 7.20 Hz, 1H), 4.21 (d, J = 10.00 Hz, 1H), 4.15 (d, J = 10.00 Hz, 1H), 1.89-1.98 (m, 2H), 1.70-1.75 (m, 1H), 1.55 (s, 3H), 1.06-1.10 (m, 6H) ppm.

Example 333


(*S*)-2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyridin-3-yl)phenoxy)pentan-2-amine



Prepared as described in Example 282 using (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-3-yl)phenoxy)pentan-2-yl)carbamate (0.04 g, 0.082 mmol) to afford crude product. The crude material was purified by prep HPLC (method B) to afford (*S*)-2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyridin-3-yl)phenoxy)pentan-2-amine .TFA (17 mg, 0.082 mmol, 37% yield) as a pale yellow solid. LCMS (ESI) *m/e* 339.2 [(M+H)⁺, calcd for C₂₀H₂₇N₄O, 339.2]; LC/MS retention time (method D); *t_R* = 1.96. LC/MS retention time (Method E); *t_R* = 1.99 min. ¹H NMR (400 MHz, *METHANOL-d₄*): δ 8.92 (dd, *J* = 1.60, 7.20 Hz, 1H), 8.60 (dd, *J* = 1.60, 4.00 Hz, 1H), 8.50 (s, 1H), 7.90-7.90 (m, 2H), 7.02-7.07 (m, 2H), 4.15 (d, *J* = 10.40 Hz, 1H), 4.09 (d, *J* = 10.00 Hz, 1H), 2.41 (s, 3H), 1.87-1.96 (m, 2H), 1.70-1.75 (m, 1H), 1.54 (s, 3H), 1.04-1.10 (m, 6H) ppm.

Example 334


4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(3-fluorocyclopentyl)pyridin-2-amine



Part A: 4-Chloro-N-(3-fluorocyclopentyl)pyridin-2-amine


The solution of 3-fluorocyclopentanamine, TFA (Synthesis described in Patent: WO2009/63244 A1, 2009) (0.066 g, 0.304 mmol) in DMSO (1 mL) cooled to 0 °C under a nitrogen atmosphere was stirred at 0 °C for 5 min. To this solution, Cs₂CO₃ (0.198 g, 0.608 mmol) was added and stirred for 5 min. 4-Chloro-2-fluoropyridine (0.05 g, 0.304 mmol) was added and the mixture heated at 90 °C for 14 h. The reaction mixture was cooled to room temperature and diluted with water (20 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with water (2x10 mL). The organic layers were dried over sodium

sulfate and concentrated under reduced pressure. The residue was purified via silica gel chromatography (ethyl acetate and pet ether) to afford 4-chloro-*N*-(3-fluorocyclopentyl)pyridin-2-amine (0.02 g, 0.078 mmol, 26% yield) as a yellow oil. LCMS (ESI) m/e 215.2 [(M+H)⁺, calcd for C₁₀H₁₃ClFN₂, 215.0]; LC/MS retention time (method A1); t_R = 1.91 min.



Part B: tert-butyl ((2S)-1-(2-chloro-4-(2-((3-fluorocyclopentyl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of (*S*)-*tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in 285) (0.037 g, 0.078 mmol), 4-chloro-*N*-(3-fluorocyclopentyl)pyridin-2-amine (0.02 g, 0.078 mmol), and tripotassium phosphate (2M Solution) (0.4 mL, 0.800 mmol) in THF (2 mL) was purged with nitrogen for 15 min. XPhos 2nd generation precatalyst (9.24 mg, 0.012 mmol) was added and the mixture purged for a further 5 min with nitrogen. The reaction mixture was then stirred at 80 °C for 12 h. The reaction mixture was cooled to room temperature and diluted with THF (20 mL) and filtered through diatomaceous earth. The diatomaceous earth bed was washed with excess of THF. The filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (ethyl acetate and pet ether) to afford *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((3-fluorocyclopentyl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.013 g, 0.015 mmol, 19% yield) as a yellow oil. LCMS (ESI) m/e 520.2 [(M+H)⁺, calcd for C₂₈H₄₀ClFN₃O₃, 520.2]; LC/MS retention time (method D); t_R = 3.14.




Part C: 4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-N-(3-fluorocyclopentyl)pyridin-2-amine


To a solution of *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((3-fluorocyclopentyl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.013 g, 0.015 mmol) in DCM (0.8 mL) cooled to 0 °C under nitrogen atmosphere was added TFA (2.5 mL, 32.4 mmol) dropwise over a period of 1 min. The mixture was warmed to room temperature and stirred for 2.5 h. The reaction mixture was concentrated under reduced pressure at lower temperature (28 °C). The residue was washed with diethyl ether (2 x 10 mL) then purified by prep HPLC (method B) to afford 4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(3-fluorocyclopentyl)pyridin-2-amine (1 mg, 1.073 μmol, 7% yield) as a pale yellow solid. LCMS (ESI) *m/e* 420.2 [(M+H)⁺, calcd for C₂₃H₃₀ClFN₃, 420.2]; LC/MS retention time (method D); *t_R* = 2.49. LC/MS retention time (Method E); *t_R* = 1.59 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 7.77-7.81 (m, 2H), 7.66 (dd, *J* = 2.40, 8.40 Hz, 1H), 7.23 (d, *J* = 8.40 Hz, 1H), 7.03-7.05 (m, 2H), 5.09-5.25 (m, 1H), 4.24-4.27 (m, 1H), 4.15 (d, *J* = 10.40 Hz, 1H), 4.10 (d, *J* = 10.40 Hz, 1H), 2.25-2.41 (m, 2H), 1.75-2.00 (m, 5H), 1.58-1.63 (m, 2H), 1.43 (s, 3H), 0.78-0.97 (m, 6H) ppm.

20

Example 335


(*S*)-1-(2-fluoro-4-(2-(trifluoromethyl) pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine






Part A: 2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one

To a stirred solution of 5-(trifluoromethyl)-1*H*-pyrazol-3-amine (1.5 g, 9.93 mmol) in ethanol (20 mL) was added sodium (*E*)-3-ethoxy-3-oxoprop-1-en-1-olate (prepared as described in Example 266) (1.508 g, 10.92 mmol) in portions and the mixture stirred for 5 min. The reaction mixture was heated at 90 °C for 14 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The reaction mixture was acidified with saturated citric acid solution (40 mL). The solid that formed was filtered through a sintered glass funnel and was washed with hexanes and water, then dried under vacuum for 2 h to afford 2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7(4*H*)-one (1 g, 4.58 mmol, 43% yield). LCMS (ESI) *m/e* 204.0 [(M+H)⁺, calcd for C₇H₅F₃N₃O, 204.1]; LC/MS retention time (Method A1); *t_R* = 1.45 min.



Part B: 7-chloro-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine


A suspension of 2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7(4*H*)-one (1 g, 4.58 mmol) in POCl₃ (12 mL, 129 mmol) was heated to 108 °C for 16 h. The reaction mixture was then cooled to room temperature and was concentrated under reduced pressure. The residue was added to stirred mixture of ice cold saturated solution of sodium bicarbonate (60 mL) and ethyl acetate (100 mL), keeping the temperature at 0 °C for 20 min. The aqueous layer was extracted with ethyl acetate (5x 100 mL). The combined organic layers washed with brine solution (100 mL), dried over sodium sulfate, and concentrated under reduced pressure to afford 7-chloro-2-(trifluoromethyl) pyrazolo[1,5-*a*]pyrimidine (0.8 g, 3.03 mmol, 66% yield) as a brown solid. The crude product was used as is for the next step without further purification. LCMS (ESI) *m/e* 222.0 [(M+H)⁺, calcd for C₇H₄ClF₃N₃, 222.0]; LC/MS retention time (method A2); *t_R* = 4.35 min.



Part C: *(S)*-tert-butyl (1-(2-fluoro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

5 A mixture of 7-chloro-2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidine (0.02 g, 0.076 mmol), *(S)*-tert-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 253, Part B) (0.034 g, 0.076 mmol), and Cs₂CO₃ (0.049 g, 0.152 mmol) in THF (2 mL) and water (0.667 mL) was purged with nitrogen for 15 min. XPhos 2nd generation
10 precatalyst (8.95 mg, 0.011 mmol) was added, purged for a further 5 min then reaction mixture was stirred at 65 °C for 14h. The reaction mixture was cooled to room temperature and diluted with THF (10 mL) then filtered through diatomaceous earth. The diatomaceous earth bed was washed with 20 mL of THF. The filtrate was concentrated under reduced pressure. The crude was purified through silica gel
15 chromatography (ethyl acetate and pet ether) to afford *(S)*-tert-butyl (1-(2-fluoro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.02 g, 0.021 mmol, 27% yield) as yellow semi-solid. LCMS (ESI) *m/e* 511.2 [(M+H)⁺, calcd for C₂₅H₃₁F₄N₄O₃, 511.2]; LC/MS retention time (method H); *t*_R = 2.78 min.

20




Part D: *(S)*-1-(2-fluoro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine

25 A solution of *(S)*-tert-butyl (1-(2-fluoro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.02 g, 0.021 mmol) in MeOH (1.5 mL) cooled to 0 °C under nitrogen atmosphere was added TFA (1.5

mL, 19.47 mmol) dropwise over a period of 1 min. The mixture was then warmed to room temperature and allowed to stir for 4 h. The reaction mixture was concentrated under reduced pressure at lower temperature (28 °C). The crude material was purified by prep HPLC (method B) to afford (*S*)-1-(2-fluoro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (1 mg, 0.021 mmol, 8% yield) as a pale yellow solid. LCMS (ESI) *m/e* 411.2 [(M+H)⁺, calcd for C₂₀H₂₃F₄N₄O, 411.1]; LC/MS retention time (method D); *t*_R = 2.56. LC/MS retention time (Method E); *t*_R = 2.11 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.71 (d, *J* = 4.40 Hz, 1H), 8.14 (dd, *J* = 2.40, 12.40 Hz, 1H), 8.04-8.07 (m, 1H), 7.44 (t, *J* = 8.80 Hz, 1H), 7.39 (d, *J* = 4.40 Hz, 1H), δ 7.14 (s, 1H), 4.25 (d, *J* = 10.40 Hz, 1H), 4.33 (d, *J* = 10.40 Hz, 1H), 1.87-1.93 (m, 2H), 1.70-1.76 (m, 1H), 1.70 (s, 3H), 1.05-1.10 (m, 6H) ppm.

Example 336


(*S*)-1-(2-chloro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine



Prepared as described in Example 282 to afford (*S*)-1-(2-chloro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (1 mg, 0.039 mmol, 4% yield) as a pale yellow solid. LCMS (ESI) *m/e* 427.0 [(M+H)⁺, calcd for C₂₀H₂₃ClF₃N₄O, 427.1]; LC/MS retention time (method D); *t*_R = 2.75 min. LC/MS retention time (Method E); *t*_R = 2.19 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.59 (d, *J* = 4.80 Hz, 1H), 8.22 (d, *J* = 2.40 Hz, 1H), 8.09 (dd, *J* = 2.00, 8.60 Hz, 1H), 7.26-7.26 (m, 2H), 7.02 (s, 1H), 4.07-4.09 (m, 2H), 1.75-1.80 (m, 2H), 1.57-1.60 (m, 1H), 1.38 (s, 3H), 0.88-0.95 (m, 6H) ppm.

Example 338


4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine



5

Part A: 4-chloro-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine


To a stirred solution of 4-chloro-2-fluoropyridine (1 g, 6.08 mmol) in DMSO (10 mL) cooled to 0 °C under a nitrogen atmosphere was added Cs₂CO₃ (3.96 g, 12.16 mmol). The mixture was stirred for 5 min. Tetrahydro-2H-pyran-3-amine
 10 (0.677 g, 6.69 mmol) was added and the mixture heated to 90 °C for 14 h. Water was added and the solution was extracted with ethyl acetate (5x50 mL). The combined organic layers were washed with water (2x50mL). The organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified via silica gel chromatography (ethyl acetate and pet ether) to afford 4-chloro-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine (0.58 g, 2.509 mmol, 41%
 15 yield) as a yellow oil. LCMS (ESI) *m/e* 213.2 [(M+H)⁺, calcd for C₁₀H₁₄ClN₂O, 213.0]; LC/MS retention time (method D); *t_R* = 1.79 min.



20 *Part B: tert-butyl ((2S)-1-(2-chloro-4-(2-((tetrahydro-2H-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A mixture of (*S*)-tert-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as

described in Example 285) (0.121 g, 0.260 mmol), 4-chloro-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine (0.05 g, 0.216 mmol), and tripotassium phosphate (2M Solution) (0.324 mL, 0.649 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen for 15 min. XPhos 2nd generation precatalyst (0.026 g, 0.032 mmol) was added and the mixture purged for a further 5 min then stirred at 80 °C for 12 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (20 mL) and filtered through diatomaceous earth. The diatomaceous earth bed was washed with 15 mL of ethyl acetate. The filtrate was concentrated under reduced pressure. The crude was purified via reverse phase HPLC. The desired fractions were concentrated under reduced pressure to afford racemic *tert*-butyl ((2*S*)-1-(2-chloro-4-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (55 mg, 0.106 mmol, 49% yield) as a pale yellow solid. LCMS (ESI) *m/e* 518.2 [(M+H)⁺, calcd for C₂₈H₄₁ClN₃O₄, 518.2]; LC/MS retention time (method H); *t_R* = 2.28 min.



*Part C: 4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-N-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine*


A solution of *tert*-butyl ((2*S*)-1-(2-chloro-4-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.01 g, 0.019 mmol) in methanol (0.5 mL) was cooled to 0 °C under a nitrogen atmosphere. The solution was stirred at 0 °C for 10 min. TFA (1.5 mL, 19.47 mmol) was added dropwise over a period of 1 min and the mixture was warmed to room temperature and allowed to stir for 2 h. The reaction mixture was concentrated under reduced pressure at lower temperature (28 °C). The residue was washed with diethyl ether (2 x 10 mL) and dried under vacuum for 10 min. Water was added to the reaction mixture was frozen in a -78 °C dry ice bath then lyophilized to afford 4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine, TFA (0.009 g, 0.016 mmol, 85% yield) as a pale yellow solid and as a mixture of diastereomers. LCMS (ESI) *m/e* 418.2 [(M+H)⁺, calcd for

C₂₃H₃₃ClN₃O₂, 418.2]; LC/MS retention time (method A1); *t*_R = 1.84 min. ¹H NMR (400 MHz, METHANOL-*d*₄) δ 7.93 (d, *J*=2.51 Hz, 1H), 7.87 (d, *J*=7.03 Hz, 1H), 7.76 - 7.80 (m, 1H), 7.34 (d, *J*=8.53 Hz, 1H), 7.26 (d, *J*=1.00 Hz, 1H), 7.20 (dd, *J*=6.78, 1.76 Hz, 1H), 4.19 - 4.28 (m, 2H), 3.75 - 3.97 (m, 3H), 3.61 - 3.68 (m, 1H), 3.47 - 3.54 (m, 1H), 2.1 - 2.2 (m, 1H), 1.66 - 1.96 (m, 6H), 1.53 (s, 3H), 1.00 - 1.06 (m, 6H) ppm.


10

Example 339

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine



15



Part A: *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2H-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate – diastereomer 1


Racemic *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2H-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared in Example 338, Parts A and B) (40 mg, 0.077 mmol) was resolved into the two diastereomers by chiral SFC (Method: Column/dimensions: Luxcellulose-4 (250 X 21.5) mm, 5u, % CO₂: 70%, % Co solvent: 30% (0.25% DEA in Methanol, Total Flow: 60 g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 257 nm).

25

Isomer 1 was concentrated under reduced pressure to afford *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2H-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-

dimethylpentan-2-yl)carbamate (0.015 g, 0.029 mmol, 14% yield) as a yellow semi-solid. LCMS (ESI) m/e 518.2 [(M+H)⁺, calcd for C₂₈H₄₁ClN₃O₄, 518.2]; LC/MS retention time (method H); t_R = 2.28 min.

Isomer 2 was concentrated under reduced pressure to afford *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.012 g, 0.023 mmol, 10% yield) as a yellow semi-solid. LCMS (ESI) m/e 518.2 [(M+H)⁺, calcd for C₂₈H₄₁ClN₃O₄, 518.2]; LC/MS retention time (method H); t_R = 2.29 min.



10

*Part B: 4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-N-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine*


A solution of *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate, **isomer 1** (0.015 g, 0.028 mmol) in methanol (0.5 mL) was cooled to 0 °C under a nitrogen atmosphere. The solution was stirred at 0 °C for 10 min. TFA (1.5 mL, 19.47 mmol) was added dropwise over a period of 1 min and the mixture was warmed to room temperature and allowed to stir for 2 h. The reaction mixture was concentrated under reduced pressure at lower temperature (28 °C). The residue was washed with diethyl ether (2 x 10 mL) and dried under vacuum for 10 min. Water was added to the reaction mixture was frozen in a -78 °C dry ice bath then lyophilized to afford 4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine, TFA (0.012 g, 0.012 mmol, 79% yield) as a pale yellow solid and as a single diastereomer. The absolute stereochemistry of pyran linkage is unassigned. LCMS (ESI) m/e 418.2 [(M+H)⁺, calcd for C₂₃H₃₃ClN₃O₂, 418.2]; LC/MS retention time (method H): t_R = 2.53 min; LC/MS retention time (method I): t_R = 1.81 min. ¹H NMR (400 MHz, METHANOL-*d*₄) δ = 7.92 (d, J =2.5 Hz, 1H), 7.88 (d, J =7.0 Hz, 1H), 7.77 (dd, J =8.5, 2.5 Hz, 1H), 7.34 (d, J =9.0 Hz, 1H), 7.23 (d, J =1.5 Hz, 1H), 7.18 (dd, J =6.8, 1.8 Hz, 1H), 4.28 - 4.19 (m, 2H), 3.98 - 3.93 (m, 1H), 3.89 - 3.76 (m, 2H), 3.76 - 3.60 (m, 1H), 3.53 - 3.42 (m, 1H), 2.13 (dd, J =12.5, 3.5

30

Hz, 1H), 1.97 - 1.82 (m, 3H), 1.79 - 1.67 (m, 3H), 1.53 (s, 3H), 1.07-1.01 (m, 6H) ppm.

Example 340

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine




*Part A: tert-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate – diastereomer 1*

*Racemic tert-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared in Example 338, Parts A and B) (40 mg, 0.077 mmol) was resolved into the two diastereomers by chiral SFC (Method: Column/dimensions: Luxcellulose-4 (250 X 21.5) mm, 5u, % CO₂: 70%, % Co solvent: 30% (0.25% DEA in Methanol, Total Flow: 60 g/min, Back Pressure: 100 bar, Temperature: 25°C, UV: 257 nm).*

Isomer 1 was concentrated under reduced pressure to afford *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.015 g, 0.029 mmol, 14% yield) as a yellow semi-solid. LCMS (ESI) *m/e* 518.2 [(M+H)⁺, calcd for C₂₈H₄₁ClN₃O₄, 518.2]; LC/MS retention time (method H); *t_R* = 2.28 min.

Isomer 2 was concentrated under reduced pressure to afford *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.012 g, 0.023 mmol, 10% yield) as a yellow semi-solid. LCMS (ESI) *m/e* 518.2 [(M+H)⁺, calcd for C₂₈H₄₁ClN₃O₄, 518.2]; LC/MS retention time (method H); *t_R* = 2.29 min.





Part B: 4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine

A solution of *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate, **isomer 2** (0.01 g, 0.019 mmol) (0.012 g, 0.023 mmol) in methanol (0.5 mL) was cooled to 0 °C under a nitrogen atmosphere. The solution was stirred at 0 °C for 10 min. TFA (1.5 mL, 19.47 mmol) was added dropwise over a period of 1 min and the mixture was warmed to room temperature and allowed to stir for 2 h. The reaction mixture was concentrated under reduced pressure at lower temperature (28 °C). The residue was washed with diethyl ether (2 x 10 mL) and dried under vacuum for 10 min. Water was added to the reaction mixture was frozen in a -78 °C dry ice bath then lyophilized to afford 4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine, TFA (0.007 g, 0.013 mmol, 57% yield) as a pale yellow solid and as a single diastereomer. The absolute stereochemistry of pyran linkage is unassigned. LCMS (ESI) *m/e* 418.2 [(*M*+*H*)⁺, calcd for C₂₃H₃₃ClN₃O₂ 418.2]; LC/MS retention time (method H): *t_R* = 2.55 min; LC/MS retention time (method I) : *t_R* = 1.80 min. ¹H NMR (400 MHz, METHANOL-*d*₄) δ = 7.93 (d, *J*=2.0 Hz, 1H), 7.88 (d, *J*=7.5 Hz, 1H), 7.78 (dd, *J*=8.5, 2.5 Hz, 1H), 7.36 - 7.33 (m, 1H), 7.25 (d, *J*=1.0 Hz, 1H), 7.19 (dd, *J*=6.8, 1.8 Hz, 1H), 4.28 - 4.20 (m, 2H), 4.00 - 3.93 (m, 1H), 3.89 - 3.84 (m, 1H), 3.82 - 3.68 (m, 1H), 3.67 - 3.57 (m, 1H), 3.54 - 3.40 (m, 1H), 2.17 - 2.09 (m, 1H), 1.98 - 1.80 (m, 3H), 1.79 - 1.64 (m, 3H), 1.53 (s, 3H), 1.07-1.04 (m, 6H) ppm.

25


Example 341

(*S*)-2,4-dimethyl-1-((7-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine



5 *Part A: (S)-tert-butyl (2,4-dimethyl-1-((7-(pyrazolo[1,5-a]pyrimidin-7-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate*

A mixture of 7-chloropyrazolo[1,5-a]pyrimidine (0.02 g, 0.130 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate (prepared as described in
 10 Example 267) (0.077 g, 0.156 mmol), triphenylphosphine (6.83 mg, 0.026 mmol), and tripotassium phosphate (0.055 g, 0.260 mmol) in 1,4-dioxane (2 mL) and water (4.69 μ L, 0.260 mmol) was purged with nitrogen for 15 min. Palladium(II) acetate (2.92 mg, 0.013 mmol) was added and the mixture was purged for a further 5 min, then the reaction mixture was heated to 100 $^{\circ}$ C for 45 min. The reaction mixture was
 15 cooled to room temperature and diluted with 1,4-dioxane (10 mL) and filtered through diatomaceous earth. The diatomaceous earth bed was washed with 15 mL of ethyl acetate. The filtrate was concentrated under reduced pressure. The crude was purified via reverse phase HPLC. The desired fractions were concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-((7-(pyrazolo[1,5-
 20 *a*]pyrimidin-7-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate (0.025 g, 0.051 mmol, 31% yield) as a yellow semi-solid. LCMS (ESI) m/e 482.2 [(M+H) $^{+}$], calcd for C₂₅H₃₂N₅O₃S, 482.2]; LC/MS retention time (Method A1); t_R = 2.81 min.





Part B: *(S)*-2,4-dimethyl-1-((7-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine

To a solution of *(S)*-*tert*-butyl (2,4-dimethyl-1-((7-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-yl)carbamate (0.025 g, 0.051 mmol) in MeOH (0.5 mL) cooled to 0 °C under a nitrogen atmosphere was added TFA (1.5 mL, 19.47 mmol) dropwise over a period of 1 min. The reaction mixture was warmed to room temperature and allowed to stir for 2 h. The reaction mixture was concentrated under reduced pressure at lower temperature (28 °C). The residue was washed with diethyl ether (2 x 10 mL) and dried under vacuum for 10 min. Water was added to the reaction mixture and it was frozen in a -78 °C dry ice bath then lyophilized to afford *(S)*-2,4-dimethyl-1-((7-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine, TFA (17.24 mg, 0.038 mmol, 75% yield) as a pale yellow solid. LCMS (ESI) *m/e* 382.2 [(M+H)⁺, calcd for C₂₀H₂₄N₅OS, 382.1]; LC/MS retention time (method A1); *t_R* = 1.73 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 9.42 (s, 1H), 8.65 (d, *J*=4.52 Hz, 1H), 8.21 (d, *J*=2.51 Hz, 1H), 8.10 (d, *J*=8.03 Hz, 1H), 7.39 (d, *J*=8.03 Hz, 1H), 7.27 (d, *J*=4.02 Hz, 1H), 6.87 (d, *J*=2.51 Hz, 1H), 4.49 (d, *J*=10.04 Hz, 1H), 4.36 (d, *J*=10.54 Hz, 1H), 1.89 - 1.96 (m, 2H), 1.75 - 1.82 (m, 1H), 1.58 (s, 3H), 1.01 - 1.11 (m, 6H) ppm.

Example 342


(S)-2,4-dimethyl-1-((7-(2-methylpyrimidin-4-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine





Part A: (S)-tert-butyl (2,4-dimethyl-1-((7-(2-methylpyrimidin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate

A mixture of 4-chloro-2-methylpyrimidine (0.018 g, 0.140 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-((7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate (0.069 g, 0.140 mmol) (prepared as described in Example 267), triphenylphosphine (7.34 mg, 0.028 mmol), and tripotassium phosphate (0.059 g, 0.280 mmol) in 1,4-dioxane (1.5 mL) and water (5.04 μ L, 0.280 mmol) was purged with nitrogen for 15 min. Palladium(II) acetate (3.14 mg, 0.014 mmol) was added and the mixture purged for a further 5 min. The reaction mixture was heated at 100 °C for 45 min. The reaction mixture was cooled to room temperature and diluted with 1,4-dioxane (10 mL) and filtered through diatomaceous earth. The diatomaceous earth bed was washed with 15 mL of ethyl acetate. The filtrate was concentrated under reduced pressure. The crude purified through reverse phase HPLC (10 mM ammonium acetate). The desired fractions were concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-((7-(2-methylpyrimidin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate (0.024 g, 0.050 mmol, 35% yield) as a yellow semi-solid. LCMS (ESI) m/e 457.2 [(M+H)⁺, calcd for C₂₄H₃₃N₄O₃S, 457.2]; LC/MS retention time (Method A1); t_R = 2.89.



Part B: (S)-2,4-dimethyl-1-((7-(2-methylpyrimidin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-amine


To a solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-((7-(2-methylpyrimidin-4-yl)benzo[d]thiazol-4-yl)oxy)pentan-2-yl)carbamate (0.024 g, 0.050 mmol) in MeOH (0.5 mL) cooled to 0 °C under a nitrogen atmosphere was added TFA (1.5 mL, 19.47

mmol) dropwise over a period of 1 min and warmed to room temperature. The reaction mixture was allowed to stir for 2 h. Solvent was concentrated under reduced pressure at lower temperature (28 °C). The residue was washed with diethyl ether (2 x 15 mL) and dried under vacuum for 10 min. Water was added to the reaction mixture was frozen in a -78 °C dry ice bath then lyophilized to afford (*S*)-2,4-dimethyl-1-((7-(2-methylpyrimidin-4-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine, TFA (0.023 g, 0.045 mmol, 91% yield) as a pale yellow solid. LCMS (ESI) *m/e* 357.2 [(M+H)⁺, calcd for C₁₉H₂₅N₄OS, 357.0]; LC/MS retention time (method H); *t_R* = 2.02 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 9.45 (s, 1H), 8.74 (d, *J*=5.52 Hz, 1H), 8.42 (d, *J*=8.53 Hz, 1H), 8.06 (d, *J*=5.52 Hz, 1H), 7.35 (d, *J*=8.53 Hz, 1H), 4.47 (d, *J*=10.04 Hz, 1H), 4.34 (d, *J*=10.54 Hz, 1H), 2.86 (s, 3H), 1.86 - 1.96 (m, 2H), 1.72 - 1.81 (m, 1H), 1.57 (s, 3H), 0.98 - 1.11 (m, 6H) ppm.


15

Example 345

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydrofuran-3-yl)pyridin-2-amine




20

Part A: 4-chloro-*N*-(tetrahydrofuran-3-yl)pyridin-2-amine

To a stirred solution of 4-chloro-2-fluoropyridine (0.094 g, 0.574 mmol) in DMSO (2 mL) cooled to 0 °C under a nitrogen atmosphere was added Cs₂CO₃ (0.374 g, 1.148 mmol) and the mixture was stirred for 5 min. Tetrahydrofuran-3-amine (0.05 g, 0.574 mmol) was added and the mixture heated to 90 °C for 14 h. Water was


added and the solution was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with water (2x20 mL). The organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified via silica gel chromatography (ethyl acetate and pet ether) to afford 4-chloro-
 5 *N*-(tetrahydrofuran-3-yl)pyridin-2-amine (0.05 g, 0.209 mmol, 36% yield) as a yellow oil. LCMS (ESI) m/e 199.2 [(M+H)⁺, calcd for C₉H₁₂ClN₂O, 199.0]; LC/MS retention time (method A1); t_R = 1.73 min.



10

Part B: tert-butyl ((2S)-1-(2-chloro-4-(2-((tetrahydrofuran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of (*S*)-*tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as
 15 described in Example 260, Part A and B) (0.113 g, 0.242 mmol), 4-chloro-*N*-(tetrahydrofuran-3-yl)pyridin-2-amine (0.04 g, 0.201 mmol), and tripotassium phosphate (2M Solution) (0.302 mL, 0.604 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen for 15 min. XPhos 2nd generation precatalyst (0.024 g, 0.030 mmol)
 20 was added and the mixture was purged for a further 5 min then stirred at 80 °C for 12 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (20 mL) and filtered through diatomaceous earth. The diatomaceous earth bed was washed with 10 mL of ethyl acetate. The filtrate was concentrated under reduced pressure. The residue was purified via reverse phase HPLC (Method B) to
 25 afford *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydrofuran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (30 mg, 0.060 mmol, 29% yield) as a yellow semi-solid. LCMS (ESI) m/e 504.6 [(M+H)⁺, calcd for C₂₇H₃₉ClN₃O₄, 504.2]; LC/MS retention time (method D); t_R = 1.11 min.




Part C: 4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-N-(tetrahydrofuran-3-yl)pyridin-2-amine

To a solution of *tert*-butyl ((2*S*)-1-(2-chloro-4-(2-((tetrahydrofuran-3-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.03 g, 0.060 mmol) in MeOH (0.5 mL) cooled to 0 °C under a nitrogen atmosphere was added TFA (1.5 mL, 19.47 mmol) dropwise over a period of 1 min and the mixture was warmed to room temperature and allowed to stir for 2 h. The reaction mixture was concentrated under reduced pressure at lower temperature (28 °C). The crude material was purified by prep HPLC (method A) to afford LCMS (ESI) *m/e* 404.3 [(M+H)⁺, calcd for C₂₂H₃₁ClN₃O₂, 404.2]; LC/MS retention time (method D); *t_R* = 1.51 min. LC/MS retention time (Method E); *t_R* = 0.83 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 7.89 - 7.95 (m, 2H), 7.78 (dd, *J*=8.78, 2.26 Hz, 1H), 7.32 - 7.37 (m, 1H), 7.20 - 7.24 (m, 2H), 4.39 - 4.41 (m, 1H), 4.19 - 4.28 (m, 2H), 3.83 - 4.06 (m, 4H), 2.38 - 2.48 (m, 1H), 2.03 - 2.04 (m, 1H), 1.81 - 1.97 (m, 2H), 1.68 - 1.75 (m, 1H), 1.53 (s, 3H), 1.00 - 1.14 (m, 6H) ppm.

Example 346

4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-N-(tetrahydrofuran-3-yl)pyridin-2-amine




Prepared as described in Example 345 to afford 4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-N-(tetrahydrofuran-3-yl)pyridin-2-amine, TFA as a pale yellow solid. LCMS (ESI) *m/e* 384.2 [(M+H)⁺, calcd for C₂₃H₃₄N₃O₂, 384.2]; LC/MS retention time (method D); *t_R* = 2.27 min. LC/MS retention time (Method E); *t_R* = 1.77 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 7.87 (d, *J*=7.03 Hz, 1H), 7.64 - 7.69 (m, 2H), 7.12 - 7.23 (m, 3H), 4.3-4.39 (m, 1H), 4.10 - 4.21 (m, 2

H), 3.68 - 4.06 (m, 4 H), 2.33 - 2.48 (m, 4 H), 1.97 - 2.06 (m, 1 H), 1.80 - 1.93 (m, 2 H), 1.67 - 1.73 (m, 1 H), 1.52 (s, 3 H), 0.98 - 1.08 (m, 6 H) ppm.

Example 347


5 1-(((3-methyl-5-(2-methylpyrimidin-4-yl)pyridin-2-yl)oxy)methyl)cyclobutanamine



Prepared as described in Example 263. 1-(((3-methyl-5-(2-methylpyrimidin-4-yl)pyridin-2-yl)oxy)methyl)cyclobutanamine, TFA (0.018 g, 0.045 mmol, 51% yield) as a pale yellow solid. LCMS (ESI) m/e 285.2 [(M+H)⁺, calcd for C₁₆H₂₁N₄O 285.2]; LC/MS retention time (method H): t_R = 0.92 min; LC/MS retention time (method I): t_R = 0.70 min. ¹H NMR (400 MHz, MeOD): δ 8.84 (d, J =2.51 Hz, 1H), 8.69 (d, J =5.52 Hz, 1H), 8.33 - 8.37 (m, 1H), 7.84 (d, J =5.52 Hz, 1H), 4.72 (s, 2H), 2.76 (s, 3H), 2.33 - 2.44 (m, 7H), 2.05 - 2.15 (m, 2H) ppm.

15 Example 351

(*S*)-1-(2-(difluoromethyl)-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine




Prepared as described in Example 351. The crude final product was purified by prep HPLC (method B) to afford (*S*)-1-(2-(difluoromethyl)-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (0.028 g, 0.056 mmol, 30% yield for the final two steps) as a pale yellow solid. LCMS (ESI) m/e 375.3 [(M+H)⁺, calcd for C₂₀H₂₅F₂N₄O 375.2]; LC/MS retention time (method H): t_R = 1.46 min; LC/MS retention time (method I): t_R = 1.20 min. ¹H NMR (400 MHz, MeOD): δ 8.56 (d, J =4.52 Hz, 1H) 8.42 (d, J =1.00 Hz, 1H) 8.34 (dd, J =8.53, 2.51 Hz, 1H) 8.22 (d, J =2.51 Hz, 1H) 7.12 - 7.42 (m, 3H) 6.79 (d, J =2.01 Hz, 1H) 4.33 (d,

$J=10.1$ Hz 1H) 4.25 (d, $J=10$ Hz, 1H) 1.80 - 1.92 (m, 2H) 1.66 - 1.74 (m, 1H) 1.53 (s, 3H) 0.99 - 1.10 (m, 6H) ppm.

Example 353



5 (S)-1-(2-(fluoromethyl)-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine



Prepared as described in Example 290. The crude final product was purified by prep HPLC (method B) to afford (S)-1-(2-(fluoromethyl)-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (0.001 g, 0.0002 mmol, 2% yield for the final two steps) as a pale yellow solid. LCMS (ESI) m/e 357.3 [(M+H)⁺, calcd for C₂₀H₂₆FN₄O 357.2]; LC/MS retention time (method H): t_R = 1.26 min; LC/MS retention time (method I): t_R = 1.29 min. ¹H NMR (400 MHz, MeOD): δ 8.57 (d, $J=4.52$ Hz, 1 H) 8.21 - 8.29 (m, 3 H) 7.32 (d, $J=9.54$ Hz, 1 H) 7.16 (d, $J=4.52$ Hz, 1 H) 6.80 (d, $J=2.51$ Hz, 1 H) 5.67 - 5.77 (m, 1 H) 5.55 - 5.65 (m, 1 H) 4.30 (d, $J=10.2$ Hz, 1 H) 4.22 (d, $J=10.1$ Hz, 1 H) 1.82 - 1.96 (m, 2 H) 1.68 - 1.77 (m, 1 H) 1.55 (s, 3 H) 1.01 - 1.12 (m, 6 H) ppm.


Example 357

20 (S)-2,4-dimethyl-1-(5-methyl-2-(pyridin-4-yl)thiazol-4-yloxy)pentan-2-amine



Part A: (S)-tert-butyl (2, 4-dimethyl-1-((5-methyl-2-(pyridin-4-yl) thiazol-4-yl) oxy) pentan-2-yl) carbamate

A solution of ethyl 5-methyl-2-(pyridin-4-yl) thiazol-4-ol (0.08 g, 0.416 mmol) in DMF (5 mL) was cooled to 0 °C. K₂CO₃ (0.173 g, 1.248 mmol) was added in portions to the reaction mixture followed by slow addition of (*S*)-*tert*-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (0.147 g, 0.499 mmol) in 1 mL DMF at 0 °C. The reaction mixture was slowly allowed to warm to room temperature and heated at 88 °C for 12 h. The reaction mixture was cooled to 0 °C and quenched with aqueous ammonium chloride solution (10 mL). The reaction mixture was extracted with ethyl acetate (2 x 20 mL). The organic layer was washed with water (2 x 20 mL) and brine (10 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2, 4-dimethyl-1-((5-methyl-2-(pyridin-4-yl) thiazol-4-yl) oxy) pentan-2-yl) carbamate (0.11 g, 0.271 mmol, 65% yield) as a brown color semi-solid. The brown solid was carried forward without further purification. LCMS (ESI) *m/e* 406.2 [(M+H)⁺, calcd for C₂₁H₃₂N₃O₃S 406.2]; LC/MS retention time (Method A1): *t*_R = 1.55 min.




Part B: (S)-2,4-dimethyl-1-(5-methyl-2-(pyridin-4-yl)thiazol-4-yloxy)pentan-2-amine


To a solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-((5-methyl-2-(pyridin-4-yl)thiazol-4-yl)oxy)pentan-2-yl)carbamate (0.11 g, 0.271 mmol) in dichloromethane (2 mL) at 0 °C was added TFA (0.418 mL, 5.42 mmol). The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The residue was purified by preparative LC/MS (method B) to afford (*S*)-2,4-dimethyl-1-(5-methyl-2-(pyridin-4-yl)thiazol-4-yloxy)pentan-2-amine (76 mg, 0.178 mmol, 66% yield) as a pale yellow solid. LCMS (ESI) *m/e* 306.0 [(M+H)⁺, calcd for C₁₆H₂₄N₃OS 306.2]; LC/MS retention time (method H): *t*_R = 1.21 min; LC/MS retention time (method I): *t*_R = 0.70 min. ¹H NMR(400 MHz, Methanol-d₄): δ 8.72-8.74 (m, 2H), 8.18-8.19 (m, 2H), 4.44-4.54 (m, 2H), 2.47 (s, 3H), 1.83-1.91 (m, 2H), 1.66-1.71 (m, 1H), 1.50 (s, 3H), 1.03-1.08 (m, 6H) ppm.

Example 358

6-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyrimidin-4-amine




5



*Part A. 6-chloro-N-(tetrahydro-2*H*-pyran-3-yl)pyrimidin-4-amine*


To a stirred solution of 4,6-dichloropyrimidine (0.35 g, 2.349 mmol) in DMF (10 mL) at 0 °C was added NaH (0.282 g, 7.05 mmol). It was stirred for 5 min and
 10 tetrahydro-2*H*-pyran-3-amine (0.238 g, 2.349 mmol) was added. The mixture was then stirred at RT overnight. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 x 50 mL). The EtOAc layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 6-chloro-*N*-(tetrahydro-2*H*-pyran-3-yl)pyrimidin-4-amine (0.22 g, 0.634 mmol, 27% yield) as a
 15 gummy residue which was carried forward without further purification. LCMS (ESI) *m/e* 214.0 [(M+H)⁺, calcd for C₉H₁₃ClN₃O 214.1]; LC/MS retention time (Method A1): *t_R* = 1.64 min.



20 *Part B. tert-butyl ((2S)-2,4-dimethyl-1-(4-(6-((tetrahydro-2*H*-pyran-3-*

yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A mixture of 6-chloro-*N*-(tetrahydro-2*H*-pyran-3-yl)pyrimidin-4-amine (0.05 g, 0.143 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.072 g, 0.143 mmol), Pd(Ph₃P)₄ (0.016 g, 0.014 mmol), and potassium phosphate (0.214 mL, 0.428 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 3 h. After cooling, the reaction mixture was concentrated, diluted with water and extracted with ethyl acetate. The ethyl acetate layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford *tert*-butyl ((2*S*)-2,4-dimethyl-1-(4-(6-((tetrahydro-2*H*-pyran-3-yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.05 g, 0.053 mmol, 37% yield) as a yellowish semi-solid which was carried forward without further purification. LCMS (ESI) *m/e* 553.2 [(M+H)⁺, calcd for C₂₈H₄₀F₃N₄O₄ 553.3]; LC/MS retention time (Method A1): *t*_R = 2.77 min.



15

Part C. 6-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-N-(tetrahydro-2H-pyran-3-yl)pyrimidin-4-amine



To a solution of *tert*-butyl ((2*S*)-2,4-dimethyl-1-(4-(6-((tetrahydro-2*H*-pyran-3-yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.1 g, 0.181 mmol) in MeOH (2 mL) at 0 °C was added 4*N* HCl in 1,4-dioxane (0.452 mL, 1.810 mmol) and stirred at RT for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative LC/MS (method B) to afford 6-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyrimidin-4-amine (0.01 g, 0.021 mmol, 12% yield) as a yellow solid. LCMS (ESI) *m/e* 453.2 [(M+H)⁺, calcd for C₂₃H₃₂F₃N₄O₂ 453.2]; LC/MS retention time (Method E): *t*_R = 1.54 min; LCMS retention time (method F): *t*_R = 2.40 min.; ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.66 (s, 1H) 8.19 (bs, 2H), 7.52 (d, *J*=9.04 Hz, 1H), 6.97 - 7.07 (m, 1H), 4.23 - 4.38 (m, 3H), 3.96 (dd, *J*=11.04,

25

2.51 Hz, 1H), 3.74 - 3.86 (m, 1H), 3.57 - 3.69 (m, 1H), 3.43 - 3.52 (m, 1H), 2.05 (s, 1H), 1.64 - 1.94 (m, 6H), 1.54 (s, 3H), 1.04 (m, 6H) ppm.


Example 361

- 5 (S)-1-(2-chloro-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine



- 10 Part A: (S)-tert-butyl (1-(2-chloro-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of (S)-tert-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (168 mg, 0.358 mmol), 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (50 mg, 0.326 mmol), Pd(Ph₃P)₄ (18.81 mg, 0.016 mmol) and 2M aq. solution of potassium phosphate (0.488 mL, 0.977 mmol) in 1,4-dioxane (4 mL) was purged with nitrogen and heated at 100 °C for 12 h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford a brown residue. The residue was purified by silica gel chromatography (15% ethyl acetate-hexane) to afford (S)-tert-butyl (1-(2-chloro-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (75 mg, 0.042 mmol, 13% yield) as a blackish gummy solid. LCMS (ESI) *m/e* 459.2 [(M+H)⁺, calcd for C₂₄H₃₂ClN₄O₃ 459.2]; LC/MS retention time (method B): *t_R* = 0.98 min.





Part B: *(S)*-1-(2-chloro-4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine

To a stirred solution of *(S)*-*tert*-butyl 1-(2-chloro-4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (60 mg, 0.131 mmol) in DCM (2 mL) at 0 °C was added 4N HCl in 1,4-dioxane (2 mL, 65.8 mmol) and stirred the mixture was stirred for 30 min. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford to afford *(S)*-1-(2-chloro-4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine (13.7 mg, 0.038 mmol, 29% yield) as a pale-yellow solid. LCMS (ESI) *m/e* 359.0 [(M+H)⁺, calcd for C₁₉H₂₄ClN₄O 359.2]; LC/MS retention time (method D): *t_R* = 1.25 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.79 (s, 1H), 8.21 (d, *J*=2.20 Hz, 1H), 8.11 (dd, *J*=8.60, 2.20 Hz, 1H), 7.58 (d, *J*=3.64 Hz, 1H), 7.35 (d, *J*=8.66 Hz, 1H), 6.89 (d, *J*=3.64 Hz, 1H), 4.10 - 4.19 (m, 2H), 1.79 - 1.92 (m, 2H), 1.64 - 1.71 (m, 1H), 1.45 (s, 3H), δ 1.03 - 1.08 (m, 6H) ppm.

Example 362


(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)benzonitrile





Part A: (S)-tert-butyl (1-(2-cyano-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (90 mg, 0.195 mmol), 4-chloro-7H-pyrrolo[2,3-*d*]pyrimidine (30 mg, 0.195 mmol), Pd(Ph₃P)₄ (11.29 mg, 9.77 μmol) and 2M aq. potassium phosphate (0.293 mL, 0.586 mmol) in 1,4-dioxane (4 mL) was purged with nitrogen and heated at 100 °C for 12h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford a brown residue. The residue was purified by silica gel chromatography (15% ethyl acetate-hexane) to afford (*S*)-*tert*-butyl (1-(2-cyano-4-(7H-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (45 mg, 0.047 mmol, 24% yield) as brown gummy solid. LCMS (ESI) *m/e* 450.2 [(M+H)⁺, calcd for C₂₅H₃₂N₅O₃ 450.2]; LC/MS retention time (method B): *t*_R = 0.94 min.




Part B (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzonitrile

To a stirred solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(7H-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (40 mg, 0.089 mmol) in DCM (2 mL) at 0 °C, 4N HCl in 1,4-dioxane (2 mL, 65.8 mmol) was added and stirred for 30 min. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford to afford (*S*)-2-

((2-amino-2,4-dimethylpentyl)oxy)-5-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)benzonitrile (5.8 mg, 0.017 mmol, 19% yield) as a pale yellow solid. LCMS (ESI) *m/e* 350.0 [(M+H)⁺, calcd for C₂₀H₂₄N₅O 350.2]; LC/MS retention time (method D): *t_R* = 1.11 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.82 (s, 1H), 8.42 - 8.49 (m, 2H), 7.60 (d, *J*=3.58 Hz, 1H), 7.45 (d, *J*=9.60 Hz, 1H), 6.92 (d, *J*=3.64 Hz, 1H), 4.17 (d, *J*=2.26 Hz, 2H), 1.86 - 1.98 (m, 1H), 1.72 - 1.80 (m, 1H), 1.61 - 1.69 (m, 1H), 1.41 (s, 3H), 1.07 - 1.09 (m, 6H) ppm.

Example 363


(*S*)-1-(4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine



Part A: (*S*)-*tert*-butyl(1-(4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (126 mg, 0.251 mmol), 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine (35 mg, 0.228 mmol), Pd(Ph₃P)₄ (13.17 mg, 0.011 mmol) and 2M aq. potassium phosphate (0.342 mL, 0.684 mmol) in 1,4-dioxane (4 mL) was purged with nitrogen and heated at 100 °C and stirred for 12 h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford a blackish residue. The residue was purified by silica gel chromatography (10% ethyl acetate-hexane) to afford (*S*)-*tert*-butyl (1-(4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-

(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.071 mmol, 31% yield) as a black gummy solid. LCMS (ESI) m/e 493.3 [(M+H)⁺, calcd for C₂₅H₃₂F₃N₄O₃ 493.2]; LC/MS retention time (method B): t_R = 1.02 min.



5


Part B: (S)-1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine

To a stirred solution of (S)-*tert*-butyl 1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.162 mmol) in DCM (4 mL) at 0 °C was added 4N HCl in 1,4-dioxane (2 mL, 8.00 mmol). The solution was stirred for 30 min. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (S)-1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine (41.8 mg, 0.102 mmol, 63% yield) as a pale yellow solid. LCMS (ESI) m/e 393.0 [(M+H)⁺, calcd for C₂₀H₂₄F₃N₄O 393.2]; LC/MS retention time (method D): t_R = 1.40 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.81 (s, 1H), 8.38 - 8.44 (m, 2H), 7.59 (d, J =3.64 Hz, 1H), 7.44 (d, J =8.41 Hz, 1H), 6.89 (d, J =3.64 Hz, 1H), 4.05 - 4.13 (m, 2H), 1.81 - 1.91 (m, 1H), 1.55 - 1.71 (m, 2H), 1.35 (s, 3H), 1.03 (m, 6H) ppm.


20

Example 364

(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzonitrile




25



Part A: (S)-tert-butyl (1-(2-cyano-4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in
 5 Example 254, Part B-G) (120 mg, 0.263 mmol), 4-chloro-7-methyl-7H-pyrrolo[2,3-*d*]pyrimidine (synthesis previously described *J. Med. Chem.*, **2012**, 55, 7193) (40 mg, 0.239 mmol), Pd(Ph₃P)₄ (13.79 mg, 0.012 mmol) and 2M aq. potassium phosphate (0.358 mL, 0.716 mmol) in 1,4-dioxane (4 mL) was purged with nitrogen
 10 and heated at 100 °C for 12 h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford a blackish residue. The residue was purified by silica gel chromatography (10% ethyl acetate-hexane) to afford (*S*)-*tert*-butyl (1-(2-cyano-4-(7-methyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-
 15 2-yl)carbamate (85 mg, 0.145 mmol, 61% yield) as a brown gummy solid. LCMS (ESI) *m/e* 464.2 [(M+H)⁺, calcd for C₂₆H₃₄N₅O₃ 464.3]; LC/MS retention time (Method C): *t*_R = 1.14 min.



20 *Part B: (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7-methyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl)benzonitrile*

To a stirred solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(7-methyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (85 mg, 0.145 mmol) in DCM (3 mL) at 0 °C was added 4N HCl in 1,4-dioxane (4 mL, 132


mmol) and the mixture stirred for 30 min. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)benzotrile (20 mg, 0.053 mmol, 36% yield) as a pale yellow solid.

- 5 LCMS (ESI) *m/e* 364.2 [(M+H)⁺, calcd for C₂₁H₂₆N₅O 364.3]; LC/MS retention time (method D): *t_R* = 1.25 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.86 (s, 1H), 8.41 - 8.46 (m, 2H), 7.59 (d, *J*=3.64 Hz, 1H), 7.44 (d, *J*=9.54 Hz, 1H), 6.92 (d, *J*=3.64 Hz, 1H), 4.15 (d, *J*=2.45 Hz, 2H), 3.95 (s, 3H), 1.85 - 1.96 (m, 1H), 1.71 - 1.79 (m, 1H), 1.60 - 1.67 (m, 1H), 1.39 (s, 3H), 1.02 - 1.07 (m, 6H), ppm.


10

Example 365

(*S*)-1-(2-fluoro-4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine




15



*Part A: (S)-tert-butyl (1-(2-fluoro-4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

- A mixture of (*S*)-*tert*-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in
20 Example 253, Part B) (119 mg, 0.263 mmol), 4-chloro-7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidine (40 mg, 0.239 mmol) (synthesis previously described *J. Med. Chem.*, **2012**, 55, 7193), Pd(Ph₃P)₄ (13.79 mg, 0.012 mmol) and 2M aq. potassium phosphate (0.358 mL, 0.716 mmol) in 1,4-dioxane (4 mL) was purged with nitrogen

and heated at 100 °C for 12h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford a blackish residue. The residue was purified by silica gel chromatography (10% ethyl acetate-hexane) to afford (*S*)-*tert*-butyl (1-(2-fluoro-4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.116 mmol, 49% yield) as a brown gummy solid. LCMS (ESI) *m/e* 457.2 [(*M*+*H*)⁺, calcd for C₂₅H₃₄FN₄O₃ 457.2]; LC/MS retention time (Method C): *t*_R = 1.18 min.



10


*Part B: (S)-1-(2-fluoro-4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine*

To a stirred solution of (*S*)-*tert*-butyl (1-(2-fluoro-4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.175 mmol) in DCM (3 mL) at 0 °C was added 4*N* HCl in 1,4-dioxane (4 mL, 132 mmol) and the solution stirred for 1h. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (*S*)-1-(2-fluoro-4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine (6.5 mg, 0.018 mmol, 10% yield) as a pale yellow solid. LCMS (ESI) *m/e* 357.0 [(*M*+*H*)⁺, calcd for C₂₀H₂₆FN₄O 357.2]; LC/MS retention time (Method E): *t*_R = 0.83 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.84 (s, 1H), 7.92 - 8.00 (m, 2H), 7.57 (d, *J*=3.64 Hz, 1H), 7.40 (t, *J*=8.63 Hz, 1H), 6.91 (d, *J*=3.64 Hz, 1H), 4.13 - 4.25 (m, 2H), 3.94 (s, 3H), 1.79 - 1.92 (m, 2H), 1.65 - 1.72 (m, 1H), 1.47 (s, 3H), 1.05 - 1.09 (m, 6H) ppm.

25


Example 366

(*S*)-2,4-dimethyl-1-(4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine



Part A: (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A mixture of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (99 mg, 0.197 mmol), 4-chloro-7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidine (synthesis previously described *J. Med. Chem.*, **2012**, 55, 7193) (30 mg, 0.179 mmol), Pd(Ph₃P)₄ (10.34 mg, 8.95 μmol) and 2M aq. solution of potassium phosphate (0.269 mL, 0.537 mmol) in 1,4-dioxane (4 mL) was purged with nitrogen and heated at 100 °C for 12h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to obtain crude residue. The residue was purified by silica gel chromatography (5-10% ethyl acetate in hexanes) to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (80 mg, 0.115 mmol, 64% yield) as a brown gummy solid. LCMS (ESI) *m/e* 507.3 [(M+H)⁺, calcd for C₂₆H₃₃F₃N₄O₃ 507.2]; LC/MS retention time (method B): *t*_R = 1.06 min.





Part B: *(S)*-2,4-dimethyl-1-(4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine

To a stirred solution of *(S)*-*tert*-butyl (2,4-dimethyl-1-(4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (80 mg, 0.111 mmol) in DCM (3 mL) at 0 °C was added 4M HCl in 1,4-dioxane (4 mL, 132 mmol) and the solution stirred for 2 h. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford *(S)*-2,4-dimethyl-1-(4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine (13.2 mg, 0.032 mmol, 29% yield) as a pale yellow solid. LCMS (ESI) *m/e* 407.2 [(M+H)⁺, calcd for C₂₁H₂₆F₃N₄O 407.2]; LC/MS retention time (method D): *t_R* = 1.70 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.86 (s, 1H), 8.37 - 8.45 (m, 2H), 7.58 (d, *J*=3.70 Hz, 1H), 7.44 (d, *J*=8.47 Hz, 1H), 6.89 (d, *J*=3.64 Hz, 1H), 4.07 - 4.22 (m, 2H), 3.95 (s, 3H), 1.83 - 1.93 (m, 1H), 1.57 - 1.75 (m, 2H), 1.38 (s, 3H), 1.03 (m, 6H) ppm.

Example 368


(S)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)thiazol-2-amine



Part A: (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-(thiazol-2-ylamino)pyrimidin-4-yl)phenoxy)pentan-2-yl)carbamate

To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2-chloropyrimidin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in
 5 Example 367) (30 mg, 0.069 mmol) in 1,4-dioxane (2 mL), thiazol-2-amine (9.00 mg, 0.090 mmol), XANTPHOS (16.00 mg, 0.028 mmol), Cs₂CO₃ (45.0 mg, 0.138 mmol) and Pd₂dba₃ (12.66 mg, 0.014 mmol) were added. The mixture was heated to 90 °C for 12 h. The reaction mixture was cooled to room temperature, concentrated, diluted with water and extracted with ethyl acetate. The ethyl acetate layer was
 10 collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-(thiazol-2-ylamino)pyrimidin-4-yl)phenoxy)pentan-2-yl)carbamate (30 mg, 0.039 mmol, 57% yield) as a brown semi-solid. LCMS (ESI) *m/e* 498.3 [(M+H)⁺, calcd for C₂₆H₃₆N₅O₃S 498.2]; LC/MS retention time (method B): *t*_R = 1.05 min.

15




Part B: (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)thiazol-2-amine


To a stirred solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-(thiazol-
 20 2-ylamino)pyrimidin-4-yl)phenoxy)pentan-2-yl)carbamate (30 mg, 0.039 mmol) in DCM (2 mL) at 0 °C was added 4N HCl in 1,4-dioxane (5 mL, 20.00 mmol) and the solution stirred for 1 h. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)thiazol-2-
 25 amine (6.3 mg, 0.015 mmol, 39% yield) as a pale yellow solid. LCMS (ESI) *m/e* 398.0 [(M+H)⁺, calcd for C₂₁H₂₈N₅OS 398.2]; LC/MS retention time (method D): *t*_R = 1.07 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.56 (d, *J*=5.77 Hz, 1H), 8.26 (dd, *J*=8.53, 2.07 Hz, 2H), 7.55 (d, *J*=5.77 Hz, 1H), 7.49 (d, *J*=4.02 Hz, 1H), 7.15 - 7.23 (m, 2H), 4.16 - 4.27 (m, 2H), 2.46 (s, 3H), 1.85 - 1.98 (m, 2H), 1.69 - 1.79 (m,
 30 1H), 1.56 (s, 3H), 1.06 - 1.09 (m, 6H) ppm.

Example 369

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-*N*-cyclopropylpyrimidin-2-amine



5




Part A: (S)-tert-butyl (1-(4-(2-(cyclopropylamino)pyrimidin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate

10 To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2-chloropyrimidin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 367) (20 mg, 0.046 mmol) in 1,4-dioxane (2 mL), cyclopropanamine (5.26 mg, 0.092 mmol), XANTPHOS (10.67 mg, 0.018 mmol), Cs₂CO₃ (30.0 mg, 0.092 mmol) and Pd₂dba₃ (8.44 mg, 9.22 μmol) were added. The mixture was heated at 90

15 °C for 12 h. The reaction mixture was cooled to room temperature, concentrated, diluted with water and extracted with ethyl acetate. The ethyl acetate layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(4-(2-(cyclopropylamino)pyrimidin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (10 mg, 0.016 mmol, 35% yield) as a brown

20 semi-solid. LCMS (ESI) *m/e* 455.3 [(M+H)⁺, calcd for C₂₆H₃₉N₄O₃ 455.3]; LC/MS retention time (method B): *t*_R = 1.01 min.




Part B: (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-N-cyclopropylpyrimidin-2-amine

To a stirred solution of (S)-tert-butyl (1-(4-(2-(cyclopropylamino)pyrimidin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (10 mg, 0.022 mmol) in DCM (2 mL) at 0 °C, 4N HCl in 1,4-dioxane (2 mL, 8.00 mmol) was added and stirred for 1 h at RT. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-N-cyclopropylpyrimidin-2-amine (3 mg, 8.38 μmol, 38% yield) as a pale yellow solid. LCMS (ESI) *m/e* 355.2 [(M+H)⁺, calcd for C₂₁H₃₁N₄O 355.2]; LC/MS retention time (method D): *t_R* = 1.55 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.28 (d, *J*=5.40 Hz, 1H), 7.96 - 8.01 (m, 2H), 7.05 - 7.13 (m, 2H), 4.06 - 4.15 (m, 2H), 2.77 (s, 1H), 2.39 (s, 3H), 1.84 - 1.91 (m, 2H), 1.66 - 1.72 (m, 1H), 1.49 (s, 3H), 1.06 - 1.09 (m, 6H), 0.84 - 0.86 (m, 2H), 0.55 - 0.60 (m, 2H) ppm.

Example 371


(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)thiazol-2-amine



Part A: (S)-tert-butyl (2,4-dimethyl-1-(4-(2-(thiazol-2-ylamino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

To a stirred solution of (S)-tert-butyl (1-(4-(2-chloropyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 367) (35 mg, 0.072 mmol) in 1,4-dioxane (3 mL), thiazol-2-amine (9.34 mg, 0.093 mmol), XANTPHOS (16.60 mg, 0.029 mmol), Cs₂CO₃ (46.7

mg, 0.143 mmol) and Pd₂dba₃ (13.14 mg, 0.014 mmol) were added and heated at 90 °C for 12 h. The reaction mixture was cooled to room temperature, concentrated, diluted with water and extracted with ethyl acetate. The ethyl acetate layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(2-(thiazol-2-ylamino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (60 mg, 0.049 mmol, 68% yield) as a brown semi-solid. LCMS (ESI) *m/e* 552.2 [(M+H)⁺, calcd for C₂₆H₃₃F₃N₅O₃S 552.2]; LC/MS retention time (method B): *t*_R = 1.19 min.



10


Part B: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)thiazol-2-amine

To a stirred solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(2-(thiazol-2-ylamino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (60 mg, 0.109 mmol) in DCM (4 mL) at 0 °C, 4N HCl in 1,4-dioxane (5 mL, 20.00 mmol) was added and stirring was continued for 1 h at RT. The reaction mixture was concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)thiazol-2-amine (12 mg, 0.026 mmol, 24% yield) as a pale yellow solid. LCMS (ESI) *m/e* 452.2 [(M+H)⁺, calcd for C₂₁H₂₅F₃N₅OS 452.2]; LC/MS retention time (method D): *t*_R = 2.56 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.68 (d, *J*=2.07 Hz, 1H), 8.64 (d, *J*=5.33 Hz, 1H), 8.52 (dd, *J*=8.72, 2.20 Hz, 1H), 7.52 (d, *J*=5.33 Hz, 1H), 7.46 (d, *J*=3.70 Hz, 1H), 7.37 (d, *J*=8.78 Hz, 1H), 7.09 (d, *J*=3.64 Hz, 1H), 4.02 - 4.10 (m, 2H), 1.79 - 1.91 (m, 1H), 1.55 - 1.67 (m, 2H), 1.32 (s, 3H), 1.02 (m, 6H) ppm.

25


Example 376

(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)-4-methylthiazol-2-amine



Part A: (S)-tert-butyl (2,4-dimethyl-1-(4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

- 5 To a stirred solution of (S)-tert-butyl (1-(4-(2-chloropyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 367) (50 mg, 0.102 mmol) in 1,4-dioxane (3 mL), 4-methylthiazol-2-amine (12.87 mg, 0.113 mmol), XANTPHOS (23.72 mg, 0.041 mmol), Cs₂CO₃ (66.8 mg, 0.205 mmol) and Pd₂dba₃ (18.77 mg, 0.020 mmol) were
- 10 added and the mixture heated at 90 °C for 16 h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford a brown residue. The residue was purified by silica gel chromatography (20% ethyl acetate in hexanes) to afford (S)-tert-butyl (2,4-dimethyl-1-(4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)-2-
- 15 (trifluoromethyl)phenoxy)pentan-2-yl)carbamate (25 mg, 0.044 mmol, 43% yield) as a yellow semi-solid. LCMS (ESI) *m/e* 566.2 [(M+H)⁺, calcd for C₂₇H₃₅F₃N₅O₃S 566.2]; LC/MS retention time (Method C): *t_R* = 1.32 min.




- 20 Part B. (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)-4-methylthiazol-2-amine

To a stirred solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (25 mg, 0.044 mmol) in DCM (2 mL) at 0 °C, 4N HCl in 1,4-dioxane (5 mL, 20.00 mmol) was added and stirred for 1 h. The mixture was then was cooled to 0 °C,
 5 diluted with water (10 mL) and extracted with ethyl acetate (2 x 20 mL). The EtOAc layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)-4-methylthiazol-2-amine (11 mg, 0.022 mmol, 49% yield) as a pale yellow solid.
 10 LCMS (ESI) *m/e* 466.2 [(M+H)⁺, calcd for C₂₂H₂₇F₃N₅OS 466.2]; LC/MS retention time (Method C1): *t*_R = 2.77 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.69 (d, *J*=2.13 Hz, 1H), 8.63 (d, *J*=5.33 Hz, 1H), 8.52 (dd, *J*=8.82, 2.35 Hz, 1H), 7.52 (d, *J*=5.33 Hz, 1H), 7.38 (d, *J*=8.78 Hz, 1H), 6.64 (d, *J*=1.07 Hz, 1H), 3.98 - 4.12 (m, 2H), 2.35 (d, *J*=1.00 Hz, 3H), 1.81 - 1.91 (m, 1H), 1.54 - 1.70 (m, 2H), 1.33 (s, 3H),
 15 1.02 (m, 6H) ppm.

Example 377

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-cyclopentylpyrimidin-2-amine




20

Part A: (S)-tert-butyl (1-(4-(2-(cyclopentylamino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2-chloropyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as
 25 described in Example 367) (50 mg, 0.102 mmol) in 1,4-dioxane (3 mL), cyclopentanamine (9.60 mg, 0.113 mmol), XANTPHOS (23.72 mg, 0.041 mmol),

Cs₂CO₃ (66.8 mg, 0.205 mmol) and Pd₂dba₃ (18.77 mg, 0.020 mmol) were added and heated at 90 °C for 16 h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford brown residue. The residue was purified by silica gel chromatography (7% ethyl acetate in hexanes) to afford (*S*)-*tert*-butyl 1-(4-(2-(cyclopentylamino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (10 mg, 0.018 mmol, 18% yield) as a yellow semi-solid. LCMS (ESI) *m/e* 537.3 [(M+H)⁺, calcd for C₂₈H₄₀F₃N₄O₃ 537.3]; LC/MS retention time (Method C): *t*_R = 1.45 min.

10





Part B: (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-N-cyclopentylpyrimidin-2-amine

To a stirred solution of (*S*)-*tert*-butyl 1-(4-(2-(cyclopentylamino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (10 mg, 0.019 mmol) in DCM (2 mL) at 0 °C, 4N HCl in 1,4-dioxane (5 mL, 20.00 mmol) was added and stirred for 1 h. The mixture was then was cooled to 0 °C, diluted with water (10 mL) and extracted with ethyl acetate (2 x 50 mL). The EtOAc layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by prep HPLC (method B) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-cyclopentylpyrimidin-2-amine (4 mg, 8.89 mmol, 48% yield) as a pale yellow solid. LCMS (ESI) *m/e* 437.2 [(M+H)⁺, calcd for C₂₃H₃₂F₃N₄O 437.2]; LC/MS retention time (method D): *t*_R = 3.14 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.45 (d, *J*=2.01 Hz, 1H), 8.33 - 8.38 (m, 1H), 8.29 (d, *J*=5.27 Hz, 1H), 7.34 (d, *J*=8.78 Hz, 1H), 7.10 (d, *J*=5.40 Hz, 1H), 4.29 - 4.38 (m, 1H), 4.14 (q, *J*=9.58 Hz, 2H), 2.04 - 2.14 (m, 2H), 1.54 - 1.89 (m, 9H), 1.41 (s, 3H), 1.03 - 1.05 (m, 6H) ppm.

25

Example 380


(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)benzonitrile



5

Part A. (S)-tert-butyl (1-(2-cyano-4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

To a stirred solution of (S)-tert-butyl (1-(4-(2-chloropyrimidin-4-yl)-2-cyanophenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in
 10 Example 367) (50 mg, 0.112 mmol) in 1,4-dioxane (3 mL) was added 4-methylthiazol-2-amine (14.11 mg, 0.124 mmol), XANTPHOS (13.00 mg, 0.022 mmol), Cs₂CO₃ (73.2 mg, 0.225 mmol) and Pd₂dba₃ (10.29 mg, 0.011 mmol). The mixture was heated at 90 °C for 12 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (25 mL) then filtered through
 15 diatomaceous earth. The filtrate was concentrated under reduced pressure to afford brown residue. The residue was purified by silica gel chromatography (5% ethyl acetate in hexanes) to afford (S)-tert-butyl (1-(2-cyano-4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (25 mg, 0.040 mmol, 36% yield) as a brown semi-solid. LCMS (ESI) *m/e* 523.6 [(M+H)⁺, calcd for
 20 C₂₇H₃₅N₆O₃S 523.2]; LC/MS retention time (method B): *t*_R = 1.09 min.




Part B. (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)benzonitrile

To a stirred solution of (S)-tert-butyl (1-(2-cyano-4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (25 mg, 0.048 mmol) in DCM at 0 °C was added 4N HCl in 1,4-dioxane (2 mL, 8.00 mmol) and the mixture stirred for 1 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 x 50 mL). The EtOAc layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by prep HPLC (method A) to afford (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)benzonitrile (10 mg, 0.023 mmol, 48% yield) as a pale yellow solid. LCMS (ESI) *m/e* 423.2 [(M+H)⁺, calcd for C₂₂H₂₇N₆OS 423.2]; LC/MS retention time (method D): *t*_R = 2.46 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.57 - 8.67 (m, 3H), 7.51 (d, *J*=5.27 Hz, 1H), 7.40 (d, *J*=8.85 Hz, 1H), 6.65 (d, *J*=1.13 Hz, 1H), 4.10 (d, *J*=1.95 Hz, 2H), 2.35 (s, 3H), 1.84 - 1.97 (m, 1H), 1.66 - 1.72 (m, 1H), 1.58 - 1.65 (m, 1H), 1.35 (s, 3H), 1.02 - 1.06 (m, 6H) ppm.


Example 381

(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)-4-methylthiazol-2-amine



Part A. (S)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)phenoxy)pentan-2-yl)carbamate

To a stirred solution of (*S*)-*tert*-butyl (1-(4-(2-chloropyrimidin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 367) (50 mg, 0.115 mmol) in 1,4-dioxane (3 mL) was added 4-methylthiazol-2-amine (14.47 mg, 0.127 mmol), XANTPHOS (13.33 mg, 0.023 mmol), Cs₂CO₃ (75 mg, 0.230 mmol) and Pd₂dba₃ (10.55 mg, 0.012 mmol) and the mixture was heated at 90 °C for 12 h. The reaction mixture was diluted with ethyl acetate (25 mL) and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to afford a brown residue. The residue was purified by silica gel chromatography (25% ethyl acetate in hexanes) to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)phenoxy)pentan-2-yl)carbamate (25 mg, 0.039 mmol, 34% yield) as a brown semi-solid. LCMS (ESI) *m/e* 512.6 [(M+H)⁺, calcd for C₂₇H₃₈N₅O₃S 512.3]; LC/MS retention time (method B): *t*_R = 1.15 min.




Part B. (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)-4-methylthiazol-2-amine

To a stirred solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)phenoxy)pentan-2-yl)carbamate (25 mg, 0.049 mmol) in DCM at 0 °C was added 4N HCl in 1,4-dioxane (2 mL, 8.00 mmol) and the mixture stirred for 1 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (2x25 mL). The EtOAc layer was collected, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by prep HPLC (method A) to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)-4-methylthiazol-2-amine (4 mg, 0.0943 mmol, 19% yield) as a pale yellow solid. LCMS (ESI) *m/e* 412.2 [(M+H)⁺, calcd for C₂₂H₃₀N₅OS 412.2]; LC/MS retention time (method D): *t*_R = 2.38 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.53 - 8.58 (m, 1H), 8.12 - 8.22 (m, 2H), 7.37 - 7.49 (m, 1H), 7.06 - 7.14 (m, 1H), 6.61 - 6.66 (m, 1H), 3.95 - 3.99 (m,

2H), 2.40 (s, 3H), 2.35 (s, 3H), 1.82 - 1.95 (m, 1H), 1.53 - 1.76 (m, 2H), 1.35 (s, 3H), 1.01 - 1.05 (m, 6H) ppm.

Example 389

5 (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclopropanecarboxamide




To a flask containing (S)-tert-butyl (1-(4-(2-aminopyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (20 mg, 0.043 mmol)
 10 (prepared as described in Example 290) was added cyclopropanecarboxylic acid (0.051 mmol, 1.2 equiv.), HATU (24.40 mg, 0.064 mmol), DIPEA (0.022 mL, 0.128 mmol) and DMF (1 mL). The reaction mixture was heated at 60 °C overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. To the residue at 0 °C was added 30% TFA in DCM (1 mL) and the
 15 mixture stirred for 30 min. The solvent was removed and the crude material was purified by reverse phase prep HPLC (Method E) to afford (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclopropanecarboxamide (13.4 mg, 0.030 mmol, 72% yield) as a pale yellow solid. LCMS (ESI) *m/e* 436.2 [(M+H)⁺, calcd for C₂₃H₂₉F₃N₃O₂ 436.2]; LC/MS
 20 retention time (method H): *t_R* = 2.54 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.93 (s, 1H), 8.40 - 8.37 (m, 2H), 8.06 - 8.01 (m, 1H), 7.93 (d, *J*=2.3 Hz, 1H), 7.49 - 7.45 (m, 2H), 4.20 (s, 2H), 2.08 - 2.00 (m, 1H), 1.87 - 1.77 (m, 1H), 1.76 - 1.69 (m, 1H), 1.63 - 1.57 (m, 1H), 1.38 (s, 3H), 0.95 - 0.91 (m, 6H), 0.86 - 0.81 (m, 4H) ppm.

25

Example 390

(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclobutanecarboxamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclobutanecarboxamide (18 mg, 0.040 mmol, 93% yield for two steps) as a pale yellow solid. LCMS (ESI) *m/e* 450.2 [(M+H)⁺, calcd for C₂₄H₃₁F₃N₃O₂ 450.2]; LC/MS retention time (method H): *t*_R = 2.73 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.45 (s, 1H), 8.43 (s, 1H), 8.37 (d, *J*=5.3 Hz, 1H), 8.09 - 7.99 (m, 1H), 7.95 (d, *J*=2.0 Hz, 1H), 7.51 - 7.45 (m, 2H), 4.21 (s, 2H), 3.40 (dt, *J*=16.9, 8.3 Hz, 1H), 2.28 - 2.18 (m, 2H), 2.16 - 2.07 (m, 2H), 1.98 - 1.90 (m, 1H), 1.82 (dt, *J*=12.2, 6.0 Hz, 2H), 1.76 - 1.70 (m, 1H), 1.64 - 1.57 (m, 1H), 1.38 (s, 3H), 0.95 - 0.92 (m, 6H) ppm.

15

Example 391

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclopentanecarboxamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclopentanecarboxamide (3.5 mg, 7.55 μmol, 18% yield for two steps) as a pale yellow solid. LCMS (ESI) *m/e* 464.2 [(M+H)⁺, calcd for C₂₅H₃₃F₃N₃O₂ 464.2]; LC/MS retention time (method H): *t*_R = 2.90 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.52 (s, 1H), 8.41 (d, *J*=1.0 Hz, 1H), 8.36 (dd, *J*=5.3, 1 Hz, 1H), 8.00 (dd, *J*=8.5, 2.3 Hz, 1H), 7.90 (d, *J*=2.3 Hz, 1H), 7.44 (dd, *J*=5.3, 1.8 Hz, 1H), 7.38 (d, *J*=8.5 Hz,

25

1H), 3.92 - 3.85 (m, 2H), 2.97 (quin, $J=7.8$ Hz, 1H), 1.90 - 1.62 (m, 7H), 1.59 - 1.52 (m, 2H), 1.43 - 1.39 (m, 2H), 1.14 (s, 3H), 0.94 - 0.90 (m, 6H) ppm.

Example 392


5 (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cyclopentylacetamide



Prepared as described in Example 389 to afford (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cyclopentylacetamide
 10 (3.3 mg, 6.91 μ mol, 16% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 478.2 [(M+H)⁺, calcd for C₂₆H₃₅F₃N₃O₂ 478.2]; LC/MS retention time (method H): t_R = 3.08 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.50 (s, 1H), 8.40 - 8.34 (m, 2H), 7.99 (dd, $J=8.8$, 2.3 Hz, 1H), 7.89 (d, $J=2.0$ Hz, 1H), 7.45 - 7.37 (m, 2H), 3.93 - 3.86 (m, 2H), 2.42 (d, $J=7.3$ Hz, 2H), 2.24 (dt, $J=15.2$, 7.7 Hz, 1H), 1.84 - 1.71 (m,
 15 3H), 1.65 - 1.39 (m, 6H), 1.24 - 1.13 (m, 5H), 0.92-0.90 (dd, $J=6.5$, 2.5 Hz, 6H) ppm.

Example 393

(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-cyclopentylpropanamide




20 Prepared as described in Example 389 to afford (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-cyclopentylpropanamide (6.7 mg, 0.014 mmol, 32% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 492.2 [(M+H)⁺, calcd for C₂₇H₃₇F₃N₃O₂ 492.3];
 25 LC/MS retention time (method H): t_R = 3.23 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.55 (s, 1H), 8.40 (s, 1H), 8.36 (d, $J=6.0$ Hz, 1H), 8.00 (dd, $J=8.8$, 2.3 Hz, 1H), 7.90 (d, $J=2.5$ Hz, 1H), 7.46 - 7.43 (m, 1H), 7.40 (d, $J=9.0$ Hz, 1H), 3.94 - 3.87 (m, 2H),

2.46 - 2.40 (m, 2H), 1.85 - 1.70 (m, 4H), 1.60 (d, $J=4.0$ Hz, 4H), 1.53 - 1.45 (m, 2H), 1.44 - 1.39 (m, 2H), 1.15 (s, 3H), 1.10 (dd, $J=11.8, 6.8$ Hz, 2H), 0.94 - 0.89 (m, 6H) ppm.

5

Example 394

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cyclohexylacetamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cyclohexylacetamide (7.6 mg, 0.015 mmol, 36% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 492.2 [(*M*+*H*)⁺, calcd for C₂₇H₃₇F₃N₃O₂ 492.3]; LC/MS retention time (method H): t_R = 3.13 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.52 (s, 1H), 8.41 (d, $J=1.0$ Hz, 1H), 8.36 (d, $J=6.0$ Hz, 1H), 8.01 (d, $J=2.5$ Hz, 1H), 7.90 (d, $J=2.5$ Hz, 1H), 7.46 - 7.43 (m, 1H), 7.39 (d, $J=9.0$ Hz, 1H), 3.94 - 3.86 (m, 2H), 2.31 (d, $J=7.0$ Hz, 2H), 1.86 - 1.75 (m, 2H), 1.74 - 1.58 (m, 5H), 1.42 (dd, $J=5.5, 2.0$ Hz, 2H), 1.28 - 1.17 (m, 3H), 1.15 (s, 3H), 1.04 - 0.95 (m, 2H), 0.94 - 0.89 (m, 6H) ppm.

20

Example 398

N-(4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)tetrahydrofuran-2-carboxamide




Prepared as described in Example 389 to afford *N*-(4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)tetrahydrofuran-2-carboxamide (8.0 mg, 0.017 mmol, 40% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 466.3 [(*M*+*H*)⁺, calcd for C₂₄H₃₁F₃N₃O₃ 466.22]; LC/MS retention time (method H): t_R = 1.87 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.88 (s, 1H),

8.42 - 8.35 (m, 2H), 8.01 (dd, $J=8.5$, 2.0 Hz, 1H), 7.92 (d, $J=2.5$ Hz, 1H), 7.54 - 7.49 (m, 1H), 7.39 (d, $J=9.0$ Hz, 1H), 4.52 (dd, $J=8.5$, 5.5 Hz, 1H), 4.00 (dt, $J=8.0$, 6.8 Hz, 1H), 3.91 - 3.82 (m, 3H), 2.28 - 2.17 (m, 1H), 2.06 - 1.96 (m, 1H), 1.95 - 1.74 (m, 3H), 1.40 (d, $J=5.5$ Hz, 2H), 1.13 (s, 3H), 0.93-0.91 (m, 6H) ppm.

5

Example 399

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cycloheptylacetamide




10 Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cycloheptylacetamide (2.7 mg, 5.34 μ mol, 12% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 506.2 [($M+H$)⁺, calcd for C₂₈H₃₉F₃N₃O₂ 506.29]; LC/MS retention time (method H): t_R = 3.31 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.50 (s, 1H), 8.40 (s, 1H), 8.35 (d, $J=5.3$ Hz, 1H), 7.98 (dd, $J=8.9$, 2.4 Hz, 1H), 7.89 (d, $J=2.3$ Hz, 1H), 7.43 (dd, $J=5.3$, 1.5 Hz, 1H), 7.37 (d, $J=8.8$ Hz, 1H), 3.88 - 3.81 (m, 2H), 2.34 (d, $J=7.3$ Hz, 2H), 2.05 - 1.94 (m, 1H), 1.87 - 1.75 (m, 1H), 1.74 - 1.65 (m, 2H), 1.64-1.35 (m, 10H), 1.28 - 1.13 (m, 2H), 1.11 (s, 3H), 0.92 - 0.90 (m, 6H) ppm.

20

Example 400

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)furan-2-carboxamide




25 Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)furan-2-carboxamide (10.4 mg, 0.023 mmol, 52% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 462.2 [($M+H$)⁺, calcd for C₂₄H₂₇F₃N₃O₃ 462.2]; LC/MS retention time (method

H): $t_R = 2.67$ min. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.69 (br. s., 1H), 8.47 - 8.41 (m, 2H), 8.04 (dd, $J=8.8, 2.3$ Hz, 1H), 8.01 - 7.94 (m, 2H), 7.64 (d, $J=3.5$ Hz, 1H), 7.53 (dd, $J=5.3, 1.8$ Hz, 1H), 7.42 (d, $J=8.5$ Hz, 1H), 6.75 - 6.70 (m, 1H), 3.94 - 3.86 (m, 2H), 1.87 - 1.75 (m, 1H), 1.47 - 1.36 (m, 2H), 1.15 (s, 3H), 0.93-0.91 (m, 6H)

5 ppm.

Example 401

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-bromofuran-2-carboxamide




10

Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-bromofuran-2-carboxamide (2.5 mg, 4.63 μmol , 11% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 540.0 $[(M+H)^+]$, calcd for $\text{C}_{24}\text{H}_{26}\text{BrF}_3\text{N}_3\text{O}_3$ 540.1]; LC/MS retention time (method H): $t_R = 2.95$ min. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.86 (br. s., 1H), 8.45 (s, 1H), 8.39 (s, 1H), 8.05 (dd, $J=8.8, 2.3$ Hz, 1H), 7.96 (d, $J=2.0$ Hz, 1H), 7.68 (d, $J=4.0$ Hz, 1H), 7.55 (dd, $J=5.0, 1.5$ Hz, 1H), 7.44 (d, $J=8.5$ Hz, 1H), 6.86 (d, $J=3.5$ Hz, 1H), 4.01 - 3.93 (m, 2H), 1.81 (dt, $J=12.8, 6.1$ Hz, 1H), 1.54 - 1.40 (m, 2H), 1.20 (s, 3H), 0.94 - 0.91 (dd, $J=6.8, 3.8$ Hz, 4H) ppm.

20

Example 402

(*S*)-2-acetamido-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)acetamide




25

Prepared as described in Example 389 to afford (*S*)-2-acetamido-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)acetamide (7.7 mg, 0.017 mmol, 38% yield for two steps) as a pale yellow solid. LCMS (ESI)

m/e 467.2 [(M+H)⁺, calcd for C₂₃H₃₀F₃N₄O₃ 467.2]; LC/MS retention time (method H): t_R = 2.03 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.59 (s, 1H), 8.42 - 8.33 (m, 2H), 8.20 (t, J =5.8 Hz, 1H), 8.01 (dd, J =8.8, 2.3 Hz, 1H), 7.91 (d, J =2.0 Hz, 1H), 7.47 (dd, J =5.3, 1.8 Hz, 1H), 7.40 (d, J =8.5 Hz, 1H), 4.00 - 3.88 (m, 4H), 1.92 - 1.86 (m, 3H), 1.86 - 1.72 (m, 1H), 1.51 - 1.38 (m, 2H), 1.17 (s, 3H), 0.92 - 0.90 (m, 6H) ppm.

Example 403


(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiophene-2-carboxamide



Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiophene-2-carboxamide (5.6 mg, 0.012 mmol, 27% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 478.0 [(M+H)⁺, calcd for C₂₄H₂₇F₃N₃O₂S 478.1]; LC/MS retention time (method H): t_R = 2.77 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.03 (s, 1H), 8.47 - 8.43 (m, 2H), 8.28 (dd, J =3.8, 1.0 Hz, 1H), 8.05 (dd, J =8.8, 2.3 Hz, 1H), 7.96 (d, J =2.3 Hz, 1H), 7.91 (dd, J =4.9, 1.1 Hz, 1H), 7.54 (dd, J =5.3, 1.8 Hz, 1H), 7.42 (d, J =8.8 Hz, 1H), 7.23 (dd, J =4.9, 3.9 Hz, 1H), 3.98 - 3.91 (m, 2H), 1.86 - 1.75 (m, 1H), 1.51 - 1.40 (m, 2H), 1.18 (s, 3H), 0.95 - 0.89 (m, 6H) ppm.

Example 404

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)pyrazine-2-carboxamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)pyrazine-2-carboxamide

(8.7 mg, 0.018 mmol, 43% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 474.2 [(M+H)⁺, calcd for C₂₄H₂₇F₃N₅O₂ 474.2]; LC/MS retention time (method H): t_R = 2.65 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.45 (br. s., 1H), 9.38 (d, J =1.5 Hz, 1H), 9.00 (d, J =2.5 Hz, 1H), 8.87 (dd, J =2.5, 1.5 Hz, 1H), 8.55 (d, J =1.0 Hz, 1H), 8.48 (d, J =5.5 Hz, 1H), 8.09 (dd, J =8.8, 2.3 Hz, 1H), 8.00 (d, J =2.5 Hz, 1H), 7.65 - 7.60 (m, 1H), 7.44 (d, J =8.5 Hz, 1H), 3.98 - 3.89 (m, 2H), 1.81 (tt, J =12.4, 6.1 Hz, 1H), 1.50 - 1.39 (m, 2H), 1.17 (s, 3H), 0.95 - 0.90 (m, 6H) ppm.

Example 405


(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-methylnicotinamide



Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-methylnicotinamide (9.0 mg, 0.018 mmol, 43% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 487.2 [(M+H)⁺, calcd for C₂₆H₃₀F₃N₄O₂ 487.2]; LC/MS retention time (method H): t_R = 2.39 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.10 (s, 1H), 8.55 (dd, J =5.0, 1.5 Hz, 1H), 8.48 (s, 1H), 8.43 (d, J =5.0 Hz, 1H), 8.06 (dd, J =8.5, 2.5 Hz, 1H), 7.96 (d, J =2.0 Hz, 1H), 7.88 (dd, J =7.8, 1.8 Hz, 1H), 7.57 - 7.53 (m, 1H), 7.43 (d, J =9.0 Hz, 1H), 7.33 (dd, J =8.0, 4.5 Hz, 1H), 3.97 - 3.90 (m, 2H), 2.59 (s, 3H), 1.85-1.76 (m, 1H), 1.47 - 1.42 (m, 2H), 1.17 (s, 3H), 0.93-0.91 (m, 6H) ppm.

Example 406

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-1*H*-1,2,3-triazole-5-carboxamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-1*H*-1,2,3-triazole-5-carboxamide (4.7 mg, 10.16 μ mol, 24% yield for two steps) as a pale yellow solid. LCMS (ESI) *m/e* 463.3 [(*M*+*H*)⁺, calcd for C₂₂H₂₆F₃N₆O₂ 463.2]; LC/MS retention time (method H): *t_R* = 1.44 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.14 (br. s., 1H), 8.50 - 8.47 (m, 2H), 8.45 - 8.42 (m, 1H), 8.07 (dd, *J*=8.5, 2.0 Hz, 1H), 7.98 (d, *J*=2.5 Hz, 1H), 7.54 (dd, *J*=5.3, 1.8 Hz, 1H), 7.45 (d, *J*=9.0 Hz, 1H), 4.02 - 3.95 (m, 2H), 1.86 - 1.77 (m, 1H), 1.54 - 1.42 (m, 2H), 1.21 (s, 3H), 0.95 - 0.92 (m, 6H) ppm.

10

Example 407

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (4.9 mg, 9.97 μ mol, 23% yield for two steps) as a pale yellow solid. LCMS (ESI) *m/e* 492.3 [(*M*+*H*)⁺, calcd for C₂₄H₂₉F₃N₅O₃ 492.2]; LC/MS retention time (method H): *t_R* = 1.58 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.38 (s, 1H), 9.66 (s, 1H), 8.43 (d, *J*=5.0 Hz, 1H), 8.39 (s, 1H), 8.10 (dd, *J*=8.8, 2.3 Hz, 1H), 8.05 - 7.97 (m, 1H), 7.57 (dd, *J*=5.3, 1.8 Hz, 1H), 7.51 (d, *J*=9.0 Hz, 1H), 4.22 (s, 2H), 2.86 (t, *J*=8.5 Hz, 2H), 2.50 (t, *J*=8.5 Hz, 2H), 1.85-1.80 (m, 1H), 1.77 - 1.70 (m, 1H), 1.63-1.58 (m, 1H), 1.39 (s, 3H), 0.96-0.92 (m, 6H) ppm.

25

Example 408

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-methylisoxazole-3-carboxamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-methylisoxazole-3-carboxamide (8.3 mg, 0.017 mmol, 41% yield for two steps) as a pale yellow solid.

LCMS (ESI) *m/e* 477.2 [(M+H)⁺, calcd for C₂₄H₂₈F₃N₄O₃ 477.2]; LC/MS retention time (method H): *t_R* = 2.82 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.12 - 10.00 (m, 1H), 8.47 - 8.44 (m, 1H), 8.36 (d, *J*=1.0 Hz, 1H), 8.05 (dd, *J*=8.5, 2.5 Hz, 1H), 7.96 (d, *J*=2.5 Hz, 1H), 7.58 (dd, *J*=5.3, 1.8 Hz, 1H), 7.41 (d, *J*=8.5 Hz, 1H), 6.76 (d, *J*=1.0 Hz, 1H), 3.96 - 3.86 (m, 2H), 2.50 (s, 3H), 1.79 (tt, *J*=12.6, 6.2 Hz, 1H), 1.47 - 1.36 (m, 2H), 1.15 (s, 3H), 0.92-0.89 (m, 6H) ppm.

Example 409

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-isopropyl-1*H*-pyrazole-3-carboxamide




Prepared as described in Example 389 to afford (*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-isopropyl-1*H*-pyrazole-3-carboxamide (4.5 mg, 8.94 μmol, 21% yield for two steps) as a pale yellow solid. LCMS (ESI) *m/e* 504.2 [(M+H)⁺, calcd for C₂₆H₃₃F₃N₅O₂ 504.2];

LC/MS retention time (method H): *t_R* = 2.76 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.30 (br. s., 1H), 9.60 (br. s., 1H), 8.47 (d, *J*=1.0 Hz, 1H), 8.41 (d, *J*=5.5 Hz, 1H), 8.05 (dd, *J*=8.8, 2.3 Hz, 1H), 7.95 (d, *J*=2.5 Hz, 1H), 7.54 - 7.51 (m, 1H), 7.42 (d, *J*=8.5 Hz, 1H), 6.63 (br. s., 1H), 3.96 - 3.87 (m, 2H), 3.07 - 2.97 (m, 1H), 1.84 - 1.76 (m, 1H), 1.43 - 1.41 (m, 2H), 1.26 (d, *J*=7.0 Hz, 6H), 1.15 (s, 3H), 0.94 - 0.91 (m, 6H) ppm.

Example 410

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(pyridin-3-ylmethyl)pyridin-2-amine




To a vial was added zinc chloride (5.83 mg, 0.043 mmol), sodium
 5 cyanoborohydride (8.06 mg, 0.128 mmol) and methanol (1 mL). The reaction mixture was stirred at RT for 1 h and to this solution was added (*S*)-*tert*-butyl (1-(4-(2-aminopyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 290) (20 mg, 0.043 mmol) and nicotinaldehyde (5.0 mg, 0.047 mmol). The reaction mixture was stirred at 60 °C
 10 overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was used for the next step without further purification.

To the crude intermediate cooled to at 0 °C was added 30 % TFA in DCM (1 mL) and the mixture was stirred for 30 min. The solvent was removed under reduced
 15 pressure and the crude material was purified by reverse phase prep HPLC (Method E) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(pyridin-3-ylmethyl)pyridin-2-amine as a pale yellow solid. LCMS (ESI) *m/e* 459.3 [(M+H)⁺, calcd for C₂₅H₃₀F₃N₄O 459.23]; LC/MS retention time (method H): *t_R* = 1.70 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.05 (d, *J*=5.0 Hz, 1H), 7.93 (dd, *J*=8.8, 2.3 Hz, 1H), 7.84 (d, *J*=2.0 Hz, 1H), 7.57 - 7.55 (m, 1H), 7.37 (d, *J*=8.5 Hz, 1H), 6.97 (t, *J*=6.0 Hz, 1H), 6.85 (dd, *J*=5.3, 1.8 Hz, 1H), 6.81 (s, 1H), 6.39 - 6.37 (m, 1H), 6.28 - 6.25 (m, 1H), 4.51 (d, *J*=6.0 Hz, 2H), 4.00 - 3.93 (m, 2H), 1.80 (dt, *J*=12.8, 6.1 Hz, 1H), 1.54 - 1.41 (m, 2H), 1.20 (s, 3H), 0.93-0.90 (m, 6H) ppm.

25

Example 411


(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(furan-2-ylmethyl)pyridin-2-amine



Prepared as described in Example 412 to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(furan-2-ylmethyl)pyridin-2-amine (4.7 mg, 10.50 μ mol, 24% yield for two steps) as a pale yellow solid. LCMS (ESI) m/e 448.2 [(M+H)⁺, calcd for C₂₄H₂₉F₃N₃O₂ 448.2]; LC/MS retention time (method H): t_R = 2.76 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.57 (d, J =2.0 Hz, 1H), 8.43 (dd, J =4.5, 1.5 Hz, 1H), 8.03 (d, J =5.5 Hz, 1H), 7.93 (dd, J =8.8, 2.3 Hz, 1H), 7.83 (d, J =2.5 Hz, 1H), 7.76 - 7.71 (m, 1H), 7.21 - 7.16 (m, 1H), 6.84 (dd, J =5.5, 1.5 Hz, 1H), 6.80 (s, 1H), 4.55 (d, J =6.0 Hz, 2H), 3.96 - 3.89 (m, 2H), 1.83 - 1.75 (m, 1H), 1.51 - 1.39 (m, 2H), 1.18 (s, 3H), 0.92 - 0.90 (m, 6H) ppm.

Example 412

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(benzo[*d*][1,3]dioxol-5-yl)pyridin-2-amine





To a microwave vial was added (*S*)-*tert*-butyl (1-(4-(2-aminopyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (20 mg, 0.043 mmol), 5-bromobenzo[*d*][1,3]dioxole (0.043 mmol, 1eq), cesium carbonate (27.9 mg, 0.086 mmol), XANTPHOS (12.38 mg, 0.021 mmol) and 1,4-dioxane (1 mL). The reaction mixture was purged with nitrogen and Pd2(dba)₃ (19.59 mg, 0.021 mmol) was added. Then reaction mixture was irradiated in a microwave at 100 °C for 1 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was used for the next step without further purification. To the crude intermediate at 0 °C was added 30 % TFA in DCM (1 mL) and the mixture was stirred for 30 min. The solvent was removed and the crude material was purified by reverse phase prep HPLC (Method E) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(benzo[*d*][1,3]dioxol-5-

yl)pyridin-2-amine as a pale yellow solid. LCMS (ESI) m/e 488.2 [(M+H)⁺, calcd for C₂₆H₂₉F₃N₃O₃ 488.2]; LC/MS retention time (method H): t_R = 2.88 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ = 9.25 (br. s., 1H), 8.16 (d, J =5.5 Hz, 1H), 8.07 - 8.02 (m, 1H), 7.95 (d, J =2.0 Hz, 1H), 7.51 - 7.41 (m, 2H), 7.24 - 7.06 (m, 2H), 7.02 - 6.96 (m, 1H), 6.88 (d, J =8.5 Hz, 1H), 5.99 (s, 2H), 4.21 (s, 2H), 1.86 - 1.80 (m, 1H), 1.76 - 1.69 (m, 1H), 1.65 - 1.57 (m, 1H), 1.39 (s, 3H), 0.98 - 0.90 (m, 6H) ppm.


Example 413

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one




Part A. methyl 2-(bromomethyl)-4-chloronicotinate

To a solution of methyl 4-chloro-2-methylnicotinate (0.5 g, 2.69 mmol) in CCl₄ (10 mL) was added NBS (0.623 g, 3.50 mmol) followed by AIBN (0.044 g, 0.269 mmol). The reaction mixture was heated at 90 °C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (10% ethyl acetate in pet ether) to afford methyl 2-(bromomethyl)-4-chloronicotinate (0.3 g, 1.090 mmol, 40% yield) as wine red oil. LCMS (ESI) m/e 264.0 (bromo pattern) [(M+H)⁺, calcd for C₈H₈BrClNO₂ 264.0]; LC/MS retention time (Method A1): t_R = 2.13 min.




*Part B. 4-chloro-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one*

A solution of methyl 2-(bromomethyl)-4-chloronicotinate (0.075 g, 0.284 mmol) in 2M methylamine in THF (0.709 mL, 1.418 mmol) was heated at 70 °C for 30 min in a pressure tube. The mixture was cooled to room temperature, concentrated under reduced pressure, diluted with water (20 mL) and extracted with dichloromethane (80 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 4-chloro-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one (0.03 g, 0.164 mmol, 58% yield) as a pale yellow solid. LCMS (ESI) *m/e* 183.0 [(M+H)⁺, calcd for C₈H₈ClN₂O 183.0]; LC/MS retention time (Method F): *t*_R = 1.43 min.



*Part C. (S)-tert-butyl (1-(2-fluoro-4-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A mixture of 4-chloro-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one (0.03 g, 0.164 mmol), (*S*)-tert-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 253, Part B) (0.074 g, 0.164 mmol), PdCl₂(dppf)-CH₂Cl₂ adduct (0.013 g, 0.016 mmol) and potassium phosphate, dibasic (0.057 g, 0.329 mmol) in 1,4-dioxane (6 mL)-water (2 mL) was heated at 100 °C for 3 h. The solution cooled to room temperature and was concentrated under reduced pressure. Water (20 mL) was added and the solution was extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in hexanes) to afford (*S*)-tert-butyl (1-(2-fluoro-4-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.015 g, 0.024 mmol, 15% yield) as a gummy liquid. LCMS (ESI) *m/e* 472.2 [(M+H)⁺, calcd for C₂₆H₃₅FN₃O₄ 472.2]; LC/MS retention time (Method F): *t*_R = 2.29 min.




Part D. (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one

5 To a stirred solution of (S)-tert-butyl (1-(2-fluoro-4-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.012 g, 0.025 mmol) in DCM (3 mL) at 0 °C was added 4N HCl in 1,4-dioxane (0.127 mL, 0.509 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method B) to afford (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one (0.007 g, 0.019 mmol, 74% yield) as a yellow solid. LCMS (ESI) *m/e* 372.0 [(M+H)⁺, calcd for C₂₁H₂₇FN₃O₂ 372.2]; LC/MS retention time (Method E): *t_R* = 0.95 min; LCMS retention time (method F): *t_R* = 1.13 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.72 (d, *J*=5.52 Hz, 1H), 7.62 (dd, *J*=12.30, 2.26 Hz, 1H), 7.48 - 7.56 (m, 2H), 7.31 (t, *J*=8.53 Hz, 1H), 4.58 (s, 2H), 4.15 - 4.31 (m, 2H), 3.23 (s, 3H), 1.83 - 1.95 (m, 2H), 1.72 (d, *J*=9.04 Hz, 1H), 1.53 (s, 3H), 1.02 - 1.14 (m, 6H) ppm.

20

Example 414


(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)benzonitrile



Prepared in a similar fashion as described in Example 413 using (*S*)-*tert*-butyl (1-(2-cyano-4-(6-methyl-5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.05 g, 0.042 mmol) in the final step to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-methyl-5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzonitrile (0.005 g, 0.013 mmol, 30% yield) as a yellow solid. LCMS (ESI) *m/e* 379.0 [(M+H)⁺, calcd for C₂₂H₂₇N₄O₂ 379.2]; LC/MS retention time (Method E): *t*_R = 0.96 min; LCMS retention time (method F): *t*_R = 1.12 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.75 (d, *J*=5.52 Hz, 1H), 8.11 (d, *J*=2.51 Hz, 1H), 8.00 - 8.06 (m, 1H), 7.52 (d, *J*=5.02 Hz, 1H), 7.39 (d, *J*=8.53 Hz, 1H), 4.59 (s, 2H), 4.33 (d, *J*=2.51 Hz, 2H), 3.23 (s, 3H), 1.85 - 2.02 (m, 2H), 1.74 (m, 1H), 1.57 (s, 3H), 1.09 (m, 6H) ppm.

Example 415


(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzonitrile



Prepared in a similar fashion as described in Example 413 using (*S*)-*tert*-butyl (1-(2-cyano-4-(5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.05 g, 0.108 mmol) in the final step to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzonitrile (0.03 g, 0.082 mmol, 76% yield) as a yellow solid. LCMS (ESI) *m/e* 365.0 [(M+H)⁺, calcd for C₂₁H₂₅N₄O₂ 365.2]; LC/MS retention time (Method E): *t*_R = 0.89 min; LCMS retention time (method F): *t*_R = 0.99 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.79 (d, *J*=5.52 Hz, 1H), 8.01 - 8.14 (m, 2H), 7.53 (d, *J*=5.02 Hz, 1H), 7.39 (d, *J*=9.04 Hz, 1H), 4.55 (s, 2H), 4.28 - 4.37 (m, 2H), 3.23 (s, 3H), 1.85 - 2.03 (m, 2H), 1.71 - 1.79 (m, 1H), 1.57 (s, 3H), 1.09 (m, 6H) ppm.

Example 416



(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one



Prepared in a similar fashion as described in Example 413 using (*S*)-*tert*-butyl (1-(2-fluoro-4-(5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 285) (0.05 g, 0.109 mmol) in the final step to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one (0.025 g, 0.068 mmol, 63% yield) as a yellow solid. LCMS (ESI) *m/e* 358.0 [(*M*+*H*)⁺, calcd for C₂₀H₂₅FN₃O₂ 358.2]; LC/MS retention time (Method E): *t*_R = 0.90 min; LCMS retention time (method F): *t*_R = 1.01 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.74 (d, *J*=5.02 Hz, 1H), 7.58 - 7.65 (m, 1H), 7.47 - 7.55 (m, 2H), 7.26 (t, *J*=8.53 Hz, 1H), 4.52 (s, 2H), 3.99 - 4.12 (m, 2H), 1.82 - 1.94 (m, 1H), 1.68 - 1.77 (m, 1H), 1.55 - 1.64 (m, 1H), 1.37 (s, 3H), 1.04 (m, 6H) ppm.


Example 417

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one



Part A. (*S*)-*tert*-butyl (1-(2-chloro-4-(5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 4-chloro-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one (0.05 g, 0.297 mmol), (*S*)-*tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (0.139 g, 0.297 mmol), Pd(Ph₃P)₄ (0.034 g, 0.030 mmol), KBr (0.046 g, 0.386 mmol) and potassium phosphate (0.445 mL, 0.890 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.06 g, 0.124 mmol, 42% yield) as a yellowish semi-solid. LCMS (ESI) *m/e* 474.2 [(M+H)⁺, calcd for C₂₅H₃₂ClN₃O₄ 474.2]; LC/MS retention time (Method F): *t*_R = 2.30 min.





*Part B. (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one*

A stirred solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.05 g, 0.105 mmol) in DCM (3 mL) at 0 °C was treated with 4N HCl in 1,4-dioxane (0.527 mL, 2.110 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method B) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one (28 mg, 0.073 mmol, 69% yield) as a yellow solid. LCMS (ESI) *m/e* 374.0 [(M+H)⁺, calcd for C₂₀H₂₅ClN₃O₂ 374.2]; LCMS retention time (method F): *t*_R = 1.13 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.74 (d, *J*=5.02 Hz, 1H), 7.84 (d, *J*=2.01 Hz, 1H), 7.67 (dd, *J*=8.53, 2.01 Hz, 1H), 7.50 (d, *J*=5.02 Hz, 1H), 7.22 (d, *J*=8.53 Hz, 1H), 4.53 (s, 2H), 4.01 - 4.12 (m, 2H), 1.82 -

1.95 (m, 1H), 1.71 - 1.81 (m, 1H), 1.58 - 1.66 (m, 1H), 1.40 (s, 3H), 1.04 (m, 6H) ppm.

Example 418


- 5 (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one



- 10 *Part A. 4-chloro-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one*


Methyl 2-(bromomethyl)-4-chloronicotinate (0.5 g, 1.890 mmol) was treated with 2M ethylamine in THF (4.73 mL, 9.45 mmol) and heated at 70 °C for 30 min in a sealed-tube. The reaction mixture was cooled to room temperature then diluted with water (150 mL) and extracted with dichloromethane (280 mL). The organic layer was separated and washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to afford 4-chloro-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one (0.35 g, 1.304 mmol, 69% yield) as yellow semi-solid.

15 LCMS (ESI) m/e 197.0 [(M+H)⁺, calcd for C₉H₁₀ClN₂O 197.0]; LC/MS retention time (Method F): t_R = 1.56 min.



Part B. (S)-tert-butyl (1-(4-(6-ethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 4-chloro-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one (0.05 g, 0.186 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.093 g, 0.186 mmol), Pd(Ph₃P)₄ (0.022 g, 0.019 mmol), KBr (0.029 g, 0.242 mmol) and potassium phosphate (0.279 mL, 0.559 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford (*S*)-*tert*-butyl (1-(4-(6-ethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.22 g, 0.166 mmol, 89% yield) as a pale semi-solid. LCMS (ESI) *m/e* 480.2 [(M+H-Bu)⁺, calcd for C₂₈H₃₇F₃N₃O₄ 536.2]; LC/MS retention time (Method A1): *t*_R = 2.66 min.




Part C. (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one

A stirred solution of (*S*)-*tert*-butyl (1-(4-(6-ethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.22 g, 0.166 mmol) in DCM (5 mL) at 0 °C was treated with 4M HCl in 1,4-dioxane (0.829 mL, 3.32 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method B) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one (0.07 g, 0.159 mmol, 96% yield) as a yellow solid. LCMS (ESI) *m/e* 436.0 [(M+H)⁺, calcd for C₂₃H₂₉F₃N₃O₂ 436.2]; LC/MS retention time (Method E): *t*_R = 1.36 min; LCMS


retention time (method F): t_R = 1.48 min. ^1H NMR (400 MHz, *METHANOL- d_4*): δ = 8.75 (d, J =5.5 Hz, 1H), 8.05 (d, J =2.5 Hz, 1H), 7.99 (dd, J =8.5, 2.5 Hz, 1H), 7.52 (d, J =5.0 Hz, 1H), 7.39 (d, J =9.0 Hz, 1H), 4.34 - 4.22 (m, 2H), 3.71 (q, J =7.5 Hz, 2H), 3.3 (s, 2H), 1.94 - 1.84 (m, 2H), 1.77 - 1.70 (m, 1H), 1.55 (s, 3H), 1.34 - 1.30 (m, 3H), 1.11 - 1.01 (m, 6H) ppm.

Example 419

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-ethyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one



10




*Part A. (S)-tert-butyl (1-(4-(6-ethyl-5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate*

15 A mixture of 4-chloro-6-ethyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one (prepared as described in Example 418) (0.05 g, 0.186 mmol), (*S*)-*tert*-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 253, Part B) (0.084 g, 0.186 mmol), $\text{Pd}(\text{Ph}_3\text{P})_4$ (0.022 g, 0.019 mmol), KBr (0.029 g, 0.242 mmol) and potassium phosphate (0.279 mL, 0.559 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na_2SO_4 , filtered, and concentrated to afford (*S*)-*tert*-

20

butyl (1-(4-(6-ethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.16 g, 0.113 mmol, 61% yield) as a pale semi-solid. LCMS (ESI) m/e 486.2 [(M+H)⁺, calcd for C₂₇H₃₇FN₃O₄ 486.3]; LC/MS retention time (Method A1): t_R = 2.58 min.

5



Part B. (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one



A stirred solution of (*S*)-*tert*-butyl (1-(4-(6-ethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.16 g, 0.113 mmol) in DCM (5 mL) at 0 °C was treated with 4M HCl in 1,4-dioxane (0.564 mL, 2.257 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method B) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one (0.025 g, 0.065 mmol, 58% yield) as a yellow solid. LCMS (ESI) m/e 386.0 [(M+H)⁺, calcd for C₂₂H₂₉FN₃O₂ 386.2]; LC/MS retention time (Method E): t_R = 1.21 min; LCMS retention time (method F): t_R = 1.13 min. ¹H NMR (400 MHz, CD₃OD): δ 8.69 (d, J = 5.60 Hz, 1H), 7.47-7.65 (m, 3H), 7.26 (m, 1H), 4.57 (s, 2H), 4.06-4.16 (m, 2H), 3.62-3.72 (m, 2H), 1.75-1.88 (m, 2H), 1.61-1.66 (m, 1H), 1.42 (s, 3H), 1.28-1.31 (m, 3H), 1.01-1.06 (m, 6H) ppm.

20

Example 420


(*S*)-1-(2-fluoro-4-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine

25




Part A. 1H-pyrrolo[3,2-b]pyridine 4-oxide

5 To a solution of 1H-pyrrolo[3,2-b]pyridine (0.85 g, 7.20 mmol) in DCM (20 mL) at 0 °C, was added *m*-CPBA (2.71 g, 8.63 mmol) and the mixture was stirred overnight at RT. The solution was warmed to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (10% methanol in dichloromethane) to afford 1H-pyrrolo[3,2-b]pyridine 4-oxide (0.85 g,
10 6.34 mmol, 88% yield) as a yellow solid, ¹H NMR (300 MHz, *DMSO-d*₆): δ 11.79 (bs, 1H), 8.03 (dd, *J*=6.04, 0.76 Hz, 1H), 7.55 - 7.62 (m, 1H), 7.45 (d, *J*=7.93 Hz, 1H), 7.08 (dd, *J*=8.31, 6.04 Hz, 1H), 6.63 - 6.69 (m, 1H), ppm.




15 *Part B. 7-chloro-1H-pyrrolo[3,2-b]pyridine*

A solution of 1H-pyrrolo[3,2-b]pyridine 4-oxide (0.85 g, 6.34 mmol) in POCl₃ (11.81 mL, 127 mmol) was heated at reflux for 6 h. The reaction mixture was concentrated under reduced pressure, quenched with saturated aqueous sodium bicarbonate and extracted with dichloromethane (50 mL). The organic layer was
20 separated, dried over sodium sulfate and concentrated under reduced pressure to afford 7-chloro-1H-pyrrolo[3,2-b]pyridine (0.85 g, 4.90 mmol, 77% yield) as a yellow solid. LCMS (ESI) *m/e* 153.2 [(*M*+*H*)⁺, calcd for C₇H₆ClN₂ 153.0]; LC/MS retention time (Method A1): *t*_R = 1.80 min.



Part C. (S)-tert-butyl (1-(2-fluoro-4-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 7-chloro-1H-pyrrolo[3,2-b]pyridine (0.05 g, 0.328 mmol), (S)-
 5 *tert*-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 253, Part B) (0.148 g, 0.328 mmol), Pd(Ph₃P)₄ (0.019 g, 0.016 mmol), KBr (0.051 g, 0.426 mmol) and potassium phosphate (0.492 mL, 0.983 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, concentrated under reduced
 10 pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford (S)-*tert*-butyl (1-(2-fluoro-4-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.25 g, 0.125 mmol, 38% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 440.2 [(M-H)⁻, calcd for C₂₅H₃₁FN₃O₃ 440.2]; LC/MS retention time
 15 (Method A1): *t_R* = 1.79 min.




Part D. (S)-1-(2-fluoro-4-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine

A solution of (S)-*tert*-butyl (1-(2-fluoro-4-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.25 g, 0.136 mmol) in DCM (5 mL) at 0 °C, was treated with 4M HCl in 1,4-dioxane (0.679 mL, 2.72 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method B) to afford (S)-1-(2-fluoro-4-(1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine (0.01 g, 0.029
 25 mmol, 21% yield) as a yellow solid. LCMS (ESI) *m/e* 342.0 [(M+H)⁺, calcd for


C₂₀H₂₅N₃O 342.2]; LC/MS retention time (Method E): *t*_R = 0.75; LCMS retention time (method F): *t*_R = 1.17 min. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.38 (bs, 1H), 8.37 (d, *J*=4.52 Hz, 1H), 7.57 - 7.69 (m, 2H), 7.49 - 7.55 (m, 1H), 7.35 (t, *J*=8.78 Hz, 1H), 7.16 (d, *J*=5.02 Hz, 1H), 6.61 - 6.68 (m, 1H), 3.88 (s, 2H), 1.84 (s, 1H), 1.45 (m, 2H), 1.18 (s, 3H), 0.89 - 1.02 (m, 6H) ppm.

Example 421

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile




10



*Part A. (S)-tert-butyl (1-(2-cyano-4-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

15 A mixture of 7-chloro-1*H*-pyrrolo[3,2-*b*]pyridine (prepared as described in Example 420) (0.05 g, 0.328 mmol), (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (0.150 g, 0.328 mmol), Pd(Ph₃P)₄ (0.038 g, 0.033 mmol), KBr (0.051 g, 0.426 mmol) and potassium phosphate (0.492 mL, 0.983 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford (*S*)-*tert*-butyl (1-(2-cyano-4-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.25 g, 0.128 mmol, 39% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 449.2 [(*M*+*H*)⁺, calcd for C₂₆H₃₃N₄O₃ 449.2]; LC/MS retention time (Method A1): *t*_R = 2.49 min.

25





Part B. *(S)*-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile

A stirred solution of *(S)*-*tert*-butyl 1-(2-cyano-4-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.25 g, 0.557 mmol) in DCM (5 mL) at 0 °C, was treated with 4N HCl in 1,4-dioxane (2.79 mL, 11.15 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method A) to afford *(S)*-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile (0.01 g, 0.027 mmol, 5% yield) as a yellow solid. LCMS (ESI) *m/e* 349.0 [(M+H)⁺, calcd for C₂₁H₂₅N₄O 349.2]; LC/MS retention time (Method E): *t_R* = 0.73 min; LCMS retention time (method F): *t_R* = 1.17 min. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.46 (bs, 1H), 8.40 (d, *J*=5.02 Hz, 1H), 8.11 (d, *J*=2.01 Hz, 1H), 8.01 (dd, *J*=8.78, 2.26 Hz, 1H), 7.69 (t, *J*=3.26 Hz, 1H), 7.44 (d, *J*=8.53 Hz, 1H), 7.19 (d, *J*=5.02 Hz, 1H), 6.67 (dd, *J*=3.26, 1.76 Hz, 1H), 4.01 (bs, 2H), 1.78 - 1.93 (m, 1H), 1.50 (m, 2H), 1.23 (s, 3H), 1.01 0.96 (m, 6H) ppm.


Example 423

(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile




Part A. 7-chloro-1-methyl-1H-pyrrolo[3,2-b]pyridine

To a solution of 7-chloro-1H-pyrrolo[3,2-b]pyridine (prepared as described in Example 420) (0.3 g, 1.612 mmol) in DMF (5 mL) at 0 °C was added NaH (0.129 g, 3.22 mmol). The mixture was stirred for 30 min at RT and then methyl iodide (0.302 mL, 4.84 mmol) was added and mixture was stirred overnight. The mixture was quenched with water (20 mL) and extracted with ethyl acetate (30 mL). The organic layer separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 7-chloro-1-methyl-1H-pyrrolo[3,2-b]pyridine (0.16 g, 0.463 mmol, 29% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 167.0 [(M+H)⁺, calcd for C₈H₈ClN₂ 167.0]; LC/MS retention time (Method A1): *t_R* = 2.65 min.

*Part B. (S)-tert-butyl (1-(2-cyano-4-(1-methyl-1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A mixture of 7-chloro-1-methyl-1H-pyrrolo[3,2-b]pyridine (0.06 g, 0.174 mmol), (S)-tert-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (0.08 g, 0.176 mmol), KBr (0.027 g, 0.226 mmol), Pd(Ph₃P)₄ (0.020 g, 0.017 mmol), and potassium phosphate (0.261 mL, 0.521 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C overnight. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (30 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford (S)-tert-butyl (1-(2-cyano-4-(1-methyl-1H-pyrrolo[3,2-b]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.02 g, 0.031 mmol, 18% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 463.2 [(M+H)⁺, calcd for C₂₇H₃₅N₄O₃ 463.2]; LC/MS retention time (Method F): *t_R* = 2.21 min.





Part C. *(S)*-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile

A solution of *(S)*-*tert*-butyl 1-(2-cyano-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.03 g, 0.065 mmol) in DCM (5 mL) at 0 °C was treated with 4*N* HCl in 1,4-dioxane (0.324 mL, 1.297 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method A) to afford *(S)*-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile (0.005 g, 0.014 mmol, 21% yield) as a yellow solid. LCMS (ESI) *m/e* 363.0 [(*M*+*H*)⁺, calcd for C₂₂H₂₇N₄O 363.2]; LC/MS retention time (Method E): *t_R* = 0.82 min; LCMS retention time (method F): *t_R* = 1.44 min. ¹H NMR (400 MHz, *METHANOL-d*₄) : δ 8.27 - 8.33 (m, 2H), 7.98 (dd, *J*=8.53, 1.00 Hz, 1H), 7.68 (d, *J*=8.53 Hz, 1H), 7.58 (d, *J*=3.51 Hz, 1H), 7.40 (d, *J*=9.04 Hz, 1H), 6.66 - 6.71 (m, 1H), 4.29 (d, *J*=4.52 Hz, 2H), 3.92 (s, 3H), 1.93 (s, 2H), 1.73 (d, *J*=8.53 Hz, 1H), 1.50 - 1.59 (m, 3H), 1.09 (m, 6.53 Hz, 6H) ppm.

Example 424


(S)-1-(4-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine





Part A. (S)-tert-butyl (1-(4-(1H-pyrrolo[3,2-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 7-chloro-1H-pyrrolo[3,2-b]pyridine (prepared as described in
 5 Example 420) (0.03 g, 0.197 mmol), (*S*)-tert-butyl(2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.337 g, 0.671 mmol), KBr (0.02 g, 0.197 mmol), Pd(Ph₃P)₄ (0.023 g, 0.020 mmol) and potassium phosphate (0.295 mL, 0.590 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C overnight. The reaction mixture was cooled to room
 10 temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-tert-butyl (1-(4-(1H-pyrrolo[3,2-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.03 g, 0.059 mmol, 30% yield) as a brown semi-solid. LCMS (ESI)
 15 *m/e* 492.2 [(M+H)⁺, calcd for C₂₆H₃₃F₃N₃O₃ 492.2]; LC/MS retention time (Method F): *t*_R = 2.10 min.




Part B. (S)-1-(4-(1H-pyrrolo[3,2-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine

A solution of (*S*)-tert-butyl (1-(4-(1H-pyrrolo[3,2-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.03 g, 0.061 mmol)
 in DCM (5 mL) at 0 °C, was treated with 4N HCl in 1,4-dioxane (0.305 mL, 1.221 mmol) and the mixture stirred for 2 h at RT. The reaction mixture was concentrated
 25 under reduced pressure and was purified by prep HPLC (method A) to afford (*S*)-1-(4-(1H-pyrrolo[3,2-b]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-

2-amine (0.005 g, 0.013 mmol, 21% yield) as a yellow solid. LCMS (ESI) m/e 392.0 [(M+H)⁺, calcd for C₂₁H₂₅F₃N₃O 392.2]; LC/MS retention time (Method E): t_R = 0.89 min; LCMS retention time (method F): t_R = 1.55 min. ¹H NMR (400 MHz, METHANOL-*d*₄) : δ 8.42 (d, J =5.02 Hz, 1H), 8.01 - 8.07 (m, 2H), 7.69 (d, J =3.51 Hz, 1H), 7.50 (d, J =9.04 Hz, 1H), 7.28 (d, J =5.02 Hz, 1H), 6.75 (d, J =3.51 Hz, 1H), 4.25 - 4.35 (m, 2H), 1.87 - 1.97 (m, 2H), 1.75 (d, J =8.53 Hz, 1H), 1.56 (s, 3H), 1.07 (m, 6H) ppm.

Example 425

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one




Part A. (*S*)-tert-butyl (2,4-dimethyl-1-(4-(5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A mixture of 4-chloro-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one (prepared as described in Example 415) (0.03 g, 0.178 mmol), (*S*)-tert-butyl(2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 290) (0.034 g, 0.178 mmol), KBr (0.028 g, 0.231 mmol), Pd(Ph₃P)₄ (0.021 g, 0.018 mmol) and potassium phosphate, dibasic (0.267 mL, 0.534 mmol) in 1,4-dioxane (3 mL) was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (15 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-tert-butyl(2,4-dimethyl-1-(4-(5-oxo-6,7-dihydro-5H-

pyrrolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.03 g, 0.057 mmol, 32% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 508.2 [(M+H)⁺, calcd for C₂₆H₃₃F₃N₃O₄ 508.2]; LC/MS retention time (Method F): *t_R* = 2.40 min.

5




Part B. (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one

A solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.025 g, 0.049 mmol) in DCM (5 mL) at 0 °C, was treated with 4N HCl in 1,4-dioxane (0.246 mL, 0.985 mmol) and stirred for 4 h. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method A) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one (0.005 g, 0.012 mmol, 24% yield) as a yellow solid. LCMS (ESI) *m/e* 408.0 [(M+H)⁺, calcd for C₂₁H₂₄F₃N₃O₂ 408.2]; LC/MS retention time (Method E): *t_R* = 1.07 min; LCMS retention time (method F): *t_R* = 1.30 min. ¹H NMR (400 MHz, *METHANOL-d*₄) : δ 8.77 (d, *J*=5.02 Hz, 1H), 8.04 (d, *J*=2.51 Hz, 1H), 7.97 (dd, *J*=8.53, 2.51 Hz, 1H), 7.53 (d, *J*=5.02 Hz, 1H), 7.33 (d, *J*=9.04 Hz, 1H), 4.52 - 4.61 (m, 2H), 4.01 - 4.13 (m, 2H), 1.94 (s, 1H), 1.81 - 1.90 (m, 1H), 1.56 - 1.74 (m, 2H), 1.36 (s, 3H), 1.03 (m, 6H) ppm.


20

Example 426

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one




25



Part A. *(S)*-tert-butyl (2,4-dimethyl-1-(4-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A solution of 4-chloro-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one (prepared as described in Example 413) (0.04 g, 0.219 mmol), *(S)*-tert-butyl(2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 290) (0.045 g, 0.219 mmol), KBr (0.034 g, 0.285 mmol), Pd(Ph₃P)₄ (0.025 g, 0.022 mmol) and potassium phosphate (0.329 mL, 0.657 mmol) in 1,4-dioxane (4 mL) was heated at 100 °C overnight. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford *(S)*-tert-butyl (2,4-dimethyl-1-(4-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.03 g, 0.055 mmol, 25% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 522.2 [(M+H)⁺, calcd for C₂₇H₃₅F₃N₃O₄ 522.2]; LC/MS retention time (Method F): *t*_R = 2.49 min.




Part B. *(S)*-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one

A solution of *(S)*-tert-butyl (2,4-dimethyl-1-(4-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.025 g, 0.048 mmol) in DCM (5 mL) at 0 °C was treated with 4N HCl in 1,4-


dioxane (0.240 mL, 0.959 mmol) and stirred for 4 h. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method A) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one (0.005 g, 0.012 mmol, 24%
 5 yield) as a yellow solid. LCMS (ESI) *m/e* 422.0 [(*M*+*H*)⁺, calcd for C₂₂H₂₇F₃N₃O₂ 422.2]; LC/MS retention time (method D): *t*_R = 1.43 min. ¹H NMR (400 MHz, *METHANOL-d*₄) : δ 8.74 (d, *J*=5.52 Hz, 1H), 8.04 (d, *J*=2.01 Hz, 1H), 7.97 (dd, *J*=8.78, 2.26 Hz, 1H), 7.52 (d, *J*=5.02 Hz, 1H), 7.35 (d, *J*=8.53 Hz, 1H), 4.58 (s, 2H), 4.15 (q, *J*=9.54 Hz, 2H), 3.23 (s, 3H), 1.88 (s, 1H), 1.76 (d, *J*=5.52 Hz, H), 1.67 (d,
 10 *J*=5.52 Hz, 1H), 1.43 (s, 3H), 1.04 (m, 6H) ppm.

Example 427

(*S*)-2,4-dimethyl-1-(2-methyl-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)pentan-2-amine




15



*Part A. (S)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)pentan-2-yl)carbamate*

20 A mixture of 7-chloro-1-methyl-1*H*-pyrrolo[3,2-*b*]pyridine (prepared as described in Example 423) (0.06 g, 0.174 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 259, Part A and B) (80 mg, 0.176 mmol), KBr (0.027 g, 0.226 mmol), Pd(Ph₃P)₄ (0.020 g, 0.017 mmol) and potassium
 25 phosphate (0.261 mL, 0.521 mmol)) in 1,4-dioxane (5 mL) was heated at 100 °C overnight. The reaction mixture was cooled to room temperature, concentrated under

reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)pentan-2-yl)carbamate (0.025 g, 0.046 mmol, 26% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 452.2 [(M+H)⁺, calcd for C₂₇H₃₈N₃O₃ 452.3]; LC/MS retention time (Method F): *t*_R = 2.13 min.




Part B. (*S*)-2,4-dimethyl-1-(2-methyl-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)pentan-2-amine


A solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)pentan-2-yl)carbamate (0.03 g, 0.066 mmol) in DCM (5 mL) at 0 °C was treated with 4N HCl in 1,4-dioxane (0.332 mL, 1.329 mmol) and stirred for 3 h. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method B) to afford (*S*)-2,4-dimethyl-1-(2-methyl-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)pentan-2-amine (0.005 g, 0.014 mmol, 21% yield) as a yellow solid. LCMS (ESI) *m/e* 352.2 [(M+H)⁺, calcd for C₂₂H₃₀N₃O 352.2]; LC/MS retention time (Method E): *t*_R = 0.90 min; LCMS retention time (method F): *t*_R = 1.46 min. ¹H NMR (400 MHz, DMSO-*d*₆) : δ 7.89 (d, *J* = 8.8 Hz, 1H), 7.76 - 7.72 (m, 2H), 7.57 (d, *J* = 8.8 Hz, 1H), 7.50 (d, *J* = 3.2 Hz, 1H), 7.06 (d, *J* = 8.8 Hz, 1H), 6.62 (m, 1H), 4.02 - 4.12 (m, 2H), 3.90 (bs, 3H), 2.37 (s, 3H), 1.73 - 1.87 (m, 2H), 1.57 - 1.66 (m, 1H), 1.40 (s, 3H), 0.96 (m, 6H) ppm.

Example 428

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one




5



*Part A. (S)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)pentan-2-yl)carbamate*

A mixture of 4-chloro-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one (prepared
 10 as described in Example 415) (0.03 g, 0.178 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(
 (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-
 yl)carbamate (prepared as described in Example 259, Part A and B) (80 mg, 0.178
 mmol), KBr (0.028 g, 0.231 mmol), Pd(Ph₃P)₄ (0.021 g, 0.018 mmol) and potassium
 phosphate (0.267 mL, 0.534 mmol) in 1,4-dioxane (3 mL) was heated at 100 °C for 3
 15 h. The reaction mixture was cooled to room temperature, concentrated under reduced
 pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic
 layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced
 pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(5-oxo-6,7-dihydro-5*H*-
 pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)pentan-2-yl)carbamate (0.025 g, 0.037 mmol,
 20 21% yield) as a brownish semi-solid. LCMS (ESI) *m/e* 454.2 [(*M*+*H*)⁺, calcd for
 C₂₆H₃₆N₃O₄, 454.2]; LC/MS retention time (Method F): *t*_R = 2.34 min.





Part B. *(S)*-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one

A solution of *(S)*-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(5-oxo-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)pentan-2-yl)carbamate (0.025 g, 0.055 mmol) in DCM (5 mL) at 0 °C was treated with 4N HCl in 1,4-dioxane (0.276 mL, 1.102 mmol) and stirred for 3 h. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method A) to afford *(S)*-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one (0.005 g, 0.014 mmol, 25% yield) as a yellow solid. LCMS (ESI) *m/e* 354.0 [(M+H)⁺, calcd for C₂₁H₂₈N₃O₂ 354.2]; LC/MS retention time (Method E): *t*_R = 0.97 min; LCMS retention time (method F): *t*_R = 1.06 min. ¹H NMR (400 MHz, METHANOL-*d*₄) : δ 8.70 (d, *J*=5.52 Hz, 1H), 7.55 - 7.60 (m, 2H), 7.48 (d, *J*=5.02 Hz, 1H), 7.05 (d, *J*=9.04 Hz, 1H), 4.51 (s, 2H), 4.03 (q, *J*=9.54 Hz, 2H), 2.38 (s, 3H), 1.74 - 1.91 (m, 1H), 1.64 (dd, *J*=14.06, 5.52 Hz, 2H), 1.42 (s, 3H), 1.04 (m, 6H) ppm.

Example 429


(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-*b*]pyridin-5-one





Part A. *(S)*-tert-butyl (1-(2-chloro-4-(6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-
b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 4-chloro-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one
5 (prepared as described in Example 413) (0.03 g, 0.164 mmol), *(S)*-tert-butyl (1-(2-
chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-
dimethylpentan-2-yl)carbamate (prepared as described in Example 285) (0.121 g,
0.260 mmol), Pd(Ph₃P)₄ (0.019 g, 0.016 mmol), KBr (0.020 g, 0.164 mmol) and
potassium phosphate, dibasic (0.029 g, 0.164 mmol) in 1,4-1,4-dioxane (5 mL) was
10 heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature,
concentrated under reduced pressure, diluted with brine and extracted with ethyl
acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and
concentrated under reduced pressure to afford *(S)*-tert-butyl (1-(2-chloro-4-(6-
methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-
15 dimethylpentan-2-yl)carbamate (0.06 g, 0.074 mmol, 45% yield) as a brownish semi-
solid. LCMS (ESI) *m/e* 488.2 [(M+H)⁺, calcd for C₂₆H₃₅ClN₃O₄ 488.2]; LC/MS
retention time (Method A1): *t*_R = 2.87 min.



20 Part B. *(S)*-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6-methyl-6,7-
dihydro-5H-pyrrolo[3,4-b]pyridin-5-one

A solution of *(S)*-tert-butyl (1-(2-chloro-4-(6-methyl-5-oxo-6,7-dihydro-5H-
pyrrolo[3,4-b]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.05 g,
0.102 mmol) in DCM (5 mL) at 0 °C was treated with 4N HCl in 1,4-dioxane (0.512


mL, 2.049 mmol) and stirred for 4 h. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method A) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one (0.03 g, 0.077 mmol, 75% yield) as a yellow solid.

5 LCMS (ESI) *m/e* 388.0 [(M+H)⁺, calcd for C₂₁H₂₇ClN₃O₂ 388.2]; LC/MS retention time (Method E): *t*_R = 1.14; LCMS retention time (method F): *t*_R = 1.20 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.71 (d, *J*=5.52 Hz, 1H), 7.84 (d, *J*=2.01 Hz, 1H), 7.66 (dd, *J*=8.53, 2.51 Hz, 1H), 7.49 (d, *J*=5.52 Hz, 1H), 7.24 (d, *J*=8.53 Hz, 1H), 4.57 (s, 2H), 4.05 - 4.21 (m, 2H), 3.22 (s, 3H), 1.76 - 1.91 (m, 2H), 1.58 - 1.73


10 (m, 1H), 1.43 (s, 3H), 1.05 (m, 6H) ppm.

Example 430

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one



15




Part A. (*S*)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(6-methyl-5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)pentan-2-yl)carbamate

20 A mixture of 4-chloro-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one (prepared as described in Example 413) (0.03 g, 0.164 mmol), (*S*)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 259, Part A and B) (80 mg, 0.176 mmol), KBr (0.025 g, 0.214 mmol), Pd(Ph₃P)₄ (0.019 g, 0.016

mmol) and potassium phosphate (0.246 mL, 0.493 mmol) in 1,4-dioxane (5 mL) was heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate (20 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(6-methyl-5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)pentan-2-yl)carbamate (0.06 g, 0.054 mmol, 33% yield) as a brown semi-solid. LCMS (ESI) *m/e* 412.2 (M+H-*t*Bu)⁺, calcd for C₂₇H₃₈N₃O₄ 468.3]; LC/MS retention time (Method A1): *t*_R = 2.73 min.

10




*Part B. (S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one*

A solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(6-methyl-5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)phenoxy)pentan-2-yl)carbamate (0.05 g, 0.107 mmol) in DCM (5 mL) at 0 °C, was treated with 4*N* HCl in 1,4-dioxane (0.535 mL, 2.139 mmol) and the mixture stirred for 4 h. The reaction mixture was concentrated under reduced pressure and was purified by prep HPLC (method A) to afford (*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one (0.025 g, 0.067 mmol, 62% yield) as a yellow solid. LCMS (ESI) *m/e* 368.0 [(M+H)⁺, calcd for C₂₂H₃₀N₃O₂ 368.2]; LC/MS retention time (Method E): *t*_R = 1.13 min; LCMS retention time (method F): *t*_R = 1.13 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.67 (d, *J*=5.02 Hz, 1H) 7.53 - 7.58 (m, 2H), 7.47 (d, *J*=5.02 Hz, 1H), 7.07 (d, *J*=9.04 Hz, 1H), 4.56 (s, 2H), 4.01 - 4.14 (m, 2H), 3.22 (s, 3H), 2.39 (s, 3H), 1.81 - 1.91 (m, 2H), 1.61 - 1.76 (m, 1H), 1.47 (s, 3H), 1.05 (m, 6H) ppm.

25

Example 448


6-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine



5

Part A. 6-chloro-N-(tetrahydrofuran-3-yl)pyrimidin-4-amine


To a stirred solution of 4,6-dichloropyrimidine (0.3 g, 2.014 mmol) in DMF (10 mL) at 0 °C, was added NaH (0.242 g, 6.04 mmol). After stirred for 5 min, tetrahydrofuran-3-amine (0.175 g, 2.014 mmol) was added and stirred overnight at
 10 RT The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (50 mL) and extracted with DCM (80 mL). The organic layer was washed with brine (40 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to afford 6-chloro-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine (0.3 g, 0.872 mmol, 43% yield) as a
 15 yellowish semi-solid. LCMS (ESI) *m/e* 200.4 [(M+H)⁺, calcd for C₈H₁₁ClN₃O, 200.1]; LC/MS retention time (method B): *t_R* = 0.60 min.



20

Part B. tert-butyl ((2S)-2,4-dimethyl-1-(4-(6-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A mixture of 6-chloro-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine (0.05 g, 0.140 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.070 g, 0.140 mmol), PdCl₂(dppf)-CH₂Cl₂-adduct (0.011 g, 0.014 mmol), and Cs₂CO₃ (0.137 g, 0.421 mmol) in 1,4-dioxane (2 mL) was heated at 80 °C overnight. The reaction mixture was cooled to room temperature then filtered through diatomaceous earth, washing the diatomaceous earth bed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel chromatography (20 % ethyl acetate in hexane) to afford *tert*-butyl ((2*S*)-2,4-dimethyl-1-(4-(6-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.12 g, 0.118 mmol, 84% yield) as a yellowish semi-solid. LCMS (ESI) *m/e* 539.2 [(*M*+*H*)⁺, calcd for C₂₇H₃₈F₃N₄O₄ 539.3]; LC/MS retention time (Method A1): *t*_R = 3.05 min.



Part C. 6-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-N-(tetrahydrofuran-3-yl)pyrimidin-4-amine


To a stirred solution of *tert*-butyl ((2*S*)-2,4-dimethyl-1-(4-(6-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.12 g, 0.223 mmol) in DCM (2 mL) at 0 °C was added TFA (0.172 mL, 2.228 mmol) and the reaction mixture was allowed to stir for 2 h at room temperature. The reaction mixture was diluted with saturated aqueous sodium bicarbonate (20 mL) and extracted with ethyl acetate (30 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative LC/MS (Method A) to afford 6-(4-

(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-
 (tetrahydrofuran-3-yl)pyrimidin-4-amine (0.008 g, 0.017 mmol, 7% yield) as a
 yellow solid. LCMS (ESI) m/e 439.2 [(M+H)⁺, calcd for C₂₂H₃₀F₃N₄O₂ 439.2];
 LC/MS retention time (Method E): t_R = 1.78 min; LCMS retention time (method F):
 5 t_R = 2.39 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.50 (d, J =1.00 Hz, 1H),
 8.24 (d, J =2.01 Hz, 1H), 8.18 (dd, J =8.78, 2.26 Hz, 1H), 7.33 (d, J =9.04 Hz, 1H),
 6.91 (d, J =1.51 Hz, 1H), 4.58 (bs, 2H), 3.96 - 4.11 (m, 4H), 3.88 (td, J =8.53, 5.52
 Hz, 1H), 3.73 (dd, J =9.04, 3.51 Hz, 1H), 2.30 - 2.40 (m, 1H), 1.95 - 2.01 (m, 1H),
 1.79 - 1.91 (m, 1H), 1.54 - 1.73 (m, 1H), 1.34 (s, 3H), 0.97 - 1.07 (m, 6H) ppm.


10

Example 449

6-(6-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-5-chloropyridin-3-yl)-*N*-
 (tetrahydrofuran-3-yl)pyrimidin-4-amine




15



Part A. 6-(5-chloro-6-fluoropyridin-3-yl)-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-
 amine

A mixture of (5-chloro-6-fluoropyridin-3-yl)boronic acid (0.035 g, 0.200
 20 mmol), 6-chloro-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine (0.04 g, 0.200 mmol),
 PdCl₂(dppf)-CH₂Cl₂-adduct (0.016 g, 0.020 mmol), and Cs₂CO₃ (0.196 g, 0.601
 mmol) in 1,4-dioxane (3 mL) was heated at 80 °C for 3 h. The reaction mixture was
 cooled to room temperature and concentrated under reduced pressure. The residue
 was diluted with water (50 mL) and extracted with DCM (80 mL). The organic layer

was washed with brine (40 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to afford 6-(5-chloro-6-fluoropyridin-3-yl)-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine (0.07 g, 0.088 mmol, 44% yield) as a yellowish semi-solid. LCMS (ESI) *m/e* 293.0 [(M-H)⁻, calcd for C₁₃H₁₃ClFN₄O 293.1]; LC/MS retention time (method D): *t_R* = 2.24 min.




Part B. 6-(6-(((S)-2-amino-2,4-dimethylpentyl)oxy)-5-chloropyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidin-4-amine

A mixture of 6-(5-chloro-6-fluoropyridin-3-yl)-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine (0.04 g, 0.136 mmol), (*S*)-2-amino-2,4-dimethylpentan-1-ol (0.018 g, 0.136 mmol), and NaH (15 mg, 0.625 mmol) in tetrahydrofuran (3 mL) was stirred at RT overnight. The reaction mixture was cooled to room temperature and filtered through diatomaceous earth. The diatomaceous earth bed was washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure and purified by preparative LC/MS (Method A) to afford 6-(6-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-5-chloropyridin-3-yl)-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine (0.005 g, 0.012 mmol, 8% yield) as a yellow solid. LCMS (ESI) *m/e* 406.2 [(M+H)⁺, calcd for C₂₀H₂₉ClN₅O₂ 406.2]; LC/MS retention time (Method E): *t_R* = 1.68 min; LCMS retention time (method F): *t_R* = 2.14 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.68 (d, *J*=2.01 Hz, 1H), 8.51 (d, *J*=1.00 Hz, 1H), 8.38 (d, *J*=2.01 Hz, 1H), 6.90 (d, *J*=1.00 Hz, 1H), 4.48 (s, 2H), 3.97 - 4.03 (m, 2H), 3.84 - 3.94 (m, 1H), 3.73 (dd, *J*=9.04, 3.51 Hz, 1H), 2.29 - 2.42 (m, 1H), 1.85 - 2.00 (m, 3H), 1.76 - 1.82 (m, 1H), 1.59 - 1.70 (m, 1H), 1.44 (s, 3H), 1.05 (m, 6H) ppm.


25

Example 452

(S)-2,4-dimethyl-1-((2-methyl-6-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)pyridin-3-yl)oxy)pentan-2-amine




5



Part A. 4-bromo-6-chloropyridazin-3-amine

To a solution of 6-chloropyridazin-3-amine (5.0 g, 38.6 mmol) in MeOH (200 mL) sodium bicarbonate (6.48 g, 77 mmol) was added and stirred at room temperature for 10 min. Bromine (1.988 mL, 38.6 mmol) was added dropwise to the reaction mixture and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure at 30 ° C. To the residue was added water (150 mL) and the mixture stirred for 10 min. The brown solid that precipitated out was collected by vacuum filtration and dried under vacuum overnight to afford 4-bromo-6-chloropyridazin-3-amine (3.75 g, 13.85 mmol, 36% yield). LCMS (ESI) *m/e* 208.4; 210.4 (bromo pattern) [(M+H)⁺, calcd for C₄H₄BrClN₃ 208.0]; LC/MS retention time (method B): *t_R* = 0.58 min.

15




*Part B. 6,8-dichloro-2-methylimidazo[1,2-*b*]pyridazine*

To 4-bromo-6-chloropyridazin-3-amine (2.5 g, 11.99 mmol) in a sealed tube was added 1-chloropropan-2-one (7.77 g, 84 mmol) and the reaction mixture was heated to 90 °C for 16 h. The reaction mixture was cooled to room temperature and ether (100 mL) was added. The solid that precipitated was collected by vacuum filtration and dried under vacuum. Water (10 mL) was added to the solid and saturated aqueous sodium bicarbonate solution was added to adjust the pH of the


25

solution to 9. A pale brown solid precipitated which was collected by vacuum filtration and dried under vacuum overnight to afford 6,8-dichloro-2-methylimidazo[1,2-*b*]pyridazine (1.0 g, 4.21 mmol, 35% yield). LCMS (ESI) *m/e* 201.9 [(M+H)⁺, calcd for C₇H₆Cl₂N₃ 201.9]; LC/MS retention time (Method C): *t_R* = 0.75 min.




*Part C. (S)-tert-butyl (1-((6-(6-chloro-2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate.*

A solution of 6,8-dichloro-2-methylimidazo[1,2-*b*]pyridazine (0.3 g, 1.485 mmol), (*S*)-*tert*-butyl (1-((6-iodo-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (prepared in similar fashion as described for 343) (0.666 g, 1.485 mmol), and hexamethylditin (0.308 mL, 1.485 mmol) in 1,4-dioxane (10 mL) was flushed with nitrogen for 5 min. Pd(Ph₃P)₄ (0.086 g, 0.074 mmol) was added and the solution again flushed for a further 5 min with nitrogen. The reaction mixture was heated in a microwave at 150 °C for 90 min. The reaction mixture was then filtered through diatomaceous earth and the diatomaceous earth bed was washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure and the crude product was purified by silica gel chromatography (60 % ethyl acetate in hexane) to afford (*S*)-*tert*-butyl (1-((6-(6-chloro-2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (0.28 g, 0.252 mmol, 17% yield). LCMS (ESI) *m/e* 488.7 [(M+H)⁺, calcd for C₂₅H₃₅ClN₅O₃ 488.2]; LC/MS retention time (method B): *t_R* = 1.04 min.



Part D. (S)-tert-butyl (2,4-dimethyl-1-((2-methyl-6-(2-methylimidazo[1,2-
b]pyridazin-8-yl)pyridin-3-yl)oxy)pentan-2-yl)carbamate

To a solution of (S)-tert-butyl (1-((6-(6-chloro-2-methylimidazo[1,2-
b]pyridazin-8-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate
5 (0.28 g, 0.255 mmol) in methanol (5 mL) was added palladium on carbon (0.043 g,
0.041 mmol) and the mixture was stirred at room temperature overnight under 1 atm
H₂. The reaction mixture filtered through diatomaceous earth and the diatomaceous
earth bed was washed with methanol (10 mL). The filtrate was concentrated under
reduced pressure to afford (S)-tert-butyl (2,4-dimethyl-1-((2-methyl-6-(2-
10 methylimidazo[1,2-b]pyridazin-8-yl)pyridin-3-yl)oxy)pentan-2-yl)carbamate (0.25 g,
0.228 mmol, 89% yield). LCMS (ESI) *m/e* 454.2 [(M+H)⁺, calcd for C₂₅H₃₆N₅O₃
454.2]; LC/MS retention time (Method G): *t*_R = 1.62 min.





15 Part E. (S)-2,4-dimethyl-1-((2-methyl-6-(2-methylimidazo[1,2-b]pyridazin-8-
yl)pyridin-3-yl)oxy)pentan-2-amine

A solution of (S)-tert-butyl (2,4-dimethyl-1-((2-methyl-6-(2-
methylimidazo[1,2-b]pyridazin-8-yl)pyridin-3-yl)oxy)pentan-2-yl)carbamate (0.25 g,
0.243 mmol) in MeOH (2 mL) was cooled to 0° C, 4M HCl in 1,4-dioxane (0.606
20 mL, 2.425 mmol) was added and stirred at room temperature. The reaction mixture
diluted with saturated sodium bicarbonate solution (20 mL), extracted with ethyl
acetate (30 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced
pressure. The crude material was purified by prep LC/MS (method A) to afford (S)-
2,4-dimethyl-1-((2-methyl-6-(2-methylimidazo[1,2-b]pyridazin-8-yl)pyridin-3-
25 yl)oxy)pentan-2-amine (0.038 g, 0.107 mmol, 44% yield) as a pale yellow solid.
LCMS (ESI) *m/e* 354.3 [(M+H)⁺, calcd for C₂₀H₂₈N₅O 354.2]; LC/MS retention time
(method H): *t*_R = 1.48 min; LC/MS retention time (method I): *t*_R = 0.79 min. ¹H
NMR (400 MHz, methanol-*d*₄): δ 8.70 (d, *J* = 8.40 Hz, 1H), 8.42 (d, *J* = 4.80 Hz,
1H), 7.94 (s, 1H), 7.79 (d, *J* = 4.80 Hz, 1H), 7.47 (d, *J* = 8.40 Hz, 1H), 4.04 (d, *J* =

26.40 Hz, 2H), 2.61 (s, 3H), 2.51 (s, 3H), 1.83-1.90 (m, 1H), 1.71-1.76 (m, 1H), 1.60-1.64 (m, 1H), 1.39 (s, 3H), 1.02-1.04 (m, 6H) ppm.

Example 453


5 (S)-1-((2-(difluoromethyl)-6-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine



10 *Part A. 6-chloro-8-(6-(difluoromethyl)-5-fluoropyridin-2-yl)-2-methylimidazo[1,2-*b*]pyridazine*


A solution of 6,8-dichloro-2-methylimidazo[1,2-*b*]pyridazine (prepared as described in Example 452) (0.12 g, 0.594 mmol), 6-bromo-2-(difluoromethyl)-3-fluoropyridine (prepared as described in Example 322) (0.134 g, 0.594 mmol), and
 15 hexamethylditin (0.123 mL, 0.594 mmol) in 1,4-dioxane (5 mL) was flushed with nitrogen for 5 min. Pd(Ph₃P)₄ (0.034 g, 0.030 mmol) was added and the reaction mixture was heated in a microwave at 150 °C for 90 min. The reaction mixture was then filtered through diatomaceous earth and the diatomaceous earth bed and washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure
 20 and the crude product was purified by silica gel chromatography (60 % ethyl acetate in hexane) to afford 6-chloro-8-(6-(difluoromethyl)-5-fluoropyridin-2-yl)-2-methylimidazo[1,2-*b*]pyridazine (0.04 g, 0.125 mmol, 21% yield) as a brown solid. LCMS (ESI) *m/e* 313.0 [(M+H)⁺, calcd for C₁₃H₉ClF₃N₄ 313.0]; LC/MS retention time (Method C): *t*_R = 1.09 min.

25



Part B. 8-(6-(difluoromethyl)-5-fluoropyridin-2-yl)-2-methylimidazo[1,2-b]pyridazine

To a solution of 6-chloro-8-(6-(difluoromethyl)-5-fluoropyridin-2-yl)-2-methylimidazo[1,2-
 5 b]pyridazine (0.04 g, 0.128 mmol) in MeOH (5 mL) was added
 palladium on carbon (0.022 g, 0.020 mmol). The mixture was then stirred at room
 temperature overnight under 1 atm H₂. The reaction mixture was filtered through
 diatomaceous earth and the diatomaceous earth bed was washed with methanol (20
 mL). The filtrate was concentrated under reduced pressure to afford 8-(6-
 10 (difluoromethyl)-5-fluoropyridin-2-yl)-2-methylimidazo[1,2-b]pyridazine (0.03 g,
 0.075 mmol, 58% yield) as a brown solid. LCMS (ESI) *m/e* 279.2 [(M+H)⁺, calcd
 for C₁₃H₁₀F₃N₄ 279.1]; LC/MS retention time (Method G): *t*_R = 2.51 min.





Part C. (S)-1-((2-(difluoromethyl)-6-(2-methylimidazo[1,2-b]pyridazin-8-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine

A solution of 8-(6-(difluoromethyl)-5-fluoropyridin-2-yl)-2-methylimidazo[1,2-
 b]pyridazine (0.03 g, 0.075 mmol), (S)-2-amino-2,4-
 dimethylpentan-1-ol (9.79 mg, 0.075 mmol), and NaH (5.97 mg, 0.149 mmol) in
 20 DMF (3 mL) was stirred at room temperature overnight. The reaction mixture was
 then filtered through diatomaceous earth and the diatomaceous earth bed was washed
 with ethyl acetate (20 mL). The filtrate was concentrated under reduced pressure.
 The crude material was purified by prep LC/MS (method B) to afford (S)-1-((2-
 (difluoromethyl)-6-(2-methylimidazo[1,2-b]pyridazin-8-yl)pyridin-3-yl)oxy)-2,4-
 25 dimethylpentan-2-amine (0.008 g, 0.020 mmol, 27% yield) as a pale yellow solid.
 LCMS (ESI) *m/e* 390.3 [(M+H)⁺, calcd for C₂₀H₂₆F₂N₅O 390.2]; LC/MS retention
 time (method H): *t*_R = 1.65 min; LC/MS retention time (method I): *t*_R = 0.84 min. ¹H
 NMR (400 MHz, CD₃OD)-d₄: δ 9.17 (d, *J* = 8.00 Hz, 1H), 8.47 (d, *J* = 4.80 Hz, 1H),

7.93-7.98 (m, 2H), 7.77 (d, $J = 9.20$ Hz, 1H), 7.07 (t, $J = 108.00$ Hz, 1H), 4.07-4.18 (m, 2H), 2.53 (s, 3H), 1.82-1.88 (m, 1H), 1.67-1.72 (m, 1H), 1.57-1.62 (m, 1H), 1.40 (s, 3H), 0.99-1.04 (m, 6H) ppm.


Example 455

5 (S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-2-fluorophenyl)pyrazolo[1,5-*a*]pyrimidin-5-amine




10 *Part A: 5-chloro-7-(2-fluoro-4-methoxyphenyl)pyrazolo[1,5-*a*]pyrimidine*

A solution of 5,7-dichloropyrazolo[1,5-*a*]pyrimidine (0.5 g, 2.66 mmol), (2-fluoro-4-methoxyphenyl)boronic acid (0.452 g, 2.66 mmol), and Cs_2CO_3 (1.733 g, 5.32 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was purged with nitrogen gas for 30 min. $\text{PdCl}_2(\text{dppf})\text{-CH}_2\text{Cl}_2$ adduct (0.217 g, 0.266 mmol) was added to the
 15 reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80 °C for 6 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (50 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The organic layer was
 20 separated, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure to afford crude product as a brown solid which was purified by silica gel-column chromatography (EtOAc in pet ether) to afford 5-chloro-7-(2-fluoro-4-methoxyphenyl) pyrazolo [1,5-*a*] pyrimidine (0.52 g, 1.873 mmol, 70% yield) as a off-white color solid. LCMS (ESI) m/e 278.0 $[(\text{M}+\text{H})^+]$, calcd for $\text{C}_{13}\text{H}_{10}\text{ClFN}_3\text{O}$
 25 278.0]; LC/MS retention time (Method C): $t_R = 1.05$ min.



Part B: N-(7-(2-fluoro-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl)acetamide

A solution of 5-chloro-7-(2-fluoro-4-methoxyphenyl)pyrazolo[1,5-
 5 *a*]pyrimidine (0.3 g, 1.080 mmol), acetamide (0.077 g, 1.296 mmol), and Cs₂CO₃
 (0.704 g, 2.161 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was purged with
 nitrogen gas for 30 min. PdOAc₂ (0.012 g, 0.054 mmol) was added to the reaction
 mixture and the solution was purged with nitrogen gas again for 10 min. The
 reaction mixture was heated at 100 °C for 4 h. The reaction mixture was
 concentrated and the residue obtained was dissolved in ethyl acetate (25 mL) and
 10 water (20 mL). The biphasic mixture was filtered through diatomaceous earth. The
 diatomaceous earth was washed with ethyl acetate (50 mL). The organic layer was
 separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to
 afford crude product as a brown solid which was purified by silica gel-column
 chromatography (EtOAc in petroleum ether) to afford *N*-(7-(2-fluoro-4-
 15 methoxyphenyl) pyrazolo [1,5-*a*] pyrimidin-5-yl) acetamide (0.22 g, 0.667 mmol,
 62% yield) as an off-white color solid. LCMS (ESI) *m/e* 301.2 [(M+H)⁺, calcd for
 C₁₅H₁₄FN₄O₂ 301.1]; LC/MS retention time (Method A1): *t*_R = 2.21 min.




Part C: 4-(5-aminopyrazolo [1,5-a]pyrimidin-7-yl)-3-fluorophenol

HBr in AcOH (34%) (5 mL, 92 mmol) was added to a round bottomed flask
 containing of *N*-(7-(2-fluoro-4-methoxyphenyl) pyrazolo [1, 5-*a*] pyrimidin-5-yl)
 acetamide (0.15 g, 0.500 mmol) at 0 °C. The reaction mixture was heated at 105 °C
 for 12 h. The reaction mixture was concentrated under reduced pressure. The
 25 residue was reconstituted with ethyl acetate/pet ether (5:5 mL), filtered and dried to


afford 4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-3-fluorophenol (0.13 g, 0.335 mmol, 67% yield) as an off-white solid which was carried forward without further purification. LCMS (ESI) *m/e* 245.0 [(M+H)⁺, calcd for C₁₂H₁₀FN₄O 245.1]; LC/MS retention time (method B): *t*_R = 0.50 min.

5



*Part D: (S)-tert-butyl (1-(4-(5-aminopyrazolo [1,5-*a*]pyrimidin-7-yl)-3-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A solution of ethyl 4-(5-aminopyrazolo [1, 5-*a*] pyrimidin-7-yl)-3-fluorophenol (0.13 g, 0.532 mmol) in DMF (5 mL) was cooled to 0 °C. K₂CO₃ (0.221 g, 1.597 mmol) was added in portions to the reaction mixture followed by slow addition of (*S*)-*tert*-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (0.187 g, 0.639 mmol) in 1 mL DMF at 0 °C. The reaction mixture was then heated at 88 °C for 12 h. The reaction mixture was cooled to 0 °C and quenched with aqueous ammonium chloride solution (10 mL). The reaction mixture was extracted with ethyl acetate (2 x 20 mL). The ethyl acetate layer was washed with water (2 x 20 mL), brine (10 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-3-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.175 mmol, 33% yield) as a brown color semi-solid which was taken for next step without purification. LCMS (ESI) *m/e* 458.2 [(M+H)⁺, calcd for C₂₄H₃₃FN₅O₃ 458.2]; LC/MS retention time (method B): *t*_R = 2.42 min.





Part E: (S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine

To a solution of (S)-tert-butyl (1-(4-(5-aminopyrazolo[1,5-a]pyrimidin-7-yl)-3-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (20 mg, 0.044 mmol) in DCM
 5 (2 mL) at 0 °C was added TFA (0.067 mL, 0.874 mmol) and the solution stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine (8 mg, 0.022 mmol, 50% yield) as a
 10 pale yellow solid. LCMS (ESI) m/e 358.4 [(M+H)⁺, calcd for C₁₉H₂₅FN₅O 358.2]; LC/MS retention time (method H): t_R = 1.00 min; LC/MS retention time (method I): t_R = 0.78 min. ¹H NMR(400 MHz, Methanol-d₄): δ 7.80 (d, J = 2.40 Hz, 1H), 7.68 (t, J = 16.80 Hz, 1H), 7.02-7.07 (m, 2H), 6.34 (s, 1H), 6.10 (d, J = 2.40 Hz, 1H),
 15 4.08-4.19 (m, 2H), 1.79-1.89 (m, 2H), 1.65-1.70 (m, 1H), 1.48 (s, 3H), 1.04-1.09 (m, 6H) ppm.

Example 456


(S)-1-(2-chloro-4-(pyrazolo[1,5-a]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine
 20





Part A: *(S)*-Tert-butyl (1-(2-chloro-4-(pyrazolo [1, 5-*a*] pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (0.05 g, 0.326 mmol), (*S*)-
 5 *tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (0.152 g, 0.326 mmol), Cs₂CO₃ (0.212 g, 0.651 mmol), and KBr (0.039 g, 0.326 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was purged with nitrogen gas for 30 min. PdCl₂ (dppf)-CH₂Cl₂ adduct (0.027 g, 0.033 mmol) was added to the reaction
 10 mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80 °C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The organic layer was
 15 separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford crude product as a brown solid which was purified by silica-gel column chromatography (pet ether/ethyl acetate) to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.08 g, 0.174 mmol, 54% yield) as an off-white solid. LCMS (ESI) *m/e* 459.2 [(M+H)⁺, calcd for C₂₄H₃₂ClN₄O₃ 459.2]; LC/MS retention time (Method A1): *t*_R = 3.28 min.
 20





Part B: *(S)*-1-(2-chloro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine

25 To a solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.08 g, 0.174 mmol) in DCM (2

mL) at 0 °C was added TFA (0.269 mL, 3.49 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) to afford (*S*)-1-(2-chloro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (73.1 mg, 0.153 mmol, 88% yield) as a pale yellow solid. LCMS (ESI) *m/e* 359.0 [(M+H)⁺, calcd for C₁₉H₂₄ClN₄O 359.2]; LC/MS retention time (method I): *t_R* = 1.22 min. ¹H NMR(400 MHz, DMSO-*d*₆): δ 8.59 (d, *J* = 4.40 Hz, 1H), 8.40 (d, *J* = 2.40 Hz, 1H), 8.30 (d, *J* = 2.40 Hz, 1H), 8.15-8.18 (m, 1H), 7.30-7.37 (m, 2H), 6.83 (d, *J* = 2.40 Hz, 1H), 3.89-3.92 (m, 2H), 1.79-1.86 (m, 1H), 1.41-1.50 (m, 2H), 1.18 (s, 3H), 0.92-0.95 (m, 6H) ppm.

Example 457


(*S*)-7-(4-((2-amino-2, 4-dimethylpentyl) oxy)-3-fluorophenyl)pyrazolo[1,5-*a*]pyrimidin-5-amine



Part A: 5-aminopyrazolo[1,5-*a*]pyrimidin-7(4*H*)-one

A solution of ethyl 3-ethoxy-3-iminopropanoate hydrochloride (5 g, 25.6 mmol) in ethanol (50 mL) cooled at 0 °C was added TEA (3.56 mL, 25.6 mmol) dropwise and the reaction mixture was stirred at room temperature for 30 min. 1*H*-pyrazol-5-amine (2.336 g, 28.1 mmol) in ethanol (10 mL) was added dropwise to the reaction mixture and the mixture was heated 80 °C for 16 h. The reaction mixture was cooled to room temperature and the white colored precipitate that formed was collected by vacuum filtration, washed with an excess of cold ethanol (10 mL), and dried to give 5-aminopyrazolo[1,5-*a*]pyrimidin-7(4*H*)-one (2 g, 13.32 mmol, 52%)

yield) as an off-white solid which was carried forward without further purification. LCMS (ESI) m/e 149.0 [(M-H)⁻, calcd for C₆H₅N₄O 149.1]; LC/MS retention time (Method A1): t_R = 0.21 min.




5

*Part B: 7-chloropyrazolo [1,5-*a*]pyrimidin-5-amine*

To 5-aminopyrazolo [1, 5-*a*] pyrimidin-7(4*H*)-one (2 g, 13.32 mmol) cooled at 0 °C was added POCl₃ (1.242 mL, 13.32 mmol) dropwise. The reaction mixture and stirred for 5 min at 0 °C then at 105 °C for 12 h. The reaction mixture was concentrated under reduced pressure to afford white colored residue. The residue was basified with 10% aqueous sodium hydroxide solution (pH~ 12) and extracted with ethyl acetate (3 x25 mL). The ethyl acetate layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 7-chloropyrazolo[1,5-*a*]pyrimidin-5-amine (1.5 g, 8.90 mmol, 67% yield) as an off-white solid. LCMS (ESI) m/e 167.0 [(M-H)⁻, calcd for C₆H₅ClN₄ 167.0]; LC/MS retention time (method A2): t_R = 0.26 min.

15




*Part C: N-(7-chloropyrazolo[1,5-*a*]pyrimidin-5-yl)acetamide*

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidin-5-amine (0.6 g, 3.56 mmol) in DCM (10 mL) was cooled to 0 °C. DIPEA (0.622 mL, 3.56 mmol) was added followed by slow addition of AcCl (0.253 mL, 3.56 mmol) and the mixture stirred for 10 min at 0 °C. The reaction mixture stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure to afford a brown colored residue. The residue was washed with ethyl acetate/petroleum ether (5 mL/15 mL) then dried to afford *N*-(7-chloropyrazolo[1,5-*a*]pyrimidin-5-yl)acetamide (0.7 g, 3.10 mmol, 87% yield) as a brown color semi-solid which was used for next step without


25

purification. ^1H NMR (400 MHz, DMSO- d_6): δ 11.94 (s, 1H), 8.31 (s, 1H), 7.88 (d, J = 2.40 Hz, 1H), 6.98 (d, J = 2.40 Hz, 1H), 2.49 (s, 3H) ppm.



5 *Part D: N-(7-(3-fluoro-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl)acetamide and 7-(3-fluoro-4-methoxyphenyl)pyrazolo [1,5-a]pyrimidin-5-amine*

A solution of *N*-(7-chloropyrazolo[1,5-*a*]pyrimidin-5-yl)acetamide (0.4 g, 1.899 mmol), (3-fluoro-4-methoxyphenyl)boronic acid (0.323 g, 1.899 mmol), and Cs_2CO_3 (1.238 g, 3.80 mmol) in 1,4-dioxane (10 mL) and water (3 mL) was purged
10 with nitrogen gas for 30 min. $\text{PdCl}_2(\text{dppf})\text{-CH}_2\text{Cl}_2$ adduct (0.155 g, 0.190 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80 °C for 6 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (50 mL) and water (40 mL). The biphasic mixture was filtered through diatomaceous earth. The
15 diatomaceous earth was washed with ethyl acetate (50 mL). The organic layer was separated, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in pet ether) to afford two products *N*-(7-(3-fluoro-4-methoxyphenyl)pyrazolo[1,5-*a*]pyrimidin-5-yl)acetamide (0.28 g, 0.932 mmol, 49% yield) as a light yellow solid LCMS (ESI) m/e 301.2
20 $[(\text{M}+\text{H})^+]$, calcd for $\text{C}_{15}\text{H}_{14}\text{FN}_4\text{O}_2$ 301.1]; LC/MS retention time (Method A1): t_R = 2.02 min and 7-(3-fluoro-4-methoxyphenyl)pyrazolo[1,5-*a*]pyrimidin-5-amine (0.12 g, 0.465 mmol, 24% yield) as a brown solid. LCMS (ESI) m/e 259.2 $[(\text{M}+\text{H})^+]$, calcd for $\text{C}_{13}\text{H}_{12}\text{FN}_4\text{O}$ 259.1]; LC/MS retention time (Method A1): t_R = 1.90 min.




*Part E: 4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenol*

To a solution of *N*-(7-(3-fluoro-4-methoxyphenyl) pyrazolo [1, 5-*a*] pyrimidin-5-yl) acetamide (0.28 g, 0.932 mmol) cooled to 0 °C was added HBr in AcOH (34%) (5 mL, 92 mmol). The reaction mixture was heated at 105 °C for 12 h.

5 The reaction mixture was concentrated under reduced pressure. The residue was reconstituted with ethyl acetate/pet ether(5:5 mL), filtered and dried to afford 4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenol (0.34 g, 0.390 mmol, 42% yield) as an off-white solid which was carried forward without further purification. LCMS (ESI) *m/e* 245.2 [(M+H)⁺, calcd for C₁₂H₁₀FN₄O 245.1]; LC/MS retention

10 time (Method A1): *t_R* = 1.69 min.


*Part F: (S)-tert-butyl (1-(4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate*

15 A solution of ethyl 4-(5-aminopyrazolo [1, 5-*a*] pyrimidin-7-yl)-2-fluorophenol (0.34 g, 0.418 mmol) in DMF (5 mL) was cooled to 0 °C. K₂CO₃ (0.173 g, 1.253 mmol) was added in portions followed by slow addition of (*S*)-*tert*-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (0.147 g, 0.501 mmol) in 1 mL DMF. The

20 reaction mixture was heated at 88 °C for 12 h. The reaction mixture was cooled to 0 °C and quenched with aqueous ammonium chloride solution (10 mL). The reaction mixture extracted with ethyl acetate (2x20 mL). The ethyl acetate layer was washed with water (2x20 mL) and brine(10 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(4-(5-

25 aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.092 g, 0.201 mmol, 48% yield) as a brown color semi-solid. The residue was taken for next step without further purification. LCMS (ESI) *m/e* 458.0

$[(M+H)^+]$, calcd for $C_{24}H_{33}FN_5O_3$ 458.2]; LC/MS retention time (Method A1): t_R = 2.09 min.




5 *Part G: (S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine*


To a solution of (*S*)-*tert*-butyl (1-(4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (20 mg, 0.044 mmol) in DCM (2 mL) at 0 °C was added TFA (0.067 mL, 0.874 mmol) and the mixture stirred for 5
10 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (*S*)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)pyrazolo[1,5-*a*]pyrimidin-5-amine (2.75 mg, 7.69 μ mol, 18% yield) as a pale yellow solid. LCMS (ESI) m/e 358.2 $[(M+H)^+]$, calcd for $C_{19}H_{25}FN_5O$ 358.2];
15 LC/MS retention time (method H): t_R = 1.05 min. ^1H NMR(400 MHz, Methanol- d_4): δ 7.85-7.89 (m, 2H), 7.74-7.77 (m, 1H), 7.36 (t, J = 17.20 Hz, 1H), 6.39 (s, 1H), 6.11 (s, 1H), 4.16-4.25 (m, 2H), 1.82-1.87 (m, 2H), 1.68-1.71 (m, 1H), 1.49 (s, 3H), 1.04-1.09 (m, 6H) ppm.

20

Example 459


(*S*)-1-(2-chloro-4-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine






*Part A: 2, 5-dimethylpyrazolo [1,5-*a*]pyrimidin-7-ol*

To a solution of 5-methyl-1*H*-pyrazol-3-amine (10 g, 103 mmol) in 1,4-dioxane (100 mL) was added ethyl 3-oxobutanoate (16.08 g, 124 mmol) dropwise followed by slow addition of AcOH (5.89 mL, 103 mmol). The reaction mixture was heated at 80 °C for 14 h. The reaction mixture was concentrated under reduced pressure. The residue was mixed with ice-water. A solid formed that was collected by vacuum filtration to afford 2, 5-dimethylpyrazolo [1, 5-*a*] pyrimidin-7-ol (7.5 g, 45.5 mmol, 44% yield) as an off-white color solid. LCMS (ESI) *m/e* 164.2 [(M+H)⁺, calcd for C₈H₁₀N₃O 164.1]; LC/MS retention time (Method A1): *t_R* = 0.58 min.




*Part B: 7-chloro-2,5-dimethylpyrazolo[1,5-*a*]pyrimidine*

2,5-Dimethylpyrazolo[1,5-*a*]pyrimidin-7-ol (3 g, 18.38 mmol) was taken in a 100 mL round bottom and cooled to 0 °C. POCl₃ (10 mL, 107 mmol) was added dropwise and the reaction mixture stirred for 5 min at 0 °C. The reaction mixture was heated at 105 °C for 12 h. The reaction mixture was concentrated under reduced pressure to afford a white colored residue. The residue was basified with 10% aqueous sodium hydroxide solution (pH~ 12) and extracted with ethyl acetate (3 x 25 mL). The ethyl acetate layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 7-chloro-2,5-dimethylpyrazolo[1,5-*a*]pyrimidine (1.8 g, 9.91 mmol, 54% yield) as an off-white solid. LCMS (ESI) *m/e* 182.2 [(M+H)⁺, calcd for C₈H₉ClN₃ 182.0]; LC/MS retention time (Method A1): *t_R* = 1.77 min.



Part C: *(S)*-tert-butyl (1-(2-chloro-4-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of 7-chloro-2,5-dimethylpyrazolo[1,5-*a*]pyrimidine (0.04 g, 0.220 mmol), *(S)*-tert-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (0.103 g, 0.220 mmol), potassium phosphate, tribasic (0.038 g, 0.220 mmol), and KBr (0.026 g, 0.220 mmol) in 1,4-dioxane (5 mL) was purged with nitrogen gas for 30 min. PdCl₂(dppf)-CH₂Cl₂ adduct (0.018 g, 0.022 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 100 °C for 6 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (25 mL) and water (20 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (30 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford *(S)*-tert-butyl (1-(2-chloro-4-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (crude yield) (0.064 g, 0.131 mmol, 60% yield) as a brown solid which was used for next step without further purification. LCMS (ESI) *m/e* 487.2 [(M+2H)⁺, calcd for C₂₆H₃₆ClN₄O₃ 487.2]; LC/MS retention time (Method A1): *t_R* = 2.91 min.




Part D: (S)-1-(2-chloro-4-(2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine


To a solution of (S)-tert-butyl (1-(2-chloro-4-(2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.084 g, 0.172 mmol) in DCM (2 mL) at 0 °C was added TFA (0.266 mL, 3.45 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (S)-1-(2-chloro-4-(2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine (52.5 mg, 0.134 mmol, 78% yield) as a pale yellow solid. LCMS (ESI) m/e 387.0 [(M+2H)⁺, calcd for C₂₁H₂₈ClN₄O 387.2]; LC/MS retention time (method H): t_R = 1.68 min; LC/MS retention time (method I): t_R = 1.29 min. ¹H NMR(400 MHz, Methanol-d₄): δ 8.27 (d, J = 2.00 Hz, 1H), 8.07-8.09 (m, 1H), 7.35 (d, J = 8.80 Hz, 1H), 6.97 (s, 1H), 6.44 (s, 1H), 4.16-4.22 (m, 2H), 2.62 (s, 3H), 2.49 (s, 3H), 1.85-1.90 (m, 2H), 1.67-1.72 (m, 1H), 1.48 (s, 3H), 1.04-1.08 (m, 6H) ppm.

Example 460

(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(pyrazolo[1,5-a]pyrimidin-7-yl)benzonitrile




20



Part A: (S)-Tert-butyl (1-(2-cyano-4-(pyrazolo[1,5-a]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

25

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (0.04 g, 0.260 mmol), (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (0.119 g, 0.260 mmol), KBr (0.031 g, 0.260 mmol), and potassium phosphate, tribasic (0.045 g, 0.260 mmol) in 1,4-dioxane (5 mL) was purged with nitrogen gas for 30 min .
 PdCl₂(dppf)-CH₂Cl₂ adduct (0.021 g, 0.026 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 100 °C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (25 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(2-cyano-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (crude yield) (62 mg, 0.138 mmol, 53% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 451.2 [(M+H)⁺, calcd for C₂₅H₃₂N₅O₃ 450.2]; LC/MS retention time (method B): *t_R* = 1.09 min.



Part B: (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile



To a solution of (*S*)-*tert*-butyl (1-(2-cyano-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 285) (0.06 g, 0.133 mmol) in DCM (2 mL) at 0 °C was added TFA (0.206 mL, 2.67 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method B) to afford (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile (41.5 mg, 0.119 mmol, 89% yield) as a pale yellow solid. LCMS (ESI) *m/e* 350.0 [(M+H)⁺, calcd for C₂₀H₂₄N₅O 350.2]; LC/MS retention time (method H): *t_R* = 1.28 min; LC/MS retention time (method I): *t_R* = 1.05 min. ¹H NMR(400 MHz,

Methanol-d₄: δ 8.59-8.63 (m, 2H), 8.49-8.51 (m, 1H), 8.25-8.28 (m, 1H), 7.50 (d, J = 8.80 Hz, 1H), 7.22 (d, J = 4.40 Hz, 1H), 6.82-6.85 (m, 1H), 4.35-4.47 (m, 2H), 1.88-1.98 (m, 2H), 1.73-1.77 (m, 1H), 1.56 (s, 3H), 1.06-1.11 (m, 6H) ppm.

5

Example 461

(*S*)-1-(2-fluoro-4-(pyrazolo [1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine




10

*Part A: (S)-tert-butyl (1-(2-fluoro-4-(pyrazolo [1, 5-*a*] pyrimidin-7-yl) phenoxy)-2, 4-dimethylpentan-2-yl) carbamate*

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (0.04 g, 0.260 mmol), (*S*)-*tert*-butyl (1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 253, Part B) (0.118 g, 0.260 mmol), KBr (0.031 g, 0.260 mmol), and potassium phosphate, tribasic (0.045 g, 0.260 mmol) in 1,4-dioxane (5 mL) was purged with nitrogen gas for 10 min. PdCl₂ (dppf)-CH₂Cl₂ adduct (0.021 g, 0.026 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 88 °C for 12 h. The reaction mixture was concentrated then dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (30 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product (*S*)-*tert*-butyl (1-(2-fluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-

25

yl)carbamate (62 mg, 0.098 mmol, 38% yield) as an off-white solid which was carried forward without further purification. LCMS (ESI) m/e 443.2 [(M+H)⁺, calcd for C₂₄H₃₂FN₄O₃ 443.2]; LC/MS retention time (Method A1): t_R = 2.33 min.



5


*Part B: (S)-1-(2-fluoro-4-(pyrazolo [1, 5-*a*] pyrimidin-7-yl) phenoxy)-2, 4-dimethylpentan-2-amine*


To a solution (*S*)-*tert*-butyl 1-(2-fluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (50 mg, 0.113 mmol) in DCM (2 mL) at 0 °C was added TFA (0.174 mL, 2.260 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by preparative LC/MS (method A) to afford (*S*)-1-(2-fluoro-4-(pyrazolo [1, 5-*a*] pyrimidin-7-yl) phenoxy)-2, 4-dimethylpentan-2-amine (15.3 mg, 0.044, 39% yield) as a pale yellow solid. LCMS (ESI) m/e 343.0 [(M+H)⁺, calcd for C₁₉H₂₄FN₄O 343.2]; LC/MS retention time (method H): t_R = 1.29 min; LC/MS retention time (method I): t_R = 1.09 min. ¹H NMR(400 MHz, Methanol)-d₄: δ 8.55 (d, J = 4.40 Hz, 1H), 8.22 (d, J = 2.40 Hz, 1H), 8.11-8.15 (m, 1H), 7.97-8.00 (m, 1H), 7.38 (t, J = 17.60 Hz, 1H), 7.16 (d, J = 4.80 Hz, 1H), 6.79 (d, J = 2.40 Hz, 1H), 4.15-4.25 (m, 2H), 1.80-1.89 (m, 2H), 1.65-1.69 (m, 1H), 1.46 (s, 3H), 1.02-1.07 (m, 6H) ppm.

20

Example 463


(*S*)-*N*-(7-(4-((2-amino-2, 4-dimethylpentyl) oxy)-3-fluorophenyl) pyrazolo [1,5-*a*] pyrimidin-5-yl) acetamide





Part A: 5-aminopyrazolo [1, 5-a] pyrimidin-7(4H)-one

A solution of ethyl 3-ethoxy-3-iminopropanoate hydrochloride (5 g, 25.6 mmol) in ethanol (50 mL) was to at 0 °C. TEA (3.56 mL, 25.6 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 30 min. 1H-pyrazol-5-amine (2.336 g, 28.1 mmol) in ethanol (10 mL) was added dropwise to the reaction mixture and was the mixture heated to reflux for 16 h. The reaction mixture was allowed to cool to room temperature and the white colored precipitate formed was collected by vacuum filtration. The white solid was washed with an excess of cold ethanol (10 mL) and dried to give 5-aminopyrazolo [1, 5-a] pyrimidin-7(4H)-one (2 g, 13.32 mmol, 52% yield) as an off-white solid which was carried forward without further purification. LCMS (ESI) *m/e* 149.0 [(M-H)⁻], calcd for C₆H₅N₄O 149.1]; LC/MS retention time (Method A1): *t_R* = 0.21 min.




15

Part B: 7-chloropyrazolo[1,5-a]pyrimidin-5-amine


5-Aminopyrazolo [1, 5-a] pyrimidin-7(4H)-one (2 g, 13.32 mmol) was taken in a 100 mL round bottom flask and cooled to 0 °C. POCl₃ (1.242 mL, 13.32 mmol) was added dropwise and the reaction mixture was stirred for 5 min at 0 °C, then heated at 105 °C for 12 h. The reaction mixture was concentrated under reduced pressure to afford a white colored residue. The residue was basified with 10% aqueous sodium hydroxide solution (pH~ 12) and extracted with ethyl acetate (3x25 mL). The ethyl acetate layer was dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 7-chloropyrazolo[1,5-a]pyrimidin-5-amine (1.5 g, 8.90 mmol, 67% yield) as an off-white solid. LCMS (ESI) *m/e* 167.0 [(M-H)⁻], calcd for C₆H₅ClN₄ 167.0]; LC/MS retention time (method A2): *t_R* = 0.6 min.

25



Part C: N-(7-chloropyrazolo[1,5-a]pyrimidin-5-yl)acetamide

A solution of 7-chloropyrazolo[1,5-a]pyrimidin-5-amine (0.6 g, 3.56 mmol) in DCM (10 mL) was cooled to 0 °C. DIPEA (0.622 mL, 3.56 mmol) was added followed by slow addition of AcCl (0.253 mL, 3.56 mmol) and the mixture stirred for 10 min at 0 °C, then at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure to afford a brown colored residue. The solid residue was washed with ethyl acetate/petroleum ether (5 mL/15 mL), dried to afford *N*-(7-chloropyrazolo[1,5-a]pyrimidin-5-yl)acetamide (0.7 g, 3.10 mmol, 87% yield) as a brown color semi-solid which carried forward without further purification. 400 MHz, DMSO- d_6 : δ 11.94 (s, 1H), 8.31 (s, 1H), 7.88 (d, J = 2.40 Hz, 1H), 6.98 (d, J = 2.40 Hz, 1H), 2.49 (s, 3H) ppm.




Part D: N-(7-(3-fluoro-4-methoxyphenyl)pyrazolo [1,5-a]pyrimidin-5-yl)acetamide and 7-(3-fluoro-4-methoxyphenyl)pyrazolo [1,5-a]pyrimidin-5-amine

A solution of *N*-(7-chloropyrazolo[1,5-a]pyrimidin-5-yl)acetamide (0.4 g, 1.899 mmol), (3-fluoro-4-methoxyphenyl)boronic acid (0.323 g, 1.899 mmol), and Cs₂CO₃ (1.238 g, 3.80 mmol) in 1,4-dioxane (10 mL) and water (3 mL) was purged with nitrogen gas for 30 min. PdCl₂(dppf)-CH₂Cl₂ adduct (0.155 g, 0.190 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80 °C for 6 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (50 mL) and water (40 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The organic layer was

separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc in pet ether) to afford two products *N*-(7-(3-fluoro-4-methoxyphenyl)pyrazolo[1,5-*a*]pyrimidin-5-yl)acetamide (0.28 g, 0.932 mmol, 49% yield) as a light yellow solid LCMS (ESI) *m/e* 301.2

- 5 [(M+H)⁺, calcd for C₁₅H₁₄FN₄O₂ 301.1]; LC/MS retention time (Method A1): *t_R* = 2.02 min and 7-(3-fluoro-4-methoxyphenyl)pyrazolo[1,5-*a*]pyrimidin-5-amine (0.12 g, 0.465 mmol, 24% yield) as a brown solid. LCMS (ESI) *m/e* 259.2 [(M+H)⁺, calcd for C₁₃H₁₂FN₄O 259.1]; LC/MS retention time (Method A1): *t_R* = 1.90 min.




10

*Part E: 4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenol*

N-(7-(3-fluoro-4-methoxyphenyl)pyrazolo[1,5-*a*]pyrimidin-5-yl)acetamide (0.28 g, 0.932 mmol) was taken in a 100 mL round bottom flask, cooled to 0 °C and HBr in AcOH (34%) (5 mL, 92 mmol) was added. The reaction mixture was heated


15 at 105 °C for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was reconstituted with ethyl acetate/pet ether (5 mL/5 mL), filtered and dried to afford 4-(5-aminopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenol (0.34 g, 0.390 mmol, 42% yield) as an off-white solid which was taken forward without further purification. LCMS (ESI) *m/e* 245.2 [(M+H)⁺, calcd for C₁₂H₁₀FN₄O 245.1];

- 20 LC/MS retention time (Method A1): *t_R* = 1.69 min.



Part F: (S)-tert-butyl (1-(4-(5-aminopyrazolo[1,5-a]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate


A solution of ethyl 4-(5-aminopyrazolo [1,5-a] pyrimidin-7-yl)-2-fluorophenol (0.34 g, 0.418 mmol) in DMF (5 mL) was cooled to 0 °C. K₂CO₃ (0.173 g, 1.253 mmol) was added in portions followed by slow addition of a solution of (S)-tert-butyl 4-isobutyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (prepared as described in Example 251, Parts A-E) (0.147 g, 0.501 mmol) in 1 mL DMF. The reaction mixture was heated at 88 °C for 12 h. The reaction mixture was cooled to 0 °C and quenched with aqueous ammonium chloride solution (10 mL). The reaction mixture extracted with ethyl acetate (2x20 mL). The ethyl acetate layer was washed with water (2x20 mL) and brine (10 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (S)-tert-butyl (1-(4-(5-aminopyrazolo[1,5-a]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.092 g, 0.201 mmol, 48% yield) as a brown color semi-solid. The residue was taken forward without further purification. LCMS (ESI) *m/e* 458.0 [(M+H)⁺, calcd for C₂₄H₃₃FN₅O₃ 458.2]; LC/MS retention time (Method A1): *t_R* = 2.09 min.



Part G: (S)-tert-butyl (1-(4-(5-acetamidopyrazolo [1,5-a]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of (S)-tert-butyl (1-(4-(5-aminopyrazolo [1,5-a] pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl) carbamate (0.05 g, 0.109 mmol) in pyridine (2 mL) was cooled to 0 °C and AcCl (7.77 µl, 0.109 mmol) was added dropwise. The reaction mixture was allowed to stir at 0 °C for 10 min then at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure to afford a brown colored residue. The residue was dissolved in ethyl acetate (20 mL) and water

(20 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(4-(5-acetamidopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.06 g, 0.055 mmol, 51% yield) as an off-white solid which was
 5 carried forward without further purification. LCMS (ESI) *m/e* 500.2 [(M+H)⁺, calcd for C₂₆H₃₅FN₅O₄ 500.2]; LC/MS retention time (Method A1): *t*_R = 2.54 min.





Part H: (S)-N-(7-(4-((2-amino-2, 4-dimethylpentyl) oxy)-3-fluorophenyl) pyrazolo
 10 *[1,5-a] pyrimidin-5-yl) acetamide*

To a solution of (*S*)-*tert*-butyl (1-(4-(5-acetamidopyrazolo[1,5-*a*]pyrimidin-7-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-yl)carbamate (52 mg, 0.048 mmol) in DCM (2 mL) at 0 °C was added TFA (0.074 mL, 0.958 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room
 15 temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (*S*)-*N*-(7-(4-((2-amino-2, 4-dimethylpentyl) oxy)-3-fluorophenyl) pyrazolo [1,5-*a*] pyrimidin-5-yl) acetamide (2 mg, 5.01 μmol, 10% yield) as a pale yellow solid. LCMS (ESI) *m/e* 400.0 [(M+H)⁺, calcd for C₂₁H₂₇FN₅O₂ 400.2]; LC/MS retention time (method H): *t*_R = 1.14 min;
 20 LC/MS retention time (method I): *t*_R = 1.11 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.09 (d, *J* = 2.40 Hz, 1H), 8.02-8.05 (m, 1H), 7.98 (s, 1H), 7.85-7.89 (m, 1H), 7.38 (t, *J* = 17.20 Hz, 1H), 6.50 (d, *J* = 2.00 Hz, 1H), 4.14-4.24 (m, 2H), 2.23 (s, 3H), 1.79-1.88 (m, 2H), 1.64-1.69 (m, 1H), 1.46 (s, 3H), 1.02-1.07 (m, 6H) ppm.

25


Example 464

(*S*)-2-((2-amino-2, 4-dimethylpentyl)oxy)-5-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile



Part A: 2, 5-dimethylpyrazolo [1,5-a]pyrimidin-7-ol


5 To a solution of 5-methyl-1H-pyrazol-3-amine (10 g, 103 mmol) in 1,4-dioxane (100 mL) was added ethyl 3-oxobutanoate (16.08 g, 124 mmol) dropwise followed by slow addition of AcOH (5.89 mL, 103 mmol). The reaction mixture was heated at 80 °C for 14 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was mixed with ice-water to afford
 10 an off-white colored solid which was collected by vacuum filtration and dried to give 2, 5-dimethylpyrazolo [1,5-a] pyrimidin-7-ol (7.5 g, 45.5 mmol, 44% yield). LCMS (ESI) m/e 164.2 [(M+H)⁺, calcd for C₈H₁₀N₃O 164.1]; LC/MS retention time (Method A1): t_R = 0.58 min.



15 *Part B: 7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidine*


2,5-Dimethylpyrazolo[1,5-a]pyrimidin-7-ol (3g, 18.38 mmol) was taken in a 100 mL round bottom and cooled to 0 °C. POCl₃ (10 mL, 107 mmol) was added dropwise and the reaction mixture stirred for 5 min at 0 °C. The reaction mixture
 20 was heated at 105 °C for 12 h. The reaction mixture was concentrated under reduced pressure to afford a white colored residue. The residue was basified with 10% aqueous sodium hydroxide solution (pH~ 12) and extracted with ethyl acetate (3x25 mL). The ethyl acetate layer was dried over Na₂SO₄, filtered, and concentrated under

reduced pressure to afford 7-chloro-2,5-dimethylpyrazolo[1,5-*a*]pyrimidine (1.8 g, 9.91 mmol, 54% yield) as an off-white solid. LCMS (ESI) *m/e* 182.2 [(M+H)⁺, calcd for C₈H₉ClN₃ 182.0]; LC/MS retention time (Method A1): *t_R* = 1.77 min.



5 *Part C: (S)-tert-butyl (1-(2-cyano-4-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate*

A solution of 7-chloro-2,5-dimethylpyrazolo[1,5-*a*]pyrimidine (0.04 g, 0.220 mmol), (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part
10 B-G) (0.101 g, 0.220 mmol), potassium phosphate, tribasic (0.038 g, 0.220 mmol), and KBr (0.026 g, 0.220 mmol) in 1,4-dioxane (5 mL) was purged with nitrogen gas for 30 min. PdCl₂(dppf)-CH₂Cl₂ adduct (0.018 g, .022 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 100 °C for 6 h. The reaction mixture was
15 concentrated and the residue obtained was dissolved in ethyl acetate (20 mL) and water (20 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (30 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a brown solid which was purified by silica gel chromatography (EtOAc in
20 pet ether) to afford (*S*)-*tert*-butyl (1-(2-cyano-4-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (52 mg, 0.109 mmol, 49% yield). LCMS (ESI) *m/e* 478.2 [(M+H)⁺, calcd for C₂₇H₃₆N₅O₃ 478.2]; LC/MS retention time (Method A1): *t_R* = 2.66 min.





Part D: *(S)*-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2,5-dimethylpyrazolo[1,5-
a]pyrimidin-7-yl)benzonitrile

To a solution of *(S)*-*tert*-butyl 1-(2-cyano-4-(2,5-dimethylpyrazolo[1,5-
a]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (52 mg, 0.109 mmol)
in DCM (2 mL) at 0 °C was added TFA (0.168 mL, 2.178 mmol) and the mixture
stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room
temperature, then was concentrated under reduced pressure. The crude material was
purified by prep LC/MS (method A) to afford *(S)*-2-((2-amino-2,4-
dimethylpentyl)oxy)-5-(2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)benzonitrile
(12.3 mg, 0.032 mmol, 30% yield) as a pale yellow solid. LCMS (ESI) *m/e* 378.0
[(M+H)⁺, calcd for C₂₂H₂₈N₅O 378.0]; LC/MS retention time (method H): *t_R* = 1.38
min; LC/MS retention time (method I): *t_R* = 1.31 min. ¹H NMR(400 MHz,
Methanol-d₄): δ 8.52 (d, *J* = 2.00 Hz, 1H), 8.40-8.43 (m, 1H), 7.44 (d, *J* = 9.20 Hz,
1H), 7.02 (s, 1H), 6.45 (s, 1H), 4.16-4.22 (m, 2H), 2.63 (s, 3H), 2.50 (s, 3H), 1.76-
1.89 (m, 2H), 1.63-1.68 (m, 1H), 1.42 (s, 3H), 1.04-1.07 (m, 6H) ppm.


Example 466

(S)-2-(2-amino-2, 4-dimethylpentyl)oxy)-5-(2-(piperidin-4-ylamino) pyridin-4-yl)
benzonitrile




Part A: Tert-butyl 4-((4-chloropyridin-2-yl) amino) piperidine-1-carboxylate

A mixture of 2-bromo-4-chloropyridine (0.05 g, 0.260 mmol), *tert*-butyl 4-aminopiperidine-1-carboxylate (0.062 g, 0.312 mmol), *tert*-butyl 4-aminopiperidine-1-carboxylate (0.062 g, 0.312 mmol), Cs₂CO₃ (0.169 g, 0.520 mmol), and BINAP (0.162 g, 0.260 mmol) in toluene (5 mL) was solution was purged with nitrogen gas for 30 min. PdOAc₂ (0.058 g, 0.260 mmol) was added to the reaction mixture and again the solution was purged with nitrogen gas for 10 min the mixture was heated at 80 °C for 12 h. The reaction mixture was concentrated, dissolved in ethyl acetate (25 mL) and water (20 mL) and biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated and dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-20% EtOAc in pet ether) to afford, *tert*-butyl 4-((4-chloropyridin-2-yl) amino) piperidine-1-carboxylate (32 mg, 0.103 mmol, 40% yield) as an off-white solid. LCMS (ESI) *m/e* 312.2 [(M+H)⁺, calcd for C₁₅H₂₂ClN₃O₂ 312.1]; LC/MS retention time (Method A1): *t*_R = 2.63 min.

*Part B: (S)-Tert-butyl 4-((4-((4-((2-((tert-butoxycarbonyl) amino)-2, 4-dimethylpentyl) oxy)-3-cyanophenyl) pyridin-2-yl) amino) piperidine-1-carboxylate*

A mixture of *tert*-butyl 4-((4-chloropyridin-2-yl)amino)piperidine-1-carboxylate (0.05 g, 0.160 mmol), (*S*)-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (0.088 g, 0.192 mmol), and potassium phosphate tribasic (0.085 g, 0.401 mmol) in THF (5 mL) and water (0.5 mL) was purged with nitrogen gas for 30 min. XPhos 2nd generation precatalyst (7.43 mg, 0.024 mmol) was added to the reaction mixture and the solution was again purged with nitrogen gas for

another 10 min. The reaction mixture was heated at 70 °C for 2 h. The reaction mixture was concentrated and the residue dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated and dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl 4-((4-(4-((2-((*tert*-butoxycarbonyl)amino)-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)amino)piperidine-1-carboxylate (80 mg, 0.026 mmol, 16% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 608.4 [(M+H)⁺, calcd for C₃₄H₅₀N₅O₅ 608.4]; LC/MS retention time (method B): *t*_R = 3.51 min.




Part C: (S)-2-(2-amino-2,4-dimethylpentyl)oxy-5-(2-(piperidin-4-ylamino)pyridin-4-yl)benzonitrile


To a solution of (*S*)-*tert*-butyl 4-((4-(4-((2-((*tert*-butoxycarbonyl)amino)-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)amino)piperidine-1-carboxylate (60 mg, 0.099 mmol) in DCM (2 mL) at 0 °C was added TFA (0.152 mL, 1.974 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (*S*)-2-(2-amino-2,4-dimethylpentyl)oxy-5-(2-(piperidin-4-ylamino)pyridin-4-yl)benzonitrile (17 mg, 0.023 mmol, 23% yield) a pale yellow solid. LCMS (ESI) *m/e* 408.2 [(M+H)⁺, calcd for C₂₄H₃₄N₃O 408.3]; LC/MS retention time (method H): *t*_R = 0.95 min; LC/MS retention time (method I): *t*_R = 0.66 min. ¹H NMR (400 MHz, *Methanol-d*₄): δ 8.02-8.05 (m, 2H), 7.96-7.99 (m, 1H), 7.37 (d, *J* = 8.80 Hz, 1H), 6.85-6.87 (m, 1H), 6.78 (s, 1H), 4.25-4.30 (m, 2H), 3.45-3.51 (m, 2H), 3.13-3.20 (m, 2H), 2.24-2.29 (m, 2H), 1.86-1.99 (m, 3H), 1.69-1.78 (m, 3H), 1.53 (s, 3H), 1.03-1.08 (m, 6H) ppm.

Example 467

(*S*)-2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine




5



Part A: (*S*)-*Tert*-butyl(2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (0.15 g, 0.977 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.588 g, 1.172 mmol), Cs₂CO₃ (0.955 g, 2.93 mmol), and KBr (0.116 g, 0.977 mmol) in 1,4-dioxane (5 mL) was purged with nitrogen gas for 30 min. PdCl₂(dppf)-CH₂Cl₂ adduct (0.080 g, 0.098 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80°C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (50 mL) and water (40 mL). The biphasic mixture was filtered through diatomaceous earth and the diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a brown solid which was purified by silica gel column chromatography (0-30% ethyl acetate in pet ether) to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.13 g, 0.264 mmol, 27% yield) as a off-white semi-solid. LCMS (ESI) *m/e* 493.2 [(M+H)⁺, calcd for C₂₅H₃₂F₃N₄O₃ 493.2]; LC/MS retention time (method B): *t*_R = 1.27 min.




Part B: *(S)*-2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine

To a solution of *(S)*-*tert*-butyl 1-(4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-ylcarbamate (0.06 g, 0.122 mmol) in DCM (2 mL) at 0 °C was added TFA (0.188 mL, 2.436 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford *(S)*-2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine, TFA (9 mg, 0.018 mmol, 15% yield) as a pale yellow solid. LCMS (ESI) *m/e* 393.0 [(M+H)⁺, calcd for C₂₀H₂₄F₃N₄O 393.2]; LC/MS retention time (method H): *t*_R = 1.67 min; LC/MS retention time (method I): *t*_R = 1.27 min. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.54-8.57 (m, 2H), 8.40-8.42 (m, 1H), 8.23 (d, *J* = 2.40 Hz, 1H), 7.43 (d, *J* = 9.20 Hz, 1H), 7.19 (d, *J* = 4.40 Hz, 1H), 6.79 (d, *J* = 2.40 Hz, 1H), 4.10-4.17 (m, 2H), 1.82-1.88 (m, 1H), 1.58-1.76 (m, 2H), 1.38 (s, 3H), 0.99-1.03 (m, 6H) ppm.

Example 468


(S)-2-(2-amino-2,4-dimethylpentylloxy)-5-(2-(tetrahydro-2*H*-pyran-4-ylamino)pyridin-4-yl)benzonitrile



Part A: 4-chloro-*N*-(tetrahydro-2*H*-pyran-4-yl)pyridin-2-amine

A mixture of 2-bromo-4-chloropyridine (0.5 g, 2.60 mmol), tetrahydro-2*H*-pyran-4-amine (0.315 g, 3.12 mmol), Cs₂CO₃ (1.693 g, 5.20 mmol), and BINAP

(1.618 g, 2.60 mmol) in toluene (30 mL) was purged with nitrogen gas for 30 min and PdOAc₂ (0.583 g, 2.60 mmol) was added. The reaction mixture was again purged with nitrogen gas for another 10 min and heated at 80 °C for 12 h. The reaction mixture was cooled to room temperature and was concentrated under reduced pressure. The residue was diluted with water (25 mL) and ethyl acetate (20 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-30% ethyl acetate in pet ether) to afford 4-chloro-*N*-(tetrahydro-2*H*-pyran-4-yl)pyridin-2-amine (150 mg, 0.705 mmol, 27% yield) as colorless oil. LCMS (ESI) *m/e* 213.2 [(M+H)⁺, calcd for C₁₀H₁₄ClN₂O 213.1]; LC/MS retention time (Method A1): *t*_R = 2.48 min.




Part B: *(S)*-*tert*-butyl (1-(2-cyano-4-(2-((tetrahydro-2*H*-pyran-4-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of 4-chloro-*N*-(tetrahydro-2*H*-pyran-4-yl)pyridin-2-amine (0.04 g, 0.188 mmol), *(S)*-*tert*-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (0.103 g, 0.226 mmol), and potassium phosphate, tribasic (0.033 g, 0.188 mmol) in THF (5 mL) and water (3 mL) was purged with nitrogen for 5 min. XPhos 2nd generation precatalyst (8.72 mg, 0.028 mmol) was added to the reaction mixture under nitrogen. The reaction mixture was again purged with nitrogen gas for 10 min and was heated at 70 °C for 12 h. The reaction mixture was concentrated and the residue obtained was diluted with water (30 mL) and ethyl acetate (30 mL). The biphasic layer was filtered through diatomaceous earth and the diatomaceous earth bed was washed with ethyl acetate (50 mL). The organic layer was separated, dried over Na₂SO₄, filtered, and concentrated to afford *(S)*-*tert*-butyl (1-(2-cyano-4-(2-

((tetrahydro-2H-pyran-4-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (60 mg, 0.118 mmol, 63% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) m/e 509.2 $[(M+H)^+]$, calcd for $C_{29}H_{41}N_4O_4$ 509.3; LC/MS retention time (Method C): t_R = 1.28 min.

5





Part C: *(S)*-2-(2-amino-2,4-dimethylpentyloxy)-5-(2-((tetrahydro-2H-pyran-4-yl)amino)pyridine-4-yl)benzonitrile

To a solution of *(S)*-*tert*-butyl 1-(2-cyano-4-(2-((tetrahydro-2H-pyran-4-yl)amino)pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (60 mg, 0.118 mmol) in dichloromethane (2 mL) at 0 °C was added TFA (0.182 mL, 2.359 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford *(S)*-2-(2-amino-2,4-dimethylpentyloxy)-5-(2-((tetrahydro-2H-pyran-4-yl)amino)pyridine-4-yl)benzonitrile (64.1 mg, 0.099 mmol, 84% yield) as a pale yellow solid. LCMS (ESI) m/e 409.2 $[(M+H)^+]$, calcd for $C_{24}H_{33}N_4O_2$ 409.2; LC/MS retention time (method H): t_R = 1.35 min; LC/MS retention time (method I): t_R = 0.82 min. ^1H NMR (400 MHz, DMSO- d_6): δ 8.19 (d, J = 2.40 Hz, 1H), 8.09-8.11 (m, 1H), 7.92 (d, J = 6.40 Hz, 1H), 7.45 (d, J = 8.80 Hz, 1H), 7.16-7.20 (m, 2H), 4.33 (s, 2H), 3.98-4.03 (m, 2H), 3.90-3.96 (m, 1H), 3.54-3.60 (m, 2H), 1.86-2.04 (m, 4H), 1.65-1.75 (m, 3H), 1.54 (s, 3H), 1.03-1.08 (m, 6H) ppm.

Example 470


(S)-4-(4-(2-amino-2,4-dimethylpentyloxy)-3-(trifluoromethyl)phenyl)-*N*-(piperidin-4-yl)pyridin-2-amine





Part A: tert-butyl 4-((4-chloropyridin-2-yl) amino) piperidine-1-carboxylate


A mixture of 2-bromo-4-chloropyridine (0.05 g, 0.260 mmol), *tert*-butyl 4-aminopiperidine-1-carboxylate (0.062 g, 0.312 mmol), *tert*-butyl 4-aminopiperidine-1-carboxylate (0.062 g, 0.312 mmol), Cs₂CO₃ (0.169 g, 0.520 mmol), and BINAP (0.162 g, 0.260 mmol) in toluene (5 mL) was purged with nitrogen gas for 30 min. PdOAc₂ (0.058 g, 0.260 mmol) was added to the reaction mixture and again the solution was purged with nitrogen gas for another 10 min. The reaction mixture was heated at 80 °C for 12 h. The reaction mixture was cooled to room temperature and was concentrated under reduced pressure. The residue was diluted with water (20 mL) and ethyl acetate (25 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to get a brown residue which was purified by silica gel column chromatography (0-30% petroleum ether/ethyl acetate) to afford *tert*-butyl 4-((4-chloropyridin-2-yl) amino) piperidine-1-carboxylate (32 mg, 0.103 mmol, 40% yield) as an off-white solid. LCMS (ESI) *m/e* 312.2 [(M+H)⁺, calcd for C₁₅H₂₃ClN₃O₂ 312.1]; LC/MS retention time (Method A1): *t*_R = 2.63 min.



Part B: (S)-tert-butyl 4-((4-((4-((tert-butoxycarbonyl)amino)-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)amino)piperidine-1-carboxylate

A solution of *tert*-butyl 4-(4-chloropyridin-2-ylamino)piperidine-1-carboxylate (0.035 g, 0.112 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-

tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.067 g, 0.134 mmol), and potassium phosphate, tribasic (0.112 mL, 0.559 mmol) in THF (5 mL) was purged with nitrogen gas for 30 min. XPhos 2nd generation precatalyst (15 mg, 0.049 mmol) was added to the reaction mixture and again the solution was purged with nitrogen gas for another 10 min. The reaction mixture was heated at 70 °C for 12 h. The reaction mixture was cooled to room temperature and was concentrated under reduced pressure. The residue was diluted with water (20 mL) and ethyl acetate (20 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product (*S*)-*tert*-butyl 4-((4-(4-((2-((*tert*-butoxycarbonyl)amino)-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)amino)piperidine-1-carboxylate (60 mg, 0.092 mmol, 82% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 651.4 [(M+H)⁺, calcd for C₃₄H₅₀F₃N₄O₅ 651.4]; LC/MS retention time (Method C): *t*_R = 1.42 min.



Part C: (*S*)-4-(4-(2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(piperidin-4-yl)pyridin-2-amine


To a solution of (*S*)-*tert*-butyl 4-((4-(4-((2-((*tert*-butoxycarbonyl)amino)-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)amino)piperidine-1-carboxylate (30 mg, 0.046 mmol) in dichloromethane (2 mL) at 0 °C was added TFA (0.071 mL, 0.922 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by preparative LC/MS (method B) to afford (*S*)-4-(4-(2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(piperidin-4-yl)pyridin-2-amine (1.5 mg, 1.94 μmol, 4% yield) as a pale yellow solid. LCMS (ESI) *m/e* 451.2 [(M+H)⁺, calcd for C₂₄H₃₄F₃N₄O 451.2]; LC/MS retention time (method H): *t*_R = 1.21 min; LC/MS retention time (method I): *t*_R = 0.93 min. ¹H

NMR(400 MHz, Methanol-d₄): δ 8.02-8.08 (m, 3H), 7.47 (d, J = 8.80 Hz, 1H), 7.14-7.18 (m, 2H), 4.26-4.34 (m, 2H), 4.09-4.13 (m, 1H), 3.50-3.56 (m, 2H), 3.15-3.24 (m, 2H), 2.30-2.34 (m, 2H), 1.85-1.93 (m, 4H), 1.72-1.77 (m, 1H), 1.55 (s, 3H), 1.03-1.08 (m, 6H) ppm.


5

Example 471

(*S*)-1-(4-(6,7-difluoroquinazolin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine



10




Part A: (S)-tert-butyl 1-(4-(6,7-difluoroquinazolin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-ylcarbamate

A mixture of 4-chloro-6,7-difluoroquinazoline (0.04 g, 0.199 mmol), (*S*)-tert-butyl 1-(2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.120 g, 0.239 mmol), potassium phosphate, tribasic (0.127 g, 0.598 mmol), and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.041 g, 0.100 mmol) in toluene (4 mL) was purged with nitrogen gas for 30 min and Pd₂(dba)₃ (0.046 g, 0.050 mmol) was added. The reaction mixture was again purged with nitrogen gas for 10 min and heated in a microwave at 110 °C for 1.5 h. The reaction mixture was cooled to room temperature and was concentrated under reduced

pressure. The residue was diluted with water (20 mL) and ethyl acetate (20 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl 1-(4-(6,7-difluoroquinazolin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-ylcarbamate (52 mg, 0.096 mmol, 48% yield) as a brown solid. The solid was carried forward without further purification. LCMS (ESI) *m/e* 540.2 [(M+H)⁺, calcd for C₂₇H₃₁F₅N₃O₃ 540.2]; LC/MS retention time (Method A1): *t_R* = 3.11 min.

10




Part B: (S)-1-(4-(6,7-difluoroquinazolin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine

To a solution of (*S*)-*tert*-butyl 1-(4-(6,7-difluoroquinazolin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-ylcarbamate (52 mg, 0.096 mmol) in dichloromethane (2 mL) at 0 °C was added TFA (0.149 mL, 1.928 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) to afford (*S*)-1-(4-(6,7-difluoroquinazolin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine (1.5 mg, 0.003 mmol, 3% yield) as a pale yellow solid. LCMS (ESI) *m/e* 440.0 [(M+H)⁺, calcd for C₂₂H₂₃F₅N₃O 440.2]; LC/MS retention time (method H): *t_R* = 2.02 min; LC/MS retention time (method I): *t_R* = 1.46 min. ¹H NMR(400 MHz, Methanol-d₄): δ 9.29 (s, 1H), 8.08-8.14 (m, 2H), 7.96-8.01 (m, 2H), 7.49 (d, *J* = 8.80 Hz, 1H), 4.18-4.25 (m, 2H), 1.76-1.89 (m, 2H), 1.64-1.69 (m, 1H), 1.45 (s, 3H), 1.05-1.08 (m, 6H) ppm.


25

Example 472

(*S*)-2, 4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)pentan-2-amine




5



Part A: (*S*)-Tert-butyl (2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)pentan-2-yl)carbamate

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (0.05 g, 0.326 mmol), (*S*)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 259, Part A and B) (0.146 g, 0.326 mmol), Cs₂CO₃ (0.212 g, 0.651 mmol), and KBr (0.039 g, 0.326 mmol) in 1,4-dioxane (10 mL) was purged with nitrogen gas for 30 min. PdCl₂ (dppf)-CH₂Cl₂ adduct (0.027 g, 0.033 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80°C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a brown solid which was purified by silica-gel column chromatography (0-40% EtOAc in pet ether) to afford (*S*)-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)pentan-2-yl)carbamate (40 mg, 0.091 mmol, 28% yield) as a light yellow semi-solid. LCMS (ESI) *m/e* 439.4 [(M+H)⁺, calcd for C₂₅H₃₅N₄O₃ 439.3]; LC/MS retention time (Method A1): *t*_R = 2.60 min.





Part B: *(S)*-2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)pentan-2-amine

5 To a solution of *(S)*-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)pentan-2-yl)carbamate (35 mg, 0.080 mmol) in DCM (2 mL) at 0 °C was added TFA (0.123 mL, 1.596 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by
10 prep LC/MS (method C) to afford *(S)*-2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)pentan-2-amine, TFA (11 mg, 0.024 mmol, 30% yield) as a pale yellow solid. LCMS (ESI) *m/e* 339.2 [(M+H)⁺, calcd for C₂₀H₂₇N₄O 339.2]; LC/MS retention time (method H): *t_R* = 2.03 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.52 (d, *J* = 4.40 Hz, 1H), 8.19 (d, *J* = 2.40 Hz, 1H), 7.99-8.04 (m, 2H), 7.09-7.16
15 (m, 2H), 6.76 (d, *J* = 2.40 Hz, 1H), 4.02-4.09 (m, 2H), 2.40 (s, 3H), 1.75-1.88 (m, 2H), 1.61-1.66 (m, 1H), 1.42 (s, 3H), 1.00-1.05 (m, 6H) ppm.

Example 473


(S)-2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine



Part A: 3-bromopyrazolo[1,5-*a*]pyrimidine


25 To a solution of pyrazolo[1,5-*a*]pyrimidine (1 g, 8.39 mmol) in acetonitrile (5 mL) was added NBS (1.494 g, 8.39 mmol) and the reaction mixture stirred at room

temperature for 8 h. The reaction mixture was concentrated under reduced pressure and the residue purified by silica gel chromatography (0-30% petroleum ether/EtOAc) to afford 3-bromopyrazolo[1,5-*a*]pyrimidine (1.2 g, 6.06 mmol, 72% yield) as a brown solid. LCMS (ESI) *m/e* 198.0 [(M+H)⁺, calcd for C₆H₅BrN₃ 198.0]; LC/MS retention time (method A2): *t*_R = 1.43 min.



*Part B: (S)-Tert-butyl (2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate*

A solution of 3-bromopyrazolo[1,5-*a*]pyrimidine (0.04 g, 0.202 mmol), (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.122 g, 0.242 mmol), and potassium phosphate tribasic (0.106 g, 0.606 mmol) in THF (5 mL) and water (0.5 mL) was purged with nitrogen gas for 30 min. XPhos 2nd generation precatalyst (9.37 mg, 0.030 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80°C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth and the diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (50 mg, 0.102 mmol, 50% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 493.3 [(M+H)⁺, calcd for C₂₅H₃₂F₃N₄O₃ 493.2]; LC/MS retention time (Method A1): *t*_R = 1.83 min.





Part C: (S)-2,4-dimethyl-1-(4-(pyrazolo[1,5-a]pyrimidin-3-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine

To a solution of (S)-tert-butyl (2,4-dimethyl-1-(4-(pyrazolo[1,5-a]pyrimidin-3-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (40 mg, 0.081 mmol) in DCM (2 mL) at 0 °C was added TFA (6.26 μ L, 0.081 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method B) to afford (S)-2,4-dimethyl-1-(4-(pyrazolo[1,5-a]pyrimidin-3-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine (10 mg, 0.024 mmol, 30% yield) as a pale yellow solid. LCMS (ESI) m/e 393.2 [(M+H)⁺, calcd for C₂₀H₂₄F₃N₄O 393.2]; LC/MS retention time (method H): t_R = 1.63 min. ¹H NMR(400 MHz, Methanol-d₄): δ 8.95-8.98 (m, 1H), 8.67-8.68 (m, 1H), 8.62 (s, 1H), 8.51 (d, J = 2.00 Hz, 1H), 8.33-8.36 (m, 1H), 7.36 (d, J = 8.80 Hz, 1H), 7.07-7.10 (m, 1H), 4.19-4.28 (m, 2H), 1.88-1.93 (m, 2H), 1.70-1.76 (m, 1H), 1.55 (s, 3H), 1.04-1.09 (m, 6H) ppm.

Example 475

4-(4-((S)-2-amino-2,4-dimethylpentyloxy)-3-(trifluoromethyl)phenyl)-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine




Part A: 4-chloro-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine

To a solution of 4-chloro-2-fluoropyridine (0.5 g, 3.80 mmol), tetrahydro-2H-pyran-3-amine (0.461 g, 4.56 mmol) in DMSO (5 mL) was added Cs₂CO₃ (2.477 g, 7.60 mmol) and the reaction mixture was heated in a microwave at 90 °C for 2 h.


- 5 The reaction mixture was allowed to cool to 0 °C and quenched with ice-water then extracted with ethyl acetate (30 mL). The aqueous layer was again extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-30% ethyl acetate in pet
- 10 ether) to afford 4-chloro-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine (0.35, 1.646 mmol, 43% yield) as a light yellow oil. ¹H NMR (400 MHz, DMSO-d₆): δ 7.92 (d, *J* = 7.20 Hz, 1H), 6.74 (d, *J* = 9.60 Hz, 1H), 6.52-6.56 (m, 2H), 3.81-3.88 (m, 2H), 3.66-3.73 (m, 1H), 3.31-3.39 (m, 1H), 3.08-3.15 (m, 1H), 1.85-1.95 (m, 1H), 1.67-1.74 (m, 1H), 1.45-1.60 (m, 2H) ppm.

15

*Part B: Tert-butyl ((2S)-2,4-dimethyl-1-(4-(2-((tetrahydro-2H-pyran-3-yl)amino)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate.*

- A mixture of 4-chloro-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine (0.04 g, 0.188 mmol), (*S*)-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl) (prepared as described in Example 255, Parts A and B) (0.113 g, 0.226 mmol), and potassium phosphate, tribasic (0.033 g, 0.188 mmol) in 1,4-dioxane (8 mL) and water (2 mL) was purged with nitrogen gas for 30 min. XPhos 2nd generation precatalyst (8.72 mg, 0.028
- 25 mmol) was added to the reaction mixture and again the solution was purged with nitrogen gas for 10 min and heated at 100 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous

earth. The diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated and dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford *tert*-butyl ((2*S*)-2,4-dimethyl-1-(4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (68 mg, 0.123 mmol, 66% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 552.2 [(M+H)⁺, calcd for C₂₉H₄₁F₃N₃O₄ 552.3]; LC/MS retention time (Method A1): *t*_R = 2.86 min.



Part C: 4-(4-((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine

To a solution of *tert*-butyl((2*S*)-2,4-dimethyl-1-(4-(2-((tetrahydro-2*H*-pyran-3-yl)amino)pyridin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (50 mg, 0.091 mmol) in DCM (2 mL) at 0 °C was added TFA (0.140 mL, 1.813 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) to afford 4-(4-((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine (20 mg, 0.044 mmol, 48% yield) as a pale yellow solid. LCMS (ESI) *m/e* 452.2 [(M+H)⁺, calcd for C₂₄H₃₃F₃N₃O₂ 452.2]; LC/MS retention time (method H): *t*_R = 1.87 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 7.87-7.99 (m, 3H), 7.31 (d, *J* = 8.40 Hz, 1H), 6.77-6.82 (m, 2H), 3.92-4.12 (m, 4H), 3.77-3.81 (m, 1H), 3.51-3.54 (m, 1H), 1.98-2.07 (m, 3H), 1.58-1.85 (m, 5H), 1.38 (s, 3H), 0.98-1.03 (m, 6H) ppm.

25


Examples 476 and 477

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine


and

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine

30



Dia 1



Dia 2

Racemic 4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine (12 mg. 0.026 mmol) prepared in Example 475 was resolved by Chiral HPLC (Method A) to afford two diastereomers. The absolute stereochemistry of the pyran linkage was not determined.

Diastereomer: 1


Part B: 4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine (1 mg. 2.148 μ mol, 8% yield) as a pale yellow solid. LCMS (ESI) m/e 452.2 [(M+H)⁺, calcd for C₂₄H₃₃F₃N₃O₂ 452.2]; LC/MS retention time (method A1): t_R = 1.95 min. HPLC purity: 98% ; HPLC retention time (method A): t_R = 5.49 min. ¹H NMR (400 MHz, Methanol-d₄): δ 7.90-8.00 (m, 1H), 7.86-7.90 (m, 2H), 7.30 (d, J = 8.40 Hz, 1H), 6.76-6.82 (m, 2H), 3.94-4.07 (m, 4H), 3.48-3.81 (m, 2H), 2.03-2.11 (m, 1H), 1.80-1.85 (m, 2H), 1.55-1.69 (m, 5H), 1.34 (s, 3H), 0.88-0.99 (m, 6H) ppm.

Diastereomer: 2


4-(4-(((S)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-N-(tetrahydro-2H-pyran-3-yl)pyridin-2-amine (4 mg. 8.59 μ mol, 33% yield) as a pale yellow solid. LCMS (ESI) m/e 452.2 [(M+H)⁺, calcd for C₂₄H₃₃F₃N₃O₂ 452.2]; LC/MS retention time (method A1): t_R = 1.95 min. HPLC purity: 98% ; HPLC retention time (method A): t_R = 5.49 min. ¹H NMR (400 MHz, Methanol-d₄): δ 7.96-8.00 (m, 1H), 7.85-7.89 (m, 1H), 7.28 (d, J = 8.00 Hz, 1H), 6.96 (s, 1H), 6.76-6.81 (m, 2H), 3.94-4.05 (m, 4H), 3.47-3.81 (m, 2H), 2.01-2.09 (m, 1H), 1.76-1.85 (m, 2H), 1.55-1.75 (m, 5H), 1.41 (s, 3H), 0.92-1.01 (m, 6H) ppm.

Example 478

(*S*)-3-(5-((2-amino-2,4-dimethylpentyl)oxy)-6-methylpyridin-2-yl)pyrazolo[1,5-*a*]pyrimidine-6-carbonitrile




5



Part A: (S)-tert-butyl (1-((6-(6-cyanopyrazolo[1,5-a]pyrimidin-3-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-*a*]pyrimidine-6-carbonitrile (0.04 g, 0.148 mmol), (*S*)-*tert*-butyl (1-((6-iodo-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 343) (0.080 g, 0.178 mmol), and Cs₂CO₃ (0.04g, 0.148 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was purged with nitrogen gas for 30 min. PdCl₂(dppf)-CH₂Cl₂ adduct (0.121 g, 0.148 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 100 °C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth and the diatomaceous earth was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford as a brown solid which was purified by silica gel chromatography (0-30% ethyl acetate in pet ether) to afford (*S*)-*tert*-butyl (1-((6-(6-cyanopyrazolo[1,5-a]pyrimidin-3-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (10 mg, 0.022 mmol, 15% yield) as a light yellow solid. LCMS (ESI) *m/e* 465.2 [(M+H)⁺, calcd for C₂₅H₃₃N₆O₃ 465.2]; LC/MS retention time (Method A1): *t*_R = 2.70 min.





Part B: (S)-3-(5-((2-amino-2,4-dimethylpentyl)oxy)-6-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidine-6-carbonitrile

To a solution of (S)-tert-butyl (1-(((6-(6-cyanopyrazolo[1,5-a]pyrimidin-3-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-yl)carbamate (40 mg, 0.086 mmol) in DCM (2 mL) at 0 °C was added TFA (6.63 µl, 0.086 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford (S)-3-(5-((2-amino-2,4-dimethylpentyl)oxy)-6-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidine-6-carbonitrile (1 mg, 2.74 µmol, 3% yield) as a pale yellow solid. LCMS (ESI) m/e 365.2 [(M+H)⁺, calcd for C₂₀H₂₅N₆O 365.2]; LC/MS retention time (method H): t_R = 1.27 min; LC/MS retention time (method I): t_R = 0.80 min. ¹H NMR(400 MHz, Methanol-d₄): δ 9.67 (d, J = 2.40 Hz, 1H), 8.95 (s, 1H), 8.79 (s, 1H), 8.31 (d, J = 8.40 Hz, 1H), 7.48 (d, J = 8.40 Hz, 1H), 4.03-4.11 (m, 2H), 2.61 (s, 3H), 1.79-1.90 (m, 2H), 1.65-1.70 (m, 1H), 1.46 (s, 3H), 1.03-1.08 (m, 6H) ppm.

Example 481


(S)-2,4-dimethyl-1-(4-(2-methylthieno[2,3-d]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine





Part A: *(S)*-tert-butyl (2,4-dimethyl-1-(4-(2-methylthieno[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate

A solution of 4-chloro-2-methylthieno[2,3-*d*]pyrimidine (0.03 g, 0.162 mmol), *(S)*-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (prepared as described in Example 255, Parts A and B) (0.090 g, 0.179 mmol), Cs₂CO₃ (0.159 g, 0.487 mmol), and KBr (0.019 g, 0.162 mmol) in 1,4-dioxane (10 mL) was purged with nitrogen gas for 30 min. PdCl₂ (dppf)-CH₂Cl₂ adduct (0.013 g, 0.016 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80 °C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (20 mL) and water (20 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed was washed with ethyl acetate (25 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford *(S)*-tert-butyl (2,4-dimethyl-1-(4-(2-methylthieno[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (crude yield) (0.06 g, 0.115 mmol, 71% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 524.2 [(M+H)⁺, calcd for C₂₆H₃₃F₃N₃O₃S 524.2]; LC/MS retention time (Method C): *t*_R = 1.60 min.




Part B: (S)-2,4-dimethyl-1-(4-(2-methylthieno[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine

To a solution of (S)-*tert*-butyl (2,4-dimethyl-1-(4-(2-methylthieno[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl)carbamate (0.03 g, 0.057 mmol) in DCM (2 mL) at 0 °C was added TFA (0.088 mL, 1.146 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) to afford (S)-2,4-dimethyl-1-(4-(2-methylthieno[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine (6 mg, 0.014 mmol, 24% yield) as a pale yellow solid. LCMS (ESI) *m/e* 424.2 [(M+H)⁺, calcd for C₂₁H₂₅F₃N₃OS 424.2]; LC/MS retention time (method H): *t_R* = 2.83 min; LC/MS retention time (method I): *t_R* = 2.08 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.26-8.29 (m, 2H), 7.80 (d, *J* = 6.00 Hz, 1H), 7.63 (d, *J* = 6.00 Hz, 1H), 7.46 (d, *J* = 8.00 Hz, 1H), 4.14-4.21 (m, 2H), 2.86 (s, 3H), 1.85-1.91 (m, 1H), 1.62-1.78 (m, 2H), 1.42 (s, 3H), 1.02-1.06 (m, 6H) ppm.

Example 482

(S)-1-(2-chloro-4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine


20



Part D: (S)-*tert*-butyl (1-(2-chloro-4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

25 A solution of 7-chloro-2-cyclopropylpyrazolo[1,5-*a*]pyrimidine (prepared as

described in Example 266, Parts A-C) (40 mg, 0.207 mmol), (*S*)-*tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (97 mg, 0.207 mmol), Cs₂CO₃ (135 mg, 0.413 mmol), and KBr (24.58 mg, 0.207 mmol) in 1,4-dioxane (10 mL) was purged with nitrogen gas for 30 min. PdCl₂ (dppf)-CH₂Cl₂ adduct (16.87 mg, 0.021 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 100°C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (60 mg, 0.064 mmol, 31% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 499.2 [(M+H)⁺, calcd for C₂₇H₃₆ClN₄O₃ 499.2]; LC/MS retention time (Method A1): *t*_R = 2.85 min.




*Part E: (S)-1-(2-chloro-4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine*

To a solution of (*S*)-*tert*-butyl (1-(2-chloro-4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.05 g, 0.100 mmol) in DCM (2 mL) at 0 °C was added TFA (0.154 mL, 2.004 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) which afforded (*S*)-1-(2-chloro-4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (21 mg, 0.040 mmol, 40% yield) as a pale yellow solid. LCMS (ESI) *m/e* 399.2 [(M+H)⁺, calcd for C₂₂H₂₈ClN₄O·TFA 399.2]; LC/MS retention time (method


H): $t_R = 2.62$ min; LC/MS retention time (method I) : $t_R = 2.07$ min. ^1H NMR(400 MHz, Methanol- d_4): δ 8.45 (d, $J = 4.80$ Hz, 1H), 8.35 (d, $J = 2.40$ Hz, 1H), 8.14-8.16 (m, 1H), 7.34 (d, $J = 8.80$ Hz, 1H), 7.05 (d, $J = 4.40$ Hz, 1H), 6.45 (s, 1H), 4.05-4.15 (m, 2H), 2.15-2.20 (m, 1H), 1.79-1.93 (m, 2H), 1.64-1.69 (m, 1H), 1.44 (s, 3H), 1.03-1.11 (m, 8H), 0.94-0.95 (m, 2H) ppm.

Example 483

(*S*)-1-(4-(2-Cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine



10




Part A: (*S*)-Tert-butyl (1-(4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

15 A solution of 7-chloro-2-cyclopropylpyrazolo[1,5-*a*]pyrimidine (prepared as described in Example 266, Parts A-C) (40 mg, 0.207 mmol), (*S*)-tert-butyl (2,4-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenoxy)pentan-2-yl) (prepared as described in Example 255, Parts A and B) (104 mg, 0.207 mmol), Cs_2CO_3 (135 mg, 0.413 mmol), and KBr (24.58 mg, 0.207 mmol) in 1,4-dioxane (10 mL) was purged with nitrogen gas for 30 min. PdCl_2 (dppf)- CH_2Cl_2 adduct (16.87 mg, 0.021 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 100°C for 12 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed

25

was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford ((*S*)-*tert*-butyl 1-(4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.033 mmol, 16% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 533.2 [(M+H)⁺, calcd for C₂₈H₃₆F₃N₄O₃ 533.3]; LC/MS retention time (Method A1): *t*_R = 3.23 min.




Part B: (*S*)-1-(4-(2-Cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine.

To a solution of (*S*)-*tert*-butyl 1-(4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (80 mg, 0.033 mmol) in DCM (2 mL) at 0 °C was added TFA (0.051 mL, 0.661 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) which afforded (*S*)-1-(4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine (3 mg, 6.94 μmol, 21% yield) as a pale yellow solid. LCMS (ESI) *m/e* 433.3 [(M+H)⁺, calcd for C₂₃H₂₈F₃N₄O 433.3]; LC/MS retention time (method H): *t*_R = 2.08 min; LC/MS retention time (method I) : *t*_R = 1.47 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.59 (d, *J* = 2.00 Hz, 1H), 8.39-8.45 (m, 2H), 7.41 (d, *J* = 8.80 Hz, 1H), 7.08 (d, *J* = 4.80 Hz, 1H), 6.46 (s, 1H), 4.06-4.12 (m, 2H), 2.11-2.17 (m, 1H), 1.81-1.88 (m, 1H), 1.56-1.69 (m, 2H), 1.34 (s, 3H), 0.98-1.10 (m, 8H), 0.90-0.95 (m, 2H) ppm.

Example 485


(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile



Part A: (*S*)-Tert-butyl (1-(2-cyano-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of 7-chloro-2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidine (25 mg, 0.113 mmol), (*S*)-tert-butyl (1-(2-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as in Example 254, Part B-G) (56.9 mg, 0.124 mmol), and potassium phosphate, tribasic (71.9 mg, 0.338 mmol in 1,4-dioxane (10 mL) was purged with nitrogen gas for 30 min. (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) chloride (16.67 mg, 0.023 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated at 80 °C for 4 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford (*S*)-tert-butyl (1-(2-cyano-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (crude yield) (40 mg, 0.077 mmol, 69% yield) as a brown solid which was carried forward without further purification.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.80 (d, *J* = 2.80 Hz, 1H), 8.43-8.50 (m, 2H), 7.17-7.56 (m, 3H), 6.94 (s, 1H), 4.03-4.18 (m, 2H), 1.56-1.83 (m, 2H), 1.46-1.53 (m, 1H), 1.43 (s, 3H), 1.28-1.35 (m, 9H), 0.89-0.96 (m, 6H) ppm.





Part B: (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)benzonitrile

To a solution of (S)-tert-butyl (1-(2-cyano-4-(2-
 5 (trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.04 g, 0.077 mmol) in DCM (2 mL) at 0 °C was added TFA (0.119 mL, 1.546 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method B) which
 10 afforded (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7-yl)benzonitrile, 2 TFA (9 mg, 0.015 mmol, 19% yield) as a pale yellow solid. LCMS (ESI) m/e 418.2 [(M+H)⁺, calcd for C₂₁H₂₃F₃N₅O 418.2]; LC/MS retention time (method H): t_R = 1.78 min; LC/MS retention time (method I): t_R = 1.37 min. ¹H NMR (400 MHz, Methanol): δ 8.74 (d, J = 4.40 Hz, 1H), 8.52-8.56 (m, 2H), 7.53 (d, J = 8.80 Hz, 1H), 7.42 (d, J = 4.40 Hz, 1H), 7.16 (s, 1H), 4.36-4.42 (m, 2H), 1.90-2.01 (m, 2H), 1.73-1.78 (m, 1H), 1.58 (s, 3H), 1.07-1.11 (m, 6H) ppm.

Example 486

20 (S)-5-((2-amino-2,4-dimethylpentyl)oxy)-2-(pyrazolo[1,5-a]pyrimidin-7-yl)isonicotinonitrile




25 Part A: 2-bromo-5-fluoroisonicotinaldehyde oxime

2-Bromo-5-fluoroisonicotinaldehyde (2 g, 9.80 mmol) and hydroxylamine

hydrochloride (1.022 g, 14.71 mmol) were dissolved in methanol (20 mL) and water (20 mL). The reaction mixture was heated at 60 °C for 5 h. The reaction mixture was concentrated under reduced pressure. The residue was diluted with saturated aqueous sodium bicarbonate and the solution was extracted with ethyl acetate. The ethyl acetate layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain 2-bromo-5-fluoroisonicotinaldehyde oxime (1.8 g, 8.22 mmol, 84% yield) as an off-white solid which was carried forward without further purification. LCMS (ESI) m/e 219.0 [(M+H)⁺, calcd for C₆H₅BrFN₂O 219.0]; LC/MS retention time (method A1): t_R = 1.63 min.


10



Part B: 2-bromo-5-fluoroisonicotinonitrile

2-Bromo-5-fluoroisonicotinaldehyde oxime (1 g, 4.57 mmol) in chloroform (20 mL) was cooled to 0 °C. POC_l₃ (2.128 mL, 22.83 mmol) was added dropwise and the reaction mixture stirred for 5 min at 0 °C. The reaction mixture was heated at 65 °C for 12 h. The reaction mixture was concentrated under reduced pressure to afford a brown colored residue. The residue was diluted with ice-water, basified with saturated aqueous sodium carbonate and extracted with ethyl acetate (3x25 mL). The ethyl acetate layer was dried over Na₂SO₄ and evaporated to afford 2-bromo-5-fluoroisonicotinonitrile (0.8 g, 3.98 mmol, 87% yield) as a brown solid that was taken for next step without further purification. ¹H NMR 400 MHz, DMSO-*d*₆: δ 8.81 (d, *J* = 4.40 Hz, 1H), 8.41-8.43 (m, 1H) ppm.

20




25

Part C: 5-fluoro-2-(pyrazolo[1,5-a]pyrimidin-7-yl)isonicotinonitrile

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (0.05 g, 0.326 mmol), 2-bromo-5-fluoroisonicotinonitrile (0.065 g, 0.326 mmol) and 1,1,1,2,2,2-hexamethyldistannane (0.107 g, 0.326 mmol) in 1,4-dioxane (2 mL) was purged with

nitrogen gas for 10 min. Pd(Ph₃P)₄ (0.038 g, 0.033 mmol) was added and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated in a microwave at 150 °C for 2 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (20 mL) and water (20 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed was washed with ethyl acetate (25 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a brown colored solid. The solid was purified by silica gel chromatography (0-40% EtOAc in pet ether) to afford 5-fluoro-2-(pyrazolo[1,5-*a*]pyrimidin-7-yl)isonicotinonitrile (30 mg, 0.125 mmol, 39% yield) as a light yellow solid. LCMS (ESI) *m/e* 240.0 [(M+H)⁺, calcd for C₁₂H₇FN₅ 240.1]; LC/MS retention time (Method A1): *t*_R = 1.97 min.





*Part D: (S)-5-((2-amino-2,4-dimethylpentyl)oxy)-2-(pyrazolo[1,5-*a*]pyrimidin-7-yl)isonicotinonitrile*

A solution of (*S*)-2-amino-2,4-dimethylpentan-1-ol (0.016 g, 0.125 mmol) in DMF (4 mL) was cooled to 0 °C and 5-fluoro-2-(pyrazolo[1,5-*a*]pyrimidin-7-yl)isonicotinonitrile (0.030 g, 0.125 mmol) was added followed by portionwise addition of NaH (9.03 mg, 0.376 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was stirred at 25 °C for 4 h. The reaction mixture was cooled to 0 °C, quenched with water (20 mL) and extracted with ethyl acetate (20 mL). The ethyl acetate layer was separated out, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) which afforded (*S*)-5-((2-amino-2,4-dimethylpentyl)oxy)-2-(pyrazolo[1,5-*a*]pyrimidin-7-yl)isonicotinonitrile (5 mg, 0.014 mmol, 95% yield) as a pale yellow solid. LCMS (ESI) *m/e* 351.2 [(M+H)⁺, calcd for C₁₉H₂₃N₆O 351.2]; LC/MS retention time (method H): *t*_R = 2.50 min; LC/MS retention time (method I): *t*_R = 2.50 min. ¹H NMR (400 MHz, Methanol-*d*₄): δ 9.46 (s, 1H), 8.77 (s, 1H), 8.58 (d, *J* = 4.80 Hz, 1H), 8.31 (d, *J* = 2.40 Hz, 1H), 7.82 (d, *J* = 4.40 Hz, 1H), 6.79 (d, *J* =

2.40 Hz, 1H), 3.58-3.82 (m, 2H), 1.85-1.92 (m, 2H), 1.77-1.82 (m, 1H), 1.52 (s, 3H), 0.98-1.02 (m, 6H) ppm.


Example 488

5 (S)-2,4-dimethyl-1-((2-methyl-6-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)pentan-2-amine



10 *Part A: 2-fluoro-5-(pyrazolo[1,5-a]pyrimidin-7-yl)nicotinonitrile*

A solution of 7-chloropyrazolo[1,5-a]pyrimidine (0.1 g, 0.651 mmol), 5-bromo-2-fluoronicotinonitrile (prepared as described in Example 487) (0.131 g, 0.651 mmol) and 1,1,1,2,2,2-hexamethyldistannane (0.213 g, 0.651 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen gas for 10 min. Pd (Ph₃P)₄ (0.075 g, 0.065 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated in a microwave at 150 °C for 2 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (20 mL) and water (20 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed was washed with ethyl acetate (25 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a brown colored solid. The solid was purified by silica gel chromatography (0-40% EtOAc in pet ether) to afford 2-fluoro-5-(pyrazolo[1,5-a]pyrimidin-7-yl)nicotinonitrile (0.032 g, 0.134 mmol, 21% yield) as a light-yellow color solid. LCMS (ESI) *m/e* 239.0 [(M)⁺, calcd for C₁₂H₆FN₅ 239.1]; LC/MS retention time (Method A1): *t_R* = 2.33 min.





Part B: *(S)*-2,4-dimethyl-1-((2-methyl-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)pentan-2-amine

A solution of *(S)*-2-amino-2,4-dimethylpentan-1-ol (0.019 g, 0.145 mmol) in
 5 DMF (4 mL) was cooled to 0 °C. NaH (3.47 mg, 0.145 mmol) was added followed
 by slow addition of 7-(5-fluoro-6-methylpyridin-2-yl)pyrazolo[1,5-*a*]pyrimidine
 (0.033 g, 0.145 mmol) and the mixture stirred for 5 min at 0 °C. The reaction
 mixture was allowed to warm to room temperature and stirred at 60 °C for 4 h. The
 reaction mixture was cooled to room temperature, quenched with water (20 mL), and
 10 extracted with ethyl acetate (20 mL). The ethyl acetate layer was separated out, dried
 over Na₂SO₄, and concentrated under reduced pressure. The crude material was
 purified by prep LC/MS (method A) to afford *(S)*-2,4-dimethyl-1-((2-methyl-6-
 (pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)pentan-2-amine (23 mg, 0.068
 mmol, 47% yield) as a pale yellow solid. LCMS (ESI) *m/e* 340.2 [(M+H)⁺, calcd for
 15 C₁₉H₂₆N₅O 340.2]; LC/MS retention time (method H): *t*_R = 1.99 min; LC/MS
 retention time (method I): *t*_R = 1.66 min. ¹H NMR (400 MHz, Methanol-*d*₄): δ 9.03 (d,
J = 8.40 Hz, 1H), 8.61 (d, *J* = 4.40 Hz, 1H), 8.27 (d, *J* = 2.40 Hz, 1H), 7.76 (d, *J* =
 4.40 Hz, 1H), 7.55 (d, *J* = 8.80 Hz, 1H), 6.81 (d, *J* = 2.40 Hz, 1H), 4.12-4.20 (m,
 2H), 2.65 (s, 3H), 1.80-1.90 (m, 2H), 1.66-1.70 (m, 1H), 1.47 (s, 3H), 1.02-1.07 (m,
 20 6H) ppm.

Example 489


(S)-1-(2,5-difluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-
 2-amine





Part A: *(S)*-tert-butyl (1-(2,5-difluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (25 mg, 0.163 mmol), *(S)*-tert-butyl (1-(2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 285) (76 mg, 0.163 mmol), Cs₂CO₃ (106 mg, 0.326 mmol), and KBr (19.37 mg, 0.163 mmol) in 1,4-dioxane (10 mL) was purged with nitrogen gas for 30 min. PdCl₂ (dppf)-CH₂Cl₂ adduct (13.29 mg, 0.016 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated in a microwave at 88 °C for 2 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (30 mL) and water (30 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed was washed with ethyl acetate (50 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford *(S)*-tert-butyl (1-(2,5-difluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (40 mg, 0.087 mmol, 53% yield) as a brown solid which was carried forward without further purification. LCMS (ESI) *m/e* 461.2 [(M+H)⁺, calcd for C₂₄H₃₁F₂N₄O₃ 461.2]; LC/MS retention time (Method A1): *t_R* = 2.73 min.





Part B: *(S)*-1-(2,5-difluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine

To a solution of (*S*)-*tert*-butyl (1-(2,5-difluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (0.04 g, 0.087 mmol) in DCM (2 mL) at 0 °C was added TFA (0.134 mL, 1.737 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was allowed to stir for 4 h at room temperature, then was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford ((*S*)-1-(2,5-difluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine, TFA (7 mg, 0.015 mmol, 17% yield) as a pale yellow solid. LCMS (ESI) *m/e* 361.2 [(M+H)⁺, calcd for C₁₉H₂₃F₂N₄O 361.2]; LC/MS retention time (method H): *t*_R = 2.04 min; LC/MS retention time (method I): *t*_R = 1.71 min. ¹H NMR(400 MHz, Methanol-*d*₄): δ 8.59 (d, *J* = 4.40 Hz, 1H), 8.20 (d, *J* = 2.40 Hz, 1H), 7.76-7.81 (m, 1H), 7.27-7.32 (m, 1H), 7.11-7.13 (m, 1H), 6.83 (d, *J* = 2.40 Hz, 1H), 4.15-4.25 (m, 2H), 1.79-1.92 (m, 2H), 1.65-1.70 (m, 1H), 1.47 (s, 3H), 1.04-1.08 (m, 6H)

15

Example 490

1,1,1-trifluoro-4-methyl-2-(((2-methyl-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)methyl)pentan-2-amine




20

Part A: 7-(5-fluoro-6-methylpyridin-2-yl)pyrazolo[1,5-*a*]pyrimidine

A solution of 7-chloropyrazolo[1,5-*a*]pyrimidine (0.1 g, 0.651 mmol), 6-bromo-3-fluoro-2-methylpyridine (0.124 g, 0.651 mmol) and 1,1,1,2,2,2-hexamethyldistannane (0.213 g, 0.651 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen gas for 10 min. Pd(Ph₃P)₄ (0.075 g, 0.065 mmol) was added to the reaction mixture and the solution was purged with nitrogen gas again for 10 min. The reaction mixture was heated in a microwave at 150°C for 2 h. The reaction mixture was concentrated and the residue obtained was dissolved in ethyl acetate (20 mL) and

water (20 mL). The biphasic mixture was filtered through diatomaceous earth (Diatomaceous earth[®]) and the bed was washed with ethyl acetate (25 mL). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a brown colored solid. The solid was purified by silica gel chromatography (0-40% EtOAc in pet ether) to afford 7-(5-fluoro-6-methylpyridin-3-yl)pyrazolo[1,5-*a*]pyrimidine (0.06 g, 0.263 mmol, 40% yield) as a light yellow solid. LCMS (ESI) *m/e* 228.22 [(M+H)⁺, calcd for C₁₂H₉FN₄ 229.2]; LC/MS retention time (Method A1): *t*_R = 2.20 min.




10

Part B: 4-methyl-N-(1,1,1-trifluoro-4-methyl-2-(((2-methyl-6-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)methyl)pentan-2-yl)benzenesulfonamide

A solution of 4-methyl-*N*-(1,1,1-trifluoro-2-(hydroxymethyl)-4-methylpentan-2-yl)benzenesulfonamide (53.5 mg, 0.158 mmol) (prepared as described in Example 273) (53.5 mg, 0.158 mmol in DMF (4 mL) was cooled to 0 °C. NaH (3.15 mg, 0.131 mmol) was added followed by slow addition of 7-(5-fluoro-6-methylpyridin-2-yl)pyrazolo[1,5-*a*]pyrimidine (30 mg, 0.131 mmol) and the mixture stirred for 5 min at 0 °C. The reaction mixture was heated at 80 °C for 4 h. The reaction mixture was cooled to 0 °C, quenched with water (20 mL), and extracted with ethyl acetate (20 mL). The ethyl acetate layer was separated out, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford 4-methyl-*N*-(1,1,1-trifluoro-4-methyl-2-(((2-methyl-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)methyl)pentan-2-yl)benzenesulfonamide (45 mg, 0.082 mmol, 63% yield) as an off-white semi-solid which was carried to next step without further purification. LCMS (ESI) *m/e* 547.59 [(M+H)⁺, calcd for C₂₆H₂₈F₃N₅O₃S 548.2]; LC/MS retention time (Method A1): *t*_R = 1.22 min.

25




Part C: 1,1,1-trifluoro-4-methyl-2-(((2-methyl-6-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)methyl)pentan-2-amine

4-Methyl-N-(1,1,1-trifluoro-4-methyl-2-(((2-methyl-6-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)methyl)pentan-2-yl)benzenesulfonamide (45 mg, 0.082 mmol) was cooled to 0 °C and sulfuric acid (2 mL, 37.5 mmol) was added dropwise then the mixture was stirred for 2 h at 0 °C. The reaction mixture was basified with cold saturated aqueous sodium bicarbonate solution (pH~8-9). The reaction mixture was extracted with ethyl acetate(3x20 mL). The ethyl acetate layer was dried over Na₂SO₄, and concentrated under reduced pressure. The crude material was purified by prep LC/MS (method A) to afford 1,1,1-trifluoro-4-methyl-2-(((2-methyl-6-(pyrazolo[1,5-a]pyrimidin-7-yl)pyridin-3-yl)oxy)methyl)pentan-2-amine (11 mg, 0.028 mmol, 95% yield) as a pale yellow solid. LCMS (ESI) *m/e* 393.40 [(M+H)⁺, calcd for C₁₉H₂₂F₃N₅O 394.3]; LC/MS retention time (method H): *t_R* = 2.04 min; LC/MS retention time (method I) : *t_R* = 1.45 min. ¹H NMR (400 MHz, Methanol-d₄): δ 9.03 (d, *J* = 8.80 Hz, 1H), 8.60 (d, *J* = 4.40 Hz, 1H), 8.26 (d, *J* = 2.40 Hz, 1H), 7.76 (d, *J* = 4.40 Hz, 1H), 7.54 (d, *J* = 8.80 Hz, 1H), 6.80 (d, *J* = 2.40 Hz, 1H), 4.25-4.31 (m, 2H), 2.59-0.00 (m, 3H), 1.98-2.04 (m, 1H), 1.71-1.92 (m, 2H), 1.01-1.09 (m, 6H) ppm.

20

Example 492

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile




Prepared in a similar fashion as described in Example 452 to give (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methylimidazo[1,2-*b*]pyridazin-8-

yl)benzonitrile (16.6 mg, 0.045 mmol, 64% yield) as a pale yellow solid. LCMS (ESI) m/e 364.2 $[(M+H)^+]$, calcd for $C_{21}H_{26}N_5O$, 364.2]; LC/MS retention time (method D): t_R = 1.34 min; LC/MS retention time (Method E): t_R = 1.01 min. ^1H NMR (400 MHz, *METHANOL-d4*): δ 8.50 (d, J = 2.00 Hz, 1H), 8.37-8.41 (m, 2H), 7.97 (d, J = 0.80 Hz, 1H), 7.37 (d, J = 9.20 Hz, 1H), 7.31 (d, J = 4.80 Hz, 1H), 4.05-4.10 (m, 2H), 2.50 (s, 3H), 1.83-1.90 (m, 1H), 1.56-1.70 (m, 2H), 1.33 (s, 3H), 1.00-1.03 (m, 6H) ppm.

Example 493


(*S*)-1-(4-(2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-amine



Prepared in a similar fashion as described in Example 452 to give (*S*)-1-(4-(2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-amine (37 mg, 0.091 mmol, 88% yield) as a pale yellow solid. LCMS (ESI) m/e 383.2 $[(M+H)^+]$, calcd for $C_{22}H_{28}FN_4O$, 383.2]; LC/MS retention time (method D): t_R = 1.65 min; LC/MS retention time (Method E): t_R = 1.20 min. ^1H NMR (400 MHz, *METHANOL-d4*): δ 8.37 (d, J = 5.20 Hz, 1H), 8.11-8.15 (m, 1H), 8.00-8.03 (m, 1H), 7.93 (s, 1H), 7.29-7.34 (m, 2H), 4.03-4.10 (m, 2H), 2.14-2.21 (m, 1H), 1.86-1.88 (m, 1H), 1.58-1.70 (m, 2H), 1.37 (s, 3H), 1.02-1.08 (m, 8H), 0.95-0.98 (m, 2H) ppm.

Example 494

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-chloro-2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile




Prepared in a similar fashion as described in Example 452 to give (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-chloro-2-cyclopropylimidazo[1,2-b]pyridazin-8-yl)benzonitrile (11 mg, 0.026 mmol, 67% yield) as a pale yellow solid. LCMS (ESI) m/e 424.0 [(M+H)⁺, calcd for C₂₃H₂₇ClN₅O, 424.2] LC/MS retention time (method D): t_R = 2.00 min; LC/MS retention time (Method E): t_R = 1.59 min. ¹H NMR (400 MHz; DMSO-*d*₆): δ 8.80-8.84 (m, 2H), 8.21 (s, 1H), 7.75 (s, 1H), 7.46 (d, J = 8.80 Hz, 1H), 3.98-3.99 (m, 2H), 2.09-2.15 (m, 1H), 1.80-1.84 (m, 1H), 1.40-1.50 (m, 2H), 1.17 (s, 3H), 0.99-1.06 (m, 2H), 0.88-0.95 (m, 8H) ppm.

10

Example 495

(S)-1-(4-(6-chloro-2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine




Prepared in a similar fashion as described in Example 452 to give (S)-1-(4-(6-chloro-2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine (14 mg, 0.031 mmol, 57% yield) as a pale yellow solid. LCMS (ESI) m/e 441.0 [(M+H)⁺, calcd for C₂₁H₂₅ClF₃N₄O, 441.2]; LC/MS retention time (method D): t_R = 2.15 min; LC/MS retention time (Method E): t_R = 1.49 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.55 (d, J = 2.00 Hz, 1H), 8.42-8.44 (m, 1H), 7.99 (s, 1H), 7.44-7.46 (m, 2H), 4.20-4.27 (m, 2H), 2.52 (s, 3H), 1.82-1.89 (m, 2H), 1.68-1.72 (m, 1H), 1.49 (s, 3H), 1.03-1.08 (m, 6H) ppm

20

Example 496


(*S*)-1-(4-(6-chloro-2-cyclopropylimidazo [1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine



Prepared in a similar fashion as described in Example 452 to give (*S*)-1-(4-(6-chloro-2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine (6.1 mg, 0.013 mmol, 29% yield) as a pale yellow solid. LCMS (ESI) *m/e* 467.0 [(*M*+*H*)⁺, calcd for C₂₃H₂₇ClF₃N₄O, 467.2]; LC/MS retention time (method D): *t_R* = 2.44 min; LC/MS retention time (Method E): *t_R* = 1.75 min. ¹H NMR (400 MHz; DMSO-*d*₆): δ 8.94 (d, *J* = 2.00 Hz, 1H), 8.69-8.72 (m, 1H), 8.23 (s, 1H), 7.77 (s, 1H), 7.50-7.52 (m, 1H), 4.18 (s, 2H), 2.09-2.15 (m, 1H), 1.81-1.84 (m, 1H), 1.57-1.65 (m, 2H), 1.33 (s, 3H), 1.02-1.04 (m, 2H), 0.96-1.02 (m, 8H) ppm.

Example 497

(*S*)-1-(2-fluoro-4-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine




To a solution of (*S*)-*tert*-butyl (1-(2-fluoro-4-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared in a similar fashion as described in Example 452) (40 mg, 0.088 mmol) in DCM (1 mL) at 0 °C was added 4N HCl in 1,4-dioxane (0.219 mL, 0.876 mmol). The mixture was warmed to room temperature and stirred for 5 h. The reaction mixture diluted with saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (30 mL). The organic layer was dried over anhydrous Na₂SO₄, concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) to

afford (*S*)-1-(2-fluoro-4-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine (3.8 mg, 9.81 μ mol, 11% yield) as a pale yellow solid. LCMS (ESI) *m/e* 357.2 [(M+H)⁺, calcd for C₂₀H₂₆FN₄O, 357.2]; LC/MS retention time (method D): *t_R* = 1.43 min; LC/MS retention time (Method E): *t_R* = 0.78 min.

5 ¹H NMR (400MHz, *METHANOL-d*₄): δ 8.40 (d, *J* = 5.20 Hz, 1H), 8.02 - 8.06 (m, 1H), 7.92-7.97 (m, 2H), 7.29-7.34 (m, 2H), 4.00-4.07 (m, 2H), 2.51 (s, 3H), 1.86-1.92 (m, 1H), 1.66-1.71 (m, 2H), 1.34 (s, 3H), 1.01-1.05 (m, 6H) ppm.

Example 498

10 (*S*)-2,4-dimethyl-1-(4-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine




Prepared in a similar fashion as described in Example 452 to give (*S*)-2,4-dimethyl-1-(4-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine (11.2 mg, 0.027 mmol, 35% yield) as a pale yellow solid. LCMS (ESI) *m/e* 407.2 [(M+H)⁺, calcd for C₂₁H₂₆F₃N₄O, 407.2]; LC/MS retention time (method D): *t_R* = 1.78 min; LC/MS retention time (Method E): *t_R* = 0.97 min. ¹H NMR (400 MHz, *METHANOL-d*₄): δ 8.34-8.43 (m, 3H), 7.96 (d, *J* = 0.80 Hz, 1H), 7.38 (d, *J* = 8.80 Hz, 1H), 7.30 (d, *J* = 4.80 Hz, 1H), 4.04-4.10 (m, 2H), 2.49 (d, *J* = 0.80 Hz, 3H), 1.81-1.86 (m, 1H), 1.55-1.69 (m, 2H), 1.34 (s, 3H), 0.98-1.02 (m, 6H) ppm.

15 20

Example 499


25 (*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile




Prepared in a similar fashion as described in Example 452 to give (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-cyclopropylimidazo[1,2-b]pyridazin-8-yl)benzonitrile (4.9 mg, 0.012 mmol, 25% yield) as a pale yellow solid. LCMS (ESI) *m/e* 390.2 [(M+H)⁺, calcd for C₂₃H₂₈N₅O, 390.2]; LC/MS retention time (method D): *t_R* = 1.70 min; LC/MS retention time (Method E): *t_R* = 1.08 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.61 (d, *J*=2.5 Hz, 1H), 8.53 - 8.49 (m, 1H), 8.40 (d, *J*=4.5 Hz, 1H), 7.95 (s, 1H), 7.41 (d, *J*=9.0 Hz, 1H), 7.34 (d, *J*=4.5 Hz, 1H), 4.15 (d, *J*=2.5 Hz, 2H), 2.19 - 2.11 (m, 1H), 1.93 - 1.86 (m, 1H), 1.79 - 1.73 (m, 1H), 1.67 - 1.61 (m, 1H), 1.40 (s, 3H), 1.09 - 1.02 (m, 8H), 0.98 - 0.94 (m, 2H) ppm.

Example 500

(S)-2,4-dimethyl-1-(2-methyl-4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-amine




15



Part A: 8-bromo-6-chloro-2-(trifluoromethyl)imidazo[1,2-*b*]pyridazine


A mixture of 4-bromo-6-chloropyridazin-3-amine (1 g, 4.80 mmol) and 3-bromo-1,1,1-trifluoropropan-2-one (2.75 g, 14.39 mmol) was heated at 90 °C for 16 h

in a pressure tube. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-20% EtOAc in pet ether) to afford 8-bromo-6-chloro-2-(trifluoromethyl)imidazo[1,2-*b*]pyridazine (600 mg, 1.917 mmol, 40% yield) as a pale yellow solid. LCMS (ESI) *m/e* 300.0 (bromo pattern) [(M+H)⁺, calcd for C₇H₃BrClF₃N₃, 300.0]; LC/MS retention time (method A2): *t_R* = 2.05 min.




*Part B: (S)-tert-butyl (1-(4-(6-chloro-2-(trifluoromethyl)imidazo [1,2-*b*]pyridazin-8-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate*

To a stirred solution of 8-bromo-6-chloro-2-(trifluoromethyl)imidazo[1,2-*b*]pyridazine (50 mg, 0.166 mmol) and (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pentan-2-yl)carbamate (74.5 mg, 0.166 mmol) in 1,4-dioxane (1 mL) was added tripotassium phosphate 3M in water (0.166 mL, 0.499 mmol). The mixture was purged with argon for 5 min and Pd(Ph₃P)₄ (19.23 mg, 0.017 mmol) was added. The reaction mixture was heated to 100 °C for 16 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (10 mL). The mixture was filtered through diatomaceous earth (Diatomaceous earth[®]), washing the bed with ethyl acetate (10 mL) and the filtrate was concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-20% EtOAc in pet ether) to afford (*S*)-*tert*-butyl (1-(4-(6-chloro-2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-yl)carbamate (50 mg, 0.091 mmol, 55% yield) as a yellow semi-solid. LCMS (ESI) *m/e* 541.2 [(M+H)⁺, calcd for C₂₆H₃₃ClF₃N₄O₃, 541.2]; LC/MS retention time (Method C): *t_R* = 1.71 min.



Part C: *(S)*-tert-butyl (2,4-dimethyl-1-(2-methyl-4-(2-(trifluoromethyl)imidazo[1,2-
b]pyridazin-8-yl)phenoxy)pentan-2-yl)carbamate

To a stirred solution of *(S)*-tert-butyl (1-(4-(6-chloro-2-
5 (trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)-2-methylphenoxy)-2,4-
dimethylpentan-2-yl)carbamate (50 mg, 0.092 mmol) in MeOH (2 mL) was added
ammonium formate (23.31 mg, 0.370 mmol) followed by palladium on carbon (19.67
mg, 0.018 mmol). The reaction mixture was heated to 70 °C for 8 h under 1 atm H₂
gas. The reaction mixture was cooled to room temperature and filtered through
10 diatomaceous earth (Diatomaceous earth[®]), washing with bed with ethyl acetate (20
mL). The filtrate was concentrated under reduced pressure and the residue was
dissolved in ethyl acetate (25 mL). The ethyl acetate layer was washed with water
(10 mL). The organic layer was separated, dried over sodium sulfate and
concentrated under reduced pressure to afford *(S)*-tert-butyl (2,4-dimethyl-1-(2-
15 methyl-4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-
yl)carbamate (40 mg, 0.060 mmol, 65% yield) as yellow semi-solid. LCMS (ESI)
m/e 507.3 [(M+H)⁺, calcd for C₂₆H₃₄F₃N₄O₃, 507.3]; LC/MS retention time (method
B): *t*_R = 1.34 min.



20

Part D: *(S)*-2,4-dimethyl-1-(2-methyl-4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-
8-yl)phenoxy)pentan-2-amine

To a solution of (*S*)-*tert*-butyl (2,4-dimethyl-1-(2-methyl-4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-yl)carbamate (35 mg, 0.053 mmol) in MeOH (1 mL) at 0 °C was added HCl 4M in 1,4-dioxane (0.263 mL, 1.050 mmol). The mixture was warmed to room temperature and stirred for 6 h.


5 The reaction mixture diluted with saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (30 mL). The organic layer was dried over anhydrous Na₂SO₄, concentrated under reduced pressure. The crude material was purified by prep LC/MS (Method A) to afford (*S*)-2,4-dimethyl-1-(2-methyl-4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-amine (14.2 mg, 0.034 mmol, 64% yield) as a pale yellow solid. LCMS (ESI) *m/e* 407.0 [(M+H)⁺, calcd for C₂₁H₂₆F₃N₄O, 407.2]; LC/MS retention time (method D): *t*_R = 1.85 min; LC/MS retention time (Method E): *t*_R = 1.58 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.57 (d, *J* = 0.80 Hz, 1H), 8.52 (d, *J* = 4.80 Hz, 1H), 8.18-8.21 (m, 1H), 8.07 (d, *J* = 2.00 Hz, 1H), 7.47 (d, *J* = 5.20 Hz, 1H), 7.10 (d, *J* = 8.40 Hz, 1H), 3.92-3.98 (m, 2H), 2.38 (s, 3H), 1.81-1.90 (m, 1H), 1.65-1.70 (m, 1H), 1.55-1.60 (m, 1H), 1.33 (s, 3H), 1.01-1.02 (m, 6H) ppm.

10

15

Example 501

(*S*)-2,4-dimethyl-1-(4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-amine




20

Prepared in a similar fashion as described in Example 500 to afford (*S*)-2,4-dimethyl-1-(4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-amine (23.5 mg, 0.059 mmol, 96% yield) as a pale yellow solid. LCMS (ESI) *m/e* 393.0 [(M+H)⁺, calcd for C₂₀H₂₄F₃N₄O, 393.1]; LC/MS retention time (method D): *t*_R = 1.71 min; LC/MS retention time (Method E): *t*_R = 1.44 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.54-8.59 (m, 2H), 8.30-8.32 (m, 2H), 7.50 (d, *J* = 4.80 Hz, 1H), 7.20-7.22 (m, 2H), 4.02-4.12 (m, 2H), 1.70-1.90 (m, 2H), 1.60-1.65 (m, 1H), 1.41 (s, 3H), 1.00-1.05 (m, 6H) ppm.

25

Example 502

(*S*)-1-(4-(imidazo[1,2-*b*]pyridazin-3-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amine




5

Prepared in a similar fashion as described in Example 473 to give (*S*)-1-(4-(imidazo[1,2-*b*]pyridazin-3-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amine (3 mg, 8.78 μ mol, 10% yield) as a pale yellow solid. LCMS (ESI) m/e 339.3[(M+H)⁺, calcd for C₂₀H₂₇N₄O, 339.2]; LC/MS retention time (method D): t_R = 1.36 min; LC/MS retention time (Method E): t_R = 0.95 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.56-8.57 (m, 1H), 8.09 (d, J = 1.60 Hz, 1H), 8.06 (d, J = 1.60 Hz, 1H), 8.03 (s, 1H), 7.99 (d, J = 2.00 Hz, 1H), 7.26-7.30 (m, 1H), 7.09 (d, J = 8.80 Hz, 1H), 3.98-4.05 (m, 2H), 2.39 (s, 3H), 1.76-1.93 (m, 2H), 1.62-1.67 (m, 1H), 1.42 (s, 3H), 1.02-1.07 (m, 6H) ppm.

15

Example 503

(*S*)-1-(2-chloro-4-(imidazo[1,2-*b*]pyridazin-3-yl)phenoxy)-2,4-dimethylpentan-2-amine




Prepared in a similar fashion as described in Example 473 to give (*S*)-1-(2-chloro-4-(imidazo[1,2-*b*]pyridazin-3-yl)phenoxy)-2,4-dimethylpentan-2-amine (6 mg, 0.016 mmol, 21% yield) as a pale yellow solid. LCMS (ESI) m/e 359.2[(M+H)⁺, calcd for C₁₉H₂₄ClN₄O, 359.1]; LC/MS retention time (method D): t_R = 2.02 min; LC/MS retention time (Method E): t_R = 1.42 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.58-8.59 (m, 1H), 8.28 (d, J = 2.00 Hz, 1H), 8.03-8.10 (m, 3H), 7.28-7.31 (m, 1H), 7.24 (d, J = 8.80 Hz, 1H), 4.00-4.06 (m, 2H), 1.83-1.91 (m, 1H), 1.71-1.76 (m, 1H), 1.58-1.63 (m, 1H), 1.37 (s, 3H), 1.00-1.03 (m, 6H) ppm.

25

Example 504

(*R*)-2,4-dimethyl-1-((3-methyl-5-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)pyridin-2-yl)oxy)pentan-2-amine



5

Prepared in a similar fashion as described in Example 500 to afford (*R*)-2,4-dimethyl-1-((3-methyl-5-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)pyridin-2-yl)oxy)pentan-2-amine (11 mg, 0.026 mmol, 17% yield) as a pale yellow solid.

LCMS (ESI) *m/e* 408.2 [(M+H)⁺, calcd for C₂₀H₂₅F₃N₅O, 408.2]; LC/MS retention time (method D): *t_R* = 2.51 min; LC/MS retention time (Method E): *t_R* = 2.16 min.



10

¹H NMR (400 MHz, METHANOL-*d*₄): δ 9.00-9.01 (m, 1H), 8.63 (d, *J* = 1.20 Hz, 1H), 8.58 (d, *J* = 4.80 Hz, 1H), 8.39-8.40 (m, 1H), 8.55 (d, *J* = 4.80 Hz, 1H), 4.47 (s, 2H), 2.40 (s, 3H), 1.86-1.91 (m, 1H), 1.77-1.82 (m, 1H), 1.62-1.67 (m, 1H), 1.45 (s, 3H), 1.02-1.07 (m, 6H) ppm.

15

Example 509

(*S*)-6-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyrimidin-4(3*H*)-one




20

Part A: 6-chloropyrimidin-4(3*H*)-one

A solution of 4,6-dichloropyrimidine (2 g, 13.42 mmol) in a mixture of 4N HCl (10.49 mL, 121 mmol)- 1,4-dioxane (10 mL)-water (10 mL) was heated to 70 °C for 6 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to afford a pink solid. Ethanol (25 mL) was added to the solid and the mixture was heated at 50 °C until the solid dissolved. The resulting pink solution was left overnight at room temperature and the precipitation formed was filtered and dried under vacuum to afford 6-chloropyrimidin-4(3H)-one (1 g, 7.51 mmol, 56% yield) as an off-white solid. LCMS (ESI) m/e 130.8 [(M+H)⁺, calcd for C₄H₄ClN₂O, 130.9]; LC/MS retention time (Method C): t_R = 0.51 min.


10



Part B: (S)-tert-butyl (1-(2-chloro-4-(6-oxo-1,6-dihydropyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate

A mixture of 6-chloropyrimidin-4(3H)-one (25 mg, 0.192 mmol), (*S*)-*tert*-butyl (1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (prepared as described in Example 260, Part A and B) (90 mg, 0.192 mmol), K₂CO₃ (79 mg, 0.575 mmol) and Pd(Ph₃P)₄ (11.07 mg, 9.58 μmol) in 1,4-dioxane (1 mL)-water (0.1 mL) was heated at 100 °C for 16 h. The reaction mixture was cooled to RT and acidified with 1.5N HCl until the pH reached 4. The solution was extracted with ethyl acetate and the layers were separated. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to afford (*S*)-*tert*-butyl (1-(2-chloro-4-(6-oxo-1,6-dihydropyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (120 mg, 0.066 mmol, 35% yield) as a yellow solid which was carried forward without further purification. LCMS (ESI) m/e 436.2 [(M+H)⁺, calcd for C₂₂H₃₁ClN₃O₄, 436.2]; LC/MS retention time(method E): t_R = 1.13 min.

25



Part C: *(S)*-6-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyrimidin-4(3H)-one

To a stirred solution of *(S)*-*tert*-butyl (1-(2-chloro-4-(6-oxo-1,6-dihydropyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-yl)carbamate (30 mg, 0.069 mmol) in MeOH (1 mL) was added HCl 1M in 1,4-dioxane (0.172 mL, 0.688 mmol) and the reaction mixture was stirred at RT for 8 h. The mixture was concentrated under reduced pressure. The crude material was purified by prep LC/MS (method C) to afford *(S)*-6-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyrimidin-4(3H)-one (2 mg, 5.42 μ mol, 8% yield) as a pale yellow solid. LCMS (ESI) *m/e* 336.2 [(M+H)⁺, calcd for C₁₇H₂₃ClN₃O₂, 336.1]; LC/MS retention time (method D): *t_R* = 1.66 min; LC/MS retention time (Method E): *t_R* = 1.47 min. ¹H NMR (400 MHz, METHANOL-*d*₄): δ 7.25 (d, *J* = 0.80 Hz, 1H), 8.16 (d, *J* = 2.40 Hz, 1H), 7.98-8.01 (m, 1H), 7.26 (d, *J* = 8.40 Hz, 1H), 7.85 (d, *J* = 3.20 Hz, 1H), 4.17-4.25 (m, 2H), 1.85-1.95 (m, 2H), 1.68-1.73 (m, 1H), 1.52 (s, 3H), 1.01-1.07 (m, 6H) ppm.

BIOLOGICAL DATA

Methods

AAK1 Kinase Assay

The assays were performed in U-bottom 384-well plates. The final assay volume was 30 μ l prepared from 15 μ l additions of enzyme and substrates (fluoresceinated peptide (5-FAM)-Aha-KEEQSQITSQVTGQIGWR-NH₂ and ATP) and test compounds in assay buffer (10 mM Tris-HCL pH 7.4, 10 mM MgCl₂, 0.01% Tween-20 and 1.0 mM DTT). The reactions were initiated by the combination of bacterially expressed, GST-Xa-hAAK1 with substrates and test compounds. The reactions were incubated at room temperature for 3 hours and terminated by adding 60 μ l of 35 mM EDTA buffer to each sample. The reactions were analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by

- comparison to EDTA quenched control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentration of reagents in the assays are ATP, 22 μ M; (5-FAM)-Aha-KEEQSQITSQVTGQIGWR-NH₂, 1.5 μ M; GST-Xa-hAAK1, 3.5 nM; and DMSO, 1.6%. Dose response curves were generated to
- 5 determine the concentration required inhibiting 50% of kinase activity (IC₅₀). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations. IC₅₀ values were derived by non-linear regression analysis. Results are shown in Table 1.

10

Table 1

Example	AAK1 IC ₅₀ (nM)
251	310
252	285
253	537
254	22
255	42
256	0.82
257	0.45
258	0.47
259	229
260	0.48
261	0.36
262	1.9
264	79
265	55
266	265
267	362
269	3.4
270	8.4
271	4.1

Example	AAK1 IC ₅₀ (nM)
272	0.8
275	2.2
276	0.9
277	1.8
281	3.4
282	36
283	0.4
284	0.6
286	47
287	0.5
288	0.9
289	58
291	34
292	0.4
293	14
294	120
295	22
296	132
302	5.3
303	0.6
321	162
322	0.4
332	94
333	99
334	15
335	262
336	15
338	35
339	17
340	110

Example	AAK1 IC ₅₀ (nM)
341	212
342	39
345	5.2
346	23
347	964
351	0.40
353	0.20
358	385
361	1.7
362	1.0
363	0.40
364	24
365	98
366	60
368	0.30
369	1.7
371	0.20
376	0.8
377	7.4
380	1.0
381	1.5
389	0.3
390	0.5
391	0.5
392	0.7
393	7.3
394	2.0
395	0.7
396	1.6

Example	AAK1 IC ₅₀ (nM)
397	0.7
398	1.0
399	5.9
400	0.3
401	0.6
402	0.5
403	0.5
404	0.7
405	2.0
406	0.3
407	0.8
408	0.5
409	0.7
410	3.6
411	1.1
412	6.4
413	765
414	47
415	3.1
416	94
417	3.6
418	29
419	1138
420	1.1
421	0.5
423	862
424	1.2
425	1.4
426	7.2
427	1738

Example	AAK1 IC ₅₀ (nM)
428	13
429	36
430	67
448	399
449	352
452	11
453	0.4
455	391
456	1.0
457	160
459	1271
460	0.6
461	2.9
463	184
464	495
466	64
467	0.4
468	54
470	138
471	6.3
472	0.5
473	112
475	15
476	125
477	50
478	11
481	52
482	1.4
483	2.7
485	4.5

Example	AAK1 IC ₅₀ (nM)
486	1370
488	4.0
489	278
490	37
492	1.8
493	15
494	222
495	66
496	297
497	11
498	0.5
499	1.2
500	30
501	69
502	144
503	62
504	606
509	6.1

AAK1 Knockout Mice

Mice homozygous (-/-) for the disruption of the AAK1 gene were prepared by two methods; gene trapping and homologous recombination.

- 5 Gene trapping is a method of random insertional mutagenesis that uses a fragment of DNA coding for a reporter or selectable marker gene as a mutagen. Gene trap vectors have been designed to integrate into introns or genes in a manner that allows the cellular splicing machinery to splice vector encoded exons to cellular mRNAs. Commonly, gene trap vectors contain selectable marker sequences that are
- 10 preceded by strong splice acceptor sequences and are not preceded by a promoter. Thus, when such vectors integrate into a gene, the cellular splicing machinery splices exons from the trapped gene onto the 5' end of the selectable marker sequence.

Typically, such selectable marker genes can only be expressed if the vector encoding the gene has integrated into an intron. The resulting gene trap events are subsequently identified by selecting for cells that can survive selective culture.

Embryonic stem cells (Lex-1 cells from derived murine strain A129), were
5 mutated by a process involving the insertion of at least a portion of a genetically engineered vector sequence into the gene of interest, the mutated embryonic stem cells were microinjected into blastocysts which were subsequently introduced into pseudopregnant female hosts and carried to term using established methods. *See, e.g., "Mouse Mutagenesis", 1998, Zambrowicz et al., eds., Lexicon Press, The*
10 *Woodlands, TX. The resulting chimeric animals were subsequently bred to produce offspring capable of germline transmission of an allele containing the engineered mutation in the gene of interest.*

AAK1-gene disrupted mice were also made by homologous recombination. In this case, the second coding exon of the murine AAK1 gene (see GenBank
15 Accession Number NM_177762) was removed by methods known in the art. *See, e.g., U.S. Patent Nos. 5,487,992, 5,627,059, and 5,789,215.*

Mice homozygous (-/-) for the disruption of the AAK1 gene were studied in conjunction with mice heterozygous (+/-) for the disruption of the AAK1 gene, and wild-type (+/+) litter mates. During this analysis, the mice were subject to a medical
20 work-up using an integrated suite of medical diagnostic procedures designed to assess the function of the major organ systems in a mammalian subject.

Homozygous (-/-) "knockout" mice were studied in conjunction with their heterozygous (+/-) and wild-type (+/+) litter mates. Disruption of the AAK1 gene was confirmed by Southern analysis. Expression of the murine homolog of AAK1
25 was detected by RT-PCR in murine brain; spinal cord; eye; thymus; spleen; lung; kidney; liver; skeletal muscle; bone; stomach, small intestine and colon; heart; adipose; asthmatic lung; LPS liver; blood; banded heart; aortic tree; prostate; and mammary gland (5 week virgin, mature virgin, 12 DPC, 3 day post-partum (lactating), 3 day post-weaning (early involution), and 7 day post-weaning (late
30 involution)).

AAK1 homozygous (-/-) and their wild-type (+/+) littermates were tested using the formalin paw test in order to assess their acute and tonic nociceptive responses. For these tests, Automatic Nociception Analyzers (purchased from the


Ozaki lab at University of California, San Diego) were used. A metal band was placed around the left hind paw of each mouse 30 minutes prior to testing. After the 30-minute acclimation period, 20 µl of 5% formalin is subcutaneously injected in the dorsal surface of the left hind paw. Mice were individually housed in cylindrical
5 chambers for 45 minutes. Fresh 5 % formalin solution was prepared by diluting formaldehyde (Formalde-fresh 20%, Fisher Scientific, Fair Lawn, NJ) with distilled water. Investigatory compounds were administered 30 minutes prior to formalin injection.

A computer recorded flinches per minute, total flinches for phase I (acute
10 phase = first 8 minutes), and total flinches for phase II (tonic phase = time between minutes 20 - 40) through an electromagnetic field. See Yaksh TL, Ozaki G, McCumber D, Rathbun M, Svensson C, Malkmus S, Yaksh MC. *An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol.*, 2001; 90:2386-402. As shown in Figure 1, phase 1 and phase 2 data were obtained
15 using homozygous (-/-) mice females (n = 16), wild-type females (n = 15), homozygous (-/-) mice males (n = 9), and wild-type males (n = 18). In all groups and in both phases, the AAK1 homozygous (-/-) mice exhibited significantly less recorded paw flinching than their wild-type (+/+) littermates.

It will be evident to one skilled in the art that the present disclosure is not
20 limited to the foregoing illustrative Examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the Examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing Examples, and all changes which come within the meaning and range of equivalency
25 of the claims are therefore intended to be embraced therein.

CLAIMS


1. A compound of formula (I)



(I),


or a pharmaceutically acceptable salt thereof, wherein:

A is selected from




wherein “” denotes the point of attachment to B;


B is selected from



wherein "*" indicates the point of attachment to R^5 and "**" indicates the point of attachment to ring A;

R^1 is selected from hydrogen, amino, $-\text{CO}_2\text{H}$, cyclopropyl, difluoromethyl, ethyl, halo, hydroxymethyl, methoxy, methoxymethyl, methyl, $-\text{NHC}(\text{O})\text{CH}_3$, $-\text{NHCO}_2\text{CH}_3$, trifluoromethoxy, trifluoromethyl,






wherein R^a is selected from hydrogen, halo and methyl;

R^2 is selected from hydrogen, cyano, $-\text{CH}_2\text{OH}$, halo, and methyl;


R^3 is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, fluoromethyl, halo, hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluoromethoxy, trifluoromethyl, $-\text{CH}_2\text{N}(\text{CH}_3)_2$, and a five-membered aromatic ring containing one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur;

R^4 is selected from hydrogen, halo, and methyl;


R^5 is selected from




R^6 is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl, and trifluoromethyl;
provided that when A is




then B is




R^1 is selected from




R^5 is selected from




2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is selected from




3. A compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein B is selected from



4. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is selected from



5. A compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein B is selected from



6. A compound selected from
- (S)-1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-amine;
 - (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2,3-dimethylpyrido[2,3-b]pyrazin-8-yl)benzonitrile;
 - (S)-1-(2-fluoro-4-(pyrido[2,3-b]pyrazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine
 - (S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-amino-3H-imidazo[4,5-b]pyridin-7-yl)benzonitrile;
 - (S)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-amine;
 - (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazol-2-amine;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazol-2-amine;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiazole-2-carboxamide;

(*S*)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)thiazole-2-carboxamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)thiazole-2-carboxamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)-4-methylthiazol-2-amine;

(*R*)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine;

(*R*)-1-((3-chloro-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine;

(*R*)-1-((5-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine;

(*S*)-2,4-dimethyl-1-((7-(2-methylpyridin-4-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine;

(*S*)-methyl 4-(4-((2-amino-2,4-dimethylpentyl)oxy)benzo[*d*]thiazol-7-yl)pyridin-2-yl)carbamate;

(*S*)-2,4-dimethyl-1-(4-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methylthiazolo[5,4-*d*]pyrimidin-7-yl)benzonitrile;

(*S*)-1-((3-chloro-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amine;

(*S*)-2,4-dimethyl-1-((3-methyl-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-2-yl)oxy)pentan-2-amine;

(*S*)-1-((2-(fluoromethyl)-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine

2-amino-2-(((2',4-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)methyl)-4-methylpentan-1-ol;

(*S*)-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(2-chloro-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(4-(imidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(2-chloro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-chloroimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(imidazo[1,2-*b*]pyridazin-8-yl)benzonitrile;

(*S*)-1-(2-fluoro-4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(2-fluoro-4-(1-methyl-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine

2,4-dimethyl-1-(4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine;

(*S*)-1-(4-(1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)benzonitrile;

(*S*)-2,4-dimethyl-1-(2-methyl-4-(2-methyl-3*H*-imidazo[4,5-*b*]pyridin-7-yl)phenoxy)pentan-2-amine;

(*S*)-1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(4-(2-(methoxymethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl)benzonitrile;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-2(3*H*)-one

2-methyl-1-((2-methyl-6-(2-methylpyrimidin-4-yl)pyridin-3-yl)oxy)propan-2-amine;

(*S*)-1-((2-(difluoromethyl)-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(2-chloro-4-(pyrazolo[1,5-*a*]pyridin-3-yl)phenoxy)-2,4-dimethylpentan-2-amine

(*S*)-2,4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyridin-3-yl)phenoxy)pentan-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(3-fluorocyclopentyl)pyridin-2-amine;

(*S*)-1-(2-fluoro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(2-chloro-4-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine;

(*S*)-2,4-dimethyl-1-((7-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine ;

(*S*)-2,4-dimethyl-1-((7-(2-methylpyrimidin-4-yl)benzo[*d*]thiazol-4-yl)oxy)pentan-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-*N*-(tetrahydrofuran-3-yl)pyridin-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-*N*-(tetrahydrofuran-3-yl)pyridin-2-amine

1-(((3-methyl-5-(2-methylpyrimidin-4-yl)pyridin-2-yl)oxy)methyl)cyclobutanamine;

(*S*)-1-(2-(difluoromethyl)-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(2-(fluoromethyl)-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2,4-dimethyl-1-(5-methyl-2-(pyridin-4-yl)thiazol-4-yl)oxy)pentan-2-amine

6-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyrimidin-4-amine;

(*S*)-1-(2-chloro-4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)benzonitrile;

(*S*)-1-(4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)benzonitrile;

(*S*)-1-(2-fluoro-4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2,4-dimethyl-1-(4-(7-methyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)thiazol-2-amine;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-*N*-cyclopropylpyrimidin-2-amine;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)thiazol-2-amine;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyrimidin-2-yl)-4-methylthiazol-2-amine;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-cyclopentylpyrimidin-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-((4-methylthiazol-2-yl)amino)pyrimidin-4-yl)benzonitrile;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyrimidin-2-yl)-4-methylthiazol-2-

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclopropanecarboxamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclobutanecarboxamide

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)cyclopentanecarboxamide

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cyclopentylacetamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-3-cyclopentylpropanamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cyclohexylacetamide

N-(4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)tetrahydrofuran-2-carboxamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-cycloheptylacetamide

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)furan-2-carboxamide

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-bromofuran-2-carboxamide;

(*S*)-2-acetamido-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)acetamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)thiophene-2-carboxamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)pyrazine-2-carboxamide;

(*S*)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-2-methylnicotinamide;

(S)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-1*H*-1,2,3-triazole-5-carboxamide
(S)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide
(S)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-methylisoxazole-3-carboxamide
(S)-*N*-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-isopropyl-1*H*-pyrazole-3-carboxamide
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(pyridin-3-ylmethyl)pyridin-2-amine;
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(furan-2-ylmethyl)pyridin-2-amine;
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(benzo[*d*][1,3]dioxol-5-yl)pyridin-2-amine;
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;
(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-methyl-5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzonitrile;
(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(5-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzonitrile;
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-ethyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;
(S)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)-6-ethyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;
(S)-1-(2-fluoro-4-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;
(S)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)benzonitrile;

(*S*)-1-(4-(1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;

(*S*)-2,4-dimethyl-1-(2-methyl-4-(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)phenoxy)pentan-2-amine;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one;

(*S*)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)-6-methyl-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-5-one

6-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine

6-(6-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-5-chloropyridin-3-yl)-*N*-(tetrahydrofuran-3-yl)pyrimidin-4-amine;

(*S*)-2,4-dimethyl-1-((2-methyl-6-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)pyridin-3-yl)oxy)pentan-2-amine;

(*S*)-1-((2-(difluoromethyl)-6-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amine;

(*S*)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-2-fluorophenyl)pyrazolo[1,5-*a*]pyrimidin-5-amine;

(*S*)-1-(2-chloro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-7-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorophenyl)pyrazolo[1,5-*a*]pyrimidin-5-amine;

(*S*)-1-(2-chloro-4-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(pyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile ;

(*S*)-1-(2-fluoro-4-(pyrazolo [1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-*N*-(7-(4-((2-amino-2, 4-dimethylpentyl) oxy)-3-fluorophenyl) pyrazolo [1,5-*a*] pyrimidin-5-yl) acetamide;

(*S*)-2-((2-amino-2, 4-dimethylpentyl)oxy)-5-(2,5-dimethylpyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile;

(*S*)-2-(2-amino-2, 4-dimethylpentyl oxy)-5-(2-(piperidin-4-ylamino) pyridin-4-yl) benzonitrile;

(*S*)-2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine;

(*S*)-2-(2-amino-2,4-dimethylpentyl oxy)-5-(2-(tetrahydro-2*H*-pyran-4-ylamino)pyridin-4-yl)benzonitrile;

(*S*)-4-(4-(2-amino-2,4-dimethylpentyl oxy)-3-(trifluoromethyl)phenyl)-*N*-(piperidin-4-yl)pyridin-2-amine;

(*S*)-1-(4-(6,7-difluoroquinazolin-4-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2, 4-dimethyl-1-(2-methyl-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)pentan-2-amine;

(*S*)-2,4-dimethyl-1-(4-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine

4-(4-((*S*)-2-amino-2,4-dimethylpentyl oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine

4-(4-(((*S*)-2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)-*N*-(tetrahydro-2*H*-pyran-3-yl)pyridin-2-amine;

(*S*)-3-(5-((2-amino-2,4-dimethylpentyl)oxy)-6-methylpyridin-2-yl)pyrazolo[1,5-*a*]pyrimidine-6-carbonitrile;

(*S*)-2,4-dimethyl-1-(4-(2-methylthieno[2,3-*d*]pyrimidin-4-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine;

(*S*)-1-(2-chloro-4-(2-cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(4-(2-Cyclopropylpyrazolo[1,5-*a*]pyrimidin-7-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidin-7-yl)benzonitrile;

(*S*)-5-((2-amino-2,4-dimethylpentyl)oxy)-2-(pyrazolo[1,5-*a*]pyrimidin-7-yl)isonicotinonitrile;

(*S*)-2,4-dimethyl-1-((2-methyl-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)pentan-2-amine;

(*S*)-1-(2,5-difluoro-4-(pyrazolo[1,5-*a*]pyrimidin-7-yl)phenoxy)-2,4-dimethylpentan-2-amine

1,1,1-trifluoro-4-methyl-2-(((2-methyl-6-(pyrazolo[1,5-*a*]pyrimidin-7-yl)pyridin-3-yl)oxy)methyl)pentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile

(*S*)-1-(4-(2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)-2-fluorophenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(6-chloro-2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile;

(*S*)-1-(4-(6-chloro-2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(4-(6-chloro-2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-1-(2-fluoro-4-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)phenoxy)-2,4-dimethylpentan-2-amine;

(*S*)-2,4-dimethyl-1-(4-(2-methylimidazo[1,2-*b*]pyridazin-8-yl)-2-(trifluoromethyl)phenoxy)pentan-2-amine;

(*S*)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(2-cyclopropylimidazo[1,2-*b*]pyridazin-8-yl)benzonitrile;

(*S*)-2,4-dimethyl-1-(2-methyl-4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-amine;

(*S*)-2,4-dimethyl-1-(4-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)phenoxy)pentan-2-amine;
(*S*)-1-(4-(imidazo[1,2-*b*]pyridazin-3-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amine;
(*S*)-1-(2-chloro-4-(imidazo[1,2-*b*]pyridazin-3-yl)phenoxy)-2,4-dimethylpentan-2-amine;
(*R*)-2,4-dimethyl-1-((3-methyl-5-(2-(trifluoromethyl)imidazo[1,2-*b*]pyridazin-8-yl)pyridin-2-yl)oxy)pentan-2-amine; and
(*S*)-6-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyrimidin-4(3*H*)-one;
or a pharmaceutically acceptable salt thereof.

7. A composition comprising a pharmaceutically acceptable amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
8. A method of inhibiting adaptor associated kinase 1 (AAK1) activity, comprising contacting AAK1 with a compound of claim 1, or a pharmaceutically acceptable salt thereof.
9. A method for treating or managing a disease or a disorder mediated by AAK1 activity, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
10. The method of claim 9, wherein the disease or disorder is selected from Alzheimer's disease, bipolar disorder, pain, Parkinson's disease, and schizophrenia.
11. The method of claim 10 wherein the pain is neuropathic pain.
12. The method of claim 11 wherein the neuropathic pain is fibromyalgia or peripheral neuropathy.




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2016/054464

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D231/12 C07D213/74 C07D213/75 C07D401/04 C07D401/12
 C07D405/12 C07D239/36 C07D239/42 C07D409/12 C07D239/72
 C07D413/12 C07D417/04 C07D417/12 C07D471/04 C07D487/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2013/134036 A1 (SQUIBB BRISTOL MYERS CO [US]) 12 September 2013 (2013-09-12) claims 1,6-13; examples 1,5-16,18,21-23,44,... -----	1-12
A	WO 2014/022167 A1 (SQUIBB BRISTOL MYERS CO [US]) 6 February 2014 (2014-02-06) claims 1,5-12; examples 1-20,28,... -----	1-12
X,P	WO 2015/153720 A1 (SQUIBB BRISTOL MYERS CO [US]) 8 October 2015 (2015-10-08) claims 1-15; examples 69-89,96,98,99,102,104,109,110,215,... -----	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 January 2017

Date of mailing of the international search report

03/02/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Ladenburger, Claude

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/054464

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013134036	A1	12-09-2013	AR 090293 A1 05-11-2014
		CA 2866671 A1 12-09-2013	
		CN 104144932 A 12-11-2014	
		EA 201491647 A1 30-12-2014	
		EP 2822952 A1 14-01-2015	
		JP 2015510881 A 13-04-2015	
		TW 201341387 A 16-10-2013	
		US 2013237555 A1 12-09-2013	
		US 2014179725 A1 26-06-2014	
		UY 34666 A 30-09-2013	
		WO 2013134036 A1 12-09-2013	
WO 2014022167	A1	06-02-2014	AR 093758 A1 24-06-2015
		CA 2880523 A1 06-02-2014	
		CN 104507941 A 08-04-2015	
		EA 201590268 A1 29-05-2015	
		EP 2880032 A1 10-06-2015	
		JP 2015528018 A 24-09-2015	
		TW 201410676 A 16-03-2014	
		US 2014038999 A1 06-02-2014	
		WO 2014022167 A1 06-02-2014	
WO 2015153720	A1	08-10-2015	AU 2015240869 A1 17-11-2016
		CA 2944466 A1 08-10-2015	
		EP 3126351 A1 08-02-2017	
		KR 20160132491 A 18-11-2016	
		SG 11201608195Q A 28-10-2016	
		WO 2015153720 A1 08-10-2015	